Genetic polymorphisms, DNA methylation and antipsychotic induced weight gain in schizophrenia patients. by Srisawat, Umarat.
Genetic polymorphisms, DNA methylation and 
antipsychotic induced weight gain in schizophrenia 
patients.
SRISAWAT, Umarat.
Available from Sheffield Hallam University Research Archive (SHURA) at:
http://shura.shu.ac.uk/20818/
This document is the author deposited version.  You are advised to consult the 
publisher's version if you wish to cite from it.
Published version
SRISAWAT, Umarat. (2015). Genetic polymorphisms, DNA methylation and 
antipsychotic induced weight gain in schizophrenia patients. Doctoral, Sheffield 
Hallam University (United Kingdom).. 
Copyright and re-use policy
See http://shura.shu.ac.uk/information.html
Sheffield Hallam University Research Archive
http://shura.shu.ac.uk
Learning and IT Services I
Collegiate Learning Centre { 
Collegiate Crescent Campus! 
Sheffield S10 2SP
?
ProQuest Number: 10702927
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 10702927
Published by ProQuest LLC(2017). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
/Genetic polymorphisms, DNA methylation and 
antipsychotic induced weight gain in 
schizophrenia patients
Umarat Srisawat
A thesis submitted in partial fulfilment of the 
requirements of Sheffield Hallam University for the 
degree of Doctor of Philosophy
July 2015
Acknowledgements
Firstly, I would like to  express my heartfe lt gratitude to both of my supervisors, 
Professor Gavin P Reynolds and Dr. Caroline F Dalton, fo r providing me w ith  the 
opportun ity to work w ith  them and the ir brilliant supervision, encouragement and 
insightful advice throughout my tim e here. I have been extremely lucky to  have both of 
you being my supervisors.
I would like to thank Dr.Helene Fachim who working w ith and being a nice friend 
sharing lovely memories; thanks fo r help and support. Many thanks to my colleagues 
and friends, Yasitha, Nat, Jen, Anna, Hanan, Yasin, Eva, Rachel, Kaled, Mariam, 
Mowafag, Tawfik, Pattrick, Richard, Clair, Marina, Sara, Malanie, Abbie, Nicola, 
Esadawi, Exta, Afnan, Amani, Callie, Nikhil, Chris, Rebecca, Robert, Amal, and Siriluk 
Veerasakul and other unmentioned friends both in BMRC and at University o f Sheffield 
fo r the ir friendship, help and support.
I would like to  thank Prof. Varanuj Chatsudthipong, Assoc.Prof. Kesorn Suwanprasert, 
Assist.Prof. Pintusorn Hansakul, Assist.Prof. Pritsana Piyabhan, Dr.Wanwarang Hiriote, 
Dr.Natwadee Poomipark, Assist.Prof. Surin Preawnim, Assist.Prof. Sophapun 
Ekarattanawong, Assist.Prof. Supaporn Vannasiri, Assist.Prof. Anyanee Burodom, 
Assist.Prof. Bhronprom Yoysungnoen, Assist.Prof. Jantarima Charoenphandhu, Dr. 
Naphatsanan Duansak, Nattapol Sukprasert, Watcharin Panunto and all the staff 
members at Physiology Division and other divisions at Department of Preclinical 
Science, Faculty o f Medicine, Thammasat University fo r the ir support.
I would also like to  thank all the members of staff at BMRC for all the ir help and 
guidance. Special thanks to  Professor Nicola W oodroofe, Marguerite Lyons, and Sarah 
W right fo r the ir help and support.
I am grateful to the Royal Thai Government fo r the funding fo r doing research, 
attending conferences and living in the UK. I am also very grateful to the Faculty of 
Medicine, Thammasat University fo r providing me an opportun ity to study in the UK.
I would like to  express my gratitude to my family, especially my mom and dad, my 
brother; a massive thanks to  my husband Channarong, as well as his fam ily members; 
million thanks fo r the ir endless love, continued support and encouragement.
This thesis is dedicated to all of my family, the Srisawats, the Sawangdees, and the 
Piromjits, in Thailand.
Publications
1. Srisawat U, Reynolds GP, Zhang ZJ, Zhang XR, Arranz B, San L, Dalton CF. 
M ethylenetetrahydrofolate reductase (MTHFR) 677C/T polymorphism is associated 
w ith antipsychotic-induced weight gain in first-episode schizophrenia. Int J 
Neuropsychopharmacol. 2014 Mar;17(3):485-90. PMID: 24229535 (see appendix).
2. Tang H, Dalton CF, Srisawat U, Zhang ZJ, Reynolds GP. Methylation at a transcription 
factor-binding site on the 5-HT1A receptor gene correlates w ith negative symptom 
treatm ent response in first episode schizophrenia. Int J Neuropsychopharmacol. 2014 
Apr;17(4):645-9. PMID: 24331356 (see appendix).
Conferences/Training attended /Poster presentations
1. BAP 2012 Summer Meeting, Flarrogate International Centre, 22nd-25th July 2012 
by the British Association fo r Psychopharmacology (BAP).
2. BNA 2013: Festival of Neuroscience, The Barbican Centre, London, 7th -10th April 
2013 by the British Neuroscience Association's biennial meeting. (Abstract and 
Poster). MTHFR genotype and antipsychotic drug-induced weight gain. British 
Neurosci. Assoc. Abstr., Vol. 22: 772, 2013, ISSN 1345-8301
3. BAP 2013 Summer Meeting, Harrogate International Centre, 28th -31st July 2013. 
(Abstract and Poster). MTHFR 677C/T genotype is associated w ith antipsychotic 
drug-induced weight gain in patients w ith schizophrenia. The British Journal of 
Psychopharmacology, August 2013, 27 Suppl, (8): A69.
4. BAP 2014 Summer Meeting, Cambridge, 20th -23rd July 2014. (Abstract and Poster). 
The effect o f DNA methylation on prom oter activity o f the 5-HT1A receptor gene. 
August 2014, 28 Suppl, (8): A109.
5. Pre-Clinical Certificate: Module 3: Experimental Design 1: Statistics and 
Experimental Design. Friday, 2nd March 2012 Research Beehive, Level 2, Room 
2.21 Old Library Building Newcastle University, Newcastle.
6. Pre-Clinical Certificate: Module 5: Functional And Advanced Techniques? The 
development of pharmacological agents - Registration fo r Sunday, 22nd July 2012, 
Harrogate.
7. Pre-Clinical Certificate: Module 6: Principles Of Psychiatry For Basic Scientists, 28th 
January 2013, Academic Psychiatry, Campus fo r Ageing and Vitality, Newcastle.
8. Pre-Clinical Certificate: Module 7: Experimental Design 2; Pre-clinical models in 
behavioural pharmacology (Core Module), 25th March 2013, Huxley Building, 
University of Brighton.
9. Training session on pyrosequencing on the 20th June 2012 in 744 by Qiagen.
10. Yorkshire Immunology Group Symposium, Sheffield, June 2013.
11. BMRC/MERI Summer and W inter Poster Session Poster Conferences, Sheffield 
Hallam University, Sheffield, 2011, 2012, 2013, and 2014.
Abstract
Antipsychotic drug-induced weight gain is a common adverse effect o f antipsychotic 
medication in patients w ith schizophrenia. Many factors including genetic and 
environmental factors may contribute to this adverse effect. The antipsychotic drugs 
and genetic factors may influence the weight gain through epigenetic mechanisms, 
including DNA methylation. The aim of this study was to  investigate the associations of 
antipsychotic drug-induced weight gain w ith genetic polymorphisms and DNA 
methylation o f HTR2C. In addition, the aim of this study was to investigate the effect of 
antipsychotic drug treatm ent on DNA methylation and mRNA expression o f HTR2C and 
on leptin secretion by adipocytes.
DNA samples from both first episode drug nave and chronic schizophrenic patients 
were genotyped using TaqMan® SNP Genotyping Assays and the extent o f DNA 
methylation was measured using bisulfite pyrosequencing. The MTHFR rsl801133 
genetic polymorphism was significantly associated w ith BMI change in firs t episode 
drug na ve Chinese Han and Spanish patients. In Chinese Han cohort, a significant 
association was also found of the MC4R rs489693 w ith BMI change. In addition, when 
patients were analysed as group receiving either risperidone or chlorpromazine, a 
significant genotype-drug interaction was observed w ith the HTR2A rs6311, and also 
found significant associations between the HTR2A rs6311 and ADRA2A rs l800544 with 
risperidone-induced weight gain.
Global DNA methylation was measured by determining methylation o f UNE-1 in 
chronic schizophrenia patients. Results show no significant association of LINE-1 
methylation w ith BMI, although the MTHFR rsl801133 and FTO rs9939609 SNPs had 
significant influence on LINE-1 methylation in this cohort. DNA methylation levels of 
the HTR2C prom oter sequence were also measured. The extent o f DNA m ethylation of 
the HTR2C prom oter sequences in samples taken before patients received 
antipsychotics was significantly higher in Chinese Han patients who subsequently had 
weight increase <7%; therefore, DNA methylation o f the HTR2C prom oter sequences 
may be a predictor fo r antipsychotic drug-induced weight gain in drug na ve patients. 
In addition, the T allele o f the HTR2C rs3813929 polymorphism was significantly 
associated w ith higher methylation o f the HTR2C prom oter sequence. This provides a 
mechanistic link between the HTR2C rs3813929 SNP and prom oter activity. The FTO 
rs9939609 SNP was significantly associated w ith DNA methylation o f the HTR2C 
prom oter sequences in Spanish male patients. In chronic patients, DNA m ethylation of 
the HTR2C prom oter sequence was not significantly associated w ith  BMI; however, it 
was significantly associated w ith the HTR2C rs3813929.
The effect o f antipsychotic drugs on the HTR2C methylation, mRNA expression, and 
leptin secretion were studied in cell culture models. Clozapine and haloperidol 
treatm ent in SH-SY5Y neuroblastoma cells show no significant change DNA 
methylation and mRNA expression o f the HTR2C. In 3T3-L1 adipocytes treated w ith 
clozapine, SB 242084, risperidone, and haloperidol show no significant changes in 
Htr2c mRNA expression and leptin secretion.
The associations o f genetic polymorphisms and DNA methylation of the HTR2C w ith 
antipsychotic drug-induced weight gain may indicate the underlying mechanisms and 
also provide genetic and epigenetic markers fo r antipsychotic drug-induced weight 
gain.
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Chapter 1: General Introduction
1.1 Schizophrenia
Schizophrenia is a chronic psychotic disorder characterized by a broad spectrum of 
disintegration of thought processes and emotional dysfunctions. In 1893, it was called 
"dementia praecox" by psychiatrist Emil Kraeplin. In 1911, schizophrenia was named 
by Eugen Bleuler, a Swiss psychiatrist, to  describe the chronic, severe, and disabling 
brain illness. The term  refers to the splitting o f mental associations tha t Bleuler 
believed was the fundamental cause of the abnormalities in schizophrenia (Emery and 
Oltmanns, 2000).
About 1% of the world's general population suffer from  this illness (Jablensky et al., 
1992). It requires a large economic burden in terms of hospitalization, chronic 
treatm ent, rehabilitation and loss o f productivity (Rice, 1999). The estimated total 
social cost o f schizophrenia in England was 11.8 billion pounds a year (Andrew et al., 
2012). This social cost was composed of the direct cost o f treatm ent and care tha t falls 
on the public fund was about 7.2 billion pounds, this equates to  an average social cost 
o f £60,000 and to  the public sector o f £36,000 per person w ith schizophrenia per year. 
These costs come from the direct costs, including in-patient hospital costs, and support 
from  community mental health teams, appearring as costs to  both society and the 
plublic sector. A huge burden of indirect costs to society includes the informal care, 
unpaid care and private expenditures to  families or friends. The costs o f lost 
productivity of patients due to  unemployment, absence from work and premature 
m orta lity represent huge costs fo r society and for the public sector due to  the loss of 
tax revenue. The low employm ent rate for patients w ith schizophrenia causes loss of 
productive capacity of £17,200 per individual, which can give rise to  an expected loss 
to  the English economy of £3.4 billion per year. This low employm ent rate also affects 
the finances of the plublic sector through losses in tax revenue (£715 m illion per 
annum) and payments of social security benefits (£470 million per year).
1
1.1.1 Signs and symptoms of schizophrenia
People w ith schizophrenia exhibit many d ifferent symptoms. The full syndrome is 
characterized by positive symptoms, negative symptoms, and cognitive impairments. 
The symptoms typically develop during the first five to ten years and then clinical 
deterioration reaches a plateau (Lewis and Lieberman, 2000). Disturbance in basic 
cognitive functions such as attention, executive function, and specific forms of 
memory, particularly working memory, are thought to be central to the behavioural 
disturbance and functional disability o f schizophrenia. Moreover, many patients have 
concomitant mood symptoms including depression and anxiety tha t may contribute to 
the 10% lifetim e incidence of suicide in schizophrenia (Lewis and Lieberman, 2000).
Positive symptoms refer to the symptoms of schizophrenia tha t seem to  be excesses of 
normal thoughts, emotions, or behaviours (Comer, 2004). Positive symptoms include 
delusions and hallucinations. Delusions, the firs t positive symptoms, are characterized 
by false beliefs. A delusional person believes things that could not be true (Emery and 
Oltmanns, 2000). For example, they believe tha t there is someone or a group of people 
trying to  harm or injure them. Common delusions include the beliefs tha t ideas of 
other people are being inserted into the patients' head, and that people can read the ir 
thoughts. Sometimes the patients believe tha t they are being controlled by 
mysterious, external forces. Another positive symptom is hallucinations characterized 
by abnormal perceptions in the absence of actual external stimuli. For example, they 
may hear voices w ithout outside stimulus which is the most common type of 
hallucination. Sights, sounds and other perceptions in the absence of external stimuli 
are also considered hallucinations.
In contrast to the active presentations o f the positive symptoms o f schizophrenia, the 
negative symptoms usually indicate the absence or insufficiency of normal behaviour 
(Barlow and Durand, 2005). Such negative symptoms as lack o f in itia tive, social 
w ithdrawal, deficits in emotional response, and lack o f self-care are displayed in 
approximately 25% of persons w ith schizophrenia (Malla et al., 2002). These emotional 
disturbances exert effects on a person's social and occupational functioning. Primary 
negative symptoms are etilogically related to  the core pathophysiology of 
schizophrenia including blunted or fla t affect, poor rapport, emotional w ithdrawal,
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passive social w ithdrawal, poor social skills, poor grooming, alogia (poverty o f speech 
or poverty of content of speech), anergia, anhedonia, apathy, and avolition. Secondary 
negative symptoms are derivative of other symptoms of schizophrenia, o ther disease 
processes, medications, or environment such as the symptoms tha t result from 
positive psychotic symptoms, depression or demoralization, or medication side effects; 
therefore, secondary negative symptoms usually respond to treatm ent of the 
underlying cause (Lindenmayer and Khan, 2006).
The th ird type of schizophrenia symptom is cognitive impairments tha t show the 
manifestations of disorganized thoughts, speech and behaviour. Cognitive 
impairments affect m ultiple domains including working memory, selective attention, 
learning, and executive function (Konopaske and Coyle, 2015). People w ith 
schizophrenia may not be able to  think logically and may display inappropriate 
behaviour such as laughing or crying at improper times. Sometimes they show bizarre 
behaviour such as accumulating objects or acting in unusual ways in public. In addition, 
disorganized speech is another set of symptoms of people w ith schizophrenia. They 
tend to say things that are not sensible. The verbal communication problem and 
disorganized thinking exert effects on patients' lives. Cognitive im pairm ent is a core 
feature o f the illness. Among the symptoms, the positive symptoms respond best to 
antipsychotic medications, whereas the negative symptoms and cognitive inpairmant 
do not responsd well. Therefore, cognitive inpairments and negative symptoms are the 
best predictors o f function outcomes of schizophrenia treatm ent (reviewed by 
Konopaske and Coyle, 2015).
1.1.2 Diagnostic criteria for schizophrenia
The diagnostic criteria used to  diagnose schizophrenia defined by the American 
Association o f Psychiatry (American Psychiatric Association, 1994), a person must 
display signs and symptoms as follows:
The diagnostic criteria for schizophrenia from the DSM-IV
A) Characteristic symptoms: tw o or more o f the follow ing, each present fo r a 
significant portion of tim e during a one-month period (or less, if successfully 
treated)
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delusions
hallucinations
disorganized speech (e.g. frequent derailment or incoherence; speaking 
in abstracts)
grossly disorganized behaviour (e.g. dressing inappropriately; crying 
frequently) or catatonic behaviour
negative symptoms, i.e., affective flattening (lack or decline in 
emotional response), alogia (lack or decline in speech), or avolition (lack 
or decline in motivation)
Note: Only one criterion A symptom is required if delusions are bizarre or 
hallucinations consist o f hearing one voice participating in a running commentary of 
the patient's behaviour or thoughts or of hearing tw o  or more voices conversing w ith 
each other.
B) Social/ occupational dysfunction: for a significant portion of the tim e since the 
onset o f the disturbance, one or more major areas of functioning such as work, 
interpersonal relations, or self-care, are markedly below the level achieved 
prior to the onset or when the onset is in childhood or adolescence, failure to 
achieve expected level o f interpersonal, academic, or occupational 
achievement.
C) Duration: continuous signs of the disturbance persist fo r at least six months. 
This six-month period must include at least one month of symptoms (or less, if 
successfully treated) tha t meet criterion A. (i.e., active-phase symptoms) and 
may include periods of prodrom al (sym ptom atic o f the onset) or residual 
symptoms. During these prodrom al or residual periods, the signs o f the 
disturbance may be manifested by only negative symptoms or tw o  or more 
symptoms listed in criterion A present in an attenuated form  (e.g., odd 
beliefs, unusual perceptual experiences).
Additional criteria (D, E and F) are also given tha t exclude a diagnosis o f schizophrenia 
if symptoms of mood disorder or pervasive developmental disorder are present. 
Additionally, a diagnosis o f schizophrenia is excluded if the symptoms are the direct
result o f a substance (e.g. drug abuse, medication) or a general medical condition.
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D) Schizoaffective and mood disorder exclusion: schizoaffective d isorder and 
mood disorder w ith psychotic features have been ruled out because e ither 
(1) no major depressive episode, manic episode, or mixed episode have 
occurred concurrently w ith the active-phase symptoms; or (2) if  mood 
episodes have occurred during active-phase symptoms, the ir to ta l duration 
has been b rie f relative to  the duration of the active and residual periods.
E) Substance/general medical condition exclusion: The disturbance is not due to  
the direct physiological effects o f a substance (e.g., a drug o f abuse, a 
m edication) or a general medical condition.
F) Relationship to  a pervasive developm ental disorder: If there is a h istory o f 
autistic disorder or another pervasive developmental disorder, the additional 
diagnosis o f schizophrenia is made only if p rom inent delusions or 
hallucinations are also present fo r at least a month (or less if successfully 
treated).
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1.1.4 Biology of schizophrenia
The study of the aetiology o f schizophrenia is ongoing. It is a m ultifactorial disease. 
There are several causes and risk factors tha t might contribute to the development of 
schizophrenia, including both environmental and genetic influences. Genetic factors 
play an im portant role in the development o f schizophrenia. Obviously, schizophrenia 
is an inherited disorder. Waddington et al. (2007) stated that;
"Schizophrenia is an inherited, likely complex genetic disorder tha t runs in 
families and the single best predictor fo r developing the illness is having an 
affected first-degree relative".
Nevertheless, many people are affected despite lacking the fam ily history. In addition, 
it has also been pointed out that the general population had an average risk of 
developing schizophrenia o f 1%; in other words, the lifetim e prevalence of 
schizophrenia is 1% worldw ide (American Psychiatric Association, 1994), whereas the 
first-degree relatives o f two parents w ith schizophrenia and monozygotic tw ins had 
risks of 46 and 48%, respectively (Gottesman, 1991). Although these figures show a 
high risk of developing schizophrenia in the first-degree relatives, none o f the 
schizophrenia tw in  studies has found tha t the risk reaches 100%. It is suggested that 
environmental factors also play an im portant role in developing schizophrenia.
There are many environmental influences that contribute to schizophrenia risk. The 
lack o f oxygen during pregnancy is an im portant factor that may lead to the disorder. 
For example, the situation o f the umbilical cord wrapping around the baby's neck 
results in the im pairm ent o f blood circulation and reduction of an oxygen delivery to 
the developing brain regions (McNeil et al., 1994). Maternal m alnutrition in the early 
months o f pregnancy can also lead to  an increased risk of schizophrenia in the 
offspring. It is similarly related to oxygen availability, because m alnutrition can cause a 
lack o f nutrient supply to the fetus's brain tissue. Normally, both oxygen and nutrients 
are im portant to normal development of the fetus's nervous system. As a result, 
impairm ent o f these factors may be a leading cause o f the brain-related disorders such 
as schizophrenia. Other environmental factors playing a role in developing 
schizophrenia are infection and drug treatm ent during pregnancy (Emery and 
Oltmanns, 2000).
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1.1.4.1 Neurodevelopmental hypothesis in schizophrenia
In normal neurodevelopment, the different brain regions are formed at d ifferent times 
during development. Therefore, the tim ing of the insult to the developing fetus is a 
major determ inant of the subsequent abnormality. Additionally, small abnormalities in 
early events can generate a large difference in subsequent stages. Beside these, 
specific molecular signals play specific roles at various stages of neurodevelopment, for 
example, noggin and follistatin play an im portant role in induction of the central 
nervous system; brain-derived neurotrophic factor (BDNF) and insulin-like growth 
factor (IGF) are the major signals fo r proliferation. Many proteins are also involved in 
neurodevelopment such as reelin and astrotactin which cause appropriate migration of 
the growing neurons to the specific location in the brain. Signals from  interneurons are 
thought to be im portant in the trim m ing process tha t occurs in adolescence. 
(Reviewed by Gupta and Kulhara, 2010). However, all of these proteins are controlled 
by specific genes. Abnormal regulation of fundamental neurodevelopmental processes 
may occur, or there may be disruption by various forms of insult, this is referred to  as a 
neurodevelopmental disorder.
The hypothesis that schizophrenia might be a neurodevelopmental disorder was firs t
proposed by Thomas Clouston who called itdevelopmental insanity (M urray and
Bramon, 2005). The neurodevelopmental hypothesis was proposed in response to
research findings of an association o f schizophrenia w ith  complications o f pregnancy
and delivery. This association was proposed by Rosanoff as early as 1934 (reviewed by
Gupta and Kulhara, 2010). In addition, several studies showed an increase in risk of
developing schizophrenia when the rate o f obstetric complications was higher (Cannon
et al., 2002; Zornberg et al., 2000; Geddes et al., 1999). Some studies reported an
association between development schizophrenia in the offspring and maternal
influenza infections, especially during the second trim ester (Mednick et al., 1988;
Kendell and Kemp, 1989; Kunugi et al., 1995). However, several studies show no
relation between maternal influenza infection and risk of schizophrenia (Crow and
Done, 1992; Selten and Slaets, 1994; Susser et al., 1994). Furthermore, an increased
risk fo r schizophrenia, about two-fold, has been reported in the offspring o f mothers
exposed to  famine in the Dutch Hunger W inter o f 1944-1945 (Susser et al., 1996). This
evidence shows an association o f schizophrenia in offspring w ith obstetric
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complications and prenatal exposure to infectious agents or toxins as well as maternal 
m alnutrition.
1.1.4.2 Neurotransmitter involvement in schizophrenia
1.1.4.2.1 Dopamine
Dopamine is a catecholamine neurotransm itter that is synthesized from  the amino acid 
tyrosine by dopaminergic neurons. The neuron stores dopamine in small 
compartments called vesicles in the axon terminals. Dopamine is released into the 
synaptic cleft through a process called exocytosis. The released dopamine in the 
synaptic cleft may undergo reuptake into the presynaptic term inal by the dopamine 
transporter on the presynaptic membrane.
To affect target cells, dopamine interacts w ith its receptors on the target cell 
membrane. Dopamine receptors are divided into two subfamilies, D l-like  receptor 
subfamily which includes the receptor subtypes D1 and D5, and D2-like receptor 
subfamily which include the receptor subtypes D2, D3 and D4 (Neve and Neve, 1997). 
Upon agonist binding, dopamine receptor signalling is mediated by the heterotrim eric 
G proteins. D l-like  receptor binding activates adenylyl cyclase through coupling to 
stim ulatory G protein Gsa /G 0|fa  subunits, resulting in an increase in the intracellular 
cAMP level. By contrast, D2-like receptors couple to G ja /G 0a  subunits to inh ib it the 
activation of adenylyl cyclase (reviewed by Neve et al., 2004).
Dopaminergic neurons originate in three cell groups located in the mesencephalon and 
diencephalon of the brain. The axons of dopaminergic neurons from  these cell groups 
provide widespread projections to regions o f the forebrain, form ing the follow ing 
three dopamine pathways in the brain.
The major pathway is the nigrostriatal pathway, where dopaminergic neurons tha t 
originate in the substantia nigra send axons projecting to  the dorsal striatum  which 
includes the caudate nucleus and putamen (CPU). This region is involved in learning to 
automatically execute complex movement triggered by a voluntary command. The 
degeneration of dopaminergic neurons in this brain region causes the m otor 
disturbances tha t are found in Parkinson's disease. Both Di and D2 receptors are found 
in the striatum.
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The second dopamine pathway: neurons originating in the ventral tegmental area 
(VTA) send axons projecting to the limbic areas o f the brain (nucleus accumbens (NAs), 
ventral striatum and amygdala), known as the mesolimbic pathway, and to  the cortex 
(medial, prefrontal, cingulate and entorhinal cortex), known as the mesocortical 
pathway. These pathways are believed to be associated w ith schizophrenia. D1-D4 
receptors are localized in the limbic areas and associated w ith these pathways.
The final pathway is the tuberoinfundibular pathway, where neurons in the 
hypothalamus secrete dopamine into the hypophysial portal blood to have effects on 
dopamine receptors of the anterior p itu itary gland, where it acts as prolactin inh ib itory 
factor. This pathway plays an im portant role in the inhibitory regulation o f prolactin 
release mediated by the D2 receptor. An increased prolactin release is one of the side 
effects o f typical antipsychotic drugs, this can lead to  problems w ith reproductive 
dysfunction in both men and women.
The classical "dopamine hypothesis of schizophrenia" proposed that a hyperactivity of 
dopaminergic transmission leads to the symptoms of schizophrenia (Carlsson, 1988). It 
has been found tha t drugs tha t are effective at decreasing psychotic symptoms are 
dopamine receptor antagonists (Carlsson and Lindqvist, 1963) which block dopamine 
D2 receptors in the mesencephalic projections to the limbic striatum especially in the 
etiology o f positive symptoms (Creese et al., 1976; Seeman and Lee, 1975). 
Additionally, amphetamine, a dopamine agonist which increases synaptic monoamine 
levels, can induce psychotic symptoms (reviewed in Lieberman et al., 1987). In 1991, 
the dopamine hypothesis was reconceptualized to  subcortical hyperdopaminergia w ith 
prefrontal hypodopaminergia (Davis et al., 1991).
The dopaminergic hypothesis of schizophrenia is founded on the major fo llow ing facts: 
the therapeutic efficiency o f neuroleptics (dopaminergic antagonists); a positive 
correlation between plasma homovanillic acid (m etabolite o f dopamine) concentration 
and the severity o f schizophrenic illness; a higher density o f dopaminergic 02- 
receptors revealed by Positron Emission Tomography (PET), particularly in the 
striatum ; and an abnormal growth-horm one response to apomorphine (dopaminergic 
agonist) (Duncan et al., 1999; Lembreghts and Ansseau, 1993).
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1.1.4.2.2 Glutamate and Gamma (y)-Aminobutyric acid (GABA)
Besides the dysfunction in the dopamine system in the brain of schizophrenic patients, 
the dysfunction in glutamate and Gamma (y)-Aminobutyric acid (GABA) also plays an 
im portant role in the pathophysiology of schizophrenia.
Glutamate is a major excitatory neurotransm itter in the central nervous system (CNS) 
which acts through multip le excitatory receptors. It is synthesized in the nerve 
terminals from  two sources including glucose and glutamine. The N-methyl-D- 
aspartate (NMDA) receptor is one of glutamate receptors associated with 
schizophrenia. The NMDA receptor hypofunction hypothesis o f schizophrenia (Olney 
and Farber, 1995; Olney et al., 1999) was proposed from the observation tha t drugs 
such as phencyclidine (PCP) and ketamine, which are NMDA receptor antagonists, have 
effects tha t mimic schizophrenia-like psychotic symptoms including delusions, 
hallucinations, thought disorder and negative symptoms (Krystal et al., 1994). In 
addition, repeated subcutaneous injections o f NMDA channel blockers caused 
neurodegenerative changes in rat cortex which included posterior cingulate 
retrosplenial cortex, anterior cingulate, hippocampus, and amygdala. Changes in these 
regions coincide w ith the structural changes seen in schizophrenia (Olney and Farber, 
1995). The primary sites o f action fo r ketamine and PCP in inducing schizophrenia-like 
psychotic symptoms and neurotoxicity were NMDA receptors expressed on the 
GABAergic interneurons in the thalamus and basal forebrain (Olney and Farber, 1995).
Gamma (y)-aminobutyric acid (GABA) is the primary inhibitory neurotransm itter in the 
CNS. It is converted from  glutamic acid by the action o f glutamic acid decarboxylase 
(GAD). Many studies indicated that neurochemical abnormalities in the GABAergic 
system are implicated in the pathophysiology of schizophrenia. Dopamine production 
in dopaminergic cells is under the direct control of GABAergic neurons. An abnormally 
low concentration of GAD leads to  a low effective concentration of GABA, and results 
in promotion of dopamine production (Kaplan and Sadock, 1995). A decreased activity 
o f GAD has been reported in schizophrenics. This decreased activity has been found in 
the nucleus accumbens, putamen, amygdala and the hippocampus. In addition, a 
decrease in numbers and abnormalities in the distribution of GABAergic neurons in the 
cortex have been associated w ith schizophrenia. A decrease in GABAergic interneurons
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(parvalbumin staining cells) in the frontal cortex and hippocampal regions have been 
reported in schizophrenia (Nestler, 1997; Benes, 2000; Reynolds et al., 2004). This 
suggests tha t loss of neuroinhibitory control of GABA, in specific regions o f the brain, 
may be responsible for some symptoms of schizophrenia.
Dysregulation in GABAergic neurotransmission can cause cognitive im pairm ent in 
patients w ith schizophrenia. The findings from post-mortem brain studies suggest an 
association of schizophrenia w ith the impairm ent of GABA-mediated synaptic 
transmission (Gonzalez-Burgos et al., 2011). Alterations in cortical GABA 
neurotransmission and decreased mRNA expression of GAD67 in PFC have been 
reported in post-mortem studies (reviewed by Volh and Lewis, 2005). Injection of 
GABA receptor antagonists into monkey PFC impairs performance on working memory 
tasks (Sawaguchi et al., 1989). The role o f GABA in mediating synaptic transmission, 
which facilitates the flow  and processing of inform ation w ith in and between brain 
regions, may be essential fo r normal cognitive function (Fries, 2009). It has been 
suggested that selective GABA-A receptor agonists may be novel therapeutic strategies 
fo r treatm ent cognitive dysfunction in patients w ith schizophrenia (Stan and Lewis, 
2012).
1.1.4.2.3 Serotonin
Serotonin (5-hydroxytryptamine, 5-HT) is a monoamine neurotransm itter synthesized 
in serotonergic neurons in the CNS and enterochrom affin cells in the gastrointestinal 
tract. 5-HT is synthesized from  essential amino acid L-tryptophan. In the brain, the 
enzyme tryptophan hydroxylase catalyzes the hydroxylation reaction to  convert 
tryptophan to  5-hydroxytryptophan (5-HTP), which is immediately decarboxylated to 
yield 5-hydroxytryptam ine (5-HT) by enzyme amino acid decarboxylase. The principle 
route o f continued metabolism for 5-HT is deamination o f the side chain by 
monoamine oxidase (MAO) yielding a 5-hydroxyindole acid aldehyde, which can be 
fu rthe r oxidized to  5-hydroxyindole 3-acetic acid (5-HIAA), a primary m etabolite  o f 5- 
HT (Figure 1.1).
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Figure 1.1: 5-HT, biosynthesis and metabolism of 5-HT
The rate-lim iting step in 5-HT synthesis is the conversion of L-tryptophan to  5- 
hydroxytryptophan (5-HTP) which is catalysed by tryptophan hydroxylase. Then the 5- 
HTP is converted to 5-HT by decarboxylation catalysed by aromatic amino acid 
decarboxylase. 5-HT degradation is the side chain deamination by monoamine oxidase 
(MAO) producing 5-hydroxyindole-3-acetic acid (5-HIAA).
Source: From (Nichols and Nichols, 2008)
Synthesized 5-HT is packaged into vesicles. The action potential o f the axon causes 
membrane depolarization and calcium influx, and subsequently 5-HT is released into 
the synaptic cleft by membrane fusion of the vesicles. 5-HT diffuses across the cleft to 
activate receptors at post-synaptic neurons to in itia te intracellular signalling cascades. 
5-HT is removed from the synaptic cleft by the serotonin reuptake transporter (SERT)
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which pumps the free 5-HT back to the neuronal term inal where it is repackaged again 
into neurotransm itter vesicles. Free 5-HT in the cytoplasm is degraded by MAO in the 
m itochondrial membrane producing the biologically inert metabolite 5-hydroxyindole- 
3-acetic acid (5-HIAA) as illustrated in Figure 1.2.
Tryptophan i  
I I 5H T   5HTP l  |
Autoreceptor
(5HTia,'ib) 5HT 5HT
5HIAA
SERT
5H T
5HT
Postsynaptic receptor + 
heterotrim eric G-protein
(5HTi/n»®r; 5HT2a/b*c»5HT4; 
5H T5A/b; 5HT6 ; 5HT7 )
Figure 1.2: Serotonin synapse model
5-HT is packaged into the vesicles after synthesized. When calcium influx induced by 
membrane depolarization, vesicles fuse w ith the presynaptic membrane to  release 5- 
HT into synaptic cleft. 5-HT diffuses across the cleft to  activate post-synaptic receptors 
inducing signalling cascades w ith in the cells. Free 5-HT in the cleft is pumped back to 
presynaptic neuron by SERT to recycle. SERT, serotonin reuptake protein; 5-HTP, 5- 
hydroxytryptophan; MAO, monoamine oxidase; 5-HIAA, 5-hydroxyindole-3-acetic acid. 
Source: From (Nichols and Nichols, 2008)
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There are seven 5-HT receptor families, 5-HT1-7. The 5-HT receptor families are mostly 
seven putative transmembrane domains, G-protein coupled receptors, but one 
member, the 5-HT3 receptor, is a ligand-gated ion channel. Concentrating on the 
major human 5-HT receptors implicated in schizophrenia and its treatm ent, 5-HT1A is 
highly localized to the hippocampus, cortical regions (particularly cingulate and 
entorhinal cortex) and mesencephalic raphe nuclei. It has been found in both 
postsynaptically and somatodendritic sites of the 5-HT neuron. A high expression o f 5- 
HT2A receptors is found in many forebrain regions, but particularly cortical regions 
(neocortex, entorhinal and p iriform  cortex, claustrum), caudate nucleus, nucleus 
accumbens, olfactory tubercle and hippocampus. 5-HT2C binding sites are widely 
distributed and present in areas of cortex (olfactory nucleus, piriform , cingulate and 
retrosplenial), limbic system (nucleus accumbens, hippocampus, amygdala) and the 
basal ganglia (caudate nucleus, substantia nigra) (Barnes and Sharp, 1999).
A hyperserotonin hypothesis fo r schizophrenia was first proposed in 1954 when 
researchers found that a serotonin agonist, lysergic acid diethylamide (LSD), could 
induce hallucinations, a symptom associated w ith schizophrenia (Woolley and Shaw, 
1954). LSD competes fo r and occupies serotonin receptor sites w ith very high potency. 
Several post-mortem studies showed 5-HT dysfunction in cortical areas in patients w ith  
schizophrenia, fo r example, there is a decrease in 5-HT2A/C receptor density (Gurevich 
and Joyce, 1997) but an increase in 5-HT1A receptor density (Simpson et al., 1996) in 
schizophrenic patients compared to  controls.
1.1.5 Treatm ent of schizophrenia
Patients w ith schizophrenia are treated in psychosocial aspects. To relieve the 
symptoms and improve patients' quality o f life, they require close care and both 
physical and mental support from clinicians, psychiatrists, and the ir families. 
Schizophrenia is a complex disorder that must be treated over an extended period o f 
tim e. Most people suffering from the disorder have to deal w ith symptoms throughout 
the ir lives. Therefore, the clinicians and psychiatrists must be concerned about the 
treatm ent not only in the acute period, but also in the long run. In other words, the 
prevention of the future psychotic symptoms is essential care fo r schizophrenia 
patients. Furthermore, the patients and fam ily members should seek advice from  a
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psychiatrist to understand and accept the ir condition. The patients as well as the ir 
families w ill gain real advantages from this and can sometimes live happily in the ir own 
communities (Buckley et al., 2015; Okpokoro and Sampson, 2014).
1.2 Antipsychotic drug treatm ent in schizophrenia
1.2.1 Typical antipsychotic drugs
It is known that all typical antipsychotics are dopamine D2 receptor antagonists which 
remain the main pharmacological treatm ent o f schizophrenia. However, dopamine D2 
antagonists are generally effective in the relief o f positive symptoms which include 
hallucinations, delusions and thought disturbances, but do not fu lly  relieve negative 
symptoms. They also have risks o f side effects including extra pyramidal syndromes 
(EPS) including akathesia, dystonia, parkinsonism and tardive dyskinesia (TD) or tardive 
dystonia. Tardive dyskinesia affects up to 20-40% o f patients receiving chronic first- 
generation antipsychotic drugs.
An example of typical antipsychotic drugs is haloperidol which has a high a ffin ity  to 
dopamine D2 receptor and is associated w ith m otor side effects. It has been found tha t 
long term  treatm ent w ith antipsychotic drugs w ith high a ffin ity  fo r DRD2 like 
haloperidol induced DRD2 receptor upregulation in human (Silvestri et al., 2000) and 
rat striatal neurons (Bernard et al., 1991). In addition, it has been found tha t 5-HT2C 
receptor antagonism reduced m otor side effects induced by both acute and chronic 
haloperidol treatm ent suggesting tha t the 5-HT2C receptor is involved in m otor side 
effects induced by typical antipsychotic drug treatm ent and also tha t 5-HT2C receptor 
antagonism could be a potential target of new antipsychotic medications due to  the 
capability to  reduce this side effects (Creed-Carson et al., 2011).
1.2.2 Atypical antipsychotic drugs
Following the proposed role o f serotonin in schizophrenia, the newer or second 
generation, "atypical", antipsychotic drugs were firs t developed. Atypical antipsychotic 
drugs block both dopamine and serotonin receptors and can reduce problem atic side 
effect of the firs t generation drugs. This growing list o f drugs including: fo r example; 
clozapine, olanzapine, risperidone, quetiapine, ziprasidone, aripiprazole and
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amisulpride. Clozapine was the first atypical antipsychotic drug tha t was clinically 
introduced in 1970s. Atypical antipsychotic drugs can reduce EPS side effects of typical 
antipsychotic drugs but some of them can induce weight gain w ith varying degrees.
Dopamine receptors and 5-HT receptors are the targets of these atypical antipsychotic 
drugs.However, o ther neurotransm itter receptors are also affected including histamine 
H I, adrenergic, and muscarinic receptors. The drugs have d ifferent metabolic effects 
and also the ir affinities to  these receptors as shown in Table 1.2. The difference of 
potential to cause metabolic side effects and differential receptor affinities may 
contribute to  variability o f weight gain among patients w ith schizophrenia.
Recently, the NIMH-funded Clinical Antipsychotic Trials in Intervention Effectiveness 
(CATIE) project found that treatm ent of psychosis w ith  atypical antipsychotic drugs is 
not significantly more effective than w ith typical antipsychotic medications, although 
atypical antipsychotic drugs showed little  benefit fo r improving cognitive symptoms 
(Lieberman et al., 2005; Carpenter and Buchanan, 2008; Crossley et al., 2010). Atypical 
antipsychotic drugs may have advantages over typical antipsychotic drugs through 
the ir better safety profile that results in better adherence to treatm ent (Melnik et al., 
2010); the differences in side effects between atypical (e.g. weight gain) and typical 
(e.g. EPS) antipsychotic medications mean tha t atypical drugs are easier to  live w ith fo r 
patients w ith schizophrenia.
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Table 1.2: Antipsychotic drug affinities for receptors relative to dopamine D2 
receptor affinity
Dopamine D2 Ki Haloperidol Clozapine Olanzapine Risperidone Paliperidone Quetiapine Ziprasidone Aripriprazole Asenapine
(nM) 2.0 431 72 4.9 9.4 567 4.0 0.95 1.0
alA-adrenergic 0.17 270 0.66 0.98 3.8 25 0.22 0.038 1.1
[12] [1.6] [109] [5.0] [2.5] [22] [18] [25] [1.2]
a2A-adrenergic <10'2 3.0 0.24 0.032 2.0 0.16 0.025 0.012
[>1000] [142] [314] [151] [4.7] [3600] [160] [74] [1.3]
Histamine HI <10'2 220 15 0.96 1.7 76 0.031 0.032 1.3
[>1000] [2.0] [4.9] [5.2] [5.6] [7.5] [130] [28] [1.0]
Muscarinic M3 <10'2 17 1.4 <10 2 <10"2 0.29 <10'2 <10'2 <102
[>1000] [25] [51] [>104] [>104] [1943] [>1000] [>1000] [>1000]
5-HT1A <10'2 4.1(a) 0.036 0.011 0.015 1.3(a) 0.053(a) 0.17*(a) 0.52(a)
[>1000] [105] [2063] [427] [640] [430] [76] [5.6] [2.5]
5-HT1B 0.012 1.1 0.14 0.091 0.087 0.52 1.0(a) <10‘2 0.33
[165] [398] [509] [53.6] [109] [1109] [4.0] [830] [4.0]
5-HT2A 0.035 81 30 29 4.9 2.8 13 0.11* 18
[57] [5.35] [3.73] [0.17] [1.9] [200] [0.30] [8.7] [0.071]
5-HT2C <10'2 46 7.2 0.41 0.2 0.22 0.31 0.043* (a) 37
[>1000] [9.44] [10.2] [12] [48] [2500] [13] [22.4] [0.035]
5-HT6 <102 25 12 <10'2 <10'2 0.30 0.066 <102 5.2
[>1000] [17] [6.0] [>1000] [>1000] [1864] [61] [642] [0.25]
Values indicate drug affinity for the receptor expressed relative to dopamine D2 receptor 
affinity, calculated (D2 Ki-^receptor Ki) from Ki data provided in the PDSP Ki Database: 
http://pdsp.med.unc.edu/pdsp.php and, for asenapine, Shahid et ol.,(2009). Receptor Ki [nM] 
is included in square brackets below the relative affinity value.
Affinity values approaching unity and above (shown in bold type) indicate the likelihood of 
substantial receptor occupancy at normal clinical doses. These relative affinities generally 
reflect antagonist or inverse agonist effects; known agonist or partial agonist effects are 
indicated (a)
The partial agonist action of aripiprazole at D2 receptors permits high D2 receptor occupancy 
by drug without the emergence of dopaminergic side effects; therefore there may be 
significant binding to some lower affinity receptors (indicated with *) due to the high relative 
concentration of available drug.
Source: From (Reynolds and Kirk, 2010)
1.3 Antipsychotic drug-induced weight gain in patients with  
schizophrenia
Weight gain is a common side effect of many second-generation antipsychotic drugs 
and usually results from increased appetite tha t brings about the subsequent excessive 
food intake. Antipsychotic drugs have differed potential to  cause weight gain and 
metabolic phenotypes. As shown in Table 1.3, clozapine and olanzapine have the 
greatest risk for weight gain and ziprasidone and aripiprazole have the least risk.
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Table 1.3: Relative likelihood o f w eight gain and m etabolic disturbances o f 
antipsychotic drugs
Glucose Metabolic
Medication Weight Gain Metabolism Dyslipidemia Syndrome
Abnormalities
Aripiprazole Low Low Low Low
Clozapine High High High High
Haloperidol Low to mild Low to mild Low Low
Olanzapine High High High High
Perphenazine Low to mild Low to mild Low Low
Risperidone Mild to moderate Mild Mild Mild
Quetiapine Moderate Moderate High Moderate
Ziprasidone Low Low Low Low
Reference source: (Hasnain et al., 2009; Hasnain et al., 2010; Patel et al., 2009; Baker et 
al., 2009; Duncan et al., 2009; Lambert et al., 2006; Sikich et al., 2008)
The 5-HT receptor is a target of atypical antipsychotics. It has been suggested tha t 5- 
HT2 receptor antagonists can reduce EPS side effect problems induced by typical 
antipsychotics and the 5-HT2 receptor is a site at which antipsychotic drugs may 
relieve the negative symptoms of schizophrenia. Additionally, clinical and preclinical 
investigations indicate that several new atypical antipsychotic drugs improve cognition 
in schizophrenic patients and some of them display a ffin ity for several 5-HT receptors, 
including 5-HT1A, 5-HT4, 5-HT6 and 5-HT7 receptors in addition to  the 5-HT2A site 
(M illan, 2000; Meltzer and Sumiyoshi, 2003). Thus, the 5-HT system has been strongly 
suggested to  be involved in pharmacological treatm ent of schizophrenia. However, 
treatm ent w ith both typical and atypical antipsychotic drugs may be associated w ith 
weight gain.
Among the second generation antipsychotic drugs, clozapine was found to  be 
associated w ith the largest mean increase in body weight (4.45 kg over 10 weeks) 
studied by meta-analysis (Allison et al., 1999). The weight gain tended to  occur mainly 
in the first year o f treatm ent. Obesity and weight gain in adulthood have been 
associated w ith significant health complications including hypertension, type II 
diabetes, coronary heart disease, stroke, gallbladder disease, osteoarthritis, sleep 
apnea, respiratory problems and some types of cancers (Rubenstein, 2005; Pi-Sunyer, 
2009).
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It has been suggested that the serotonin system may be involved in regulating feeding 
behavior and weight gain. Both animal and human studies have shown that increasing 
serotonin causes decreased feeding and decreasing serotonin results in increased 
feeding (Comuzzie and Allison, 1998). Many studies have focused on the 5-HT2C 
receptors regarding the control of feeding and weight gain. The evidence supporting 
the role of the 5-HT2C receptor in feeding behavior was studied in 5-HT2C receptor 
knockout mice which found that the knockout mice tha t lack the 5-HT2C receptor were 
overweight compared to w ild-type mice (Tecott et al., 1995). The 5-HT2C receptor 
gene is located on the X chromosome at q24 (M ilatovich et al., 1992). It has a 
prom oter region which contains a polymorphism at position -759 in the 5' flanking 
region consisting of a C to T transversion. This 5' flanking region contains regulatory 
regions and a putative transcription factor binding region tha t may affect gene 
expression. This 5' flanking region contains many potential binding sites fo r various 
transcription factors including API, AP2, bHLH, GCF, HNF-5, LF-A1, NF-E1, NF-IL6, NF- 
kB, and TCF-1 (Xie et al., 1996). Among these transcription factor binding sites, the 
sites nearby the -759C/T and -697G/C SNPs are TCF-1, LF-A1, and bHLH, the SNPs may 
exert influence through the ir effect on the conformation of DNA tha t affects the 
a ffin ity for these transcription factors (Shastry, 2009). In humans, this 5-HT2C receptor 
polymorphism has been associated w ith the development o f obesity and type II 
diabetes in normal subjects; the researchers found that the variant T allele showed a 
higher frequency in the non-obese indicating a protective effect of this allele (Yuan et 
al., 2000). In one of the most consistently replicated pharmacogenetic findings, 
Reynolds et al has identified a common SNP (-759C/T) in the 5-HT2C receptor gene 
(HTR2C) that contributes substantially to  initial drug-induced weight gain (Reynolds et 
al., 2002; Templeman et al., 2005; M iller et al., 2005). Further studies have reported 
tha t this SNP has effects on prom oter activity (Hill and Reynolds, 2007, 2011); it seems 
likely tha t it is this effect on gene expression tha t mediates the association between 
HTR2C genotype and antipsychotic drug-induced weight gain.
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1.3.1 Normal body weight control
1.3.1.1 Regulation of food intake (Appetite)
Short-term regulation of appetite and satiety involves nutrient concentrations and 
hormonal signals to the CNS. During the inter-meal intervals, hunger develops in 
response to decreasing nutrients in blood circulation such as glucose, fa tty  acids, and 
amino acids and also increasing ghrelin hormone which is secreted from  the stomach 
during gastric emptying. A fter a meal, there are increasing nutrient concentrations and 
satiety hormones including 5-HT, cholecystokinin (CCK), PYY3-36, insulin, glucose-like 
peptides-1 (GLP-1) and decreasing hunger signals; these factors act on the CNS to 
inh ib it hunger and stimulate a feeling o f fullness (Wilding, 2010).
Long-term regulation of energy balance depends on the magnitude of energy stores 
and involves leptin which is secreted from  adipocytes. Leptin receptors and 
downstream signalling pathways are in the hypothalamus. When fa t mass is low and 
leptin decreases below a critical level, hunger signals are stimulated in hypothalamus 
such as neuropeptide Y (NPY) while pro-opiomelanocortin (POMC) is inhibited, 
resulting in stimulated food intake and inhibited thermogenesis (Wilding, 2010).
Energy balance is under the control o f the CNS, and the most im portant region is the 
hypothalamus. There are several hypothalamic nuclei involved in energy metabolism, 
including the arcuate nucleus (ARC), paraventricular nucleus (PVN), dorsomedial 
hypothalamus (DMH), ventromedial hypothalamus (VMH), and lateral hypothalamic 
area (LHA) (Hetherington and Ranson, 1940; Schwartz et al., 2000). Nucleus 
accumbens, amygdala, nucleus of the solitary tract and the area postrema are also 
involved in energy homeostasis (Schwartz et al., 2000). The firs t order neurons are 
located in ARC while the second order neurons are in other hypothalamic regions such 
as PVN, DMH, VMH, and LHA as illustrated in Figure 1.3 (Reynolds and Kirk, 2010). 
These hypothalamic nuclei receive signals from  both peripheral tissue hormones such 
as leptin, insulin, and ghrelin, and also signals from  extra-hypothalamic brain areas 
such as dopamine, serotonin, and noradrenaline.
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Figure 1.3: Relationship between neuropeptides, neurotransm itters and pathways in 
appetite  regulation in rat hypothalamus
Diagram illustrating the hypothalamic nuclei and the relationship between the 
appetite regulation neuropeptides, neurotransm itter, and pathways involved in 
appetite regulation. Orexigenic neuropeptides, neurotransm itters, and pathways are 
presented in green, anorexigenic are shown in red. □, leptin receptors; ARC, arcuate 
nucleus; AgRP, agouti-related peptide; BBB, blood brain barrier, CART, cocaine and 
amphetamine-related transcript; CCK, cholecystokinin; CRH, corticotrophin releasing 
hormone; DMH, dorsomedial nucleus; LHA, lateral hypothalamus; ME, median 
eminence; MCH, melanin-concentrating hormone; NPY, neuropeptide Y; POMC, 
proopiomelanocortin; PVN, paraventricular nucleus; TRH, thyrotrophin  releasing 
hormone; VMH, ventromedial hypothalamus.
Source: From (Reynolds and Kirk, 2010)
22
The neurons in the ARC play an im portant role in regulating energy balance between 
food intake and energy expenditure. There are two neuronal groups in the ARC: the 
neuropeptide Y (NPY)/agouti-related protein (AgRP) neuron (orexigenic effect) and the 
pro opiomelanocortin (POMC)/cocaine- and amphetamine-related transcript (CART) 
neurons (anorexigenic effect) as shown in Figure 1.4. They receive peripheral 
hormonal signals including satiety factors such as leptin, insulin, CCK, bombesin, 
enterostatin, and GLP-1, and peripheral orexigenic factors such as ghrelin and 
adiponectin. These peripheral hormones have a direct influence on the neuropeptides 
in the hypothalamus.
The neuropeptides in ARC are affected by these peripheral signals which have d ifferent 
pathways in regulating food intake and energy expenditure as shown in Figure 1.4; fo r 
example: leptin and insulin stimulate POMC/CART and inhibit NPY/AgRP neurons 
leading to  increased POMC/CART neuropeptides and decreased NPY/AgRP 
neuropeptides, and ultim ately inh ib it food intake (Bell et a!., 2005). Whereas, ghrelin 
secreted from the stomach during gastric emptying directly stimulates its receptors, 
growth hormone secretagog receptors (GHSRs) on NPY/AgRP neurons (M eier and 
Gressner, 2004) which results in increased food intake.
Neurons in ARC have interaction w ith each other such as GABA secreted from  
NPY/AgRP neurons inhibits POMC neurons (Cowley et a!., 2001). They project to 
second-order neurons including PVN and LHA. The NPY/AgRP neurons release NPY 
which bind to  NPY 1 receptor (Y1R) while POMC/CART neurons release a-melanocyte 
stimulating hormone (a-MSH) which bind to MC4R in PVN neurons. Second-order 
neurons project to the nucleus of the solitary tract (NTS) where satiety signals are 
processed.
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Figure 1.4: Hypothalamic contro l o f central energy balance
The ARC neurons, NPY/AgRP (orexigenic) and POMC/CART (anorexigenic), are
influenced by peripheral hormones including; PYY3-36 secreted from  colon inhibits 
NPY/AgRP via NPY Y2 receptor (Y2R); leptin from  adipocytes and insulin from  pancreas 
inh ib it NPY/AgRP but stimulate POMC/CART via leptin receptor (LEPR) and insulin
receptors, respectively; ghrelin from stomach stimulates NPY/AgRP via growth
hormone secretagog receptors (GHSRs). The NPY/AgRP neurons can inhib it
POMC/CART through GABA release. The downstream second-order neurons are 
influenced by the ARC neurons via NPY Y1 receptor (Y1R) and melanocortin receptor 
(MC4R) and also received modifying signals from  neurotransm itters such as dopamine, 
serotonin, and endocannabinoids. Source: From (Bell et a!., 2005)
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1.3.1.2 Regulation of metabolism
Body weight maintenance requires the balance between energy intake and energy 
expenditure and also balance between macronutrient intake and macronutrient 
oxidation. Individuals who have a tendency to gain weight seem to  have low energy 
expenditure, low spontaneous physical activity, low fat oxidation, or low sympathetic 
activity in addition to  excess energy intake (Galgani and Ravussin, 2008).
There are three components o f energy expenditure including the basal metabolic rate, 
the therm ic effect o f food (dietary thermogenesis), and the energy consumed during 
physical work, o f which the la tter part accounts fo r a variable amount o f tota l energy 
expenditure (Ravussin et a!., 1986). The basal metabolic rate is the energy required to 
maintain normal metabolism fo r example during sleep, normal breathing, and at rest. 
Although basal metabolic rate is not a large portion o f tota l energy expenditure, it may 
help determine the ability to resist weight gain in response to  overfeeding. The 
therm ic effect o f food is the energy used in food digestion and storage. The energy 
used for protein is the greatest, intermediate fo r carbohydrate, and very low fo r fats. 
This may partly explain why a high fa t intake is more likely to develop weight gain 
(Wilding, 2010).
Low energy expenditure due to  relative low resting metabolic rate and 24-hour energy 
expenditure is a risk factor fo r body weight gain (Ravussin et a t, 1988; Tataranni et at.,
2003). Spontaneous physical activity accounts fo r 8-15% of tota l daily energy 
expenditure (Ravussin et a i , 1986), and low spontaneous energy expenditure is related 
to  weight gain and fat mass gain (Zurlo et a!., 1992; Levine et a!., 1999).
Sympathetic activity is related to  energy expenditure in all components including 
resting metabolic rate (Spraul et a t, 1993), therm ic effect o f food (Schwartz et a t, 
1988), and spontaneous physical activity (Christin et a t, 1993). Spraul et a t (1993) 
found tha t individuals (Pima Indians) prone to  obesity have lower rates o f muscle 
sympathetic activity compared to weight-matched Caucasians.
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1.3.2 Weight gain in patients w ith schizophrenia
Weight gain in patients w ith schizophrenia and other mental disorders is one common 
physical health problem which can result in progression towards the development of 
metabolic syndrome, diabetes, dyslipidemia, hypertension, and cardiovascular disease. 
The prevalence of obesity and metabolic syndrome in schizophrenia patients 
(particularly women) is about two-fo ld comparing to general population (Dickerson et 
al., 2006; De Hert et a i, 2006). Weight gain in patients w ith schizophrenia receiving 
antipsychotic drugs is likely to be due to  an accumulation of fat mass, particularly 
abdominal fa t reflected by an increase in waist-hip ratio (Stedman and Welham, 1993). 
Using magnetic resonance imaging an increased subcutaneous and intra-abdominal fat 
deposition was found in first episode drug naive schizophrenia patients who had 
received antipsychotic drugs fo r 10 weeks (Zhang et a i, 2004).
There are many factors contributing to  weight gain in patients w ith schizophrenia. In 
addition to antipsychotic drug treatm ent, the disease conditions of schizophrenia and 
its consequences, the dietary, lifestyle, physical activity, and the psychological and 
motivational factors; these may partly contribute to weight gain. The weight gain 
among patients w ith schizophrenia receiving antipsychotic drug treatm ent has high 
variability which may be the result of the contribution of the genetic, environmental, 
behavioural, and neurochemical factors.
The genetic factors which contribute to differences in the inherent biological processes 
between individuals are likely to  contribute to the variability of weight gain. The initial 
body weight or body mass index (BMI) before treatm ent is associated w ith  greater 
weight gain follow ing treatm ent w ith antipsychotic drugs (Lambert et a i, 2005). The 
genetic variation may also determ ine the d ifferent degree o f antipsychotic drug- 
induced weight gain. Genetic polymorphisms of other candidate genes are also 
implicated in antipsychotic drug-induced weight gain (Balt et a i, 2011) and are 
described in the next section (see section 1.4).
Other environmental, life style, and behavioural factors tha t influence energy balance 
are also likely to  contribute to  the variability o f weight gain. For example, the negative 
symptoms such as apathy and social w ithdrawal can lead to  reduced propensity to
26
exercise, or because of weight gain, patients feel resistant to exercise socially. The side 
effect of antipsychotic drugs such as sedation may cause decreased physical activity.
Exposure to antipsychotic drugs, particularly second-generation drugs, are likely to 
cause weight gain (Newcomer, 2005). Although clozapine and olanzapine are the 
greatest risk factors fo r weight gain, other drugs also have influence on weight gain in 
various degrees, these may be due to  each drug exerting its action to a d ifferent 
degree on d ifferent neurotransm itter systems including serotonergic, dopaminergic, 
adrenergic, histaminergic and others (Reynolds and Kirk, 2010; Panariello et al., 2011) 
as shown in Table 1.2 (see section 1.2.2).
1.3.3 Mechanisms of atypical antipsychotic drug-induced weight gain
The mechanisms underlying antipsychotic drug-induced weight gain are not 
completely understood. Weight gain results from  excess energy intake over energy 
expenditure and antipsychotic drugs can affect these parameters in many ways; fo r 
example: by increasing appetite or decreasing satiety, affecting food preferences, 
changing blood circulating hormones, changing metabolic rate, inducing sedation. 
Therefore, antipsychotic drugs can induce weight gain through an influence on many 
interacting systems as shown in Figure 1.5.
Behaviour
Control of food intake 
(hypothalamic and 
mesolimbic)
Figure 1.5: Overview of mechanisms involved in antipsychotic drug-induced weight 
gain.
The mechanisms may involve many levels including behavioural, neural, and endocrine 
systems where antipsychotic drugs can directly or indirectly act at all these sites. 
Source: Adapted from  (Goudie et al., 2005)
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The mechanisms underlying antipsychotic drug-induced weight gain that have been 
investigated in most detail to  date are drug effects on receptors because many 
receptors tha t are the targets of antipsychotic drugs are involved in food intake and 
body weight regulation.
1.3.3.1 Disruption of hypothalamic control of energy balance
The disruption of hypothalamic control of energy homeostasis may be a mechanism of 
antipsychotic drug-induced weight gain. The role of the circulating hormone from 
adipose tissue, leptin, which acts at its receptor in the hypothalamus in the regulation 
o f food intake and energy expenditure, provides clues as to  the mechanism. Several 
studies have reported an increase in plasma leptin in patients receiving antipsychotic 
drugs both fo r 10 weeks treatm ent in first episode drug nave patients (Zhang et a i,
2004) and 1 year treatm ent (Perez-lglesias et al., 2008). Increased leptin levels are also 
related to  antipsychotic drugs induced weight gain; the magnitude of increased plasma 
leptin is positively correlated w ith the magnitude of increase in BMI 
(Venkatasubramanian et al., 2010). This is a normal response when body weight 
increases which increases fat deposition and results in increased leptin secretion from  
adipocytes. But the increased plasma leptin levels fail to  suppress food intake in 
patients receiving antipsychotic drugs. Therefore, it has been suggested tha t there may 
be disruptions o f leptin signaling in the hypothalamus by the antipsychotic drugs 
(Reynolds and Kirk, 2010). However, the mechanisms by which plasma leptin levels 
increase in patients receiving antipsychotic drugs still unclear. It could be a normal 
response w ith body weight gain which increases fa t deposition results in increased 
leptin secretion from adipocytes; however, a study reported tha t atypical antipsychotic 
treatm ent increased leptin secretion in human adipocytes in vitro  (Sarvari et al., 2014). 
Therefore, peripheral drug effect on adipocyte secreting leptin cannot be excluded.
In addition, the genetic polymorphism o f leptin gene [LEP), -2548A/G is associated w ith  
antipsychotic drug-induced weight gain. The G allele o f the SNP is associated w ith  
greater weight increase follow ing antipsychotic drug treatm ent in firs t episode 
schizophrenia patients (Templeman et al., 2005). The LEP -2548A/G also has a reported 
interaction w ith the HTR2C -759C/T polymorphism on BMI and waist circumference in 
chronic schizophrenia patients (Yevtushenko et al., 2008). Presence o f the LEP -2548G
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allele in patients w ith the HTR2C -759C allele is associated with higher BMI and waist 
circumference (Yevtushenko et al., 2008) and obesity (Gregoor et al., 2010).
Several neurotransm itter systems are involved in food intake and body weight 
regulation and many receptors in these neurotransm itter systems are the targets of 
the antipsychotic drugs. These neurotransm itter systems include serotonin, histamine, 
noradrenaline and dopamine.
1.3.3.1.1 Serotonin receptors
It is well known tha t the 5-HT plays an im portant role in regulating food intake. 
Considering the second-generation o f antipsychotic drugs have differences in 5-HT 
receptor a ffin ity compared to first-generation antipsychotic drugs, 5-HT receptors 
therefore have been of interest to search fo r molecular mechanisms of antipsychotic 
drug-induced weight gain. 5-HT is a potent satiety signal illustrated by 5-HT 
adm inistration decreasing food intake in rodents (Blundell and Leshem, 1975). The 5- 
HT1A and 5-HT2C receptors are related to  food intake regulation. 5-HT1A agonists 
increase food intake (Dourish et al., 1985) while 5-HT2C agonists decrease food intake 
(Clifton et al., 2000).
5-HT1A receptor agonists increase food intake in animals (Voigt et al., 2002). Clozapine 
which causes weight gain is a 5-HT1A partial agonist and has high a ffin ity  fo r the 
receptor, whereas olanzapine which also cause weight gain has low a ffin ity  fo r this 
receptor (Richelson and Souder, 2000). Moreover, ziprasidone and aripiprazole which 
do not cause weight gain are 5-HT1A partial agonists (Reynolds and Kirk, 2010).
5-HT2C antagonists can increase food intake and weight gain in rats (Bonhaus et al., 
1997) and also attenuate the decreased food intake which is induced by 5-HT2C 
agonists (Clifton et al., 2000; Hayashi et al., 2005). Another study in mice, knockout of 
the 5-HT2C receptor results in increased feeding and obesity (Tecott et al., 1995). 
Antipsychotic drugs such as clozapine and olanzapine which are related to  the greatest 
weight gain have high affinities fo r the 5-HT2C receptors.
It has been suggested tha t 5-HT regulates NPY in mice (Redrobe et al., 2005). The 5-HT 
1B/2C receptor agonist meta-Chlorophenylpiperazine (mCPP) results in the rat in
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decreased food intake and NPY levels in the PVN indicating that the NPY may mediate 
the effect o f 5-HT on food intake (Dryden et al., 1996). The PVN is an im portant region 
involving food intake and body weight regulation and it is rich in the 5-HT2C receptor 
(Abramowski et a i, 1995; Clemett et a i, 2000). In addition, 5-HT2C also has an 
interaction w ith leptin; 5-HT2C antagonists attenuate the decreased food intake which 
is induced by leptin in rats (Hay-Schmidt et a i,  2001). Antipsychotic drug treatm ent 
can affect NPY neuron expression; chronic treatm ent w ith clozapine results in an 
increase in NPY-immunoreactive cell density in rat arcuate nucleus (Kirk et al., 2006), 
indicating tha t antagonism of the 5-HT2C receptors may, in part, result in disinhibition 
o f the NPY neurons and also indicates the role of NPY in clozapine-induced weight 
gain.
The role o f the 5-HT2C receptor in antipsychotic drug-induced weight gain is also 
demonstrated by pharmacogenetic studies. For example, Yuan et a i  (2000) have 
identified several haplotypes of genetic polymorphisms (-995G/A, -759C/T and - 
697G/C) in the prom oter region of the 5-HT2C receptor gene which are associated w ith 
obesity and diabetes in which the frequency of -995/-759/ and -697/ variants (A-T-C) 
was higher in non-obese subjects and non-diabetic subjects. The association o f the 
HTR2C -759C/T w ith antipsychotic drug-induced weight gain is mentioned previously in 
section 1.3. In addition, the T allele o f the HTR2C is associated w ith higher leptin levels 
(Templeman et a i, 2005).
1.3.3.1.2 Histamine receptors
Histamine is involved in food intake regulation. Antihistamine drugs enhance food 
intake and increase appetite (Orthen-Gambill, 1988). Histamine H I (H I) receptors may 
be involved in antipsychotic drug-induced weight gain through influence on food 
intake regulation and lower physical acitivity (enery expenditure) because H I 
antagonism also cause sedation (Richelson and Souder, 2000). Many antipsychotic 
drugs have high histamine H I receptor affinities which are closely correlated w ith 
antipsychotic drug-induced weight gain such as tha t w ith clozapine and olanzapine. 
The H I receptor a ffin ity is suggested to be the most reliable predictor o f weight gain 
(Wirshing et a i, 1999). Consistent studies in animals show tha t H I receptor 
antagonism increases feeding in rodents and H I knockout mice are prone to  weight
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gain (Masaki et al., 2001; Masaki et al., 2004). In these H I knockout mice exhibit 
partially attenuated leptin-induced feeding suppression (Masaki et al., 2001; Masaki et 
al., 2004). These findings indicate the involvement of histamine neurons and the H I 
receptors regulating food intake in affecting downstream signaling o f leptin in the 
brain.
Olanzapine treatm ent, but not aripiprazole or haloperidol treatm ent, reduces H I 
receptor mRNA expression in the ARC and downstream regions (Han et al., 2008). In 
addition, olanzapine treatm ent increases histamine neurotransmission which may be 
related to the change in receptor expression (Davoodi et al., 2008). Furthermore, 
olanzapine, clozapine, and quetiapine, but not risperidone, enhance H l-receptor- 
mediated 5' adenosine monophosphate-activated protein kinase (AMPK) in the 
hypothalamus (Kim et al., 2007). Risperidone and quetiapine have relative similar 
effects on weight gain but exhibit d ifferent effect on AMPK in the hypothalamus 
suggesting tha t there are other receptors such as 5-HT2C receptors in conjunction w ith 
dopamine D2 receptor tha t may also contribute to  weight gain in d iffe rent degrees 
w ith d ifferent drugs.
1.3.3.1.3 Adrenergic receptors
The adrenergic system plays a role in food intake regulation. Acute injections of 
noradrenaline (norepinephrine) into rat PVN cause hyperphagia and chronic injections 
result in body weight gain (Leibowitz et al., 1984). Two subtypes of alpha-adrenergic 
receptors (a l-  and a2-adrenoceptors) w ith in  the hypothalamic PVN exert opposing 
effects on food intake regulation. Injection o f the a l-adrenocepto r agonists, 
phenylpropanolamine (PPA), cirazoline, methoxamine, or 1-phenylephrine into the rat 
PVN decrease food intake (Wellman and Davies, 1992), and systemic injections of the 
a l-adrenerg ic antagonist prazosin (PRAZ) can effectively reverse the anorexia induced 
by systemic injections of PPA as well as cirazoline (Wellman and Davies, 1992). 
Adm inistration of the a2-adrenoceptor agonist, clonidine, stimulates food intake when 
injection either into PVN (Goldman et al., 1985) or periphery (McCabe et al., 1984). 
Antagonist actions at a l-adrenoceptors o f antipsychotic drugs could account fo r 
weight gain (Richelson and Souder, 2000; Reynolds and Kirk, 2010). In addition, the
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genetic polymorphism of the a2A-adrenoceptors may also be involved in antipsychotic 
drug-induced weight gain (Park et al., 2006).
Beta-adrenoceptors ((3-adrenoceptors) also play a role in body weight regulation. 
Knockout mice for all (3-adrenoceptors ((31/(32/(33) develop a progressive obesity in 
adulthood (Bachman et al., 2002) indicating the role o f these receptors in resistance to 
obesity. In addition, implication o f (3-adrenoceptors in weight gain is suggested by 
pharmacogenetic studies. Meta-analysis of human studies found tha t the genetic 
polymorphism of (33-adrenoceptor (Trp64Arg) is associated w ith obesity (Fujisawa et 
al., 1998; Hoffstedt et al., 1999; Thomas et al., 2000); w ith  the presence of the arginine 
allele exhibiting higher BMI and predicting weight gain. One study in schizophrenia 
patients found a trend (p=0.1) between the Trp64Arg polymorphism and clozapine- 
induced weight gain (Basile et al., 2001). However, others studies fail to  observe the 
association (Allison and Heo, 1998). The central (3-adrenoceptors are not the sites of 
antipsychotic drugs. And the two drugs w ith the highest liability fo r weight gain, 
clozapine and olanzapine do not have significant a ffin ity fo r (3-adrenoceptors.
1.3.3.1.4 Dopamine receptors
Dopamine plays an im portant role in determ ining food intake through action in many 
areas of the brain including hypothalamus. The effects of dopamine can vary 
depending on brain areas and its concentrations. Dopamine release in nucleus 
accumbens is associated w ith the reinforcement effect in feeding (Hajnal et al., 1997). 
In the hypothalamus, dopamine release in hypothalamic VMN and LHA affects the 
feeding pattern by influencing duration o f meal consumption (the size o f a meal) and 
the frequency of meals (Meguid et al., 2000). Amphetamine-induced anorexia is 
completely reversed by receiving the selective dopamine D1 receptor antagonist, but it 
is not affected by treatm ent w ith the selective D2 receptor antagonist (G ilbert and 
Cooper, 1985). However, intrahypothalam ic injections o f sulpiride, a specific D2 
receptor blocker, can attenuate amphetamine-induced anorexia in food-deprived rats 
and increase feeding and water drinking in satiated rats (Parada et al., 1988). In 
addition, D2 receptor antagonists illustrate the ir influence on feeding behaviour 
(Clifton et al., 1991). These studies suggest a role o f dopamine and its receptors in 
feeding regulation. Measurement by using PET and [C -ll]rac lop ride  (a radioligand fo r
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the dopamine D2 receptor), brain dopamine D2 receptor availability found to  be lower 
in obese individuals compared to controls; this decreased availability of dopamine D2 
receptor in obese subjects is correlated w ith increased BMI (Wang et al., 2001). Thus, 
it has been suggested that obese individuals have a dopamine deficiency which cause 
an increase in food intake leading to obesity. Treatment w ith antipsychotic drugs may 
decrease dopamine and induced food intake. However, atypical antipsychotic drugs 
which are associated w ith higher incidence o f weight gain have lower D2 receptor 
occupancy at effective doses compared to typical antipsychotic drugs (Kapur et al., 
2000; Pilowsky 2001).
1.4 Genetic variants associated with antipsychotic drug-induced 
weight gain in patients with schizophrenia
In addition to  the HTR2C -759C/T polymorphism tha t has influence on antipsychotic 
drug-induced weight gain as mentioned above (section 1.3), there are many other 
genetic polymorphisms that have been proposed or reported to  be associated w ith 
antipsychotic drug-induced weight gain which are shown in Table 1.4.
Table 1.4: Candidate genes associated w ith  antipsychotic drug-induced w e ight gain
Gene Name Location Function(s)* SNP related 
AIWG
Reference
ADIPOQ Adiponectin 3q27 fat metabolism, 
insulin sensitivity, 
direct anti-diabetic, 
anti-atherogenic and 
anti-inflammatory 
activities
rsl501299 (Wu et al., 
2011)
ADRA2A Adrenoceptor 
alpha 2A
10q25.2 modulation of 
neurotransmission, 
smooth muscle 
contraction, and 
thermoregulation
rsl800544 (Park et al., 
2006; Wang 
et al., 2005b; 
Sickert et al., 
2009)
ADRB3 Adrenoceptor 
beta 3
8pl2 lipolysis and 
thermogenesis
rs4994 (Ujike et al., 
2008)
BDNF Brain-derived
neurotrophic
factor
llp l4 .1 survival and 
differentiation of 
neurons, synaptic 
transmission and 
neuroplasticity
rs6265 (Zhang et al., 
200;, Zai et 
al., 2012; Tsai 
et al., 2011)
CCKBR Cholecystokinin 
B receptor
l lp l5 .4 anxiety, nociception, 
neuroleptic activity, 
gastric acid 
release, gastric
rs2929183 (Tiwari et al., 
2010b)
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Gene Name Location Function(s)* SNP related 
AIWG
Reference
mucosal cell growth 
and histamine release
CNR1 Cannabinoid 
receptor 1
6ql4-
q l5
is involved in the 
cannabinoid-induced 
CNS effects (including 
alterations in mood 
and cognition)
rs806378 (Tiwari et a i, 
2010a)
DRD2 Dopamine D2 
receptor
llq23.2 modulation of 
locomotion, reward, 
reinforcement and 
memory and learning
rs6277,
rsl079598,
rsl800497,
rs4436578,
rsl799732
(Muller et al., 
2012; Hong et 
al., 2010; 
Lencz et al., 
2010)
FTO Fat mass and 
obesity- 
associated 
protein
16ql2.2 Dioxygenase (repairs 
alkylated DNA and 
RNA by oxidative 
demethylation), 
regulation of 
energy homeostasis, 
body size and body 
fat accumulation
rs9939609,
rs9922047
(Reynolds et 
al., 2013; 
Song et al., 
2014; Tiwari 
et al., 2011)
GHRL Ghrelin 3p26-
p25
stimulation of hunger, 
appetite, gastric acid 
secretion and 
gastrointestinal 
motility, and adiposity
rs27647 (Yang et al., 
2012)
GNB3 Guanine 
nucleotide 
binding protein 
(G protein), 
beta
polypeptide 3
12pl3 modulator or 
transducer in various 
transmembrane 
signaling systems
rs5443 (Ujike et al., 
2008; Wang 
et al., 2005a)
HTR2A Serotonin 2A 
receptor
13ql4-
q2 i
appetite control, 
regulation of neural 
activity, perception, 
cognition, mood, 
behavior, sleep, and 
thermoregulation,
rs6311
rs6313
(Mou et al., 
2005; Ujike et 
al., 2008)
LEP Leptin 7q31.3 regulation of energy 
homeostasis, obesity, 
reproduction, glucose 
homeostasis, bone 
formation, wound 
healing and 
immune system
rs7799039,
rs4731426
(Templeman 
et al., 2005; 
Wu et al., 
2011; Kuo et 
al., 2011; 
Srivastava et 
al., 2008)
LEPR Leptin receptor lp31 receptor for 
mediating leptin 
effects
rsll37101 (Gregoor et 
al., 2009; 
Gregoor et 
al., 2011)
MC4R Melanocortin 4 
receptor
18q22 energy homeostasis, 
somatic growth,
rs489693,
rsl7782313,
(Malhotra et 
al., 2012;
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Gene Name Location Function(s)* SNP related 
AIWG
Reference
pigmentation, 
inflammation, 
immunomodulation, 
steroidogenesis, and 
temperature control
rs8087522,
rs2229616
Czerwensky 
et al., 2013a, 
2013b,
Chowdhury et 
al., 2013; Kuo 
eta!., 2011)
MTHFR Methylene­
tetrahydrofolate
reductase
lp36.3 key enzyme in folate 
metabolism, 
important in 
epigenetic 
modification
rsl801131,
rsl801133
(Ellingrod et 
at., 2008; van 
Winkel et al., 
2010a, 
2010b)
NPY Neuropeptide
Y
7pl5.3 control of feeding, 
circadian rhytm, 
pituitary hormone 
release, anxiolysis
rsl6147,
rs5573,
rs5574
(Tiwari et al., 
2013)
PPARG Peroxisome
proliferator-
activated
receptor
gamma
3p25 regulation of
adipocyte
differentiation
rsl801282 (Herken et al., 
2009)
SNAP-
25
Synaptosomal- 
associated 
protein, 25kDa
20pl2-
p ll.2
regulation of
neurotransmission
release
rsl051312,
rs3746544,
rs8636
(Musil et al., 
2008)
AIWG, antipsychotic drug-induced weight gain; *data from database 
(www.genecards.org)
From Table 1.4, some of the genetic polymorphisms which are strong candidate 
polymorphisms associated w ith antipsychotic drug-induced weight gain include those 
in: MTHFR which is a strong candidate gene associated w ith epigenetic modification 
and metabolic syndrome; HTR2A and ADRA2A, which are antipsychotic drug target 
receptors and involved in appetite control; FTO, MC4R, and BDNF which are the strong 
candidate genes associated w ith BMI in GWAS; GNB3 which is involved in mediating 
the serotonergic effect. These strong candidate polymorphisms associated w ith 
antipsychotic drug-induced weight gain on which this work has focused w ill be 
described in the follow ing section.
1.4.1 MTHFR
Recently, genetic variants of the m ethylenetetrahydrofolate reductase (MTFIFR) gene 
have been proposed as potential predictors for antipsychotic induced metabolic side 
effects (Kuzman and Muller, 2012). MTHFR exerts an im portant role in fo late  and 
homocysteine metabolism by catalysing the reduction o f 5,10-
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m ethylenetetrehydrofolate to 5-m ethylenetetrahydrofolate (5-MTHF), which is used in 
methionine synthesis from homocysteine. The methionine is fu rther converted to  S- 
adenosylmethionine (SAM), which is a major methyl donor in a wide variety of 
enzymatic processes including the methylation of DNA (Fox and Stover, 2008). MTHFR 
deficiency can increase serum homocysteine while the decrease in 5-MTHF and SAM 
causes deficits in DNA methylation, DNA synthesis and repair, and may predispose to 
neurodevelopmental and oncogenic processes resulting in the development o f many 
disorders including cardiovascular disease, renal failure, cancer and congenital 
abnormalities (Ueland et al., 2001).
High plasma homocysteine is a risk factor fo r metabolic syndrome (Yakub et al., 2014), 
although the link between homocysteine and metabolic syndrome is not well 
established. Elevated homocysteine also is an independent risk factor fo r 
cardiovascular diseases such as coronary heart disease and stroke (Selhub 2008; Wang 
et al., 2007a). Homocysteine has been shown to  be a throm bogenic and atherogenic 
substrate that may be lead to atherosclerotic phenomena and adverse cardiometabolic 
events (Guilland et al., 2003). Hyperhomocysteinemia also has been linked to 
hypertension (Yakub et al., 2014; Lim and Cassano, 2002; Wang et al., 2014) via 
homocysteine-induced arterio lar vasoconstriction (Vermeulen et al., 2001; M ujum dar 
et al., 2002), vascular endothelia injury (Harker et al., 1983), and decreased vasodilator 
responsiveness (Cheng et al., 2011). On the other hand, homocysteine has been linked 
to lower high-density lipoproteins (HDL) (Yakub et al., 2014; Baszczuk et al., 2014). 
Global DNA hypomethylation in vascular smooth muscle cells has been suggested as a 
mechanism linking homocysteine to atherosclerosis (Obeid and Herrmann, 2009) as 
well as lipid accumulation in tissues (Yideng et al., 2007).
The functional polymorphisms of MTHFR located w ith in  the coding region include
677C/T (rsl801133) and 1298A/C (rsl801131). The T allele o f the 677C/T SNP causes
an amino acid substitution from  an alanine to  a valine at codon position 222 (exon 4)
(Frosst et al., 1995). The C allele o f the 1298A/C results in a change from  a glutamine
to alanine at codon position 429 (exon 7) and is found in the regulatory region o f the
MTHFR enzyme (van der Put et al., 1998). The variant alleles o f these SNPs (T allele o f
677C/T and C allele of the 1298A/C) are associated w ith reduction in MTHFR enzyme
activity (Le Marchand et al., 2002). Therefore, the SNPs located in coding regions tha t
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alter amino acids may affect protein funtion throught alteration of conformation or 
stability of protein especially at the catalytic binding site. In addition to  a change in the 
encoded amino acids (nonsynonymous), SNPs can be silent (synonymous) or occur in 
the noncoding regions. They may influence prom oter activity (and so gene expression), 
messenger RNA (mRNA) conformation (stability), and subcellular localization of mRNAs 
and/or proteins and hence may produce disease (Shastry, 2009), fo r example the T 
allele o f the MTHFR 677C/T is significantly associated w ith schizophrenia (Lochman et 
al., 2013).
The association of MTHFR polymorphisms w ith metabolic syndrome has been reported 
in the general population. Obesity has been associated w ith MTHFR 1298A/C (Terruzzi 
et al., 2007) and 677C/T genotypes (Lewis et al., 2006). Carriage of the 677T allele is 
associated w ith insulin resistance (Chen et al., 2010; Lunegova et al., 2011). 
Association of the 677T allele w ith central obesity, hypertriglyceridemia and low levels 
o f HDL cholesterol was also reported in the la tter study (Lunegova et al., 2011). A 
replicated study reported tha t the 677T allele but not the 1298A/C polymorphism of 
MTHFR was associated w ith a greater risk o f developing metabolic syndrome and the 
TT genotype was associated w ith risk o f insulin resistance w ith  greater central 
adiposity induced by antipsychotic treatm ent (Ellingrod et al., 2008, 2012). Others 
have reported the association o f metabolic syndrome in schizophrenia w ith the 
1298A/C polymorphism in 518 Caucasian patients (van Winkel et al., 2010a). These 
authors also reported tha t the 1298C variant was associated w ith an increased weight 
and impaired glucose tolerance in 104 Caucasian patients who had received 
antipsychotic treatm ent fo r 3 months (van Winkel et al., 2010b).
1.4.2 ADRA2A
Genetic variants of the adrenergic a-2a receptor (ADRA2A) gene have been proposed 
as a predictor fo r antipsychotic drug-induced weight gain. ADRA2A receptor has a 
critical role in regulating hypothalamic-pituitary-adrenal (HPA) axis and in regulating 
neurotransm itter release from  sympathetic and adrenergic nerves in the brain (Delitala 
et al., 1994; Langer, 1997; Hein et al., 1999). This receptor plays an im portant role in 
lipolysis, thermogenesis and also regulation of food intake (Park et al., 2006; Arner,
1992). Activation at alpha-2 adrenergic receptors decreases heat production and
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lipolysis rate (Arner, 1992). In addition, direct injection of a selective alpha-2 
adrenergic receptor agonist into the PVN of rats resulted in increased food intake 
(Wellman et al., 1993). Obesity-prone rats showed lack of ability to alter brain alpha-2 
adrenergic receptors in regulating glucose levels (Levin and Planas, 1993). In addition, 
a direct overexpression of ADRA2A in pancreatic beta cells of transgenic mice may 
alter the regulation of insulin secretion and glucose metabolism (Devedjian et al., 
2000 ).
The -1291C/G polymorphism is located in the prom oter region or regulatory region of 
the ADRA2A gene and could therefore affect the gene expression and so a lter receptor 
density. Previous findings found tha t the -1291C/G polymorphism was significantly 
associated w ith receptor binding and density (Deupree et al., 2006). The C allele o f this 
SNP is significantly associated w ith a protective effect for schizophrenia risk (Lochman 
et al., 2013). The G allele shows a better response to  methamphetamine treatm ent 
(Cheon et al., 2009; Polanczyk et al., 2007). This SNP has been reported to be 
associated w ith body fat accumulation (Garenc et al., 2002) and sympathetic-HPA 
system in the hypothalamus (Rosmond et al., 2002a).
The ADRA2A -1291C/G polymorphism has been associated with olanzapine-/clozapine- 
induced weight gain in Asian schizophrenia patients (Park et al., 2006; Wang et al., 
2005b); G allele carriers showed more weight gain. However, European samples have 
shown the opposite; the G allele was reported to  be protective against weight gain 
follow ing antipsychotic treatm ent (Sickert et al., 2009); some studies did not observe 
an association of the SNP w ith weight gain or metabolic syndrome in schizophrenia 
patients (De Luca et al., 2011; Risselada et al., 2010).
1.4.3 HTR2A
The 5-HT2A receptor is an im portant site of action of atypical antipsychotic agents 
(Kane, 1994). Several post-mortem studies have shown a decrease in 5-HT2A receptor 
density in the fronta l cortex o f schizophrenic patients (M ita et al., 1986; Laruelle et al.,
1993). In addition, association between the HTR2A 102T/C polymorphism and 
schizophrenia has been reported (Arranz et al., 1995; Williams et al., 1996).
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The 5-HT2A receptor is also involved in food intake and cortisol secretion (Currie and 
Coscina, 1998; Rittenhouse et al., 1994). There is evidence illustrating the role of 
cortisol in abdominal obesity (Bjorntorp and Rosmond, 2000). It has long been 
recognized that the serotonin is involved in regulating cortisol secretion or HPA axis 
function (Dinan, 1996), and it has been suggested tha t cortisol secretion is regulated 
by central 5-HT2A (Rittenhouse et al., 1994). Furthermore, adm inistration of 5-HT2A 
receptor agonists decreased the NPY stimulated food intake in rats (Currie and 
Coscina, 1998).
The HTR2A -1438G/A polymorphism is located in the prom oter region and is 
associated w ith prom oter activity; the presence of an A allele has greater prom oter 
activity relative to  the G allele (Parsons et al., 2004), although an earlier study failed to 
find the difference between the G and A alleles in luciferase reporter gene expression 
(Spurlock et al., 1998). Therefore, the effect o f genetic polymorphism on 
transcriptional activity o f the HTR2A gene to bring about a difference in receptor 
expression is still unknown.
In the general population, the HTR2A -1438 GG genotype is associated w ith  greater 
BMI, waist-to-hip ratio, and abdominal sagittal diameter along w ith less suppression of 
cortisol suggesting the involvement o f the HPA-axis and serotonergic system in the 
pathology of abdominal obesity (Rosmond et al., 2002b). In addition, the HTR2A - 
1438A allele is associated w ith lower energy intake and alcohol consumption in a 
French sample of overweight subjects (Aubert et al., 2000); however, the association 
was not significant after correction fo r the number o f comparisons. Some studies 
found tha t the HTR2A -1438G/A was not related to  BMI or obesity (Aubert et al., 2000; 
Hinney et al., 1997). The HTR2A -1438G/A was associated w ith clinical response to  
clozapine in which homozygosity fo r the G allele was more frequent among non­
responders than in responders (Arranz et al., 1998). Ujike et al. (2008) reported the 
association between multip le genetic polymorphisms of the 102T allele o f HTR2A 
rs6313, the 825T allele o f G-protein beta3 subunit (GNB3), the 23Cys allele of HTR2C 
w ith olanzapine-induced weight gain in schizophrenia patients in Japan). O ther studies 
reported the association between the 102T allele and risperidone-induced weight gain 
in Chinese patients, and the association between TT genotype and weight gain in
Caucasians w ith multip le antipsychotic drug treatm ents (review by (Balt et al., 2011).
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Another study found no significant association of the HTR2A -1438G/A polymorphism 
w ith antipsychotic drug-induced weight gain in Chinese Han patients w ith 
schizophrenia (Mou et a i, 2005). The HTR2A -1438G/A is in complete linkage 
disequilibrium (LD) w ith the HTR2A 102C/T polymorphism (A w ith T) (McMahon et al., 
2006).
1.4.4 MC4R
The melanocortin-4-receptor (MC4R) is a key in regulating food intake, body weight, 
and glucose homeostasis (Cone, 2006). MC4R is a G protein-coupled receptor activated 
by cx-Melanocyte-stimulating hormone (a-MSH) and blocked by agouti-related protein 
(AgRP) (Hinney et a i,  2013; Tao 2010). MC4R is not only associated w ith regulation of 
energy balance by decreasing food intake and increasing energy expenditure (Fan et 
a i,  1997), it has also been associated w ith nutrient absorption, lipid metabolism, 
adiposity, thermogenesis, insulin secretion, and appetite (Adan et a i,  2006; Malhotra 
et al., 2012). In addition, the melanocortin pathway has interactions w ith  other 
pathways or hormones such as leptin, 5-HT (Zhou et al., 2007), NPY, AgRP, POMC 
(Biebermann et al., 2012), and autonomic nervous system (Rossi et al., 2011; Sohn et 
al., 2013), glucagon-like peptides (Guan et al., 2012; Ma et al., 2007), cholecystokinin 
(Fan et al., 2004), and vagal afferent fibers (Gautron et al., 2010).
The MC4R is a very strong candidate gene influencing antipsychotic drug-induced 
weight gain. The rsl7782313, a common genetic variant is located 188 kb downstream 
from  MC4R gene has no known functional relevance but it has been recently identified 
as a gene for obesity susceptibility in a genome-wide association study (GWAS) of 
249,796 individuals (Speliotes et a i, 2010) in which the C allele has been associated 
w ith higher BMI, food intake, body fa t mass, weight, and risk o f obesity (Loos et a i,  
2008; Stutzmann et a i,  2009; Xi et a i, 2012; Loos 2011). The mechanistic link may be 
due to the risk allele o f this polymorphism influencing reward mechanisms, particularly 
in females because a recently study reported tha t female homozygous risk allele 
carriers showed significant increase in grey m atter volume in the right amygdala, 
which is a region known to  influence eating behaviour, and in the right hippocampus 
(Horstmann et a i,  2013). In addition, the obesity effect o f the risk allele may be due 
cerebral insulin resistance (Tschritter et a i,  2011). It has been hypothesized tha t the
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polymorphism may down-regulate the MC4R function or MC4R expression but fu rther 
study is required to address this question.
There have been two studies investigating the association of the rsl7782313 C/T and 
antipsychotic drug-induced weight gain; the firs t study found the significant 
association between the C allele and weight gain after a 4-week second generation 
antipsychotic drug treatm ent in Caucasian patients (Czerwensky et al., 2013a). 
However another study did not observe any association between rsl7782313 and 
antipsychotic drug-induced weight gain after a 14-week treatm ent in European- 
ancestry patients (Chowdhury et al., 2013). Therefore, further studies are needed to 
confirm  the association of this polymorphism w ith antipsychotic drug-induced weight 
gain.
Another SNP, the rs489693 A/C polymorphism located approximately 190 kb 
downstream from  the MC4R gene has no known functional relevance but it has been 
identified in GWAS to be associated w ith second generation antipsychotic drug- 
induced weight gain in 4 cohorts (Malhotra et al., 2012) in which the AA genotype was 
associated w ith greater weight gain. This finding has been replicated in another study 
o f Caucasian schizophrenia patients (Czerwensky et al., 2013b).
1.4.5 GNB3
The G-protein beta3 subunit (GNB3) protein plays im portant roles in intracellular signal 
transduction and adipogenesis (Allison et al., 1999; Comuzzie and Allison, 1998; 
Malbon, 1997). The GNB3 825C/T polymorphism is located on exon 10 o f the GNB3 
gene; the T allele was found to  be associated w ith the alternative splicing w ith  a 
deletion of 41 amino acids, this splicing variant is active (enhances G-protein 
activation) and increases cellular responses, and thus increased In vitro  cell 
proliferation and increased intracellular signal transduction (Siffert et al., 1998). The 
polymorphism has been associated w ith many pathophysiological conditions, fo r 
example: the T allele is associated w ith an increased risk fo r hypertension (Siffert et al., 
1998), BMI and obesity (Siffert et al., 1999), type II diabetes (Kiani et al., 2005), and 
depression (Klenke et al., 2011). The influences of GNB3 825C/T polymorphism on 
lipolysis has been also reported tha t the T allele results in decreased GNB3 production
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in fa t cells and thus inh ib it lipolysis via p i- ,  p2~, and p2a-adrenergic receptor signalling 
(Ryden et a i, 2002).
The TT genotype of the GNB3 825C/T polymorphism has been associated with 
antipsychotic drug-induced weight gain in Japanese schizophrenia patients who are 
receiving olanzapine fo r 8-24 weeks (Ujike et al., 2008) and also in Chinese 
schizophrenia patients who are receiving clozapine fo r 13 months (Wang et al., 2005a). 
However, several studies and meta-analyses failed to observe a significant association 
(Tsai et al., 2004; Park et al., 2009; Bishop et al., 2006; Souza et al., 2008). These 
controversies suggest tha t more studies are needed to  elucidate this association. 
Interestingly, the C allele o f the GNB3 825C/T polymorphism which exhibits lower 
signal transduction has been associated w ith clinical improvement w ith antipsychotic 
treatm ent in schizophrenia patients (M uller et al., 2005; Kohlrausch et a i, 2008). This 
finding suggesting tha t the genetic susceptibility fo r decreased signal transduction may 
enhance antipsychotic efficacy as well as antipsychotic adverse effects.
1.4.6 BDNF
Brain-derived neurotrophic factor (BDNF) plays critical roles in the nervous system 
including neuronal cell growth and maintenance, d ifferentiation, activity-dependent 
plasticity and survival o f neurons in the central nervous system (Noble et al., 2011). 
BDNF influences many neurotransm itters such as noradrenergic, dopaminergic, 
serotonergic, glutamatergic, and cholinergic neurotransm itters (Gratacos et a i,  2007; 
Russo-Neustadt, 2003; Tapia-Arancibia et a i,  2004). Therefore, BDNF is implicated in 
many mental disorders and disturbed behaviors (Russo-Neustadt, 2003). Serum BDNF 
was found to  be decreased in schizophrenia patients (Zakharyan and Boyajyan, 2014). 
In addition, the antipsychotic drugs may also affect the synthesis of BDNF in the brain; 
chronic olanzapine or risperidone treatm ent resulted in decrease BDNF in rat brains 
(Angelucci et a i,  2000; Angelucci et a i,  2005).
It is reported tha t BDNF is im portant in food intake and body weight regulation
(Lebrun et a i,  2006). Studies in animals and humans indicated tha t hypothalamic BDNF
and its receptor, tropomyosin-related kinase B (TrkB) appear to inh ibit food intake and
increase energy expenditure, being therefore related to body weight gain and obesity
(Unger et a i, 2007; Toriya et a i, 2010; Zhang et a i, 2007). On the other hand, brain
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infusion of BDNF in rats resulted in appetite suppression, weight loss, and increases in 
5-HT (Pelleymounter et al., 1995). BDNF is highly expressed in the VMN hypothalamus 
(Unger et al., 2007) which is involved in regulation of energy balance. Nicholson et al. 
(2007) demonstrated tha t activation of MC4R causes an increase in BDNF release from  
hypothalamus in both in vitro  and in vivo experiments, indicating that BDNF is an 
im portant downstream mediator of MC4R signaling in regulation of food intake. The 
effect of BDNF in MC4R signaling is dependent on TrkB activation (Tsao e ta l., 2008).
The BDNF rs6265 G/A polymorphism is a missense change (G196A) in the coding exon 
of the BDNF gene at position 66 which results in a non-conservative amino acid change 
from  valine to  methionine and it appears to disrupt cellular processing, protein 
trafficking, and activity-dependent BDNF secretion (Egan et al., 2003; Chen et al.,
2004). This SNP was also associated w ith the dendritic targeting disruption o f BDNF 
mRNA (Chiaruttini et al., 2009). The Met allele (or A allele) has been associated w ith 
decreased BDNF in schizophrenia patients (Zakharyan and Boyajyan, 2014), while the 
Val/Val genotype was associated w ith the improvement in clinical symptom response 
to  olanzapine (Nikolac Perkovic et al., 2014) and clozapine (Zai et al., 2012; Zhang et 
al., 2013b). However, other studies have found no association of the polymorphism 
w ith treatm ent response to  risperidone (Xu et al., 2010), clozapine (Hong et al., 2003), 
chlorpromazine (Xu et al., 2008), or typical antipsychotic drugs (Anttila et al., 2005). 
The genetic polymorphism of BDNF rs6265 M e t/M e t (or AA) genotype has been 
reported to be associated w ith  antipsychotic drug-induced weight gain, especially in a 
male subgroup in Chinese chronic schizophrenia (Zhang et al., 2008). Furthermore, a 
haplotype of BDNF rs6265 and BDNF rsl519480 (G-A haplotype) was associated w ith 
atypical antipsychotic drug-induced weight gain in European ancestry chronic 
schizophrenia (Zai et al., 2012). However, one study did not find the association 
between the BDNF rs6265 G/A polymorphism and antipsychotic drug-induced weight 
gain in Chinese chronic schizophrenia treated w ith atypical antipsychotic drugs 
including clozapine, olanzapine, or risperidone but the BDNF rs ll03 0 10 1  TT genotype 
and the rsll030101-T-alle le-re lated haplotype (rs ll030101 , rs6265, and rsl2291186) 
was also associated w ith weight gain (Tsai et al., 2011).
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1.4.7 FTO
The fat mass and obesity-associated gene (FTO) gene was the first obesity-related gene 
discovered by large-scale GWAS in 2007 and it was strongly associated w ith BMI and 
obesity (Frayling et a i,  2007) which was replicated in d ifferent populations (Fawcett 
and Barroso, 2010). Epidemiological and functional studies suggest tha t FTO confers an 
increased risk fo r obesity through change in food intake and preference (Loos and Yeo, 
2014). FTO is highly expressed in the hypothalamus which regulates energy balance 
(W ilier et a i,  2009). The expression of FTO has been associated w ith food intake. 
Studies in mice reported that complete or partial inactivation o f the Fto gene 
protected from  obesity (Church et a i,  2009; Fischer et a i, 2009) whereas the 
overexpression o f Fto increased food intake and obesity (Church et a i,  2010). The 
expression of FTO is nutritionally regulated; deprivation o f the essential amino acids 
caused down-regulation of FTO mRNA and protein in mouse and human cell lines 
suggesting a role o f FTO in sensing of essential amino acid availability (Cheung et a i, 
2013). The FTO protein is involved in the hypothalamic leptin signaling pathway (Wang 
et a i, 2011). These findings suggested that the expression of FTO and leptin signaling 
pathway may influence the regulation o f food intake.
Another biological function of FTO is a nucleic acid demethylase. Several in vitro  
studies have shown that FTO is a single-stranded DNA and RNA demethylase and is 
involved in nucleic acid repair or modification processes (Jia et a i,  2008; Gerken et a i,  
2007; Han et al., 2010), and this role of FTO may influence the expression of certain 
genes through epigenetic modification.
The FTO rs9939609 polymorphism is located in intron-1 o f the FTO gene (Cheung and 
Yeo, 2011), and the association of the m inor A allele o f the polymorphism w ith 
increased BMI has been well documented (Frayling et al., 2007; Qi et al., 2014). The 
FTO rs9939609 polymorphism has been associated gene expression; the A allele o f FTO 
rs9939609 was associated w ith increased levels o f the FTO transcripts studied in skin 
fibroblasts and peripheral blood (Berulava and Horsthemke, 2010). The FTO rs9939609 
m inor A allele was also associated w ith increases in tota l, fat, and prote in dietary 
intake (Timpson et a i, 2008; Speakman et a i,  2008), and increased hunger and 
decreased satiety (Wardle et a i,  2008; den Hoed et a i,  2009). In addition, the
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participants w ith the A allele o f the FTO rs9939609 polymorphism were more likely to 
prefer a meat-based diet compared w ith the TT participants who preferred a plant- 
based diet (Yang et al., 2014).
There have been several studies that demonstrated the association of polymorphisms 
of FTO w ith DNA methylation of FTO gene itself. Bell et al. studied the genotype- 
epigenetic interaction and identified haplotype-specific methylation in the FTO LD 
block (46kb) T2DM/obesity-susceptibility locus. They found increased DNA methylation 
on an FTO obesity susceptibility haplotype tagged by the rs8050136 risk allele A. The 
FTO obesity susceptibility haplotype contained rsl421085 (C allele), rsl7817449 (G 
allele), rs8050136 (A allele) which was a tagged risk allele, rs3751812 (T allele), 
rs9939609 (A allele), rs7202116 (G allele), and rs9930506 (G allele) which were in 
complete linkage disequilibrium (LD) (Bell et al., 2010). Toperoff et al. (2012) reported 
a significant hypomethylation of a CpG site in the firs t intron of the FTO gene o f type 2 
diabetes mellitus (T2DM) subjects relative to controls and this effect was independent 
o f the polymorphism; the CpG methylation site is located near rs ll2 1 9 8 0  which is a 
T2DM/obesity-associated polymorphic site. These studies demonstrate the association 
of FTO DNA methylation and associated diseases as well as the association between 
the FTO polymorphisms and FTO DNA methylation tha t might provide an epigenetic 
marker o f diseases.
Not only FTO polymorphisms had an effect on DNA methylation in FTO gene itself, it 
also had an effect on DNA methylation on other genes; the first evidence was provided 
by Almen et al. (2012) using genome-wide analysis to determine the association o f the 
FTO rs9939609 w ith epigenetic changes in Greek preadolescent girls and they reported 
a significant d ifferential methylation level in many genes between carriers o f the FTO 
rs9939609 TT and AA (risk allele), and also found a significant d ifferential m ethylation 
level in many genes between obesity and normal-weight female controls.
Not only DNA methylation, but also RNA methylation is influenced by FTO. An in vitro  
study showed tha t recombinant human FTO protein exhibited slightly higher efficiency 
in oxidative demethylation of 3-methyluracil (3-meU) in single-stranded RNA (ssRNA) 
than 3-methylthym ine (3-meT) in single-stranded DNA (ssDNA) which suggesting tha t 
the methylated RNAs are the preferred substrates fo r FTO (Jia et al., 2008). Analysis of
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global N(6)-methyladenosine (m(6)A) modification o f RNA in the midbrain and striatum 
of Ffo-deficit mice found that there was an increase in adenosine methylation in a 
subset of RNAs im portant fo r neuronal signaling, including dopamine transmission 
(Hess et al., 2013). Study in mice showed the Fto gene was a transcriptional coactivator 
tha t enhanced the binding of the CCAAT/enhancer binding proteins (C/EBPs) to 
unmethylated and methylated DNA, this results in promotion of the transcriptional 
functions of C/EBP family, suggesting a role o f Fto in epigenetic regulation of 
adipogenesis (Wu et al., 2010).
Association between the FTO rs9939609 polymorphism and antipsychotic drug- 
induced weight gain has been published. A study in first episode Chinese Han 
schizophrenia patients (n=250) demonstrated that the body weight and BMI o f the TT 
genotype carriers were significantly lower than those of the A allele patients both at 
baseline and after risperidone treatm ent fo r 6 months (Song et a i, 2014). In another 
study o f first episode schizophrenia patients in Spain (n=239) found a significant 
association of the AA genotype of the FTO rs9939609 polymorphism w ith the higher 
baseline BMI compared to  AT/TT group but there was no significant difference of 
weight increase between tw o groups of genotype after 1 year antipsychotic treatm ent 
(Perez-lglesias et a i, 2010). Reynolds et al. (2013) demonstrated tha t the A allele of 
the FTO rs9939609 polymorphism has been associated w ith BMI in chronic 
schizophrenia patients but not w ith weight gain in first-episode schizophrenia patients, 
although the AA genotype had higher baseline weight and baseline BMI than T allele 
carriers. However, other studies in chronic schizophrenia failed to  observe the 
association between the polymorphism and BMI or antipsychotic drug-induced weight 
gain (Watanabe et al., 2012; Shing et al., 2014).
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1.5 Epigenetic factors associated with antipsychotic drug- 
induced weight gain
1.5.1 Epigenetic mechanisms
Normally, a cell contains the complete hereditary inform ation in the form  of DNA. The 
complete DNA sequences in a cell are known as the genome. The basic building blocks 
of DNA are nucleotides tha t contain bases Adenine (A), Thymine (T), Cytosine (C), and 
Guanine (G). The DNA chain wraps around histones form ing a structure known as 
nucleosome. M ultip le nucleosomes form  chromatin. The chemical m odification on 
DNA and histones that does not alter the DNA sequences which control gene 
expression, is known as epigenetics; in other words, epigenetics is the study of changes 
in gene function that does not involve changes in DNA sequence. The epigenetic field is 
growing rapidly; but the definition o f epigenetic terms is still evolving. Mann (2014) 
has summarized current definitions of epigenetics as shown in Table 1.5.
Table 1.5: Some current defin itions o f epigenetics
The study of changes in gene expression, which occur in organisms w ith d ifferentiated 
cells, and the m itotic inheritance of given patterns of gene expression' (Holliday,
1994).
The study of m itotically and/or meiotically heritable changes in gene function that 
cannot be explained by changes in DNA sequence' (Riggs et al., 1996).
'...the structural adaptation o f chromosomal regions so as to  register, signal or 
perpetuate altered activity states' (Bird, 2007).
'An epigenetic tra it is a stably heritable phenotype resulting from  changes in a 
chromosome w ithout alterations in the DNA sequence' (Berger et al., 2009).
'...the inheritance of variation (-genetics) above and beyond (epi-) changes in the DNA 
sequence' (Bonasio et al., 2010).
Source: From (Mann, 2014)
The main mechanisms of epigenetics include DNA methylation, histone protein 
modifications, and the non-coding RNA strands. DNA methylation and histone protein 
modifications can regulate gene expression through inducing the change in chromatin 
structure while the activity o f non-coding RNA strands can regulate gene expression at
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the transcriptional and post-transcriptional levels; it plays role in chromatin 
remodeling, histone modification, DNA methylation targeting, and gene silencing. Non­
coding RNA molecules are functional RNA that are transcribed from  DNA but are not 
translated into proteins. They have a wide range of functions, including control of 
chromosome dynamics, splicing, RNA editing, translational inhibition and mRNA 
destruction (M attick and Makunin, 2006).
1.5.1.1 DNA methylation
DNA methylation refers to  the covalent addition of a methyl group to  position 5 of the 
cytosine pyrim idine ring (C) o f a cytosine-guanine dinucleotide (CpG) on DNA, giving 
rise to 5-methylcytosine (5mC). In mammalian cells, approximately 3% to 5% of the 
cytosine residues in genomic DNA are present as methylated cytosine (5mC) (Ehrlich et 
at., 1982), and 70% to 80% o f 5mC residues are found in the CpG islands (Bird, 1986). 
CpG islands are often located at the promoters or regulatory regions o f the house­
keeping genes and can be also observed in the tissue-specific genes (Antequera, 2003). 
Unmethylated CpG islands are associated w ith the housekeeping genes, whereas the 
CpG islands of many tissue-specific genes are found to be methylated, except in the 
tissue where they are expressed. CpG islands are also located in coding region of the 
genes or the downstream of the transcription start site such as human APOE gene 
(Larsen et o i, 1992). Methylation o f CpG islands downstream of transcription in itia tion 
site does not block the transcriptional in itiation or elongation in mammalian cells 
(Jones, 1999).
In mammals, DNA methylation is involved in many biological processes including the 
genomic imprinting, X-chromosome inactivation, regulation o f gene expression, and 
silencing o f transposable elements (Li and Zhang, 2014). The correct pattern o f DNA 
methylation is necessary fo r normal mammalian development (Li et o i, 1993, 2002). 
Aberrant DNA methylation due to  failure to maintain correct methylation patterns can 
lead to  several diseases including neurodevelopmental defects, neurodegenerative, 
neurological diseases, autoimmune diseases, and cancers (Lv et a i,  2012).
DNA methylation is known to  be associated w ith silencing of genes; however, there are
an increasing number of genes found to  be activated by DNA m ethylation such as
mouse insulin-like growth factor 2 (Igf2 ) in which DNA methylation blocks the binding
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of repressor proteins to  a silencer element in the gene (M urrell et al., 2001; Eden et 
al., 2001).
DNA methylation regulates gene expression through several mechanisms including: (1) 
methylation of cytosine residues can directly prevent the binding o f transcription 
regulatory factors to  the ir target sites on DNA sequences. In this way, DNA methylation 
affects gene transcription by changing transcription factor binding a ffin ity to  a gene 
promoter. (2) DNA methylation can affect gene expression through many methyl-CpG- 
binding proteins (MECPs) which read the DNA methylation pattern. There are 6 MECPs 
tha t have been identified in mammals including MECP2, MBD1, MBD2, MBD3, MBD4 
and Kaiso (Li, 2002). Methyl-CpG-binding protein contains a methyl-CpG-binding 
domain (MBD) and a transcription repression domain (TRD). The MECPs can bind to 
methylated DNA and insulates the binding o f the transcription factor to  DNA. For 
example, MECP2 forms the complex w ith histone deacetylase (HDACs) and a co­
repressor protein, Sin3a, to repress transcription in methylation-dependent manner 
(Nan et a i,  1998; Jones et al., 1998). The MECP2-Sin3a-HDAC provides the firs t 
molecular evidence linking DNA methylation to histone deacetylation in transcription 
repression. Another example, MBD2 can form  a complex w ith the m ultisubunit NuRD 
complex, which contains an ATP-dependent chromatin-rem odelling protein, Mi-2, and 
HDACs (Zhang et al., 1999; Wade et al., 1999). The MBD2-NuRD complex previously 
known as MeCPl can repress methylated promoters and also remodel methylated 
chromatin (Feng and Zhang, 2001). This evidence provides a mechanistic link between 
DNA methylation and histone deacetylation in transcriptional repression. (3) DNA 
methylation can alter chromatin structure in which methylated DNA leads to  more 
compact DNA by the action of chromatin remodeling enzymes, thereby affect 
accessibility o f transcription factors and/or DNA binding proteins to  heterochrom atin. 
The model of the mechanism of DNA methylation on gene transcription is illustrated in 
Figure 1.6.
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Figure 1.6: Mechanism models o f the effect o f DNA m ethylation on gene expression. 
Transcription can be initiated in unmethylated DNA sequences (A); DNA methylation 
can affect gene transcription in several ways including; (B) methylated CpG 
dinucleotide interfere binding o f transcription factors tha t are sensitive to methylated 
DNA to DNA resulting in in itiation of transcription cannot occur; (C) Methyl-CpG- 
binding proteins can bind to methylated DNA and insulates transcription factor binding 
to  DNA; (D) methylated DNA can be made more compact to  heterochrom atin by 
chromatin remodeling enzymes tha t affect accessibility of the transcription factors. TF, 
transcription factor; RNA Pol, RNA polymerase; MeCP2, methyl CpG binding protein 2; 
Sin3a, SIN3 transcription regulator fam ily member A; HDAC, histone deacetylases. 
M odified from : (Zhang and Pradhan, 2014)
DNA methylation involves the enzymatic methylation of CpG sites. DNA m ethylation 
takes place after DNA replication and is catalysed by DNA methyltransferase (DNMTs) 
using S-adenosyl methionine as the methyl donor. A number o f DNA methyltransferase 
enzymes (DNMT1, DNMT2, DNMT3a and DNMT3b) have been identified by 
biochemical and sequence analysis. The maintenance DNMT1 uses hem i-methylated 
DNA as a preferential tem plate, so it plays an im portant role in maintaining the 
identical methylation pattern after DNA replication tha t is characteristic fo r each type 
of differentiated cell (Turker and Bestor, 1997). DNMT3a and DNMT3b catalyse de
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novo methylation because they can methylate both hemi-methylated and 
unmethylated DNA templates w ith equal efficiency (Xie et al., 1999). Therefore, they 
are critical fo r the establishment of DNA methylation during development (Okano et 
al., 1999). Importantly, the activity of DNMTs and DNA CpG methylation in a variety of 
tissues, including CNS, are sensitive to the social environment, ischemia, 
environmental toxins, nicotine, alcohol, psychostimulants, and antipsychotic drugs 
(reviewed by Akbarian, 2010).
DNA methylation is lim ited by the availability o f the methylation substrate, S-adenosyl 
methionine, the synthesis o f which is under the control o f MTHFR as mentioned 
previously in section 1.4.1. MTHFR is thus im portant in DNA methylation (Lucock, 
2000) in which its functional genetic variants can influence the extent of such 
methylation (de Arruda et al., 2013). The T allele o f the common MTHFR 677C/T 
genotype results in reduced enzyme activity, and elevated plasma homocysteine under 
conditions of impaired folate status (Ueland et al., 2001). This and other 
polymorphisms of MTHFR are reported as genetic risk factors fo r several disorders and 
drug-induced side effects including weight gain and metabolic pathology in subjects 
receiving antipsychotic drugs (van Winkel et al., 2010a; Ellingrod et al., 2008). 
Conceivably this could indicate tha t MTHFR polymorphisms might interact w ith  SNPs in 
other genes (e.g. the -759C/T HTR2C SNP) in determ ining the extent o f drug-induced 
weight gain.
1.5.1.2 Histone modifications
Histone modifications refer to  the addition and removal o f the covalent moieties to 
the specific amino acid residues of the histone protein. Histones are the main protein 
component o f chromatin. The core histones which are H2A, H2B, H3, and H4 form  the 
nucleosome. Histone modifications are covalent post-translational modifications. 
These modifications which include acetylation, methylation, and phosphorylation 
influence the degree to which the DNA associates w ith the histones. Histone 
modifications result in chromatin structure remodeling tha t can affect gene expression 
regulation. Chromatin condensation to  heterochromatin impedes gene expression, 
while unwinding to  euchromatin encourages transcription. Generally, histone 
acetylation and phosphorylation promote gene transcription whereas histone
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methylation has been associated w ith both repressed and activated gene transcription 
(reviewed by Jiang et al., 2008; Meaney and Ferguson-Smith, 2010). The effect of each 
histone modification can be highly residue-specific. The effect o f histone methylation 
on gene expression depends on the exact amino acid residue methylated and also the 
number o f methyl groups being added (reviewed by Rahn et al., 2013).
Each type of histone modification which includes addition and removal o f chemical 
groups is catalysed by specific enzymes. For instance, the addition of acetyl groups to 
histones in histone acetylation is catalysed by histone acetyltransferases (HATs) 
whereas the removal o f acetyl groups (histone deacetylation) is catalysed by histone 
deacetylases (HDACs).
1.5.1.3 Non-coding RNAs
Non-coding RNAs (ncRNAs) or non-protein coding RNAs are transcribed, but not 
translated into proteins. They are transcribed in tissue-specific and cell-specific 
patterns to regulate cell d ifferentiation and development. Non-coding RNAs act as the 
regulators of gene expression and epigenetics. They are subdivided into 4 subclasses 
based on length, characteristics and function including microRNAs (miRNAs), piwi- 
interacting RNAs (piRNAs), small interfering RNAs (siRNAs), and long-non-coding RNAs 
(IncRNAs) (Kaikkonen et al., 2011). For example, 20-24 nucleotide-long miRNAs have 
been postulated to control the activity o f approximately 50% o f all protein-coding 
genes in a cell at the post-transcriptional level (Krol et al., 2010). A recent report 
suggests that miRNAs can destabilize the target mRNA to reduce protein expression 
(Guo et al., 2010).
PiRNAs are small ncRNAs of 24-31 nucleotides tha t have the primary role in 
suppression of transposon activity during germ line development (Brennecke et al., 
2007; Gunawardane et al., 2007) and in somatic cells (Malone et al., 2009). However, 
the regulation of the transposon activity in mammals during spermatogenesis also 
occurs through de novo DNA methylation and this process is regulated by piRNAs 
(Kuramochi-Miyagawa eta l., 2008).
SiRNAs (20-24 nucleotides) mediate post-transcriptional silencing similar to  miRNA 
silencing. SiRNAs have also been found to  direct gene silencing at sequence-specific
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transcriptional level by increasing epigenetic modifications characteristic of 
heterochromatin (Carthew and Sontheimer, 2009; Grewal, 2010). SiRNAs also play a 
role in regulating genome functions and it has been suggested tha t siRNAs may play a 
similar role as piRNAs in suppressing transposon activity (Watanabe et al., 2006; Yang 
and Kazazian, 2006).
LncRNAs are the majority o f the non-protein-coding transcripts. LncRNAs, which are 
arbitrarily considered as >200 nucleotides in length are transcribed from  various 
regions of eukaryotic genomes and can be classified according to  the ir proxim ity to 
protein coding genes including sense, antisense, bidirectional, intronic, and intergenic 
(Ponting et al., 2009). These IcnRNAs are im portant regulators fo r epigenetic 
modification, transcription, and translation and they play crucial roles in cell 
d ifferentiation, development and disease progression processes (Nie et al., 2012). A 
large number o f IncRNAs recruit chromatin modifying enzymes tha t facilitate 
chromatin modification and u ltim ately changing gene expression (Schmitz et al., 2010). 
The IncRNAs also play roles in X chromosome inactivation. One of tw o copies o f the X 
chromosome of the female mammalian genome needs to  be transcriptionally silent to 
have proper levels of gene expression. The process o f X chromosome inactivation is 
mediated by the X chromosome inactivation centre which consists o f four ncRNAs 
genes (Xist, Tsix, Jpx, and Ftx). The IncRNA Xist RNA is loaded onto X chromosome by 
YY1 protein which is a bivalent protein capable of binding both RNA and DNA (Jeon and 
Lee, 2011). Xist RNA induces chromosome-wide silencing by spreading along the X 
chromosome and recruiting polycomb repressive complexes (PRC) which mediates 
DNA methylation, histone hypoacetylation, and MacroH2A deposition throughout the 
entire targeted X chromosome resulting in transcriptional inactivation o f e ither the 
paternal or maternal copy of the X chromosome (Pinter et al., 2012).
1.5.2 The role of epigenetic modifications
It is now well known that epigenetics plays an essential role in normal development 
and disease susceptibility in adults (Dolinoy et al., 2007). Epigenetic alterations 
contribute to a number o f age related disorders including cancer and autoim m une 
disorders (Lu et al., 2006) as well as many nervous system diseases including
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neurodevelopmental disorders, brain cancer, neurodegenerative diseases, and mental 
illness that includes schizophrenia (Zhang et al., 2013d).
DNA methylation regulates gene expression and also helps stabilize chromatin. DNA 
hypomethylation can lead to  genomic instability by predisposing to  strand breakage 
and derepression of repetitive sequences (Lu et al., 2006). In addition, DNA 
hypomethylation of CpG in prom oter regions can result in gene activation which brings 
about aberrant gene expression (Attwood et al., 2002).
The effect o f DNA hypomethylation on genomic instability is the chromosomal 
translocations in DNMT (DNMT1 and/or DNMT3b) deficiency studied in DNMT- 
deficient HCT116 cells (Karpf and Matsui, 2005). In addition, DNA methylation plays an 
im portant role in regulating activity o f the transposable elements (TEs) which are 
mobile DNA sequences representing a substantial fraction of most genomes. Insertions 
of the transposable elements w ith in genome are the source of genetic variation and 
may be the cause of genetic dysfunction and influence gene expression tha t u ltim ately 
result in cancer and other human diseases. The TE repeats can induce chromosome 
rearrangement; in addition, the TE insertions can alter gene expression through many 
modifications fo r example by creating new polyadenylation sites or new exons 
(exonization), by exon skipping or splicing, and also by the alteration o f regulatory 
sequences (Chenais, 2015). DNA methylation is known to inh ib it transpositional 
activity o f diverse transposons. For example, silent transposable elements are 
methylated in plants (Martienssen, 1998) and also in animals (Yoder et al., 1997), and 
they can be reactivated in m ethylation-defective mutants (Miura et al., 2001; Walsh et 
al., 1998).
Global DNA hypomethylation is commonly found in a number o f cancers, including 
thyroid, breast, cervical, prostate, stomach, lung, bladder, esophagus, colorectum, and 
liver (reviewed by Arooj et al., 2013). The alteration in global methylation is considered 
to  be mainly due to  hypomethylation o f repetitive sequences fo r example long 
interspersed nuclear element 1 (LINE-1).
In contrast to  hypomethylation, DNA hyperm ethylation, particularly o f CpG islands or
prom oter CpGs can result in inappropriate gene silencing and development o f disease
states. For example, hypermethylation o f CpG islands of the tum or suppressor gene
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leads to silencing of the gene and predisposes to carcinogenesis (Attwood et al., 2002). 
Hypermethylation of specific genes may correlate w ith  decreased gene expression that 
associated w ith disease condition. For instance, the fibulin-1 (FBLN1), a m u lti­
functional extracellular matrix protein, prom oter CpGs hypermethylation is found in 
accordance w ith downregulation o f FBLN1 protein and mRNA levels in colorectal 
cancer (Xu et al., 2015), renal cell carcinoma (Xiao et al., 2013), and gastric cancer 
(Cheng et al., 2008).
1.5.3 Association of DNA methylation and schizophrenia
Schizophrenia is associated w ith multiple risk factors, including both environmental 
and genetic influences (section 1.1.4). There are several genetic factors that have been 
reported to  be associated w ith schizophrenia and antipsychotic treatm ent response 
and side effects such as BDNF and FITR2A (section 1.4). The study of epigenetic 
regulators o f gene expression including DNA methylation and histone modifications is 
an attractive field to  explore the molecular pathology of schizophrenia.
To date, recent studies provided evidence tha t pathogenesis of psychiatric disorders 
may be due to epigenetic aberrations. Researchers focus on the DNA methylation 
changes in schizophrenia postmortem brain, especially in prefrontal areas of cerebral 
cortex. Epigenetic alterations in dopaminergic system genes were reported in 
schizophrenia and bipolar disorder (Abdolmaleky et al., 2008). Hypermethylation- 
mediated silencing of the reelin gene (RELN), which encodes a glycoprotein essential 
fo r brain development and neuronal connectivity, was reported in the fronta l lobe of 
post-mortem brain which was correlated w ith schizophrenia and bipolar disorder 
(Abdolmaleky et al., 2005; Grayson et al., 2005). Hypomethylation membrane-bound 
catechol-O-methyltransferase (MB-COMT), which is involved in dopamine degradation, 
was also reported in schizophrenia and bipolar disorder compared to  control subjects 
and this hypomethylation was associated w ith significant higher MB-COMT transcript 
level (Abdolmaleky et al., 2006).
Related to  serotonin receptor genes, it has been found tha t DNA methylation status
was increased in HTR1A gene prom oter in schizophrenia (Carrard et al., 2011) which
may be the cause of the alteration of the receptor expression (Hashimoto et al., 1991;
Sumiyoshi et al., 1996). In addition, methylation at a transcription factor-binding site
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on the 5-HT1A receptor gene close to  the functional polymorphism, -1019C/G (rs6295) 
correlates w ith negative symptom treatm ent response in first episode schizophrenia 
patients (Tang et al., 2014). In addition, the hypomethylation of 5-HT2A receptor gene 
at and around 102T/C polymorphic site was reported in schizophrenia and bipolar 
disorder (Ghadirivasfi et al., 2011; Abdolmaleky et al., 2011), but prom oter DNA o f the 
HTR2A was hypermethylated at and around the -1438A/G polymorphic site 
(Abdolmaleky et al., 2011), and these epigenetic changes influence expression of the 
HTR2A gene (Abdolmaleky et al., 2011). DNA hypermethyation of the serotonin 
transporter (5-HTT) prom oter and its correlation w ith the reduction in 5-HTT 
expression were reported in drug naive schizophrenia patients both in DNA from saliva 
and post-mortem brain samples (Abdolmaleky et al., 2014). These studies support the 
epigenetic influences in etiology of psychotic disease and might provide new targets in 
antipsychotic drug development..
1.5.4 Association of epigenetic factors and antipsychotic drug-induced 
weight gain
The genetic risk factors have been of interest and provide a focus for much research 
investigating the causes of disease and treatm ent responses. Recently the epigenetic 
factors have also been extensively researched. In addition to  genetic factors, 
environmental factors such as nutritional, chemical and physical factors have the 
potential to  alter gene expression through epigenetic modification. In other words, 
epigenetic mechanisms are influenced by the environment. Several factors have been 
shown to  modulate epigenetic modification, fo r example, age (Bjornsson et al., 2008), 
sun exposure (Gronniger et al., 2010), radiation exposure (Chaudhry and Omaruddin, 
2012), diet (Heijmans et al., 2008; McKay et al., 2012), alcohol consumption (Philibert 
et al., 2012; Zhang et al., 2013a), tobacco smoking (Flom et al., 2011; Wangsri et al., 
2012), and air pollution (Tarantini et al., 2009; Salam et al., 2012); some of these 
factors such as age could be a confounding factor in establishing a correlation study 
relating to DNA methylation. Treatment w ith antipsychotic drugs can also affect 
epigenetic modifications which will be described in the next section (section 1.5.4.1).
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1.5.4.1 Antipsychotic drugs and epigenetic modifications
Study of a mouse model w ith relevance to schizophrenia found that clozapine and 
sulpiride but not haloperidol or olanzapine treatm ent induced DNA demethylation as 
well as histone acetylation at reelin and GAD67 promoters in the frontal cortex and 
striatum (Dong et a i, 2008; Guidotti et al., 2009). However, olanzapine treatm ent in 
rats caused genome-wide DNA methylation change in genes of dopamine 
neurotransmission in hippocampus, cerebellum and liver (Melka et al., 2014). This 
research group analysed DNA methylation extents w ith in  a tota l 40 genes in dopamine 
(DA) pathway and found tha t 19 genes including genes encoding fo r DA receptors (D l, 
D2, and D5), DA transporter, DA synthesis, and DA metabolism (COMT) had d ifferent 
methylation between olanzapine and control rats, and most (17/19) genes showed 
increased methylation (Melka et al., 2013). This study supports the dopamine 
hypothesis o f schizophrenia tha t olanzapine may reduce DA activity by changing DNA 
methylation. Melas et al. (2012) found decreased global DNA methylation in patients 
w ith schizophrenia compared to  normal controls, especially in early onset o f disease, 
and they also found tha t global DNA methylation was increased to nearly the levels of 
normal controls in patients receiving haloperidol. These data suggest tha t epigenetic 
changes influenced by disease and/or antipsychotic treatm ent may involve, in part, the 
symptom response and also may account fo r certain adverse effects including weight 
gain after antipsychotic drug treatm ent. Further studies are required to  understand 
the effect o f antipsychotic drugs on epigenetic change, gene expression and variable 
outcome to treatm ent.
1.5.4.2 Epigenetic modifications and antipsychotic drug-induced weight gain
A recent study reported the association of lower DNA methylation of the HTR2A gene 
prom oter w ith decreased body weight, BMI, and fat mass after six months of weight 
loss treatm ent in subjects w ith metabolic syndrome (Perez-Cornago et al., 2014) 
indicating the influence of epigenetic modification in genes of the serotonin system on 
body weight change in response to  drug treatm ent. Few studies have investigated the 
relationship between epigenetic mechanisms and antipsychotic drug-induced weight 
gain. Two studies have investigated the association between DNA methylation of the 
MTHFR and COMT genes and metabolic syndrome in schizophrenia. Burghardt et al.
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(2012) studied the MTHFR 677C/T poylmorphism and LINE-1 DNA methylation in 133 
patients w ith schizophrenic disorder. They did not find an association between global 
LINE-1 methylation and MTHFR genotypes, but they found a significant interaction 
between the MTHFR 677C/T variant and gender on global LINE-1 DNA m ethylation, in 
which females w ith the MTHFR 677TT genotype had the lowest global LINE-1 DNA 
methylation level compared w ith other groups.
Another study found a significant association between the COMT V a ll58M e t (rs4680) 
polymorphism, COMT prom oter methylation, physical activity, and metabolic 
syndrome in 85 patients w ith schizophrenia receiving atypical antipsychotic treatm ent 
(Lott et al., 2013). They observed that the COMT genotype was a significant indicator 
o f methylation status at tw o CpG sites in the COMT prom oter region. They found tha t 
physical activity had a negative correlation w ith COMT prom oter m ethylation in 
Val/Val homozygous patients whereas positive correlation was found in M e t/M e t 
carriers. In addition, patients w ith M e t/M e t genotype had a positive correlation 
between COMT prom oter methylation and metabolic syndrome. These findings 
indicate tha t prom oter methylation of COMT is influenced by its genotype and physical 
activity. These data indicate the influence of a genetic polymorphism on DNA 
methylation and this relationship may influence the interindividual variation in 
symptom response and adverse effects in schizophrenia patients received 
antipsychotic drugs.
Many of the functional consequences of genetic polymorphisms, particularly those in 
prom oter regions tha t may influence binding o f transcription factors, are likely to 
affect gene expression. Additionally, some polymorphisms may modify the CpG 
sequences tha t are the sites o f DNA methylation, and thus may influence gene 
transcription by affecting this methylation. Particularly notable in pharmacogenetic 
findings is tha t the SNPs in HTR2C tha t are associated w ith drug-induced weight gain 
are often also at CpG sites o f DNA methylation -  e ither d irectly disrupting CpG 
sequences (e.g. the -759C/T SNP, -697G/C SNP) or close to  other CpG sites. Thus DNA 
methylation provides a further potential influence on drug induced weight gain -  by, 
fo r example methylation of the -759C site or nearby CpG sites - in addition to  the 
established pharmacogenetic association of HTR2C SNPs.
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1.6 Main objectives
Overall aim
The hypothesis is tha t genetic factors may influence antipsychotic drug-induced weight 
gain. In addition to  the -759C/T polymorphism of the HTR2C gene, the genetic 
polymorphisms of several candidate genes related to antipsychotic drug-induced 
weight gain including HTR2A, ADRA2A, BDNF, GNB3, MC4R, FTO, and MTHFR may have 
influence on antipsychotic drug-induced weight gain. These genes encode drug target 
receptors, hormones or neuropeptides involved in food intake regulation, or genes 
tha t might be involved in DNA methylation modification. In addition, epigenetic factors 
may also influence antipsychotic drug-induced weight gain. DNA methylation o f CpGs 
in the prom oter sequences of the HTR2C may associate w ith antipsychotic drug- 
induced weight gain, and it also may be affected by those genetic polymorphisms. 
Moreover, antipsychotic drugs may affect DNA methylation levels o f the HTR2C 
prom oter sequences tha t may cause alteration in mRNA expression. Furthermore, 
antipsychotic drugs may affect leptin secretion from  adipocytes which may be 
mediated by changing HTR2C mRNA expression. The genotype discrim ination of 
genetic polymorphisms, the extent o f DNA methylation, the expression o f mRNA, and 
the secretion o f leptin were measured by using a variety o f molecular, biochemical and 
cell culture based assays.
The specific goals were:
1. To investigate the influence of SNPs on antipsychotic drug-induced weight gain in
patients w ith  schizophrenia.
2. To investigate the association of DNA methylation in the prom oter region o f the 
HTR2C gene on antipsychotic drug-induced weight gain in patients w ith 
schizophrenia.
3. To investigate the genotype effect o f SNPs on DNA methylation in the HTR2C gene.
4. To investigate the effect of antipsychotic drug treatm ent on DNA m ethylation and 
mRNA expression of the HTR2C gene in neuroblastoma cells.
5. To investigate the effect of antipsychotic drug treatm ent on leptin secretion and 
Htr2c gene expression in mouse adipocyte cells.
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Chapter 2: Association of genetic polymorphisms 
and antipsychotic drug-induced weight gain in 
patients with schizophrenia
2.1 Introduction
Schizophrenia is a severe, complex and chronic disorder which fo r many patients is 
inadequately treated. Antipsychotic drugs can in many individuals relieve the positive 
psychotic symptoms but have various adverse effects; notably several o f the drugs can 
induce a substantial weight gain in susceptible individuals, particularly second 
generation antipsychotics such as clozapine, olanzapine and risperidone (reviewed by 
Panariello et al., 2011). However, first-generation antipsychotic drugs (FGAs) also have 
been linked to  weight gain to  a lesser degree (Lett et al., 2012). This weight gain may 
not only increase treatm ent non-compliance but also affect m orbid ity from  metabolic 
consequences including lipid abnormalities, insulin resistance and diabetes mellitus 
(Henderson et al., 2000). W eight gain also reduces quality of life in patients suffering 
from  schizophrenia (Lett et al., 2012; Allison et al., 2003). Patients receiving 
antipsychotic treatm ent can develop metabolic abnormalities w ith increased risk of 
cardiovascular disease and m orta lity (Casey et al., 2004; DE Hert et al., 2009). The 
mean age of death fo r schizophrenia patients is 22.5 years younger than general 
population (57.4 years fo r schizophrenia and 79.9 years fo r general population) 
(Tiihonen et al., 2009). This difference is, in part, attributable to  the metabolic side- 
effects o f antipsychotic treatm ent (Gautam and Meena, 2011).
Susceptibility to antipsychotic-induced weight gain varies substantially between 
individuals in ways tha t cannot be fully explained by differences between d iffe rent 
drug effects or other environmental factors. Thus genetic influences are strongly 
implicated, and associations between many genetic polymorphisms and antipsychotic 
drug-induced weight gain have been reported. The most consistently reported genetic 
factors involved in antipsychotic induced weight gain include polymorphisms in genes 
fo r 5-hydroxytryptam ine 2C (5-HT2C), 5-HT2A, adrenergic alpha 2A and melanocortin 4
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receptors, as well as leptin and fa t mass and obesity associated (FTO) genes (Reynolds, 
2012).
The inter-individual variability o f weight gain in response to antipsychotic drug 
treatm ent is partly due to genetic variability. The most consistent genetic variant 
associated w ith antipsychotic drug-induce weight gain is the -759C/T polymorphism of 
HTR2C gene, o f which the T allele is a protective allele against obesity (Yuan et a i, 
2000) and antipsychotic drug-induced weight gain in both firs t episode (Templeman et 
a i,  2005; Reynolds et a i, 2002) and chronic schizophrenia patients (M ille r et a i, 2005; 
Ellingrod et a i,  2005). The 5-HT2C receptor is involved in obesity and food intake 
regulation. Adm inistration of a 5-HT2C receptor antagonist resulted in increased food 
intake and weight gain in rats (Bonhaus et a i,  1997). 5-HT2C receptor antagonist can 
attenuate the reduced food intake which is induced by 5-HT2C agonists (Hayashi et a i,
2005). It is a target fo r atypical antipsychotic drugs such as clozapine and olanzapine 
which have high affinities fo r the 5-HT2C receptor (Roth et a i, 2004; Reynolds and Kirk, 
2010). Endogenous 5-HT inhibits neuropeptide Y (NPY) (Heisler et a i,  2006) which 
controls satiety. Clozapine (the 5-HT2C receptor antagonist) disinhibits hypothalamic 
NPY neurons resulting in elevated NPY (Kirk et a i, 2006). 5-HT increases POMC activity 
via 5-HT2C receptor by modulating POMC neuronal excitability (Roepke et a i,  2012; 
Qiu et a i, 2007; Sohn et a i, 2011). Therefore, it has been suggested the involvem ent 
o f 5-HT2C receptor mechanisms in atypical antipsychotic drug-induced weight gain is 
by modulating POMC and NPY activity (Balt et a i, 2011).
The HTR2C -759C/T polymorphism is located in the prom oter region near the
regulatory transcription factor binding sites which may affect gene expression (Xie et
a i, 1996). The transcription factor binding sites located nearby the -759C/T SNP are
TCF-1, LF-A1, and bHLH (Xie et a i, 1996). Yuan et a i (2000) demonstrated tha t the
HTR2C prom oter haplotype containing either the -997A, -759T or -697C allele has
increased prom oter activity in Chinese hamster embryonic carcinoma cells. The same
prom oter haplotype showed decreased expression in SH-SY5Y neuroblastoma cells (Hill
and Reynolds, 2007). The haplotype of 4 polymorphisms containing -759T or -977G
(the study did not include the -697G/C site) resulted in increased prom oter activ ity in
human cell lines, HEK293t and TE671 (Buckland et a i,  2005). Another study did not
find any significant influence of the prom oter haplotype containing -759T and -697C
61
and other 5' polymorphisms on prom oter activity while haplotype w ith -759T and - 
697C showed 21% less activity compared to  the major haplotype; -759C and -697G 
(McCarthy et al., 2005). The d ifferent findings may be due to  the difference of 
prom oter fragm ent sequences tha t included -697 or not and addition o f o ther SNPs. 
Although the function of individual prom oter polymorphisms in regulating prom oter 
activity is unclear, the removal or addition of a particular site may affect the prom oter 
activity since some sites may affect the a ffin ity o f the transcription factor binding site. 
The methods used for transfection including transient or stable transfection may also 
influence the findings. The transfected plasmid DNA is usually not integrated into the 
host genome in transient transfection; therefore, the foreign DNA is diluted through 
mitosis or degraded. In stable transfection, the transfected plasmid DNA is integrated 
into host genome and is replicated when cell mitosis occurs; therefore, the transfected 
gene remains in the genome of the cell and daughter cells (reviewed by Kim and 
Eberwine, 2010). In addition, the different cell lines used in transfection may 
contribute to  the different findings; the d ifferent cell lines provide d ifferent 
transcriptional machinery or regulatory elements required for transcription o f the 
gene. Furthermore, the d ifferent plasmid constructs also contribute to  the d ifferent 
findings. The prom oter enhancers such as SV40 or CMV viral enhancer in both 
experimental and reference plasmids used in the luciferase assay have strong activity 
compared to  the plasmids w ithout the enhancer and this may affect the transcription 
rate of the tested plasmid. It has been proposed tha t the reduced prom oter activity of 
the T allele o f the -759C/T polymorphism of the HTR2C may results in the decreased 
expression o f the 5-HT2C receptors leading to subsequent compensatory changes in 
other systems in regulating food intake (Hill and Reynolds, 2007). The alteration in 5- 
HT2C receptor expression influenced by prom oter polymorphisms might be involved in 
antipsychotic drug-induced weight gain.
The T allele o f HTR2C -759C/T polymorphism was associated w ith higher plasma leptin 
levels at baseline in schizophrenia patients compared to  C/CC genotype (Templeman et 
al., 2005). However, the mechanistic link or interaction between leptin and 5-HT2C 
receptor is still unclear and needs fu rther study to  elucidate the interaction o f these 
tw o pathways. Leptin induction of central 5-HT turnover via a nitric oxide dependent 
pathway has been reported (Calapai et al., 1999). There is evidence showing tha t
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central leptin-induced anorexia is mediated via the 5-HT2C receptor and the specific 
5-HT2C receptor antagonist (SB 242084) attenuated anorexia induced by leptin 
adm inistration (von Meyenburg et al., 2003a). Peripheral adm inistration of the 5-HT 
precursor (5-hydroxytryptophan) increases serum leptin in mice (Yamada et al., 1999). 
Immuno-histochemical evidence suggests an inverse relationship between 5-HT and 
leptin levels in the hypothalamus and dorsal raphe (Fernandez-Galaz et al., 2010). A 
study in 5-HTT deficient mice found tha t increased 5-HT in various brain regions was 
paralleled by increased leptin levels (Chen et al., 2012). However, the change in leptin 
could be independent o f 5-HT and both leptin and 5-HT may have separate pathways 
in the control o f food intake (Halford and Blundell, 2000). Thus, fu rthe r experimental 
verification is required.
In addition to  the HTR2C -759C/T polymorphism, there are other genetic risk factors 
tha t are likely to contribute to  determ ining weight gain associated w ith  antipsychotic 
drug treatm ent, including polymorphisms for leptin, melanocortin receptor 4, 
adrenergic a2A and g-protein beta3 among many others (Reynolds, 2012). In addition, 
the associations of the other genetic polymorphisms w ith antipsychotic drug-induced 
weight gain were previously discussed in chapter 1 and are summarized in Table 2.1.
Table 2.1: Summary and main finding of the association between SNPs and 
antipsychotic drug-induced weight gain
SNPs Patient Main findings Reference
MTHFR
677C/T,
MTHFR
1298A/C
58 schizophrenia patients 
receiving atypical 
antipsychotic drugs fo r 
>12 months (cross- 
sectional analysis),, 
treated at least 12 months 
w ith various antipsychotics
the 677T allele but not the 
1298A/C of MTHFR was 
associated w ith a greater 
risk o f developing metabolic 
syndrome and the TT 
genotype was associated 
w ith risk o f insulin 
resistance w ith greater 
central adiposity induced by 
antipsychotic treatm ent
Ellingrod 
et al., 2008
MTHFR 
677C/T, 
MTHFR 
1298A/C
237 subjects w ith bipolar 
or schizophrenia receiving 
an antipsychotic fo r at 
least 6 months (cross- 
sectional analysis), various 
antipsychotics (54% were 
under poly-pharmacy),
Not associated w ith BMI 
but the MTHFR 677T was 
related to age, smoking, 
and metabolic syndrome
Ellingrod 
et al., 2012
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SNPs Patient Main findings Reference
72% were white
MTHFR
677C/T,
MTHFR
1298A/C
518 patients w ith a 
schizophrenia spectrum 
disorder, 97.3% were 
white), olanzapine, 
clozapine, quetiapine, 
risperidone, palipeidone
MTHFR A1298C, but not 
C677T, was associated w ith 
the metabolic syndrome, 
C/C genotypes having a 2.4 
times higher risk compared 
to A/A genotypes
van Winkel 
et al., 2010a
MTHFR
677C/T,
MTHFR
1298A/C
104 schizophrenia 
patients, a 3-month 
follow-up period after 
in itiation of an SGAs, 
various antipsychotics, 
some taken medication for 
other somatic disorders 
(e.g. hypertension)
The 1298C variant, but not 
C677T was associated w ith 
increased w e ig h t, waist 
circumference, fasting 
glucose and impaired 
glucose tolerance
van Winkel 
et al., 2010b
ADRA2A
-291C/G
62 Korean chronic 
schizophrenia, (not FEP), 
long-term olanzapine 
treatm ent (> 3 months)
The G allele was 
significantly higher 
frequency in patients who 
had severe weight gain 
(>10% weight increased 
from  baseline)
Park et al., 
2006
ADRA2A
-291C/G
93 Chinese chronic 
schizophrenia treated w ith 
clozapine (14±6.2 months)
The GG genotype had 
higher body weight gain 
than CC genotype
Wang et al., 
2005b
ADRA2A
-291C/G
129 chronic schizophrenia 
or schizoaffective disorder 
(60 European-Americans 
and 39 African-Americans), 
6-14 weeks treated with 
clozapine/olanzapine
The C allele carriers gained 
more weight compared to 
GG genotype in European- 
Americans but not in 
African-Americans
Sickert et al., 
2009
ADRA2A
-291C/G
139 schizophrenia patients 
w ith various ethnicity, 6-14 
weeks treatm ent w ith 
clozapine (91), olanzapine 
(22), haloperidol (12), 
risperidone (14)
No association w ith weight 
gain
De Luca 
et al., 2011
ADRA2A
-291C/G
470 schizophrenia 
patients, cross-sectional 
study
No association w ith 
metabolic syndrome
Risselada 
et al., 2010
HTR2A
rs6313
164 schizophrenia patients 
in Japan, olanzapine
The 102T allele o f HTR2A 
was associated with 
olanzapine-induced weight
Ujike et al., 
2008
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SNPs Patient Main findings Reference
treatm ent (8-24 weeks) gain
HTR2A
-1438G/A
84 (FEP) Chinese Han 
schizophrenia patients, 10 
weeks of treatm ent w ith 
risperidone or 
chlorpromazine
No association o f the 
/-/77?2/4-1438G/A w ith 
weight gain
Mou et al., 
2005
MC4R
rsl7782313
345 white inpatients 
schizophrenia, various 
atypical antipsychotics 
(clozapine, olanzapine, 
risperidone, paliperidone, 
quetiapine, or amisulpride) 
treatm ent for 4 weeks
The C-allele had a 
significantly higher risk of 
weight gain and BMI 
increase
Czerwensky 
et al., 2013a
MC4R
rsl7782313
224 schizophrenia patients 
(European-ancestry), 14 
weeks treatm ent
No association w ith weight 
gain
Chowdhury 
et al., 2013
MC4R
rs489693
4 cohorts consisted of 139 
pediatric patients w ith first 
exposure to SGAs treated 
w ith SGAs for 12 weeks. 
The 3 additional cohorts 
consisted of 73, 40, and 92 
subjects treated fo r 6 and 
12 weeks.
The AA genotype was 
associated w ith greater 
weight gain
Malhotra 
et al., 2012
MC4R
rs489693
341 Caucasian inpatients 
schizophrenia receiving at 
least one SGA drug 
(olanzapine, clozapine, 
risperidone, paliperidone, 
quetiapine, or amisulpride) 
fo r 4 weeks
A-allele showed a 2.2 times 
higher weight increase
Czerwensky 
et al., 2013b
GNB3
825C/T
164 schizophrenia patients 
in Japan, olanzapine 
treatm ent (8-24 weeks)
T allele was significantly 
associated w ith olanzapine- 
induced weight gain
Ujike et al., 
2008
GNB3
825C/T
134 Chinese schizophrenia 
patients, long-term 
treatm ent w ith clozapine 
(13.4 months)
Patients w ith the TT 
genotype had significantly 
greater weight gain
Wang et al., 
2005a
GNB3 87 treatm ent-resistant 
schizophrenic patients,
Not associated w ith 
clozapine-induced body
Tsai e t al.,
65
SNPs Patient Main findings Reference
825C/T clozapine treatm ent fo r 4 
months
weight change 2004
GNB3
825C/T
79 Korean schizophrenic 
patient group receiving 
olanzapine treatm ent at 
least 3 months
No association w ith weight 
gain
Park et a i, 
2009
GNB3
825C/T
42 schizophrenia patients 
treated w ith olanzapine 
fo r 6 weeks
No association w ith weight 
gain
Bishop et al., 
2006
GNB3
825C/T
a meta-analysis o f 18,903 
subjects
CC genotype showed a 
trend association w ith 
lower BMI
(Souza et al., 
2008)
BDNF
rs6265
196 Chinese schizophrenia 
on long-term antipsychotic 
medication
M e t/M e t (or AA) genotype 
was associated w ith weight 
gain, w ith strong effect in 
male but not female
Zhang et al., 
2008
BDNF
rs6265
257 schizophrenia patients 
o f European ancestry
a haplotype of rs6265 and 
rsl519480 (G-A haplotype) 
was associated w ith atypical 
antipsychotic drug-induced 
weight gain
Zai et al., 
2012
BDNF
rs6265
481 schizophrenic patients 
treated w ith clozapine (n = 
266), olanzapine (n = 79), 
or risperidone (n = 136) for 
an average of 49.2 ± 28.2 
months
The BDNF Val66Met SNP 
was not associated with 
body weight gain, but the 
BDNF rs ll03 0 10 1  TT 
genotype was associated 
w ith weight gain
Tsai et al., 
2011
FTO
rs9939609
250 Chinese Han 
schizophrenia patients 
(FEP), risperidone 
treatm ent fo r 6 months
The TT genotype carriers 
had significantly lower body 
weight and BMI than the A 
allele (both at baseline and 
after treatm ent)
Song et al., 
2014
FTO
rs9939609
239 schizophrenia patients 
in Spain (FEP), 1 year 
antipsychotic treatm ent
The AA genotype was 
significant associated w ith 
the higher baseline BMI 
compared to AT/TT group 
but the weight increase 
between tw o groups of 
genotype was not 
significant difference after 1 
year antipsychotic
Perez- 
Iglesias 
et al., 2010
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SNPs Patient Main findings Reference
treatm ent
FTO
rs9939609
Chronic and FEP 
schizophrenia patients
The A allele was associated 
w ith BMI in chronic 
schizophrenia patients but 
not w ith weight gain in first- 
episode schizophrenia 
patients, although the AA 
genotype had higher 
baseline weight and 
baseline BMI than T allele
Reynolds 
et al., 2013
FTO
rs9939609
351 chronic schizophrenia 
and 342 age- and sex- 
matched healthy subjects
No association between the 
SNP and BMI or weight gain 
in patients w ith 
schizophrenia but the 
carriers of A allele had 
significant higher BMI than 
those of TT genotype in 
healthy subjects
Watanabe 
et al., 2012
FTO
rs9939609
218 chronic schizophrenia 
or schizoaffective disorder 
treated mostly w ith 
clozapine or olanzapine for 
up to  14 weeks
No association between the 
polymorphism and BMI or 
antipsychotic drug-induced 
weight gain
Shing et al., 
2014
BMI, body mass index; FEP, First episode psychosis; SGAs, Second generation 
antipsychotics
Therefore, these SNPs were studied to investigate the ir influence on weight gain in 
firs t episode or BMI in chronic patients w ith schizophrenia. These SNPs are strong 
candidates relating to  epigenetic modification (MTHFR polymorphisms), 
neurotransm itter receptors fo r antipsychotic drugs (ADRA2A and HTR2A), the GWAS 
SNPs associated w ith BMI and obesity [FTO, MC4R, and BDNF), and the 5-HT signaling 
transduction (GNB3).
2.1.1 TaqMan®-based SNP Genotyping
The principle o f the TaqMan®-based SNP genotyping technology relies on the S'-B' 
nuclease activity o f Taq polymerase and fluorophore-based detection. In addition to 
unlabelled specific primers (forward and reverse primers) targeting the region flanking 
the SNP site, each SNP assay contains tw o TaqMan® fluorescent probes w ith the same
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sequence except at the SNP site, w ith one probe complementary to  the first allele and 
the other probe complementary to the second allele. 5' end of each probe is labelled 
or attached covalently w ith a d ifferent fluorophore (VIC or FAM) as a reporter. 3' ends 
of both probes are covalently linked to  a non-fluorescent quencher preventing 
liberation of the reporter fluorescence if the probe is not degraded.
In the PCR cycling, during the denaturation step DNA was denatured to  separate 
double-stranded DNA into single-stranded DNA providing DNA templates fo r the 
follow ing annealing step in which primers bind specifically to DNA tem plate while 
probes hybridize specifically to the targeted SNP site. During PCR extension or 
polymerisation step, the binding probe is displaced and cleaved by the 5' nuclease 
activity o f the Taq polymerase which releases the reporter and quencher dyes and 
then the fluorescence of corresponding fluorophore is detected. Only the perfectly 
hybridized probes are destroyed by exonuclease activity of Taq polymerase, since a 
mismatched probe does not bind to  DNA template; therefore, it w ill not be recognized 
and cut by the Taq polymerase; therefore, un-hybridized probe not complem entary to 
the SNP site remains intact and the fluorescence of tha t reporter is suppressed (Figure 
2.1).
The fluorescent signals fo r the tw o reporter dyes are measured at the end o f the PCR 
cycle. These signals are normalized using the signal o f a th ird dye fo r example ROX dye, 
o f which the fluorescent intensity is proportional to the tem plate DNA concentration 
and the extent o f the PCR reaction. Typically, the reporter dye signals are visualized in 
a plot (Figure 2.2). The ratio o f the signals w ill be indicative o f the genotype o f the 
sample (Table 2.2).
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A) Hybridization
Perfect match TaqMan0 Probe
IVI 0
3’
C
G
Single m ismatch TaqMan0 Probe
5* 3’
Q
/
5'
B) Polymerisation
Q
3’
- C
-G- 5* -G
Probe cleavage: signal Probe displacement: no signal
C) Polymerisation completed
V ) Dye1: VIC® dye Q Quencher
( J )  Dye2: FAM™ dye j aq q n a  polymerase
—► Forward primer
Figure 2.1: Overview of TaqMan® based SNP genotyping principle
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Allele D iscrim ination Plot (SNP Assay: SNP Assay 1)
2 .3
t.s
1.3
Cl.8
•  m
0.3
0.1 0.3 0.5 0.7 0.9 1.1
A l le le  1
Legend
♦  Homozygous 1 /1 •  Homozygous 2/2
*  Heterozygous 1 !2 xUndetermined
Figure 2.2: Genotyping result discriminating 3 groups of alleles
Figure shows homozygous allele 1 (red), homozygous allele 2 (blue), and heterozygous 
both alleles (green) w ith undeterm ined negative control.
Table 2.2: Categorization of SNP from fluorescent signal ratio after genotyping
VIC® dye fluorescence only Homozygosity fo r allele 1
FAM™ dye fluorescence only Homozygosity fo r allele 2
Both fluorescence signals Heterozygosity fo r allele 1 and allele 2
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2.1.2 Aims
The main objective o f the work reported in this chapter is to identify single-nucleotide 
polymorphisms associated w ith antipsychotic drug-induced weight gain.
1. To investigate the influence of polymorphisms in the MTHFR, ADRA2A, HTR2A, 
MC4R, GNB3, BDNF, and FTO genes on antipsychotic drug-induced weight gain in firs t 
episode schizophrenia patients.
2. To investigate the influence of polymorphisms in the MTHFR gene on body weight in 
chronic schizophrenia patients.
3. To investigate the gene-gene and drug-gene interactions on weight gain and body 
mass index follow ing antipsychotic drug treatm ent.
4. To investigate the influence of previous findings in the HTR2C -759C/T, FTO 
rs9939609, and/or leptin -2548A/G polymorphisms on antipsychotic drug induced 
weight gain and BMI, as well as the gene-gene and drug-gene interactions.
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2.2 Materials and methods
2.2.1 Study population and DNA samples
DNA samples used in this study were from  three d ifferent populations; tw o cohorts of 
first-episode, in itia lly antipsychotic drug-na'Ve patients w ith schizophrenia (Spanish 
and Chinese cohorts) and one cohort o f chronic schizophrenia patients (Belfast 
cohort). All patients received treatm ent according to normal clinical practice as 
described below in section 2.2.1.1-2.2.1.3 and gave w ritten  informed consent to  the 
procedure of the study. Ethical approval fo r the studies was granted by the relevant 
local ethical committees.
2.2.1.1 Chinese first episode drug naive schizophrenia patients
Chinese Han (n=182) cohort of first-episode, in itia lly antipsychotic drug-na'Ve patients 
who met DSM-IV criteria for schizophrenia were studied. Patients who had evidence of 
previous antipsychotic drug treatm ent or other medical or neurological illness, and 
fam ily history o f diabetes or eating disorder were excluded. Height and weight to 
determ ine body-mass index (BMI) were measured on in itiation o f antipsychotic drug 
treatm ent and after 8 or 10 weeks and weight gain was determined by change in BMI 
over the treatm ent period. Blood samples were collected on the in itia tion of 
antipsychotic drug treatm ent. Initial antipsychotic drug treatm ent consisted prim arily 
o f chlorpromazine (n=60) and risperidone (n=114); eight patients received clozapine, 
fluphenazine or sulpiride.
2.2.1.2 Spanish first episode drug naive schizophrenia patients
A Spanish Caucasian (n=72) cohort of first-episode, in itia lly antipsychotic drug-na i/e
schizophrenia patients diagnosed by DSM-IV criteria were studied. Patients w ith
comorbid DSM-IV diagnosis o f substance abuse or dependence, or w ith any physical
illness, were excluded from the study. None of the patients had a prior history o f
medication w ith antipsychotic, antidepressant or mood stabilizer drugs. Height and
weight to  determ ine BMI were measured on in itiation o f antipsychotic drug trea tm ent
and after 3 months and weight gain was determined by change in BMI over the
treatm ent period. Blood samples were collected on in itiation o f antipsychotic drug
treatm ent. Initial antipsychotic drug treatm ent consisted primarily o f risperidone
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(n=21) or olanzapine (n=22) and tw o received both, others had quetiapine (n=10), 
haloperidol (n=8) or ziprasidone (n=6) w ith three other treatments.
2.2.1.3 Belfast series of chronic schizophrenia patients
In this cross-sectional study, a series o f patients from  Northern Ireland w ith a DSM-IV 
diagnosis o f schizophrenia or schizoaffective disorder currently receiving antipsychotic 
drug therapy (n=72) were studied. All patients were of Irish/British Caucasian descent, 
except one Malaysian Chinese. Each patient was interviewed about personal disease 
history and fam ily psychiatric disease, diabetes and smoking history. All patients were 
tested fo r random blood glucose level, cholesterol, high-density (HDL) and low-density 
lipoproteins (LDL), and triglycerides; blood pressure and waist circumference were 
measured and body mass index (BMI) calculated from weight and height. These data 
were used to  determine metabolic syndrome which was defined using the 
International Diabetes Federation (IDF) criteria (w w w .idf.org) by presence of central 
obesity, i.e. waist circumference >94 cm in men and >80 cm in women, plus any tw o 
fu rthe r risk factors from  the following:
(a) raised triglycerides (>1.7 m m ol/l) or specific treatm ent fo r this lipid abnormality;
(b) reduced HDL cholesterol (<1.03 m m ol/l in men and <1.29 m m ol/l in women) or 
specific treatm ent fo r this lipid abnormality;
(c) raised blood pressure (systolic >130 mmHg or diastolic >85 mmHg) or trea tm ent o f 
previously diagnosed hypertension;
(d) raised fasting blood glucose (>5.6 m m ol/l) or previously diagnosed type 2 diabetes.
Patients received antipsychotic drugs consist o f clozapine (n=12), olanzpine (n=10), 
risperidone (n=10), haloperidol (n= l), amisulpride (n=3), aripiprazole (n=2), 
zuclopenthixol (n=2), flupentixol (n=12), quetiapine (n=3), chlorpromazine (n=2), 
sulpiride (n=2), trifluoperazine (n=3), zotapine (n=5), fluphenazine (n= l), thioridazine 
(n= l), one received zuclopenthixol and amisulpride, one received zuclopenthixol and 
chlorpromazine, and one was not receiving antipsychotics.
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2.2.2 Genotyping assays
Genomic DNA previously isolated from blood using standard techniques was 
genotyped fo r polymorphisms including MTHFR 677C/T (rsl801133), MTHFR 1298A/C 
(rsl801131), ADRA2A -1291C/G (rsl800544)/ MC4R rsl7782313 C/T, MC4R
rs489693A/C, GNB3 825C/T (rs5443), HTR2A -1438G/A (rs6311) and BDNF 196G/A 
(rs6265) using Custom TaqMan® SNP Genotyping Assays (Applied Biosystems, USA). 
The HTR2C -759C/T was genotyped previously in all cohorts. The FTO rs9939609 
genotype was genotyped previously in Spanish and Belfast cohorts by Professor Gavin 
Reynolds' research group (Reynolds et a i, 2013) and was included in analyses in this 
study of both genetic association and epigenetic association (next chapter) to 
antipsychotic induced weight gain. The genotyping SNPs and the ir cohorts are listed in 
Table 2.3.
Table 2.3: Genotyping SNPs and cohorts that have been genotyped.
rs number Gene Genetic
variants
TaqMan®SNP 
Genotyping Assay ID
Cohorts Previous
data
rs3813929 HTR2C -759C/T Spanish,
Chinese,
Belfast
rsl801133 MTHFR 677C/T
Ala222Val
C_1202883_20 Spanish,
Chinese,
Belfast
rsl801131 MTHFR 1298 A/C 
Glu429Ala
C_850486_20 Spanish,
Chinese,
Belfast
rsl800544 ADRA2A 1291C/G C_7611979_10 Chinese -
rsl7782313 MC4R C/T C 32667060 10 Chinese -
rs489693 MC4R A/C C_3058718_10 Chinese -
rs5443 GNB3 825C/T C_2184734_10 Chinese -
rs6311 HTR2A -1438G/A C_8695278_10 Chinese -
rs6265 BDNF 196G/A C_11592758_10 Chinese -
rs9939609 FTO A/T C_30090620_10 Chinese Spanish,
Belfast
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Genotyping PCR reactions were set up in a 96-well qPCR plate in a tota l volume of 10 
jul as listed in Table 2.4. Control was also set up by adding DNase-free water instead of 
gDNA. The reactions were set up in duplicate. The plate was covered with adhesive 
film  and centrifuged briefly before running on a StepOne Plus Real-Time PCR System 
(Applied Biosystems, USA) according to  PCR run condition in Table 2.5.
Table 2.4: PCR reaction set up for genotyping using TaqMan® SNP Genotyping Assays
PCR reaction component Volume for 10 pL PCR reaction 
(|iL/well)
TaqMan®GTXpress™ Master Mix (2x) 5.0
Custom TaqMan® SNP Genotyping Assays (40x) 0.25
Genomic DNA tem plate (1-10 ng) 2.0
DNase-free water 2.75
Table 2.5: PCR condition for genotyping using TaqMan® SNP Genotyping Assays
Stage Step Temperature Time
Holding DNA polymerase activation 95 °C 20 sec
Cycling Denature 95 °C 3s
(40 cycles) Anneal/Extend 60 °C 30 s
Allelic discrim ination was performed using a post-read tem perature 25°C.
2.2.3 Statistical analysis
All statistical analysis o f results was performed using SPSS version 18.0. Data were 
expressed as mean ± standard deviation. Stepwise linear regression was used to  
determ ine where appropriate, the potential confounding effects o f baseline BMI, sex, 
and age on weight gain. Univariate analysis o f variance was used to  determ ine the 
association between genotypes or genetic risk factor and clinical measures. Also, it was 
used to determine any gene-gene interaction and drug-gene interaction. The 
Bonferroni post hoc analysis was performed in olanzapine (Spanish), and risperidone 
and chlorpromazine (Chinese) subgroups after finding a drug-genotype interaction. 
The subgroup o f antipsychotic drugs was analyzed based on receptor binding
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characteristic o f antipsychotic drugs. Chi-squared analysis was used to  determine the 
association between categorical measures including genotype, sex distribution, 
percentage of weight change more or less than 7% which is considered clinically 
significant and is consistent w ith the Food and Drug Adm inistration's defin ition of 
significant weight gain fo r studies of psychotropic drugs (Sachs and Guille, 1999), 
present/absence of central obesity and metabolic syndrome.
Hardy-Weinberg Equilibrium was calculated by web tool 
(http://www.had2know.com /academ ics/hardy-weinberg-equilibrium -calculator-2- 
alleles.html). Linkage disequilibrium (LD) of the MTHFR 677C/T and 1298A/C as well as 
the MC4R rsl7782313 and rs489693 polymorphisms were analysed by SHEsis (Shi and 
He, 2005).
In the present study, an association of the -759C/T polymorphism of the HTR2C w ith 
weight gain which had previously been reported in these cohorts (Reynolds et al., 
2002; Templeman et al., 2005; Yevtushenko et al., 2008) was also included in a 
combined analysis w ith other SNPs in each cohort. In the Belfast cohort, the FTO 
rs9939609 polymorphism was also included in a combined analysis w ith  o ther SNPs.
Statistical significance was assumed fo r p values less than 0.05. The largest sample size 
of 171 subjects (Chinese cohort) had approximately 90% power to identify a significant 
genotype difference for a medium effect size o f 0.5.
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2.3 Results (Part 1): First-episode antipsychotic drug naive 
schizophrenia
2.3.1 General characteristics of population studies and genotyping 
results
General characteristics o f population studies o f first-episode antipsychotic drug na ive 
Chinese Han and Spanish patients w ith schizophrenia are shown in Table 2.6. 5-10% of 
samples from each cohort underwent repeated genotyping and provided reproducible 
results (data not shown).
2.3.1.1 Chinese Han cohort
The genotype distributions and allele frequency fo r all genotyped SNPs are listed in 
Table 2.7. Genotype frequencies did not deviate from  Hardy-Weinberg equilibrium 
expectations fo r all SNPs (p>0.05) (Table 2.7). Previous HTR2C -759C/T SNP data had 
genotype distribution C=68, T=13 in male, and CC=73, CT/TT=25 in female, and the 
allele d istribution in each gender was not significantly d ifferent (x2=2.374, p=0.123).
On regression analyses, baseline BMI but not age had a significant confounding effect 
on weight gain after 8-10 weeks treatm ent (F=19.90, P<0.001), whereas age had a 
significant confounding effect on baseline BMI (F=8.78, p=0.003). Therefore, the 
subsequent analyses were carried out w ith adjustment fo r age or baseline BMI as 
covariates.
2.3.1.2 Spanish cohort
The genotype distributions and allele frequency fo r all genotyped SNPs are listed in 
Table 2.8. Genotype frequencies did not deviate from  Hardy-Weinberg equilibrium  
expectations fo r all genotyped SNPs (p>0.05) (Table 2.8). Previous HTR2C -759C/T SNP 
data had genotype distribution C=42, T = l l  in male, and CC=12, CT/TT=7 in female, and 
the genotype distribution in each gender was not significantly d iffe rent (x2=1.93, 
p=0.165). In addition, previous FTO rs9939609 data had genotype distribution AA=14, 
AT=35, and TT=21 which are in Hardy-Weinberg equilibrium (x2=0.0074, p =0.933) and 
the allele frequency fo r A allele was 0.45 and T allele was 0.55.
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On regression analyses, age but not baseline BMI had a significant confounding effect 
on weight gain at 3 months after treatm ent (F=7.026, P=0.010). Therefore, the 
subsequent analyses were carried out w ith adjustment for age as a covariate.
Table 2.6: General characteristics of Spanish and Chinese Han cohorts
Chinese Han Total Males Females
Number 182 83 99
Age (years) 26.24 ±7.35 26.3017.40 26.1917.34
Baseline weight (kg) 58.83 ±10.69 65.12110.25 53.55 1 7.84
Baseline BMI (kg/m 2) 21.34 ±2.87 22.1612.93 20.65 1 2.64
Change in BMI (kg/m 2) 1.2111.21 1.27 11.30 1.1511.12
Spanish Total Males Females
Number 72 53 19
Age (years) 25.35 1 6.80 24.1915.63 28.581 8.70
Baseline weight (kg) 63.361 12.37 67.241 11.38 52.561 7.89
Baseline BMI (kg/m 2) 21.8913.70 22.4613.62 20.3113.53
Change in BMI (kg/m 2) 2 .1811.60 2.2811.53 1 .9011.80
Data is expressed as mean ± SD.
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Table 2.7: Genotype distribution and allele frequency in Chinese Han cohort
rs number Gene Genetic
variants
Genotype
distribution
Allele
frequency
Chi-Square, 
p value
rsl801133 MTHFR 677C/T CC=54,
CT=94,
TT=28
C=0.57, T=0.43 %2=1.4899
p =0.222
rsl801131 MTHFR 1298 A/C AA=114,
AC=56,
CC=5
A=0.81, C=0.19 X2=0.3643 
p =0.546
rsl800544 ADRA2A 1291C/G CC=21,
CG=81,
GG=69
C=0.36/ G=0.64 X2=0.1383 
p =0.710
rsl7782313 MC4R C/T CC=13,
CT=51,
TT=109
C=0.22, T=0.78 %2=3.7890 
p =0.052
rs489693 MC4R A/C AA=7,
AC=55,
CC=112
A=0.20, C=0.80 %2=0.0058 
p =0.939
rs5443 GNB3 825C/T CC=40,
CT=83,
TT=50
C=0.47, T=0.53 %2=0.2406 
p =0.624
rs6311 HTR2A -1438G/A GG=38,
GA=86,
AA=49
G=0.47, A=0.53 X2=0.0006
p =0.982
rs6265 BDNF 196G/A GG=39,
GA=89,
AA=45
G=0.48, A=0.52 X2=0.1567 
p =0.692
rs9939609 FTO A/T AA=3,
AT=35,
TT=141
A=0.11; T=0.89 X2=0.2294 
p =0.631
Table 2.8: Genotype distribution and allele frequency in Spanish cohort
rs number Gene Genetic
variants
Genotype
distribution
Allele
frequency
Ch-Square, 
p value
rsl801133 MTHFR 677C/T CC=20,
CT=36,
TT=13
C=0.55,
T=0.45
%2=0.2047 
p =0.652
rsl801131 MTHFR 1298 A/C AA=45,
AC=21,
CC=3
A=0.80,
C=0.20
X2=0.0759 
p =0.784
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2.3.2 Association of MTHFR 677C /T and 1298A/C polymorphisms with  
weight gain in first episode drug naive schizophrenia patients
2.3.2.1 MTHFR 677C/T
Table 2.9: Effect o f MTHFR 677C/T polym orphism  on changes in body w e ight in firs t 
episode drug na'K/e schizophrenia patients
MTHFR 677C/T genotype
CC CT TT p value
Chinese Han sample n=54 n=94 n=28
Sex M/F (%male) 25/29 (46.3%) 57/65 (46.7%) 13/15 (46.4%) 0.998a
Age (years) 25.0416.84 26.2117.18 28.45 18.60 0.136
Baseline BMI (kg/m2) 20.9912.69 21.4312.77 21.92 1 3.53 0.607c
Change BMI (kg/m2) 1.5811.25 0.9211.15 1.43 11.10 0.003b
Spanish sample n=20 n=36 n=13
Sex M/F (%male) 14/6 (70.0%) 29/7 (80.6%) 9/4(69.2%) 0.5783
Age (years) 27.6018.34 24.2515.69 23.921 6.96 0.168
Baseline BMI (kg/m2) 21.4413.78 22.061 3.70 22.2914.01 0.780
Change BMI (kg/m2) 2.8611.53 2.091 1.44 1.85 1 1.81 0.049c
a p values obtained from Chi-squared test, o ther p values obtained from  univariate 
analysis o f variance test, b analyses w ith baseline BMI as a covariate, c analyses w ith 
age as a covariate. Data is expressed as mean ± SD.
As shown in Table 2.9, the baseline BMI, age, and sex distribution of both samples 
were not significantly d ifferent between genotypes of the MTHFR 677C/T 
polymorphism. Dividing genotype into tw o groups by combining m inor risk (T) allele 
carriers found that the CC genotype had greater changes in BMI than T allele carriers: 
1.58±1.25 versus 1.0411.16 kg/m 2 in Chinese (p=0.012) and 2.8611.53 versus 
2.02+1.54 kg/m 2 in the Spanish sample (p=0.017) (Figure. 2.3). Analysis in the 
subgroup of Chinese Han schizophrenia patients who had received risperidone, the CC 
carriers had higher BMI change than T allele carriers; 1.6911.24 (n=33) versus 
1.0011.17 kg/m 2 (n=75), p=0.051.
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Figure 2.3: The association between MTHFR 677C/T genotype and w e ight gain 
The T allele o f the MTHFR 677C/T polymorphism shows significantly lower in BMI 
change in both cohorts; (a) Chinese Han and (b) Spanish comparing to  CC genotype. 
Data is expressed as mean ± SEM.
Dividing the Spanish cohort into patients who had received or did not receive 
olanzapine, and the Chinese cohort into those receiving either risperidone or 
chlorpromazine, did not identify a significant drug x MTHFR 677C/T genotype 
interaction (p=0.193 and p=0.667 fo r Spanish and Chinese cohort, respectively). These 
results indicate tha t the genotype effect o f the MTHFR 677C/T on weight gain is 
independent o f drug effect; in other word, the genotype effect on weight gain is not 
d ifferent between drug treatments.
2.3.2.2 MTHFR 1298A/C
The baseline BMI, age, and sex distribution of both study populations were not 
significantly associated w ith the MTHFR 1298A/C polymorphism (Table 2.10). Dividing
81
the sample into two genotype groups by combining m inor risk (C) allele found tha t the 
changes in BMI o f both study populations were still not significantly d ifferent between 
1298A/C AA genotype and C allele carriers: 1.27±1.24 versus 1.0811.17 kg/m 2 in 
Chinese Han samples (p=0.242) and 2.1811.66 versus 2.4011.45 kg/m 2 in Spanish 
samples (p=0.621) respectively.
Table 2.10: Effect o f MTHFR 1298A/C polym orphism  on changes in body w eight in 
firs t episode drug na‘K/e schizophrenia patients
MTHFR 1298A/C genotype
AA AC CC p value
Chinese Han sample n=114 n=56 n=5
Sex M/F (%male) 53/61 (46.5%) 24/32 (42.9%) 4/1 (80%) 0.279a
Age (years) 26.5417.77 25.611 6.61 27.2015.54 0.710
Baseline BMI (kg/m2) 21.4713.06 21.201 2.59 21.7811.51 0.895c
Change BMI (kg/m2) 1.271 1.24 1.041 1.18 1.63 10.94 0.228b
Spanish sample n=45 n=21 n=3
Sex M/F (%male) 32/13 (71.1%) 17/4 (81%) 3/0(100%) 0.412a
Age (years) 25.3617.36 24.7616.38 25.001 1.73 0.949
Baseline BMI (kg/m2) 21.9213.62 21.9914.16 21.4513.76 0.973
Change BMI (kg/m2) 2.1811.66 2.4611.52 2.0310.99 0.807c
a p values obtained from Chi-squared test, o ther p values obtained from univariate 
analysis o f variance test, b analyses w ith baseline BMI as a covariate, c analyses w ith 
age as a covariate. Data is expressed as mean 1 SD.
Dividing the Spanish cohort into patients who had received or did not receive 
olanzapine, and the Chinese cohort into those receiving either risperidone or 
chlorpromazine, did not identify a significant drug x MTHFR 1298A/C genotype 
interaction (p=0.296 and p=0.363 fo r Spanish and Chinese cohort, respectively).
The MTHFR 677C/T and 1298A/C polymorphisms were in strong linkage disequilibrium 
in both Chinese and Spanish cohorts: D'=0.866, r2=0.127 fo r Chinese and D'1.000, 
r2=0.198 fo r Spanish cohort.
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2.3.2.3 Gene-gene in te ra c tio n
Previous findings in these tw o cohorts (Reynolds et al., 2002; Templeman et al., 2005) 
showed the T allele o f the HTR2C -759C/T polymorphism had a protective effect 
against antipsychotic-induced weight gain. Association o f this polymorphism w ith 
changes in BMI were as follows: in the Chinese cohort T allele carriers 0.71+1.11 kg/m 2 
(n=38), C/CC genotype 1.33±1.21 kg/m 2 (n=141), p=0.004; in the Spanish cohort T 
allele carriers 1.24±1.46 kg/m 2 (n=16), C/CC genotype 2.4811.54 kg/m 2 (n=50) p=0.012. 
Previous findings in the Spanish cohort showed the FTO rs9939609 had no influence on 
BMI change (Reynolds et al., 2013).
The relationship between the effects o f the HTR2C -759C/T and the MTHFR 677C/T 
polymorphisms was investigated. Analysing the association o f weight gain w ith both 
polymorphisms together in each cohort, no significant interaction between the 
polymorphisms was detected but a significant overall effect was observed (p<0.001 in 
Chinese sample; p=0.019 in Spanish sample) indicating an independent effect of the 
tw o polymorphisms. Thus carriage of tw o risk factors (HTR2C C/CC genotype and 
MTHFR 677 CC genotype) was significantly associated w ith mean BMI gains in Chinese 
and Spanish cohorts (Table 2.11).
Table 2.11: Combined genetic risk genotype o f HTR2C -759C/T and MTHFR 677C/T
Number 
o f risk 
genotype
Chinese Han Spanish
BMI change 
(kg/m 2)
n p value BMI change 
(kg/m 2)
n p value
0 0.63 11.20 25 0.001 1.3611.57 10 0.005
1 1.1011.11 107 2.1411.46 39
2 1.8111.26 41 3.23 11.46 14
BMI change values are expressed as mean ± SD. p value was obtained from  univariate 
analysis o f variance w ith  baseline BMI and age as covariates fo r Chinese and Spanish 
cohorts, respectively.
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2.3.3 Association of ADRA2A rsl800544 (-1291C/G) polymorphism 
with weight gain in Chinese Han schizophrenia patients
The baseline BMI, age, and sex distribution o f were not significantly associated w ith 
the ADRA2A -1291C/G polymorphism (Table 2.12). Dividing genotypes into tw o  groups 
by combining risk (G) allele carriers found tha t the G allele carriers tended to  have a 
greater change in BMI than that o f CC genotype but this did not reach statistical 
significance: 1.25±1.21 versus 0.84±1.09 kg/m 2 (p=0.126). However, there was a non­
significant indication of drug x ADRA2A -1291C/G genotype interaction in the analysis 
o f patients receiving either risperidone or chlorpromazine (p=0.072). Therefore, post 
hoc analysis was performed in a subgroup of patients who had received risperidone 
and this analysis found a significantly greater change in BMI in G allele carriers than CC 
genotype: 1.30±1.19 kg/m 2 (n=91) versus 0.47±1.14 kg/m 2 (n=12), p=0.027 (Figure 
2.4).
Table 2.12: Effect of ADRA2A -1291C/G polymorphism on changes in body weight in 
Chinese Han schizophrenia patients
ADRA2A -1291C/G genotype
CC CG GG p value
Chinese Han sample n=21 n=81 n=69
Sex M/F (%male) 8/13 (38.10%) 39/42 (48.15%) 33/36 (47.8%) 0.695a
Age (years) 25.14±7.02 25.801 6.88 26.8818.09 0.537
Baseline BMI (kg/m2) 21.3613.07 21.1312.79 21.69 + 2.94 0.601c
Change BMI (kg/m2) 0.8411.09 1.2411.29 1.2511.13 0.279b
Baseline weight (kg) 57.761 12.18 58.281 10.48 60.231 10.62 0.496d
Weight change (kg) 2.1713.05 3.381 3.60 3.4313.16 0.2066
Weight change (%) 4.3414.91 6.161 6.55 6.1115.51 0.2476
Weight increase>7% n=8/13 (38.1%) n=37/81 (45.7%) n=33/69 (47.8%) 0.735a
a p values obtained from  Chi-squared test, o ther p values obtained from  univariate 
analysis o f variance test, b analyses w ith baseline BMI as a covariate, c analyses w ith 
age as a covariate, d analyses w ith age and sex as covariates, 6 analyses w ith  baseline 
weight as a covariate. Data is expressed as mean ± SD.
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Figure 2.4: The association between ADRA2A -1291C/G genotype and w eight gain in 
Risperidone trea tm en t group o f Chinese Han cohort
The relationship between the effects o f the ADRA2A -1291C/G, the HTR2C -759C/T, 
and the MTHFR 677C/T polymorphisms was investigated. Analysing the association of 
weight gain w ith ADRA2A -1291C/G and HTR2C -759C/T or ADRA2A -1291C/G and 
MTHFR 677C/T polymorphisms or all three polymorphisms together, no significant 
interaction between the polymorphisms was detected but a significant overall effect 
was observed (p<0.001) both in tota l cases and in the subgroup receiving risperidone 
treatm ent indicating an additive effect of the three polymorphisms.
2.3.4 Association of HTR2A rs6311 (-1438G/A) polymorphism with 
weight gain in Chinese Han schizophrenia patients
The baseline BMI, age, and sex distribution were not significantly associated w ith  the 
HTR2A -1438G/A polymorphism (Table 2.13). Dividing genotype into tw o groups by 
combining risk (A) allele carriers found that the A allele carriers had a slightly greater 
change in BMI than tha t of GG genotype but this did not reach statistical significance: 
1.25±1.15 versus 1.03±1.36 kg/m 2 (p=0.326). However, there was a significant drug x 
HTR2A -1438G/A genotype interaction in the analysis o f patients receiving either 
risperidone or chlorpromazine (p=0.017) (Figure 2.5). Therefore, post hoc analysis was 
performed in the subgroup of patients who had received risperidone and this found a 
significant greater change in BMI in A allele carriers than GG genotype: 1.3511.18 
kg/m 2 (n=79) versus 0.7911.20 kg/m 2 (n=26), p=0.047 (Figure 2.6).
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Table 2.13: Effect of HTR2A -1438G/A polymorphism on changes in body weight in
Chinese Han schizophrenia patients
HTR2A -1438G/A genotype
GG GA AA p value
Chinese Han sample n=38 n=86 n=49
Sex M/F (%male) 18/20 (47.37%) 43/43 (50%) 20/29 (40.8%) 0.5883
Age (years) 24.9717.83 26.9116.82 25.6517.87 0.349
Baseline BMI (kg/m2) 21.45 ± 2.77 21.221 2.89 21.4913.01 0.657c
Change BMI (kg/m2) 1.0311.36 1.311 1.17 1.1511.11 0.509b
Baseline weight (kg) 60.21110.69 58.471 10.88 58.621 10.66 0.310d
Weight change (kg) 2.8613.83 3.5413.29 3.0913.11 0.609e
Weight change (%) 5.2117.18 6.5115.68 5.53 + 5.38 0.5326
Weight increase>7% n=14/38 (36.8%) n=46/86 (53.5%) n=19/49 (38.8%) 0.119a
a p values obtained from Chi-squared test, other p values obtained from  univariate 
analysis o f variance test, b analyses w ith baseline BMI as a covariate, c analyses w ith 
age as a covariate, d analyses w ith age and sex as covariates,e analyses w ith  baseline 
weight as a covariate. Data is expressed as mean ± SD.
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Figure 2.5: The interaction between HTR2A -1438G/A genotype and antipsychotic 
drug treatment on weight gain in Chinese Han cohort in the analysis of subgroup of 
patients receiving either risperidone or chlorpromazine
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Figure 2.6: The association between HTR2A -1438G/A genotype and w e ight gain in 
risperidone trea tm en t group o f Chinese Han cohort
The relationship between the effects o f the HTR2A -1438G/A, the ADRA2A -1291C/G, 
the HTR2C -759C/T, and the MTHFR 677C/T polymorphisms was investigated. 
Analysing the association o f weight gain w ith HTR2A -1438G/A polymorphism and the 
other three polymorphisms together, no significant interaction between the 
polymorphisms was detected but a significant overall effect was observed (p<0.002) 
both in the analysis o f to ta l cases and in a subgroup of risperidone treatm ent 
indicating an additive effect of the four polymorphisms.
2.3.5 Association of rsl7782313 and rs489693 polymorphisms near 
MC4R gene with weight gain in Chinese Han schizophrenia 
patients
The baseline BMI, age, and sex distribution were not significantly associated w ith  
polymorphisms near MC4R; rsl7782313 C/T polymorphism (Table 2.14) and rs489693 
A/C polymorphism (Table 2.15).
Dividing MC4R rsl7782313 genotype into tw o groups by combining m inor risk (C) allele 
found that changes in BMI were not significantly d ifferent between MC4R rsl7782313 
TT genotype and C allele carriers: 1.31±1.06 (n=109) versus 1.02±1.39 kg/m 2 (n=64), 
p=0.163. However, TT genotype had a higher frequency of percentage of weight 
changes over than 7% (n=56/109, 51.38%) compared to C allele carriers (n=23/64, 
35.94%), x 2=3 .874, p=0.049. No drug x MC4R rsl7782313 genotype interaction was
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observed when analysing patients receiving either risperidone or chlorpromazine 
(p=0.822).
The MC4R rs489693, dividing by genotype into two groups by combining C allele vs AA 
genotype based on BMI change found tha t BMI change in the C allele carriers was 
significantly greater than tha t o f carriers w ith AA homozygous genotype: 1.25±1.21 
(n=167) versus 0.31±1.19 (n=7) kg/m 2 (p=0.040)(Figure 2.7). The genotype distribution 
of AA and AC/CC was not significantly d ifferent between groups of patients who had 
weight changes more than 7% and less than 7%. The percentage of weight change in C 
allele carriers was higher than tha t of AA genotype: 6.16±6.00 vs 1.45±5.69% 
(p=0.052). No drug x MC4R rs489693 genotype interaction was observed when analysis 
patients receiving either risperidone or chlorpromazine (p=0.810).
The relationship between the effects of the HTR2C -759C/T, MTHFR 677C/T, MC4R 
rsl7782313 and MC4R rs489693 polymorphisms was investigated. No significant 
interaction between the HTR2C -759C/T or MTHFR 677C/T and the MC4R rsl7782313 
as well as MC4R rs489693 polymorphisms in the ir effect on BMI change was detected 
in this Chinese Han cohort.
The MC4R rsl7782313 and rs489693 polymorphisms were in weak LD: D'=0.196, 
r2=0.007.
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Table 2.14: Effect of MC4R rsl7782313 C/T polymorphism on changes in body weight
in Chinese Han schizophrenia patients
MC4R rsl7782313 genotype
CC CT TT p value
Chinese Han sample n=13 n=51 n=109
Sex M/F (%male) 6/7 (46.15%) 26/25 (50.98%) 49/60 (44.9%) 0.775a
Age (years) 24.4616.63 25.45 1 5.97 26.6518.00 0.443
Baseline BMI (kg/m2) 21.1112.52 21.661 3.32 21.23 12.72 0.529c
Change BMI (kg/m2) 0.9711.41 1.03 11.40 1.3111.06 0.354b
Baseline weight (kg) 58.9219.15 60.691 12.35 58.05 1 10.07 0.328d
Weight change (kg) 2.6513.75 2.7813.89 3.5613.02 0.4508
Weight change (%) 4.8617.26 5.35 17.22 6.3615.10 0.6836
Weight increase>7% n=4/13 (30.8%) n=19/51 (37.3%) n=56/109 (51%) 0.132a
a p values obtained from Chi-squared test, o ther p values obtained from univariate 
analysis o f variance test, b analyses w ith baseline BMI as a covariate, c analyses w ith 
age as a covariate, d analyses w ith age and sex as covariates,8 analyses w ith  baseline 
weight as a covariate. Data is expressed as mean ± SD.
Table 2.15: Effect o f MC4R rs489693 A/C polym orphism  on changes in body w e ight in 
Chinese Han schizophrenia patients
MC4R rs489693 genotype
AA AC CC p value
Chinese Han sample n=7 n=55 n=112
Sex M/F (%male) 4/3 (57.14%) 26/29 (47.27%) 50/62 (44.6%) 0.791a
Age (years) 24.71 + 6.58 25.66 + 6.55 26.67 + 7.79 0.603
Baseline BMI (kg/m2) 21.5812.49 21.43 1 3.15 21.38 + 2.74 0.916c
Change BMI (kg/m2) 0.3111.19 1.21 + 1.35 1.26 + 1.13 0.119b
Baseline weight (kg) 61.29 + 8.06 59.49 1 11.54 58.49 + 11.54 0.775d
Weight change (kg) 0.93 + 3.27 3.26 + 3.71 3.41 + 3.19 0.2058
Weight change (%) 1.45 + 5.69 6.14 + 7.03 6.16 + 5.46 0.1498
Weight increase>7% n=l/7  (14.3%) n=25/55 (45.5%) n=54/112 (48%) 0.2163
a p values obtained from Chi-squared test, o ther p values obtained from univariate 
analysis o f variance test, b analyses w ith baseline BMI as a covariate, c analyses w ith 
age as a covariate, d analyses w ith age and sex as covariates,0 analyses w ith  baseline 
weight as a covariate. Data is expressed as mean ± SD.
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Figure 2.7: The association between MC4R rs489693 A/C genotype and w eight gain in 
Chinese Han cohort
2.3.6 Association of GNB3 rs5443 (825C/T) polymorphism with weight 
gain in Chinese Han schizophrenia patients
The baseline BMI, age, and sex distribution were not significantly associated w ith  the 
GNB3 825 C/T (Table 2.16). Dividing genotype into tw o  groups by combining m inor (C) 
allele carriers found that changes in BMI were not significantly d iffe rent between 
GNB3 rs5443825 C allele carriers and TT genotype: 1.23±1.24 (n=123) versus 1.13±1.10 
kg/m 2 (n=50), p=0.503. No significant difference of weight changes and percentage of 
weight changes were found between TT genotype and C allele carriers. Genotype 
distribution was not d ifferent between groups of patients who had percentages of 
weight changes over 7% and less than 7%. No drug x GNB3 825C/T genotype 
interaction was observed when analysing patients receiving e ither risperidone or 
chlorpromazine (p=0.459).
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Table 2.16: Effect o f GNB3 825 C/T polym orphism  on changes in body w eight in
Chinese Han schizophrenia patients
GNB3 825C/T genotype
CC CT TT p value
Chinese Han sample n=40 n=83 n=50
Sex M/F (%male) 20/20 (50%) 37/46 (44.58%) 24/26 (48%) 0.8363
Age (years) 26.73 17.01 25.7517.22 26.2817.94 0.781
Baseline BMI (kg/m2) 20.77 1 2.65 21.7112.95 21.20 + 2.93 0.149c
Change BMI (kg/m2) 1.2011.34 1.2511.18 1.13 11.10 0.569b
Baseline weight (kg) 57.15 110.58 60.171 11.21 58.1719.97 0.053d
Weight change (kg) 3.0913.77 3.4313.32 3.1113.12 0.5926
Weight change (%) 6.1916.90 6.0616.00 5.5715.11 0.6396
Weight increase>7% n=21/40(52.5%) n=37/83 (44.6%) n=21/50 (42%) 0.588a
a p values obtained from Chi-squared test, other p values obtained from  univariate 
analysis o f variance test, b analyses w ith baseline BMI as a covariate, c analyses w ith 
age as a covariate, d analyses w ith age and sex as covariates,e analyses w ith baseline 
weight as a covariate. Data is expressed as mean ± SD.
2.3.7 Association of BDNF rs6265 196G/A (Val66Met) polymorphism 
with weight gain in Chinese Han schizophrenia patients
The baseline BMI, age, and sex distribution were not significantly associated w ith the 
BDNF rs6265 G/A (Table 2.17). Dividing genotype into tw o groups by combining m inor 
risk (G) allele carriers found tha t changes in BMI were not significantly d ifferent 
between BDNF rs6265 G allele carriers and AA genotype: 1.1411.20 (n=128) versus 
1.3611.19 kg/m 2 (n=45), p=0.519. No significant difference of weight changes and 
percentage of weight changes were found between AA genotype and G allele carriers. 
Genotype distribution was not d ifferent between groups of patients who had 
percentages of weight changes over 7% and less than 7%. No drug x BDNF rs6265 G/A 
genotype interaction was observed when analysis patients receiving e ither risperidone 
or chlorpromazine (p=0.100).
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Table 2.17: Effect o f BDNF rs6265G/A polym orphism  on changes in body w e ight in
Chinese Han schizophrenia patients
BDNF rs6265 (Val66Met) genotype
GG GA AA p value
Chinese Han sample n=39 n=89 n=45
Sex M/F (%male) 16/23 (41.03%) 41/48 (46.07%) 24/21 (53.3%) 0.519a
Age (years) 25.33 17.38 25.9817.34 27.1117.44 0.526
Baseline BMI (kg/m2) 21.6813.25 21.4512.92 20.85 1 2.44 0.234c
Change BMI (kg/m2) 1.1611.41 1.1411.10 1.3611.19 0.788b
Baseline weight (kg) 59.541 12.31 59.48 1 10.45 57.1819.87 0.054d
Weight change (kg) 3.0413.77 3.13 13.15 3.7213.41 0.725s
Weight change (%) 5.9017.30 5.5415.32 6.8015.91 0.742s
Weight increase>7% n=15/39(38.5%) n=39/89 (43.8%) n=25/45 (55.6%) 0.2583
a p values obtained from Chi-squared test, other p values obtained from  univariate 
analysis o f variance test, b analyses w ith baseline BMI as a covariate, c analyses w ith 
age as a covariate, d analyses w ith age and sex as covariates,8 analyses w ith baseline 
weight as a covariate. Data is expressed as mean ± SD.
2.3.8 Association of FTO rs9939609 A/T polymorphism with weight 
gain in Chinese Han schizophrenia patients
The baseline BMI, age, and sex distribution were not significantly associated w ith  the 
FTO rs9939609 A/T (Table 2.18). Dividing genotype into tw o groups by combining the 
risk allele A and AT/TT genotype (Perez-lglesias et al., 2010) found tha t changes in BMI 
were not significantly d ifferent between FTO rs9939609 AA genotype and T allele 
carriers: 1.02±1.46 (n=3) versus 1.2111.20 kg/m 2 (n=176), p=0.937. No significant 
difference of weight changes and percentage of weight changes were found between 
AA genotype and T allele carriers. Genotype distribution was not d iffe rent between 
groups of patients who had percentages of weight changes over 7% and less than 7%. 
No drug x FTO rs9939609 genotype interaction was observed when analysis patients 
receiving either risperidone or chlorpromazine (p=0.752).
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Table 2.18: Effect o f FTO rs9939609A/T polym orphism  on changes in body w eight in
Chinese Han schizophrenia patients
FTO rs9939609 genotype
AA AT TT p value
Chinese Han sample n=3 n=35 n=141
Sex M/F (%male) 1/2 (33.33%) 14/21 (40%) 67/74 (47.5%) 0.660a
Age (years) 32.0011.73 27.1917.27 25.92 17.39 0.260
Baseline BMI (kg/m2) 22.2912.03 20.9812.62 21.45 12.93 0.525c
Change BMI (kg/m2) 1.0211.46 1.2910.96 1.1911.26 0.987b
Baseline weight (kg) 60.671 12.22 56.8019.42 59.361 10.92 0.459d
Weight change (kg) 2.5013.91 3.43 12.62 3.23 13.51 0.9476
Weight change (%) 4.9716.65 6.3214.60 5.8916.32 0.9748
Weight increase>7% n=2/3(66.7%) n=18/35 (51.4%) n=61/141 (43%) 0.517a
a p values obtained from Chi-squared test, other p values obtained from  univariate 
analysis o f variance test, b analyses w ith baseline BMI as a covariate, c analyses w ith 
age as a covariate, d analyses w ith age and sex as covariates,0 analyses w ith baseline 
weight as a covariate. Data is expressed as mean ± SD.
2.3.9 Association of combined five polymorphisms associated with 
weight gain in Chinese Han schizophrenia patients
Taking the results o f part one in the first episode schizophrenia patients together, 
there were five polymorphisms tha t showed significant associations w ith BMI gains 
from  both the analysis o f tota l cases as well as a subgroup of patients who had 
received risperidone; HTR2C -759C/T, MTHFR 677C/T, MC4R rs489693 A/C, ADRA2A - 
1291C/G, and HTR2A -1438 G/A polymorphisms. The HTR2C -759C/T, MTHFR 677C/T, 
and MC4R rs489693 A/C polymorphisms were associated w ith weight gain in the 
analysis o f tota l cases, while the ADRA2A -1291C/G and HTR2A -1438 G/A 
polymorphisms were associated w ith weight gain in the analysis o f a subgroup of 
patients who had received risperidone, although MTHFR 677C/T showed a trend of CC 
genotype w ith a higher BMI gain than T allele carriers (p=0.051).
Analysis o f the gene-gene interactions among these polymorphisms did not show a 
significant interaction in ethier the analysis o f tota l cases or as a subgroup o f patients
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who had received risperidone, but always found a significant overall effect indicating
an additive effect of these polymorphisms on BMI change.
Analysing the association o f weight gain w ith five polymorphisms together, carriage of 
5 risk genotypes [HTR2C C/CC, MTHFR 677 CC, MC4R rs489693 AC/CC, ADRA2A CG/GG, 
HTR2A GA/AA genotype) was significantly associated w ith mean BMI gains o f 1.98 
kg/m 2 (n=24); smaller BMI gain values fo r subjects carrying fewer risk genotypes was 
observed; however, no patients carried either 0 or 1 risk genotype as shown in Table
2.19.
Table 2.19: Combined genetic risk genotype o f the HTR2C -759C/T, MTHFR 677C/T, 
MC4R rs489693 A/C, ADRA2A -1291C/G, and HTR2A -1438 G/A polym orphism s in 
Chinese Han cohort
Number of Chinese Han Chinese Han
risk (total cases) (risperidone subgroup)
genotype BMI change 
(kg/m 2)
n p value BMI change 
(kg/m 2)
n p value
2 0.05 ±0.52 10 <0.001 -0.05 ± 0.44 5 <0.001
3 0.93 ± 1.24 53 0.76 ±1.19 30
4 1.28 ±1.18 78 1.31 ±1.21 48
5 1.98 ±0.93 24 2.21 ±0.75 14
BMI change values are expressed as mean ± SD. p value was obtained from  univariate 
analysis o f variance w ith baseline BMI as a covariate.
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2.4 Results (Part 2): Chronic schizophrenia patients
2.4.1 General characteristics of population studies and genotyping 
results
The general characteristics of Belfast chronic schizophrenia patients are listed in Table
2.20. The genotype distributions fo r all genotyped SNPs are listed in Table 2.21. A 5% 
of samples underwent repeated genotyping and obtained reproducible results (data 
not shown). Genotype frequencies for MTHFR 677C/T and 1298A/C did not deviate 
from  Hardy-Weinberg equilibrium expectations (p>0.05) (Table 2.21). Previous HTR2C - 
759C/T SNP data had genotype distribution 0=33, T=8 in male, and CC=20, CT/TT=11 in 
female, and the genotype distribution in each gender was not significantly d ifferent 
(X2=2.318, p=0.128). In addition, previous FTO rs9939609 data had genotype 
distribution AA=14, AT=27, and TT=31 which was in Hardy-Weinberg equilibrium  
(x2=3.0496, p =0.081) and the allele frequency for A allele was 0.38 and T allele was
0.62.
On regression analyses, age and sex did not have a significant confounding effect on 
BMI. Sex had significant confounding effects on plasma leptin (d f= l, F=61.364, p<0.001 
and d f= l, F=19.491, p<0.001 respectively) and waist:hip ratio (d f= l, F=6.320, p=0.014), 
and HDL (d f= l, F=7.817, p=0.007). Therefore, the subsequent analyses were carried 
out w ith adjustment fo r sex variables as covariates as appropriate.
Table 2.20: General characteristics of chronic schizophrenia patients (Belfast cohort)
DNA series Belfast
Sex (M,F) n=72 (41,31)
Age (years) 44.07 ± 11.28
BMI (kg/m2) 28.4616.87
Weight (kg) 81.941 19.37
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Table 2.21: Genotype d istribu tion  and allele frequency in Belfast cohort
rs number Gene Genetic
variants
Genotype
distribution
Allele
frequency
Ch-Square, 
p value
rsl801133 MTHFR 677C/T CC=34,
CT=31,
TT=7
C=0.69,
T=0.31
X2=0.0003 
p =986
rs!801131 MTHFR 1298 A/C AA=38,
AC=30,
CC=4
A=0.74,
C=0.26
X2=0.3771 
p =0.539
2.4.2 Association of MTHFR 611C /T  and 1298A/C polymorphisms with 
body weight in chronic schizophrenia patients
2.4.2.1 MTHFR 677C/T
Table 2.22: Effect o f MTHFR 677C/T polym orphism  on the measurements o f obesity 
and presence o f m etabolic syndrome in chronic schizophrenia patients
MTHFR 677C/T genotype
CC CT TT p value
n=72 34 31 7
Sex M/F (%male) 18/16 (52.9%) 19/12 (61.3%) 4/3 (57.1%) 0.794a
Age (years) 43.29 ± 11.72 45.4219.70 41.861 16.15 0.652
BMI (kg/m2) 29.35 18.39 27.8115.18 27.0615.31 0.580
Weight (kg) 82.831 23.01 82.641 18.78 78.93 1 15.01 0.897
Waist circumference (cm) 101.42 119.35 99.13115.22 98.361 14.74 0.836
W aist: hip ratio 0.9410.12 0.9010.10 0.9210.12 0.221b
BMI >30 kg/m2 n=15/33(45.5%) n=9/30(30%) n=2/7 (28.6%) 0.396a
Triglycerides (mmol/l) 2.4411.51 2.1911.59 1.4310.56 0.264
HDL (mmol/l) 1.0710.33 1.1910.28 1.2610.33 0.101b
Central obesity n=24/32(68.8%) n=24/31(77.4%) n=4/7(57.1%) 0.537a
Metabolic syndrome n=13/33(39.4%) n=14/31(45.2%) n=3/7(42.9%) 0.896a
a p values obtained from Chi-squared test, other p values obtained from  univariate 
analysis o f variance test, b analyses w ith sex as a covariate. Data is expressed as mean
± SD.
As shown in Table 2.22, sex distribution, age, BMI, weight, waist circumference,
waist:hip ratio, triglycerides, HDL, and presence of central obesity and metabolic
syndrome were not significantly associated w ith the 677C/T MTHFR polymorphism .
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Nor were the BMI significantly d ifferent between 677C/T CC genotype and T allele 
carriers: 29.35±8.39 kg/m 2 (n=33) versus 27.66±5.14 kg/m 2(n=37), p=0.310; however, 
it was noted tha t T allele carriers had 1.69 kg/m 2 lower BMI compared to  CC genotype. 
Similar to BMI, a lower frequency of patients who had BMI over than 30 kg/m 2 was 
observed in T allele carriers (n = ll/3 7 , 29.73%) compared to CC genotype group 
(n=15/33, 45.45%) but it did not reach a statistically significant level.
2A.2.2 MTHFR 1298A/C
Table 2.23: Effect o f MTHFR 1298A/C polym orphism  on the measurements o f obesity 
and presence o f metabolic syndrome in chronic schizophrenia patients
MTHFR 1298A/C genotype
AA AC CC p value
n=72 38 30 4
Sex M/F (%male) 23/15 (60.5%) 17/13 (56.2%) 1/3 (33.3%) 0.394a
Age (years) 43.791 10.11 45.001 13.07 39.75 1 8.06 0.672
BMI (kg/m2) 28.53 ± 6.95 27.85 1 6.12 32.35 1 11.59 0.472
Weight (kg) 83.321 19.94 80.05 1 19.06 90.75 1 35.47 0.570
Waist circumference (cm) 100.89 1 16.75 97.83 1 15.28 109.25130.63 0.422
W aist: hip ratio 0.92 + 0.10 0.9010.12 0.9711.16 0.298b
BMI >30 kg/m2 n=12/36(33.3%) n=12/30(40%) n=2/4(50%) 0.736s
Triglycerides (mmol/l) 2.2711.56 2.1811.40 2.2712.07 0.972
HDL (mmol/l) 1.1710.31 1.1210.31 0.9710.34 0.212b
Central obesity n=29/37(78.4%) n=20/29(69%) n=3/4(75%) 0.685s
Metabolic syndrome n=18/37(48.7%) n=ll/30(36.7%) n=l/4(25%) 0.474s
a p values obtained from Chi-squared test, o ther p values obtained from  univariate 
analysis o f variance test, b analyses w ith sex as a covariate. Data is expressed as mean
± SD.
As shown in Table 2.23, sex d istribution, age, BMI, weight, waist circumference, 
waist:hip ratio, triglycerides, HDL, and presence o f central obesity and metabolic 
syndrome were not significantly associated w ith the 1298A/C MTHFR polymorphism. 
Nor were the BMI significantly d ifferent between 1298A/C AA genotype and C allele 
carriers: 28.53±6.95 kg/m 2 (n=36) versus 28.38±6.88 kg/m 2(n=34), p=0.927.
The MTHFR 677C/T and 1298A/C polymorphisms were in strong LD in this chronic 
(Belfast) cohort: D'=1.000, r2=0.163.
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2.4.3 Previous findings and gene-gene interaction
Previous findings in this chronic schizophrenia patient group showed tha t neither the 
HTR2C -759C/T nor leptin -2548A/G polymorphisms was significantly associated w ith 
measures of obesity including BMI, BMI>30 kg/m 2, central obesity, and waist 
circumference; whereas, the leptin -2548A/G, but not HTR2C -759C/T polymorphism 
was significantly associated w ith metabolic syndrome (Yevtushenko et a!., 2008). These 
effects were not apparent in re-analysis in this study probably due to the smaller 
sample size. In addition, previous findings also reported a significant association 
between the FTO rs9939609 polymorphism and the measurements o f obesity in this 
cohort including BMI, waist circumference, waist:hip ratio, and central obesity 
(Reynolds et a l.„ 2013). Re-analysis in this study still observed the association between 
the FTO rs9939609 polymorphism and BMI in which each A allele was associated with 
greater BMI: AA=31.95±7.27 (n=13), AT=29.26±7.37 (n=27), TT=26.22±5.51 (n=30), 
p=0.029.
The relationships between the effects o f the FTO rs9939609A/T polymorphism and 
other polymorphisms including HTR2C -759C/T, MTHFR 677C/T, MTHFR 1298A/C, and 
leptin -2548A/G were investigated and no interactions between genotypes o f these 
polymorphisms were observed. No drug-FTO rs9939609 genotype interaction was 
observed when patients were analysed as groups who had received either clozapine or 
olanzapine (p=0.614).
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2.5 Discussion
The experiments in this chapter aimed to  investigate the association of genetic 
polymorphisms w ith antipsychotic drug-induced weight gain and BMI in patients w ith 
schizophrenia. These genetic polymorphisms are in the genes relating to  antipsychotic 
drug-induced weight gain, food intake regulation, and DNA methylation processes. 
Various functional polymorphisms from  strong candidate genes were genotyped using 
custom TaqMan SNP genotyping assays in first episode and chronic schizophrenia 
patients.
2.5.1 MTHFR 677C/T associated with antipsychotic drug-induced 
weight gain in first episode patients with schizophrenia
This study indicated tha t the MTHFR FFI1Q.IT polymorphism is associated w ith 
antipsychotic induced weight gain in first-episode patients w ith  schizophrenia. 
Individuals carrying the T allele showed less weight gain compared to the common CC 
genotype after 8-10 weeks or 3 months treatm ent w ith antipsychotic drugs. This 
finding was observed in tw o patient cohorts o f d ifferent ethnicity, this indicates the 
effect to be a robust and reproducible one. The study had 90% power to  identify a 
medium (0.50) effect size in the main cohort; previous studies o f association of the 
well-replicated -759C/T polymorphism o f HTR2C w ith antipsychotic drug-induced 
weight gain in a subgroup of the Chinese sample and in the Spanish sample have 
demonstrated substantially larger effect sizes of 0.90 and 0.86 respectively (Reynolds 
et al., 2002; Templeman et a!., 2005). In order fo r pharmacogenetic risk factors to 
explain a good proportion of the variance and thereby to  have substantial predictive 
value, strong effects are needed. This study is aided substantially by the cohorts 
studied here; each only included first-episode patients who had never previously 
received antipsychotic drug treatm ent. This eliminates much of the variance associated 
w ith prior drug treatm ent, which can induce significant weight gain w ith in  a few weeks 
of initial treatm ent (Zhang et a!., 2004).
The absence of an effect in the 1298A/C polymorphism, despite it being in strong 
linkage disequilibrium (high D' values) w ith the significantly associated 677 genotype,
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presumably relates to the large differences in allele frequency between the two 
polymorphisms, as reflected by low r2 values.
In tw o previous cross-sectional studies the 677C/T polymorphism was associated with 
metabolic syndrome follow ing antipsychotic drug treatm ent (Ellingrod et al., 2008; 
2012), although these authors find the 677T allele to be a risk factor, while this study 
found a consistent effect o f the 677T allele in protecting against antipsychotic drug- 
induced weight gain. This may well indicate the difference between effects on initial 
weight gain and its long-term consequences, in which differing pharmacogenetic 
influences are apparent (Reynolds et al., 2013). In another study the 1298A/C but not 
677C/T polymorphism was associated w ith metabolic syndrome in schizophrenia (van 
Winkel et al., 2010a). The one previous longitudinal study of changes in weight and 
metabolic parameters follow ing 3 months treatm ent w ith second generation 
antipsychotics also found an association w ith the 1298A/C but not 677C/T 
polymorphism (van Winkel et al., 2010b). This study differed from  the present 
investigation of firs t episode drug na'K/e patients in tha t weight but not BMI were 
measured, and the 104 patients were older (mean 31.3y) w ith firs t admission on 
average over 6y previously; thus prior treatm ent may well have confounded 
subsequent weight gain. However the ir finding that the 1298A allele is associated w ith 
less weight gain is not inconsistent w ith the result of this study given the close linkage 
disequilibrium between the tw o polymorphisms studied. As discussed by van Winkel et 
al (2010b), there are no clinical or ethnic factors identified tha t may be responsible fo r 
the discrepancies between these findings, although it is notable tha t most studies 
were not powered to identify significant differences between the effects o f the tw o 
closely linked polymorphisms. Nevertheless these various reports all indicate tha t 
functional genetic variation in MTHFR can influence antipsychotic drug-induced weight 
gain.
It is conceivable tha t pharmacogenetic associations such as that identified here may 
vary depending on the treatm ent regime. D ifferent drugs may have d iffering 
mechanisms underlying the ir effect on body weight -  certainly the greater effect o f 
olanzapine over risperidone and several other antipsychotics supports this -  and these 
pharmacological mechanisms may be d ifferentia lly influenced by genetic
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polymorphisms; however, fu rther work needs to address the possible drug specificity 
o f such pharmacogenetic findings.
There was no significant interaction between -759C/T of HTR2C and 677C/T of MTHFR 
on antipsychotic induced weight gain indicating that both polymorphisms exert 
independent influences on this side effect.
The exact mechanism by which MTHFR polymorphisms m ight contribute to 
determ ining antipsychotic drug-induced weight gain is unclear. Both variant alleles of 
677C/T and 1298A/C MTHFR polymorphisms cause decreased enzyme activity 
(Weisberg et al., 1998), although it is not easy to distinguish effects o f tw o  closely- 
linked polymorphisms in vivo. MTHFR is an im portant enzyme in one-carbon 
metabolism and, via its role in DNA synthesis and methylation (Sugden, 2006), may 
influence gene expression (Jirtle and Skinner, 2007); such epigenetic effects could be 
involved in antipsychotic drug-induced weight gain. Diminished levels o f genomic DNA 
methylation (Stern et al., 2000) and gene-specific DNA methylation (Burghardt et al., 
2012) have been reported to  be associated w ith the 677TT genotype. It is therefore 
possible that decreased MTHFR enzyme activity in 677TT genotype results in 
decreased DNA methylation of genes involved in body weight regulation tha t was 
investigated in the next chapter.
DNA methylation status is influenced by gene-nutrient interaction. It has been 
suggested tha t the MTHFR 677TT genotype affects DNA methylation status through an 
interaction w ith folate status (Friso and Choi, 2002). These authors found tha t genomic 
DNA methylation in peripheral blood mononuclear cells was directly correlated w ith 
folate status, inversely correlated w ith homocysteine levels, and only 677TT subjects 
w ith low folate accounted fo r decreased DNA methylation (Friso et al., 2002). Thus 
folate status in addition to the 677C/T MTHFR polymorphism might modulate DNA 
methylation of genes relating to  the regulation of food intake, energy expenditure, or 
body weight regulation, and thus could be an unexplored factor contributing to the 
variance in this and previous studies.
In conclusion, this present study indicates the association of the MTHFR 677C/T single
polymorphism with weight gain follow ing initial antipsychotic drug treatm ent in first-
episode psychotic patients. Furthermore, the effect o f the 677T allele appears to  have
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a protective effect additional to that of the well-established HTR2C -759T allele against 
antipsychotic induced weight gain. These two polymorphisms, in addition to  several 
other possible genetic factors, might be valuable as pharmacogenetic markers o f this 
im portant and lim iting side effect.
2.5.2 ADRA2A rsl800544 (-1291C/G) and HTR2A rs6311 (-1438G/A 
polymorphisms associated with antipsychotic drug-induced 
weight gain in first episode patients with schizophrenia 
receiving risperidone
The present finding did not identify an association o f the ADRA2A -1291C/G and the 
HTR2A -1438G/A polymorphisms w ith weight gain in first episode Chinese Han 
schizophrenia patients, but drug-genotype interactions were identified. Post hoc 
analysis in a subgroup of patients who had received risperidone showed association of 
the ADRA2A -1291C/G and the HTR2A -1438G/A polymorphisms w ith weight gain.
Individuals carrying the G allele o f the ADRA2A -1291C/G showed more weight gain 
compared to  the common CC genotype after 8-10 weeks treatm ent w ith risperidone. 
This finding is consistent w ith tw o Asian population studies; although w ith differences 
in drug treatm ent: olanzapine treatm ent at least 3 months in Korean chronic 
schizophrenia patients (Park et al., 2006) and clozapine treatm ent in chronic Chinese 
schizophrenia patients (Wang et al., 2005b). Taken together, this suggests tha t this 
polymorphism may have an influence in both initial drug na ve and long-term weight 
gain. However, this finding is not inconsistent w ith Sickert et al who found tha t the G 
allele was a protective allele against clozapine-/olanzapine-induced weight gain in 
European schizophrenia patients (Sickert et al., 2009). This study differed from  the 
present investigation in that ethnicity was European-Americans and African- 
Americans, and the drug treatm ent consisted o f olanzapine and clozapine fo r 6-14 
weeks. Thus it may well indicate the difference in ethnicity may be responsible fo r the 
discrepancies between these findings.
The underlying mechanism of the association between the ADRA2A -1291C/G 
polymorphism w ith risperidone induced weight gain is unclear. It may relate to  the role 
o f the adrenergic system on energy balance regulation via the control of
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thermogenesis, lipolysis (Park et al., 2006; Arner, 1992), food intake (Wellman et al., 
1993), and glucoregulation (Levin and Planas, 1993). The ADRA2A -1291C/G 
polymorphism has been found to  be associated w ith body fat accumulation (Garenc et 
al., 2002). The genetic influence of this polymorphism on weight change might be due 
to an influence on the sympathetic-HPA system (Rosmond et al., 2002a) and the 
regulation of neurotransm itter release (Langer, 1997). As the ADRA2A -1291C/G 
polymorphism is located in the prom oter region of the alpha2a-adrenoceptor gene it 
may influence transcription regulation and gene expression. The alteration in receptor 
expression due to a genetic variant may cause changes in hypothalamic regulation of 
food intake and lipid metabolism that might result in weight gain. Further study 
regarding the influence o f ADRA2A -1291C/G on receptor expression is required. 
Risperidone has high a ffin ity at the alpha-2 adrenergic receptor and a trend of 
risperidone-/AD/?/42A -1291C/G genotype interaction was observed in this study; thus, 
via its effect on the receptor, the drug may cause glucose and lipid metabolism 
changes via sympathetic-HPA system resulting finally in changes in body weight (Wang 
et al., 2005b; Rosmond et al., 2002a).
Individuals carrying the A allele of the HTR2A -1438G/A showed more weight gain 
compared to  the common GG genotype after 8-10 weeks treatm ent w ith risperidone. 
This finding is consistent w ith previous studies which reported the association o f the 
102T allele of the HTR2A (rs6313), which is in complete LD w ith -1438A allele o f HTR2A 
(rs6311), and antipsychotic drug-induced weight gain across d ifferent ethnicities (Ujike 
et al., 2008; Balt et al., 2011), although there were difference in drugs; olanzapine in 
Japanese, risperidone in Chinese, and m ultip le drug treatm ent in Caucasian patients 
w ith schizophrenia. However, one finding by Mou et al. showing no association of the 
HTR2A -1438G/A and weight gain is not inconsistent w ith results in the present study 
even though the first episode Chinese Han received risperidone or chlorpromazine for 
10 weeks (Mou et al., 2005). The lack o f significant association in the Mou study might 
be due to  smaller sample size (n=84).
The A allele of the HTR2A -1438G/A was associated w ith weight gain in patients who
had received risperidone treatm ent in this study but this is not in line w ith findings in
general population studies as those found the GG genotype was associated w ith  higher
energy intake (Aubert et al., 2000) and greater BMI (Rosmond et al., 2002b). The
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different finding may well indicate tha t the effect o f the polymorphism together w ith 
the effect of antipsychotic drugs on weight gain in patients w ith schizophrenia was 
different from the general population as well as d ifferent between d ifferent kinds of 
antipsychotic drugs as shown in the drug-genotype interaction results section 2.3.4. 
On the other hand, there are studies that did not find the association between the 
HTR2A -1438G/A and BMI or obesity (Aubert et al., 2000; Hinney et al., 1997). The 
d ifferent findings might be due to the d ifferent methods used fo r assessing energy 
intake, the individual factors such as disease symptoms, diet, physical activity, the 
environmental factors, and the psychosocial and socioeconomic handicaps, as well as 
ethnic differences. Therefore, the association of HTR2A -1438G/A polymorphism and 
obesity in the general population as well as in antipsychotic drug treatm ents need to 
be confirmed.
The mechanisms underlying the association of the HTR2A -1438G/A polymorphism and 
antipsychotic drug-induced weight gain are unknown. The explanation might be that 
risperidone, which is a potent antagonist of 5-HT2A receptor may increase NPY to 
stimulate food intake and may also change the cortisol level and ACTH concentrations 
through effects on 5-HT2A (Currie and Coscina, 1998; Rittenhouse et al., 1994). The 
HTR2A -1438G/A polymorphism is located in the prom oter region and is associated 
w ith prom oter activity; the presence of an A allele has greater prom oter activity 
relative to the G allele (Parsons et al., 2004). In addition, the A allele o f the HTR2A 
-1438G/A polymorphism was associated w ith better clinical response to  clozapine 
(Arranz et al., 1998). Therefore, it is possible tha t the genetic polymorphism may affect 
transcription of HTR2A gene to bring about a difference in receptor expression and 
consequently affect treatm ent response as well as weight gain through 5-HT2A 
receptor regulating food intake and cortisol secretion. The interaction between the 
receptor action o f risperidone and the HTR2A -1438G/A polymorphism may explain the 
association w ith risperidone-induced weight gain found in this study.
There was no significant interaction between the associations of-1291C/G o f ADRA2A, 
-1438G/A of HTR2A, -759C/T o f HTR2C, and 677C/T of MTHFR w ith antipsychotic drug- 
induced weight gain indicating tha t these polymorphisms exert independent influences 
on this side effect.
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In conclusion, this study demonstrates novel associations of the ADRA2A -1291C/G and 
HTR2A -1348G/A polymorphisms w ith weight gain follow ing risperidone treatm ent in 
first-episode Chinese Han schizophrenia patients.
2.5.3 Association of rsl7782313 and rs489693 polymorphisms near 
MC4R gene and antipsychotic drug-induced weight gain in first 
episode patients with schizophrenia
The human melanocortin 4 receptor gene (MC4R) is a very strong candidate gene fo r 
involvement in antipsychotic drug-induced weight gain. The aim of this study was to 
investigate whether the genetic polymorphisms near the MC4R gene, rsl7782313 and 
rs489693, associate w ith antipsychotic drug-induced weight gain in first-episode 
Chinese Han schizophrenia patients. The results in this study indicated tha t rs489693 
but not rsl7782313 was associated w ith antipsychotic drug-induced weight gain in 
these subjects. Individuals carrying the C allele o f rs489693 showed more weight gain 
compared to the AA genotype after 8-10 weeks treatm ent. This finding is opposite to 
previous findings tha t found the significant association of the AA genotype w ith weight 
gain in schizophrenia patients who had received second generation antipsychotics 
(M alhotra et al., 2012; Czerwensky et al., 2013b). The d ifferent findings compared w ith 
the present study may be due to the difference in ethnicity. Other factors may also 
influence the result such as prior drug treatments, environmental factors, and clinical 
factors including age (e.g. Czerwensky et al. (2013b) studied patients aged 19 years of 
age or younger). Czerwensky et al. (2013a) also found the association o f the C allele of 
rsl7782313 w ith weight gain after 4-week treatm ent. A lack of significant association 
o f this SNP w ith weight gain in the present study may be due to the longer treatm ent 
duration (8-10 week-treatment). This result was similar to  a study by Chowdhury et al., 
(2013) tha t did not find an association of this SNP w ith weight gain a fter 14-week 
treatm ent. Further studies are needed to  confirm the association o f this polymorphism 
and antipsychotic drug-induced weight gain.
The rs489693 and rsl7782313 are not in linkage disequilibrium in this study while 
Malhotra et al (2012) find in the ir sample tha t they are in strong LD; although w ith  low 
r2 values. The m inor allele frequencies (A=0.20 fo r rs489693 and C=0.22 fo r 
rsl7782313) were lower than those in previous studies; however, they did not deviate
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from  HapMap data fo r Chinese Han (A=0.189 fo r rs489693, C=0.193 for rsl7782313) 
(http://hapm ap.ncbi.nlm .nih.gov/cgi-perl/gbrowse/hapm ap28_B36). This may be 
another factor responsible for the discrepancies of the findings.
There was no significant interaction between the rs489693, rsl7782313, HTR2C - 
759C/T, and MTHFR 677C/T polymorphisms on antipsychotic drug-induced weight gain 
indicating tha t these polymorphisms exert independent influences on this side effect.
The exact mechanism underlying the association o f rs489693 and antipsychotic drug- 
induced weight gain is unknown. No functional relevance of this polymorphism is 
known. The rs489693 may be controlled by other remote regulatory sites located at 
considerable distance from  the polymorphism such as the folding of chromosome 
(Espinoza and Ren, 2011), thus factors affecting chromosome folding may influence 
the role o f this polymorphism on weight gain. It is also possible tha t rs489693 may be 
linked to another polymorphism that has actual biological function in the regulation of 
body weight; for example: a polymorphism in the MC4R prom oter region tha t might 
influence MC4R gene expression.
2.5.4 Association of GNB3 rs5443825 C/T, BDNF rs6265 (Val66Met), 
and FTO rs9939609 A/T polymorphisms with weight gain in 
Chinese Han schizophrenia patients
The G-protein beta3 subunit gene (GNB3) 825C/T polymorphism is a strong candidate
gene related to  antipsychotic drug-induced weight gain (Balt et al., 2011). Therefore,
the association of this polymorphism and antipsychotic drug-induced weight gain was
investigated. No association between the GNB3 825C/T polymorphism and weight gain
in first episode Chinese Han schizophrenia was observed in this study. This result has
not replicated previous findings (Ujike et al., 2008; Wang et al., 2005a) tha t found the
T allele to  be associated w ith antipsychotic drug-induced weight gain. Those studies
differed from  the present study in tha t inpatients w ith schizophrenia receiving
olanzapine fo r 17.9 weeks or clozapine fo r 13.4 months were investigated, whereas
risperidone was the main drug treatm ent in first-episode schizophrenia patients in this
study; thus prior treatm ent, current treatm ent and treatm ent duration may influence
the finding. It is possible tha t this polymorphism might be associated w ith  weight gain
in long-term treatm ent and response to certain antipsychotic drug treatm ents.
106
However, the lack of significant association between the polymorphism and weight 
gain found in this study supported several previous studies showing no association in 
Asian and Caucasian studies (Tsai et al., 2004; Park et al., 2009; Bishop et al., 2006). 
The present study found a trend for association o f the CC genotype w ith  lower 
baseline weight (p=0.053) as well as lower baseline BMI. These trends were similar to 
previous studies; there was a trend of TT allele w ith weight gain after olanzapine 
treatm ent fo r 6 weeks in Caucasians (Bishop et al., 2006) and a meta-analysis also 
reported a trend of CC genotype association w ith lower BMI and lower antipsychotic 
drug-induced weight gain (Souza et al., 2008). The lack of significant association found 
in this study is likely the result o f a modest gene effect and the small sample size. Thus 
w ith inconsistent findings of the association between the GNB3 825C/T polymorphism 
and antipsychotic drug-induced weight gain, fu rther studies w ith larger sample sizes 
are needed.
Recent studies in animals and humans have found tha t BDNF plays an im portant role in 
food intake and body weight regulation (Unger et al., 2007; Toriya et al., 2010; Zhang 
et al., 2007). The role of the BDNF polymorphism in antipsychotic drug-induced weight 
gain has not been examined in first-episode schizophrenia patients; therefore, the 
association between the BDNF rs6265 G/A polymorphism and antipsychotic drug- 
induced weight gain in first-episode schizophrenia was determined in this study. No 
significant association between the polymorphism and weight gain in firs t episode 
Chinese Han schizophrenia was observed in the present study, although the AA 
genotype (M et/M e t) showed a higher BMI change and weight change than carriers o f 
the G allele.
This finding was not consistent w ith previous studies tha t found a significant
association between the M e t/M e t (AA) genotype of the BDNF rs6265 polymorphism
and greater body weight gain after chronic antipsychotic drug treatm ent in Chinese
patients w ith schizophrenia (Zhang et al., 2008). That study differed from  the present
investigation in tha t subjects received chronic treatm ent w ith m ultiple antipsychotic
drugs fo r 18y on average; thus BDNF rs6265 may be a marker fo r long-term rather than
initial weight gain. However, other studies found haplotypes which included BDNF
rs6265 G/A polymorphism (rs6265-rsll030101-rsl2291186, G-T-A) associated w ith
antipsychotic drug-induced weight gain in Chinese, chronic patients w ith schizophrenia
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(Tsai et al., 2011). The A allele o f BDNF rsl519480 and the haplotype of BDNF rs6265 
and BDNF rsl519480 (G-A haplotype) were also found to  be associated w ith weight 
gain in European ancestry chronic patients w ith schizophrenia (Zai et al., 2012). The 
BDNF rs6265 is in strong linkage disequilibrium w ith the BDNF rs ll0 3 0 1 0  (Licinio et al.,
2009) and rsl519480 (Zai et al., 2012). It is also possible tha t rs6265 does not have a 
direct effect or has a modest effect on antipsychotic drug-induced weight gain, but it is 
the other SNPs in linkage disequilibrium or haplotype patterns in the BDNF gene that 
might have the strong effect on antipsychotic drug-induced weight gain.
The association of the FTO rs9939609 polymorphism w ith food intake has been well 
documented and it is a gene that is strongly associated w ith BMI and obesity in 
d iffe rent populations (Frayling et al., 2007, Fawcett and Barroso, 2010). In addition, 
FTO is a demethylase tha t can modulate epigenetic processes in both DNA and RNA 
that might affect expression o f a certain subgroup of genes and eventually influence 
food intake and body weight regulation. The present study aimed to determ ine the 
association of the FTO rs9939609 polymorphism w ith antipsychotic drug-induced 
weight gain in Chinese first-episode schizophrenia patients. No significant association 
between the polymorphism and weight gain or baseline BMI was observed in this 
study, although those homozygous fo r the risk allele A had a higher baseline BMI and 
baseline weight that the AT/TT group.
This result is consistent w ith  a previous study (Reynolds et al., 2013) tha t found no 
significant association between the FTO rs9939609 polymorphism w ith antipsychotic 
drug-induced weight gain in first-episode Caucasian schizophrenia patients although 
the AA genotype had higher baseline weight and baseline BMI than T allele carriers. 
Studies in larger samples are more likely to  detect any significant association between 
genetic polymorphism and BMI or body weight at baseline (Perez-lglesias et al., 2010; 
Song et al., 2014). However, after antipsychotic treatm ent, changes in BMI or body 
weight were inconsistent. Therefore, the absence of significant association between 
the SNP and weight gain in this study might be due to a small sample size relative to 
the modest FTO genotype effect on antipsychotic drug-induced weight gain. Further 
studies in independent large sample size are needed to elucidate the role o f the FTO 
polymorphism in antipsychotic drug-induced weight gain.
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2.5.5 Association of genetic polymorphisms with body weight in 
chronic schizophrenia patients
The association o f the MTHFR 677C/T and MTHFR 1298A/C polymorphisms w ith body 
weight in chronic schizophrenia patients was also determined in this study. No 
significant association between the MTHFR 677C/T or MTHFR 1298A/C polymorphism 
and BMI was detected, although the CC genotype of the MTHFR 677C/T polymorphism 
showed the higher BMI, waist-hip ratio, frequency of subjects who have BMI>30kg/m2, 
and triglyceride level than T allele group. This might be due to the modest effect o f the 
MTHFR polymorphisms on body weight together w ith a very small sample size tha t 
reduces the statistical power to  detect the modest genotype effect on body weight.
However, the effect of FTO rs9939609 A/T polymorphism on BMI was still found in this 
subgroup tha t has been reported previously (Reynolds et al., 2013); the AA genotype 
was associated w ith higher BMI than the T allele carriers. The present finding was not 
in line w ith other studies; the significant association o f the A allele w ith  greater BMI 
was found in healthy subjects but not in Japanese chronic schizophrenia patients 
(Watanabe et al., 2012). Another study found a trend of AA genotype gained higher 
weight in European chronic schizophrenia patients receiving antipsychotic drugs fo r up 
to  14 weeks (Shing et al., 2014). These studies differed from  the present investigation 
in tha t the 351 patients were older (mean 52.32y) than this study (mean 44.07y) and 
there was a ethnicity difference in Watanabe's study, while there was m ultip le 
antipsychotic drug treatm ents fo r 6 or 14 weeks in 3 subgroups of patients w ith  small 
sample sizes in Shing's study.
The mechanisms underlying the association of the FTO rs9939609 polymorphism and 
antipsychotic drug-induced weight gain remain poorly understood. The FTO gene is 
highly expressed in the hypothalamus which regulates the energy balance (W ilier et 
al., 2009). The overexpression o f FTO has been associated w ith increased food intake 
and obesity (Church et al., 2009; Church et al., 2010). The A allele o f FTO rs9939609 
was associated w ith increased levels o f the FTO transcripts (Berulava and Horsthemke,
2010). The FTO protein is a demethylase involved in demethylation o f DNA and RNA 
(Jia et al., 2008; Gerken et al., 2007; Han et al., 2010) tha t may influence the 
expression of the FTO gene itself (Bell et al., 2010) or other genes (Almen et al., 2012).
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Fto-deficient mice showed an increase in adenosine methylation in a subset of RNAs 
im portant fo r neuronal signaling, including dopamine transmission (Hess et al., 2013). 
Therefore, it is possible tha t FTO may also influence other neurotransm itter pathways 
tha t could influence food intake regulation. The FTO protein is involved in the 
hypothalamic leptin signaling pathway (Wang et al., 2011). Study in mice showed the 
Fto gene was a transcriptional coactivator tha t enhanced the binding o f C/EBPs to  both 
unmethylated and methylated DNA tha t promoted transcriptional functions o f the 
C/EBP fam ily in adipogenesis (Wu et al., 2010). The SNPs located in non-coding regions 
such as FTO rs9930609, which is located in the first intron, may influence prom oter 
activity (gene expression), messenger RNA (mRNA) conformation (stability), and/or 
proteins (Shastry, 2009).This may cause differences in expression and structure of FTO 
tha t may result in d ifferential functional ability such as the binding o f FTO protein to 
the C/EBPs and subsequent binding to unmethylated and methylated DNA which may 
change the extent o f adipogenesis. Collectively, these findings suggest tha t the FTO 
polymorphism may modulate food intake through epigenetic modification o f certain 
genes as well as certain groups of RNAs relating to  neurotransm itter systems involved 
in energy balance and may result in the alteration of FTO and other genes' expression 
tha t bring about the modification of energy balance and also adipogenesis. Further 
studies are required to  elucidate the role o f FTO in antipsychotic drug-induced weight 
gain or obesity risk.
2.5.6 Limitations in this study
This study has some lim itations. First, the sample size is small that leads to a decrease 
in statistical power to detect small or modest genetic effects. However, every cohort 
has been observed previously and a significant association of the polymorphism and 
weight gain or BMI can be detected depending on the effect size. Larger sample size 
studies are needed to confirm the association between the polymorphism and 
antipsychotic drug-induced weight gain. Second, the chronic study is a cross-sectional 
study and could not determine the change in BMI during each antipsychotic drug 
treatm ent. Third, environmental factors which could contribute to  the weight gain 
such as diet, physical activity, were not assessed. These factors may influence body 
weight in this study. Taking these lim itations into account, fu rther investigations are
needed to  understand the genetic risk o f antipsychotic drug- induced weight gain.
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2.5.7 Conclusions
The findings in this chapter demonstrate that the MTHFR 677C/T polymorphism is 
associated w ith antipsychotic drug-induced weight gain in the first-episode drug-na we 
schizophrenia in both Chinese Han and Spanish patients in which the T allele was a 
protective allele fo r antipsychotic drug-induced weight gain.
This MTHFR 677C/T showed an additive effect to the well-established HTR2C -759C/T 
polymorphism. Therefore, these two genetic polymorphisms m ight be valuable as 
pharmacogenetic markers o f weight gain follow ing antipsychotic treatm ent. The 
association between the MC4R rs489693 and antipsychotic drug-induced weight gain 
observed in this study remains in need of fu rther study to elucidate and replicate this 
association.
The analysis o f a subgroup of patients who had received risperidone indicated tha t the 
polymorphisms of the ADRA2A -1291C/G and HTR2A -1438G/A were associated w ith 
risperidone-induced weight gain. In addition, the CC genotype of the MTHFR 677C/T 
polymorphism showed a trend of higher BMI gain than the T allele carriers in this 
group.
Combined analysis o f five genetic polymorphisms showed that there were no gene- 
gene interactions between each pair o f polymorphisms indicating the additive effect o f 
each significant finding on BMI change.
Therefore, in addition to the genetic polymorphism of the HTR2C prom oter region, the 
MTHFR 677C/T and the MC4R rs489693 polymorphisms may be used as genetic 
markers fo r antipsychotic drug-induced weight gain in firs t episode schizophrenia 
patients. In addition, the ADRA2A -1291C/G and HTR2A -1438G/A polymorphisms may 
be used as genetic markers fo r risperidone-induced weight gain. The gene-gene and 
gene-drug interactions provide more understanding o f the mechanism underlying 
antipsychotic drug-induced weight gain. However, fu rthe r studies w ith larger sample 
sizes are required to  confirm these findings.
I l l
Chapter 3: Association of DNA methylation and 
antipsychotic drug-induced weight gain in patients 
with schizophrenia
3.1 Introduction
Not only genetic factors influence antipsychotic drug-induced weight gain as described 
in the previous chapter, but also epigenetic factors may play im portant roles in 
antipsychotic drug-induced weight gain. DNA methylation is one of the most widely 
studied epigenetic mechanisms in the regulation of gene expression. Changes in DNA 
methylation both in genome-wide and gene-specific levels have been reported relating 
to body weight. For example, Crujeiras et al. (2013) found that the weight-regainers 
had higher methylation levels than non-regainers in POMC and lower levels on NPY 
CpG sites; the lower methylation levels o f POMC were associated w ith  weight-loss 
maintenance, while lower methylation levels o f the NPY prom oter were associated 
w ith  higher risk o f weight regain. Burgio et al. (2015) summarise the recent findings of 
epigenetic biomarkers which include many genes related to  obesity and type 2 
diabetes mellitus; fo r example: the methylation status o f CpG islands located in clock 
genes (CLOCK, BMAL1 and PER2) was associated w ith obesity, metabolic syndrome and 
weight loss; lower methylation of the leptin gene was found in infants born to  pre­
pregnancy obese mothers; increased DNA methylation of the insulin prom oter was 
found in type 2 diabetes mellitus. Moreover, many factors have influences on DNA 
m ethylation such as exercise, diet, medications, as well as medical conditions or 
diseases.
Several studies have investigated the changes in DNA methylation in patients w ith 
schizophrenia. Melas et al. (2012) determined genome-wide DNA m ethylation levels in 
blood from  schizophrenia patients and reported a global DNA hypom ethylation 
independent of drug treatm ent which was most prom inent in early-onset 
schizophrenia. In addition, haloperidol treatm ent was associated w ith  greater 
methylation. Gene-specific DNA methylation associated w ith schizophrenia has also 
been examined. Hypermethylation o f the prom oter regions of soluble catechol-o-
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methyltransferase (S-COMT) in patients w ith schizophrenia was reported (Melas et al., 
2012). In addition, DNA hypermethylation of 5-HTT prom oter and its correlation w ith 
the reduction in 5-HTT expression were reported in drug nave schizophrenia patients 
both in DNA from  saliva and post-mortem brain samples (Abdolmaleky et al., 2014). 
The correlation between GTP cyclohydrolase (GCH1) prom oter hyperm ethylation and 
the reduction in GCH1 expression was reported in the blood of first-episode 
schizophrenia patients (Ota et al., 2014). This enzyme catalyzes the conversion o f GTP 
to  D-erythro-7,8-dihydroneopterin triphosphate, the firs t and rate-lim iting step in 
tetrahydrobiopterin  (BH4) synthesis. BH4 is an im portant cofactor fo r the 
hydroxylation of the aromatic amino acids by phenylalanine hydroxylase (PAH), 
tyrosone-3-hydroxylase (TH), and tryptophan 5-hydroxylase (TPH); therefore, GCH1 
plays an im portant role in the synthesis o f dopamine and serotonin (Richardson et al., 
2005). In addition, downregulation of GAD67, reelin (RELN), BDNF, and other genes 
expressed in telencephalic GABAergic and glutamatergic neurons in schizophrenia and 
bipolar disorder patients was correlated w ith hyperm ethylation on the ir prom oter 
domains (Guidotti et al., 2005; Costa et al., 2007). These data indicate the im portant 
role of DNA methylation in regulating gene expression as well as its involvem ent in the 
pathophysiology of schizophrenia. Dysregulation o f DNA methylation may therefore 
provide a new target fo r antipsychotic drug action. The reversal o f DNA 
hypermethylation in specific genes involved in schizophrenia in order to  restore the ir 
gene expression is a potential pharmacological strategy (Guidotti and Grayson, 2014).
In addition to schizophrenia itself, o ther environmental factors affecting schizophrenic 
patients including antipsychotic medication also influence epigenetic modification. 
Study in a mouse model w ith relevance to  schizophrenia demonstrated tha t clozapine 
and sulpiride but not haloperidol or olanzapine treatm ent induced DNA dem ethylation 
as well as histone acetylation at reelin and GAD67 promoters in the mouse fronta l 
cortex and striatum (Dong et al., 2008; Guidotti et al., 2009). However, olanzapine 
treatm ent in rats caused genome-wide DNA methylation change in genes of dopamine 
neurotransmission in the hippocampus, cerebellum and liver (Melka et al., 2014). The 
changes in methylation include increases in methylation in 1,140, 1,294 and 1,313 
genes and a decrease in 633, 565 and 532 genes in the hippocampus, cerebellum and 
liver, respectively. Most genes affected are tissue specific. Only 41 affected genes
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showed an increase and no genes showed a decrease in methylation in all three 
tissues. The affected genes are involved in pathways affecting dopamine signalling, 
molecular transport, neuronal development and functions in the hippocampus; 
adrenergic receptor signalling and synaptic long-term potentiation in the cerebellum; 
and tissue morphology, cellular assembly and organization in the liver. These data 
suggest that epigenetic changes after antipsychotic drug treatm ent may underlie the 
improvement o f symptoms and may also account fo r certain adverse effects including 
weight gain after antipsychotic drug treatm ent.
Although epigenetic mechanisms are targets fo r environmental factors, genetic factors 
also influence epigenetic modifications and this genetic-epigenetic interaction may 
contribute to the phenotypes. The interaction between the MTHFR 677C/T variant, 
gender, and global DNA methylation, as measured using a LINE-1 DNA methylation 
assay has been reported to be associated w ith metabolic syndrome in schizophrenia 
patients, in which females w ith the MTHFR 677TT genotype had the lowest global 
methylation level compared w ith other groups (Burghardt et al., 2012). Another study 
reported a significant association between the COMT V a ll58M et (rs4680) 
polymorphism, COMT prom oter methylation, physical activity, and metabolic 
syndrome in patients w ith schizophrenia (Lott et al., 2013). In addition, they observed 
tha t the COMT genotype was a significant indicator of methylation status at tw o  CpG 
sites in the COMT prom oter region. These data indicate the influence o f genetic 
polymorphisms on DNA methylation and this relationship may influence the in ter­
individual variation in symptom response and adverse effects in schizophrenia patients 
receiving antipsychotic drugs.
This chapter describes the examination of the association between antipsychotic drug-
induced weight gain and DNA methylation in the HTR2C prom oter sequences near the
HTR2C -759C/T, the most consistent polymorphism associated w ith antipsychotic drug-
induced weight gain in firs t episode and chronic schizophrenia patients. In addition,
associations between polymorphisms, especially MTHFR and FTO polymorphisms tha t
play an im portant role in DNA methylation, and the extent o f DNA m ethylation, were
determined. The results from  this chapter may provide the mechanistic link between
the genetic risk factor o f the HTR2C, MTHFR, and FTO polymorphisms and
antipsychotic drug-induced weight gain and may also provide an epigenetic marker fo r
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this adverse effect. DNA methylation levels were measured using pyrosequencing of 
the bisulfite modified genomic DNA by PyroMark Q24 pyrosequencer.
3.1.1 Principles of pyrosequencing method
DNA methylation levels of the target DNA sequences can be determined using bisulfite 
conversion and pyrosequencing. There are many steps to  complete in determining 
DNA methylation status including genomic DNA extraction, bisulfite treatm ent, PCR 
and gel electrophoresis, and pyrosequencing. A work flow  is shown in Figure 3.1.
Figure 3.1: Work flow for DNA methylation study
3.1.1.1 Bisulfite conversion of genomic DNA
The bisulfite treatm ent o f extracted genomic DNA results in conversion of 
unmethylated cytosine to uracil while methylated cytosine remains a methylated 
cytosine. Therefore, bisulfite treatm ent creates d ifferent DNA sequences for 
methylated and unmethylated DNA as shown in Table 3.1 fo r example. It is the most 
critical step fo r the correct measurement o f DNA methylation because incomplete 
conversion of unmethylated cytosine residues results in higher methylation levels than 
the correct level. The complete conversion is achieved by incubating the DNA in high 
concentration of bisulfite salt at high tem perature and low pH tha t are harsh 
conditions which often lead to  DNA fragm entation and loss of DNA during fu rthe r 
purification. As shown in Figure 3.2, in the bisulfite treatm ent reaction, all 
unmethylated cytosines are sulfonated, deaminated and desulfonated, converting to 
uracils, while methylated cytosines (5-methylcytosines) remain unaltered.
Sulfonation Hydrolytic Alkali
NH2 NH2 deamination Q desulfonation 9
hs°3 n A  h;o hnA  oh
0 H  0 ^ ^ N ^ ^ S 0 3 ^  O ^ ' N  S 0 3‘ h s ° 3  O ^ ' N
h h NH; H H
cytosine cytosine uracil uracil
sulphonate sulphonate
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Figure 3.2: Bisulfite reaction converting unm ethylated cytosine to  uracil base
Modified from Pappas et al., (2013)
Table 3.1: M odification o f DNA sequence a fte r b isu lfite  trea tm ent
Original sequence Bisulfite modified sequence
Unmethylated DNA 
Methylated DNA
N-C-G-N-C-N-C-G-N-C-N
N-C-G-N-C-N-C-G-N-C-N
N-U-G-N-U-N-U-G-N-U-N
N-C-G-N-U-N-C-G-N-U-N
3.1.1.2 Amplification of bisulfite converted DNA
Bisulfite treated DNA is then amplified by PCR. In this step, the uracil bases are 
converted to  thym ine while methylated cytosine is presented as cytosine (Figure 3.3). 
In the PCR reaction, it is necessary tha t one of the PCR primers in the opposite 
direction o f the sequencing primer must be labelled w ith biotin. The biotinylated 
prim er is im portant in the preparation of the single-stranded DNA tem plate fo r 
pyrosequencing; in the vacuum work station, biotin molecules are immobilized by 
binding to the streptavidin beads. The principle o f PCR is described in the next chapter 
(see section 4.1.3).
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Figure 3.3: Changing in DNA sequences fo llow ing  b isu lfite  conversion and PCR steps 
Bisulfite treatm ent converts unmethylated cytosine to  uracil while methylated cytosine 
remains cytosine. During PCR, uracil is converted to  thym ine while methylated cytosine 
was presented as cytosine.
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3.1.1.3 Gel electrophoresis of amplified DNA
The PCR product is run on agarose gel to determ ine tha t the product of the expected 
length has been obtained before processing the subsequent pyrosequencing. The 
result from  gel electrophoresis also indicates the intensity of the PCR product that can 
be used to  approximate the amount o f PCR product used in pyrosequencing as well as 
checking fo r contamination in the negative PCR reaction.
3.1.1.4 Pyrosequencing
Pyrosequencing is based on sequencing by synthesis which can be used to  quantify 
DNA methylation at specific CpG sites w ith in  the target region of interest. In addition, 
pyrosequencing can be used for DNA sequencing, genotyping and SNP analysis, allele 
quantification, and whole genome sequencing.
The principle o f pyrosequencing is described by the manufacturer's resource as 
follows;
Step 1: Preparation of DNA template and hybridization with sequencing primer
The amplified PCR products are separated into the single-stranded DNA for 
pyrosequencing by the PyroMark Q24 vacuum workstation which consists o f a series of 
solutions fo r denaturation and washing the DNA. A fter denaturation, a single-stranded 
biotinylated PCR product is separated and allowed to hybridize w ith the sequencing 
primer (Figure 3.4). The hybridized primer and tem plate are incubated w ith the 
enzymes (DNA polymerase, ATP sulfurylase, luciferase, and apyrase) as well as the 
substrates (adenosine 5' phosphosulfate (APS), and luciferin).
Step 2: Incorporation of the first dNTP to DNA template
When the first deoxyribonucleotide triphosphate (dNTP) is added to the reaction and if 
it is complementary to  the base in the tem plate strand, the DNA polymerase enzyme 
catalyzes the incorporation of the dNTP into the new strand DNA next to  the 
sequencing primer. Each incorporation event is accompanied by release of 
pyrophosphate (PPi) in a quantity equimolar to the amount o f incorporated nucleotide 
(Figure 3.4).
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Biotinylated reverse PCR primer o
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Polymerase
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i i i r
3'
Sequencing primer
Polymerase
(DNA)n + dNTP (DNA)n+, + PPi
Figure 3.4: Pyrosequencing showing hybridization of sequencing primer with 
biotinylated single-stranded DNA template (step 1) and incorporation of the 
complementary nucleotide into sequencing primer (step 2).
Step 3: Enzymatic reactions convert PPi to pyrogram peak
A released pyrophosphate (PPi) is converted to ATP by the enzyme ATP sulfurylase in 
the presence of adenosine 5' phosphosulfate (APS) substrate. This ATP drives the 
conversion of luciferin to oxyluciferin mediated by the luciferase enzyme. This 
conversion reaction generates visible light in amounts tha t are proportional to  the 
amount o f ATP. The light signal is detected by a charge coupled device (CCD) chip and 
seen as a peak (pyrogram) in the raw data output. The height o f each peak (light signal) 
is proportional to the number o f nucleotides that are incorporated (Figure 3.5).
Step 4: Degradation of unincorporated nucleotides and ATP
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Unincorporated nucleotides and ATP are degraded continuously by apyrase which is a 
nucleotide-degrading enzyme (Figure 3.6). When degradation is complete, another 
nucleotide is added to start the next cycle of enzymatic reactions.
Sulfurylase
/
LightAPS+PPi ATP
luciferin oxyluciferin
\
Luciferase
i
ATP Light
Time
Nucleotide incorporation generates light 
seen as a peak in the Pyrogram trace
Figure 3.5: Pyrosequencing step 3 showing enzymatic reactions convert PPi to 
pyrogram peak.
Figure 3.6: Pyrosequencing step 4 showing degradation of unincorporated 
nucleotides and ATP by apyrase enzyme.
Step 5: Sequential addition of dNTPs
Addition o f dNTPs is performed sequentially according to the dispensation sequences.
As the process continues, the complementary DNA strand is elongated and the
nucleotide sequence is determined from  the signal peaks in the pyrogram trace (Figure
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dNTP
Apyrase
dNDP + dNM P + phosphate
Apyrase
AT? ADP + AMP + phosphate
3.7). In the pyrosequencing processes, the deoxyadenosine alpha-thio triphosphate 
(dATPaS) is used as a substitute for the natural deoxyadenosine triphosphate (dATP), 
because it is efficiently used by the DNA polymerase, but not recognized by the 
luciferase.
Nucleotide sequence
G C -  A GG CC T
C G CG A TT
Nucleotide added
Figure 3.7: Pyrosequencing step 5 showing a sequential add ition o f dNTPs to  
generate the nucleotide sequence represented by signal peaks in the pyrogram trace.
Analysing DNA methylation level at each CpG site
The ratio o f cytosine and thym ine showing at each CpG site is determ ined, and it 
reflects the methylation level o f that CpG site in genomic DNA. The calculation 
equation of the methylation level at each CpG site is as follow ing equation.
Methylation level (%) = peak height o f C*100/(peak height of C + peak height o f T)
3.1.2 Aims
1. To investigate the relationship between DNA methylation o f the HTR2C 
prom oter sequences near the HTR2C -759C/T polymorphism, and the 
sequences from  position +1 to  +14 relative to the -759C/T polymorphism, and 
antipsychotic drug-induced weight gain in first episode schizophrenia patients.
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2. To investigate the effect of DNA methylation of the HTR2C promoter sequence 
near the HTR2C -759C/T polymorphism, and global DNA methylation, with BMI 
in chronic schizophrenia patients.
3. To investigate the influence of genetic polymorphisms of the HTR2C -759C/T, 
MTHFR 677C/T, MTHFR 1289A/C and FTO rs9939609 A/T on the extent of DNA 
methylation in first episode and chronic schizophrenia patients.
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3.2 Materials and methods
3.2.1 Study population and DNA samples
The study populations in this chapter were the same as in the previous chapter 
including the tw o cohorts o f first-episode, in itia lly antipsychotic drug-naive patients 
w ith schizophrenia (Spanish and Chinese cohorts) and one cohort of chronic 
schizophrenia patients (Belfast cohort). All patients received treatm ent according to 
normal clinical practice and gave w ritten  informed consent to the procedure of the 
study; which was approved by local ethical committees. The characteristics o f studied 
populations were described previously in the section 2.2.1.
3.2.2 Primer design
There were tw o regions o f interest for DNA methylation of HTR2C gene; the first 
region is located in the prom oter region of HTR2C gene near the -759C/T and includes 
the -697G/C polymorphism (from -698 to -640 relative to  -759C/T), identified by the 
PubMed gene bank (GeneBank accession number NG_012082.1). The second region is 
located at position +1 to +14 relative to  the -759C/T polymorphism identified and 
designed by Qiagen, the Hs_H77?2C_01_PM PyroMark® CpG assay (Cat.no. 
PM00033691). The sequence alignments of both regions are shown in Figure 3.8.
Another region of interest was the LINE-1 human transposon DNA consensus sequence 
including three CpG sites in positions o f 331 to 318 o f LINE-1 (GeneBank accession 
number X58075.1). LINE-1 methylation represents the genome-wide or global DNA 
methylation.
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Figure 3.8: Sequence alignments o f HTR2C gene containing tw o  regions fo r DNA 
m ethylation  study
Figure shows HTR2C -697G/C and Hs_H77?2C_01_PM as underlined sequences w ith 
CpG methylation sites shown in bold. HTR2C rs3813929 (-759C/T) and rs518147 (- 
697G/C) were highlighted in green.
The HTR2C -697G/C primers were designed using PyroMark Assay Design Software 2.0 
(Qiagen) whereas UNE-1 primers (PyroMark® Q24 CpG LINE-1) and Hs_H7/?2C_01_PM 
PyroMark® CpG assays were purchased from Qiagen. Primer sequences fo r PCR and 
pyrosequencing are listed in Table 3.2.
Table 3.2: The sequences o f primers used in DNA m ethylation study
Primer Sequence PCR
length
HTR2C -697G/C Fwd: 5'- GTTAGTAGGTTTTAGATGTATTAAGAGAT-3' 
Rev: 5/-[btn]AACAACCAAAACTAACAATCTAAC-3/ 
Seq: 5 '- GAGGTAGGAG 1 1 1 IGGTGTTTG-3'
241 bp
Hs_H7/?2C_01_PM 
PyroMark CpG assay
Unknown primer sequences but included the 
sequence to  analyse of CGCGCAAATCGCGA
159 bp
UNE-1 PyroMark® 
CpG assay
Unknown primer sequences but included the 
sequence to analyse of CTCGTGGTGCGCCGTTT
146 bp
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3.2.3 DNA methylation in different cohorts
Table 3.3 shows the DNA methylation assays in each cohort.
Table 3.3: D ifferent DNA m ethylation assays were investigated in each study 
population.
Belfast V
Chinese V S X
Spanish V V X
3.2.4 Bisulfite conversion of genomic DNA
There were tw o bisulfite conversion kits used in this study, the EpiTech Plus DNA 
Bisulfite kit and EpiTech Fast DNA Bisulfite kit (Qiagen). The general procedure was the 
same fo r bisulfite conversion; genomic DNA was exposed to bisulfite which mediated 
conversion of unmethylated cytosines to uracils. The converted single-stranded DNA 
was then bound to  the membrane of a MinElute DNA spin column followed by washing 
and desulfonation. Then washing was performed to  remove the desulfonation agent. 
Finally, converted DNA was eluted.
These tw o kits from  Qiagen used spin column technology and provided reagents in 
aliquots tha t more convenient. In addition, the reagents are supplied in a unique 
form ulation, fo r example, bisulfite mix which provided the optimal pH fo r complete 
conversion of cytosine to uracil w ithout the need fo r tedious pH adjustment. The 
difference between the tw o kits was the Bisulfite Mix o f the EpiTech Plus Bisulfite Kit 
was a powder tha t need to be dissolved in 800 jllI RNase-free water before use while 
the bisulfite solution in the EpiTech Fast Bisulfite Conversion kit was ready-to-use 
solution. In addition, DNA protect buffer was used to prevent the fragm entation of 
DNA usually associated w ith bisulfite treatm ent at high tem peratures and low pH. In 
addition, the DNA protect buffer also provided effective denaturation to separate 
double-stranded to  single-stranded DNA that is necessary fo r complete cytosine 
conversion. Moreover, the DNA protect buffer contains a pH indicator dye which has a 
green colour which should turn to  blue after addition to the bisulfite m ixture indicating
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sufficient mixing and correct pH for the bisulfite conversion reaction. Another 
difference from the first kit is a series of incubation steps which were performed in the 
therm al cycler.
The procedure was carried out according to the manufacturer's protocols as follows. 
The bisulfite reaction was setup at room tem perature in a 0.2 ml PCR tube containing 
gDNA, bisulfite solution, and DNA protect buffer in a tota l volume of 140 pi as shown 
in Table 3.4. The combined volume of DNA and RNase-free water was depended on 
the concentration of DNA, 20 pi fo r high concentration and up to  40 pi fo r low 
concentration DNA samples.
Table 3.4: Bisulfite reaction components
Component High concentration DNA 
(1-2 pg)
Low concentration DNA 
(1-500 ng)
DNA Variable 1-20 pi Variable 1-40 pi
RNase-free water Variable Variable
Bisulfite solution 85 pi 85 pi
DNA Protect buffer 35 pi 15 pi
Total volume 140 pi 140 pi
The bisulfite reaction was mixed thoroughly indicated by DNA protect buffer turn ing 
from  green to blue. Then the reaction m ixture was incubated in a therm al cycler w ith 
heated lid programmed as listed in Table 3.5.
The differences between EpiTech Plus DNA Bisulfite Kit and the EpiTech Fast DNA 
Bisulfite Conversion kit were the series o f incubation steps in the therm al cycler fo r 
which the EpiTech Plus required about 5 hours whereas 30-50 minutes were required 
fo r the EpiTech Fast kit fo r DNA denaturation and subsequent sulfonation and cytosine 
deamination.
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Table 3.5: Bisulfite treatment thermal cycler conditions
EpiTech Plus Bisulfite Kit EpiTech Fast Bisulfite Conversion kit
Step Time Temperature Step Time Temperature
Denaturation 5 min 95°C Denaturation 5 min 95°C
Incubation 25 min 60°C Incubation 10-20 min 60°C
Denaturation 5 min 95°C Denaturation 5 min 95°C
Incubation 85 min 60°C Incubation 10-20 min 60°C
Denaturation 5 min 95°C Hold Indefinite 20°C
Incubation 175 min 60°C
Hold Indefinite 20°C
The next step was cleanup of bisulfite converted DNA. The complete bisulfite reaction 
from  the thermal cycler was briefly centrifuged and transferred to a 1.5 ml tube. Then 
310 pi of freshly prepared buffer BL containing 10 pg/m l carrier RNA was added to 
each tube followed by mixing and brief centrifugation. Absolute ethanol, 250 pi, was 
added to each tube followed by pulse vortexing fo r 15 seconds and brief 
centrifugation. The mixture was transferred into the MinElute DNA spin column and 
then centrifuged at maximum speed fo r 1 minute. The flow-through was discarded. 
Wash buffer (buffer BW) 500 pi was added to each spin column and then centrifuged 
at maximum speed for 1 minute. The flow-through was discarded. Desulfonation 
buffer (buffer BD) 500 pi was added and then the lid of the spin column was closed 
before incubation at room tem perature for 15 minutes. Then the spin column was 
centrifuged at maximum speed for 1 minute. The flow-through was discarded. Wash 
buffer 500 pi (buffer BW) was added followed by centrifugation and discard the flow ­
through. The wash step was repeated one additional time. Absolute ethanol, 250 pi, 
was added to  each spin column followed by centrifugation. Another additional 
centrifugation of the spin column into a new collection tube was perform ed at 
maximum speed fo r 1 m inute to  remove any residual liquid before the elution step. 
The spin column was placed into a new 1.5 ml tube and 15-20 pi o f elution buffer 
(buffer EB) was added directly onto the center o f the spin column membrane. The lid 
o f the spin column was gently closed. The spin column was incubated at room 
tem perature for 1 minute followed by centrifugation fo r 1 minute at 15,000xg (12,000 
rpm) to elute the DNA. The bisulfite converted DNA was stored at -20°C until use.
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3.2.5 Amplification of bisulfite treated DNA by PCR
Bisulfite converted DNA was amplified by PCR to amplify the region of interest using 
the PyroMark PCR kit (Qiagen). The PCR reaction was set up in a 0.2 ml PCR tube in a 
tota l volume of 25 pi containing 10-50 ng of bisulfite converted DNA, PyroMark PCR 
Master Mix, 2x (HotStartTaq DNA Polymerase, 3 mM MgCI2, dNTPs), and primers 
according to Table 3.6. The final concentration o f PCR primers and MgCI2 were 0.2 pM 
and 1.5 mM, respectively. The negative PCR reaction was also set up in every PCR 
setup to  detect possible contamination. All PCR reaction tubes were briefly centrifuged 
before placing into the thermal cycler.
Table 3.6: PCR reaction composition for amplification of bisulfite converted DNA
Component Volume per reaction
PyroMark PCR Master Mix, 2x 12.5 pi
CoralLoad Concentrate, lOx 2.5 pi
PCR Primers (5 pM) 1 pi (0.2 pM  final conc.)
RNase-free water variable
Bisulfite converted DNA tem plate 1-5 pi (10-50 ng)
Total volume 25 pi
The thermal cycler instruments used in this study including the Veriti™  Thermal Cycler 
(Applied Biosystems, USA), the TC-5000 gradient therm al cycler (TECHNE, USA), the 
MWG-Biotech Primus 96 Plus Thermal Cycler and the Primus 25 Thermal Cycler 
(Biotech Equipment Sales Inc., CA). The therm al cycler, w ith heated lid, was 
programmed according to PCR conditions in Table 3.7. The PCR products were stored 
at 2-8°C overnight or at -20°C fo r longer storage. 5-20 pi o f PCR product was used for 
subsequent pyrosequencing analysis while 5 pi was run on an agarose gel to  check the 
product and possible contamination.
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Table 3.7: Optimized PCR condition using thermal cycler
PCR cycling Time Temperature
Initial heat activation 15 min 95°C
Denaturation 30 s 94°C
45-50 -< Annealing 30 s 50°C, 56°C, 60°C *
cycles Extension 30 s 72°C
Final extension 10 min 72°C
Hold Indefinite 4°C
*The annealing tem perature fo r LINE-1, HTR2C -697G/C and Hs_/-/77?2C_PM were 50°C, 
60°C, and 56°C, respectively.
3.2.6 Checking PCR product by agarose gel analysis
The amplified PCR product of bisulfite modified DNA was assessed fo r the specificity of 
PCR amplification in which a single product at the expected size was obtained. In 
addition, the intensity o f the PCR product on the gel was used to approximate the 
amount fo r use in pyrosequencing. Moreover, any possible contamination during the 
PCR processes was also assessed.
The 2.0% (w/v) gel was prepared by adding 40 ml o f lxTAE or TBE to  0.8 g o f agarose 
powder. The mixture was then heated to melt and dissolve the agarose thoroughly 
using a microwave for 1 minute. A fter the gel was completely melted and cooled down 
to  about 60°C, the gel was mixed w ith 0.4 pi o f 5 mg/m l ethidium bromide solution 
immediately prior to  pouring into a prepared gel casting plate w ith a plastic comb. The 
agarose gel was allowed to set at room tem perature. Once the agarose gel was ready, 
it was then placed into an electrophoresis tank filled w ith 1XTAE buffer.
5 pi o f PCR product was loaded directly onto the agarose gel w ithout prior addition o f 
loading buffer because the PCR product contained the CoralLoad® Concentrate which 
contains a gel loading reagent and 2 gel tracking dyes. 5 pi of 100 bp DNA marker 
(GeneRuler 100 bp DNA Ladder, Cat.no. SM0241, Thermo Scientific, UK) was also 
loaded onto the gel.
Electrophoresis was carried out at 100V for approximately 50 minutes or until the dye 
had reached the bottom  of the gel to ensure the appropriate separation of DNA ladder 
and PCR products. Then the gel was viewed under a UV light or CCD camera fitted  to  a 
UV transilum inator. The gel was exposed to  UV until a clear image was obtained.
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3.2.7 Pyrosequencing
Pyrosequencing was carried out using the PyroMark Q24 systems. There were 4 main 
steps to complete the analysis o f DNA methylation using pyrosequencing including (1) 
assay and run setup, (2) immobilization of PCR products to streptavidin sepharose HP 
beads, (3) preparation of samples fo r pyrosequencing analysis, (4) quantification of 
CpG methylation as described by manufacturer.
3.2.7.1 Assay and run setup
The assay fo r CpG methylation analysis was setup in PyroMark Q24 Software (Qiagen) 
by selecting "New CpG Assay" and entering the nucleotide sequence in "Sequence to 
Analyze". Dispensation order o f nucleotides was created by clicking a "Generate 
Dispensation Order" button and the internal control fo r the completion of bisulfite 
treatm ent was manually added by adding a C dispensation before or a fter the 
dispensation of T that was converted from C. The assay was saved. This assay setup 
was performed only the firs t tim e the assay was run. The gene bank sequence, the 
sequence to analyze which was the sequence after bisulfite conversion, and the 
dispensation order (included internal control fo r bisulfite conversion) o f each DNA 
methylation assay are listed in Table 3.8. The dispensation orders were presented as 
histograms as shown in Figure 3.9.
The run file was created by selecting "New Run" and the plate was setup by adding the 
assay parameters to  each wells. The run setup file was saved into a USB stick. A list o f 
required volumes of reagents and the plate setup can be printed out from  "Pre Run 
Inform ation" from  the "Tools" menu bar.
More inform ation about how to  setup the assays and run the files is provided in the 
PyroMark® Q24 Software User Guide (Qiagen).
Before starting the next steps, the PyroMark Q24 system and the heat block were 
turned on to  warm up. The heat block was set at 80°C and the plate holder was also 
placed on the heat block.
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Table 3.8: The DNA sequences o f each DNA m ethylation assay
Sequence
HTR2C -697G/C assay (Number of CpG site : 5)
Gene bank Sequence:
CG G AG G ACG CTT CCTT CCTC AG ATG C ACCG AT CTT CCCG ATACTG CCTTT G G AG CG G CT 
Sequence to  Analyze:
YGGAGGAYGTTTTTTTTTTTAGATGTATYGATTTTTTYGATATTGTTTTTGGAGYGGTT 
Dispensation order:
ACT CG G AGT AT CGT CT AG AT GT CG AT CGT ATT CG AT CAT GTT GAT GT CG
Hs_H77?2C_01_PM PyroMark CpG assay (Number of CpG site : 4)
Gene bank Sequence: CGCGCAAATCGCGA 
Sequence to Analyze: YGYGTAAATYGYGA 
Dispensation order: GTCGTCGTCAATCGTCG
Hs_LINE-l PyroMark® CpG assay (Number o f CpG site : 3)
Gene bank Sequence: CTCGTGGTGCGCCGTTT 
Sequence to Analyze: TTYGTGGTGYGTYGTTT 
Dispensation order: GCTCGTGTAGTCAGTCG
The methylation cytosine sites are in bold (C or Y) or highlighted in blue; the internal 
controls for completion o f bisulfite treatm ent (C) were highlighted in yellow; Y was 
described fo r pyrimidine (C or T); the underline in HTR2C -697G/C assay was the 
position of-697G/C polymorphism.
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(A) HTR2C -697G/C CpG assay
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Figure 3.9: Histograms for dispensation order of CpG assays for HTR2C -697G/C (A), 
Hs_H77?2C_01_PM (B), and LINE-1(C). The controls (C or cytosine) for completion of 
bisulfite treatment are highlighted in yellow.
3.2.7.2 Immobilization of PCR products to streptavidin sepharose HP beads
In this step, DNA tem plate was immobilized to  streptavidin sepharose HP beads for 
subsequent analysis using the PyroMark Q24. The reactions were set up in 24-well PCR 
plates in the tota l volume of 80 pi according to Table 3.9. The PCR plate was sealed 
using adhesive film  to  ensure tha t no leakage is possible between the wells. The PCR 
plate was agitated constantly at 1,400 rpm for 10 minutes at room tem perature (15- 
25°C) using a mixer. As sepharose beads sediment quickly, the capturing o f beads in 
the next step to prepare samples fo r pyrosequencing was performed im m ediately 
once the agitation was completed. During agitation, the biotin-labelled DNA was 
immobilized to streptavidin-coated beads.
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Table 3.9: Components o f master m ix and PCR product fo r DNA im m obilization
Component Volume per sample
Pyromark binding buffer, 2x 40 pi
Streptavidin sepharose HP beads 2 pi
RNase-free water 18 pi or less
PCR product 20 pi or less
Total volume 80 pi
3.2.7.3 Preparation of samples fo r pyrosequencing analysis
This step was carried out using the PyroMark Q24 Vacuum W orkstation (Qiagen) to 
prepare single-stranded DNA tem plate and anneal the sequencing primer to  the 
tem plate before pyrosequencing analysis. The Vacuum work station was prepared 
before starting by filing five separate troughs according to Figure 3.10. The filte r probe 
was washed once tim e by flushing w ith high-purity water (M illi-Q  18.2MQxcm) in 
trough 5. Trough 5 was refilled w ith 70 ml high-purity water.
PyroMark Q24 Vacuum Workstation
IB
1 Ethanol (70%) 50 ml
2 Denaturation 40 ml
3 Wash Buffer ( lx ) 50 ml
4 High-purity w ater 50 ml
5 High-purity w ater 70 ml
Parking position PyroMark plate
Figure 3.10: PyroMark Q24 Vacuum W orkstation preparation
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The sequencing primer was diluted to the concentration of 0.3 pM in annealing buffer 
(Qiagen) and 25 pi of 0.3 pM sequencing primer was added to the PyroMark Q24 plate.
Once the PCR plate agitation was completed, the beads containing immobilized DNA 
tem plate were captured immediately w ith in 1 m inute since the plate was agitated 
according to manufacturer's protocol. The PCR plate was placed in the workstation. 
The pump was switched on and the vacuum switched on to apply vacuum to  the tool. 
The filte r probes were carefully lowered into the PCR plate for 15 seconds until all 
beads were captured. The tool was carefully picked up and transferred to  trough 1 
containing 70% ethanol to  flush the filte r probes fo r 5 seconds. The PCR reaction 
components except fo r the immobilized DNA tem plate were washed out in this step. 
Then the tool was moved to  trough 2 containing denaturation solution fo r 5 seconds. 
The double-stranded DNA was separated into single-stranded DNA; only the 
biotinylated strands were captured by beads. Unbiotinylated strands and denaturation 
solution were completely washed when the filte r probes was flushed in trough 3 
containing wash buffer fo r 10 seconds. The tool was raised to beyond 90° vertical fo r 5 
seconds to drain liquid from  the filte r probes before holding the too l over the 
PyroMark plate. The vacuum switch was turned o ff before lowering the filte r probes 
into the PyroMark plate containing sequencing primer. The beads were released by 
gently shaking the too l in the wells fo r 15 seconds. The tool was then transferred to 
trough 4 containing the high-purity water and agitated fo r 10 seconds before moving 
to trough 5 containing the high-purity water and applying vacuum to  flush the filte r 
probes fo r 5 seconds. The tool was raised to  beyond 90° vertical fo r 5 seconds to  drain 
the liquid from  the filte r probes before the vacuum switch was o ff and then the tool 
was placed in the parking position. The vacuum pump was turned off.
The PyroMark plate containing the pyrosequencing templates and sequencing prim er 
was heated at 80°C for 2 minutes using the PyroMark Q24 plate holder. The samples 
were cooled down to room tem perature fo r at least 5 minutes before proceeding in 
the PyroMark Q24 pyrosequencer. During the tim e the samples were cooled down, the 
sequencing primers annealed to the templates.
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3.2.7.4 Quantification of CpG methylation
The PyroMark Gold Q24 reagents including dNTPs, enzyme, and substrate mixtures, 
which were purchased from Qiagen were carefully loaded w ithout air bubbles into the 
PyroMark Q24 cartridge according to the volume reported in the pre run inform ation. 
All reagents and the cartridge were allowed to reach room tem perature before placing 
into the PyroMark Q24 followed by placing the PyroMark plate on the heating block. 
The USB stick w ith set up run file was inserted into pyrosequencer, and then 
pyrosequencing was started. When pyrosequencing was finished, the processed run 
file  was automatically saved to  the USB stick. The plate was discarded and the 
cartridge was cleaned according to the PyroMark Q24 user manual guide. The 
PyroMark Q24 was shutdown and switched off.
The processed run file was analyzed in the CpG mode in PyroMark Q24 Software. The 
quantification of CpG methylation and quality assessment were displayed above each 
CpG site in the program trace. For reliable results the manufacturer had recommended 
tha t the single peak heights should be above 30 relative light units (RLU) which was set 
as the 'required peak height for passed quality' in assay setup.
3.2.8 Statistical Analyses
All statistical analyses were carried out using SPSS for W indow.
The methylation levels of all CpG sites were tested fo r outliers and normal d istribution 
before testing association. Stepwise linear regression was used to  analyse the 
confounding effect of age or gender on methylation levels. The partial correlation were 
used in analysing the correlation between methylation at each CpG site and interval or 
ratio scale variables such as baseline weight, baseline BMI or BMI, weight change, BMI 
change. The association between genetic polymorphisms and DNA m ethylation was 
analyzed using a general linear model (univariate analysis o f variance) w ith  covariates 
as appropriate. Mann-W hitney U test and Kruskal-Wallis one-way ANOVA test were 
used if the data were not normally distributed. Chi-square was used to  analyze the 
difference between categorical variables. Significant differences between means were 
determined at a level o f p < 0.05.
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3.3 Results
3.3.1 Validation of methodology: DNA methylation study
The validation of the method fo r determ ining DNA methylation using bisulfite 
treatm ent of genomic DNA and pyrosequencing was determined as described below.
1. DNA samples were tested fo r the precision o f the bisulfite treatm ent throughout 
pyrosequencing. Initially, DNA samples were subjected to 3 bisulfite treatm ents, then 
each bisulfite modified DNA was amplified by PCR and subsequently pyrosequenced 
together. Figure 3.11A shows the DNA methylation levels o f three d ifferent bisulfite 
treatm ents (per sample) fo r the determ ination o f LINE-1 methylation. The coefficients 
o f variation were less than 5% (1.15-3.10%). The result indicates high precision o f 
m ultip le bisulfite reactions.
2. 3 modified DNA samples were tested fo r the precision o f the PCR step. Each bisulfite 
modified DNA was amplified by 3 independent PCRs, and then underwent 
pyrosequencing together. Figure 3.11B shows the DNA methylation levels o f three 
d ifferent PCRs (per bisulfite modified DNA sample) in determ ination o f 
Hs_/-/77?2C_01_PM methylation. The variation coefficients were less than 10% (0.83- 
7.33%). The result indicates the high precision o f m ultip le PCR reactions.
3. 3 modified DNA samples were tested fo r the precision o f the pyrosequencing step. 
Each PCR product underwent pyrosequencing separately (3 times). Figure 3.11C shows 
the DNA methylation levels o f three d ifferent pyrosequencing which were performed 
using the same PCR product fo r determ ination of the HTR2C -697A/C m ethylation. The 
coefficients o f variation were less than 10% (0.5-9.5%). The result indicates the high 
precision o f m ultiple pyrosequencing.
The results o f DNA methylation levels o f each sample were calculated fo r coefficient o f 
variation (CV) using the follow ing formula:
Coefficient o f variance (%) = Standard deviation *100 /  Mean
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Figure 3.11: DNA methylation levels and coefficient of variation showing the 
precision of each step of DNA methylation measurement
(A) precision o f bisulfite treatm ent step, (B) precision of PCR step, and (C) precision of 
pyrosequencing step.
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3.3.2 DNA methylation of the HTR2C promoter sequences and global 
methylation in chronic schizophrenia patients (Belfast cohort)
DNA methylation levels o f two regions o f the HTR2C gene and one region o f LINE-1 
were investigated in the chronic Belfast cohort. The mean age of male patients was 
42.6y (n=41) and 46.ly  fo r female (n=31). Gender was significantly related to 
methylation in both HTR2C regions in which females had higher methylation levels 
than males at all CpG sites (p<0.05), and the CpGl o f LINE-1 (p=0.016). Age was 
significantly associated w ith some CpGs including the CpG -691, -670, -661, and -644 of 
the HTR2C-697G/C region, and the CpGl and CpG2 o f the Hs-/-/77?2C_01_PM region 
(p<0.05) in which methylation levels wereincreased w ith age. Age did not associate 
w ith methylation o f LINE-1. The mean age of patients receiving olanzapine or clozapine 
(37.ly )  was significantly lower than tha t o f the remaining patients receiving all o ther 
drugs (47.2y, p<0.001). Therefore, gender and age were included as covariates in 
subsequent analyses as appropriate. The methylation of LINE-1 at all CpG sites was 
normally distributed; thus parametric tests were used in analyses, whereas the non- 
parametric tests were used in analysing the association o f the HTR2C -697G/C and 
Hs_H77?2C_01_PM regions where results were not normally distributed.
3.3.2.1 Global DNA methylation
M ethylation of LINE-1 was not associated w ith age at any of the 3 CpG sites (Figure 
3.12) in either male or female subgroups (p>0.05). However, it was associated w ith 
gender; the methylation levels o f the LINE-1 in males was significantly higher than tha t 
o f females at CpGl o f the LINE-1 region (male 78.98±1.44%, n=36 vs female 
78.04±1.67%, n=30, p=0.016) while the other tw o  CpG sites showed the same pattern 
(Figure 3.13A). In addition, tobacco smoking was also associated w ith  m ethylation o f 
LINE-1; smokers had higher methylation of the LINE-1 than non-smoking patients and 
the difference reached statistical significance at CpG3 (p=0.019) as shown in Figure 
3.13B.
Patients receiving olanzapine or clozapine had slightly lower global DNA m ethylation 
levels than those patients receiving all o ther drugs (Figure 3.13C) but it did not reach 
statistical significance. No significant association of obesity (BMI>30 kg /m 2), central
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obesity, or metabolic syndrome and methylation levels was observed at any CpG sites 
of this region (Figure 3.13 D-F).
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Figure 3.12: Association o f age w ith  global LINE-1 DNA m ethylation in chronic 
(Belfast) cohort
The figure shows no correlation o f age and global methylation of the LINE-1 at CpGl 
(A), CpG2 (B), and CpG3 (C).
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The influence of the polymorphisms and the extent of DNA methylation o f the LINE-1 
were investigated and results show tha t patients who carried the AA genotype of the 
FTO rs9939609, associated w ith higher BMI in this cohort, were more likely to have 
higher LINE-1 methylation than the T allele carriers although this did not reach 
significance (p=0.055 at CpG3) (Figure 3-14A).
The HTR2C -759C/T and the MTHFR 1298A/C polymorphisms did not influence the 
methylation levels o f LINE-1 (Figure 3-14 B and D). The MTFIFR 677C/T polymorphism, 
T allele showed a significant influence on LINE-1 methylation at CpG3 (p=0.026, 
correcting fo r smoking) compared to CC genotype (Figure 3-14C).
In addition, the interaction between the MTFIFR 677C/T polymorphism and gender, 
controlling fo r smoking (p=0.042, overall effect 0.006, r2=0.165) (Figure 3-15A).
Females w ith the T allele had higher methylation than those w ith CC genotype at CpG3 
(p=0.003, overall effect 0.010, r2=0.255). There was a significant interaction between 
the MTFIFR 677C/T polymorphism and smoking on LINE-1 methylation at CpG3 
(p=0.009, overall effect p=0.001, r2=0.213)(Figure 3-15B). Smoking increased LINE-1 
methylation at CpG3 in patients who carried the MTHFR 677T allele (67.33±1.37%, 
n=22) compared to  CC genotype carriers (65.88±1.19%, n=18), p=0.001, r2=0.227.
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(Belfast) cohort.
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3.3.2.2 DNA methylation of the HTR2C-697G/C region
There was a gender effect on methylation of the HTR2C -697G/C region, females had 
significantly higher methylation than males at all CpG sites (p<0.001) as shown in 
Figure 3.16A. This is because of the HTR2C gene is located on chromosome X, thus 
females have more methylation in order to inactivate one of sex chromosome. A 
similar pattern o f lower methylation of the HTR2C -697G/C region o f smokers was 
opposite w ith tha t o f the LINE-1 (Figure 3.16B); however, the olanzapine or clozapine 
treatm ent showed similar patterns in LINE-1 methylation; treatm ent w ith these drugs 
had slightly lower methylation of the HTR2C-697G/G region (Figure 3.16C). No 
significant association of the BMI obesity (>30 kg/m 2), central obesity, and metabolic 
syndrome and methylation levels was observed at any CpG sites o f this region (Figure 
3.16 D-F), although there was a similar pattern o f higher methylation in patients who 
had BMI obesity (>30 kg/m 2) or central obesity.
The influence of polymorphisms on methylation of the HTR2C -697G/C regions showed 
only the HTR2C -759C/T polymorphism had a significant association w ith  methylation 
levels. All CpG sites except CpG -698 showed a similar pattern tha t carriers w ith  C/CC 
genotype had lower methylation levels than T allele carriers and the statistical 
significance were reached at CpG-670 (p=0.020) and CpG-661 (p=0.030) (Figure 3.17B). 
The GG genotype of the leptin -2548G/A polymorphism showed significantly higher 
methylation at CpG-698 (p=0.023)(Figure 3.17E). The FTO rs9939609, the MTHFR 
677C/T, and the MTHFR 1298A/C polymorphisms did not influence the m ethylation of 
this region o f the HTR2C (Figure 3.17 A,C,D).
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Figure 3.16: DNA m ethylation o f the HTR2C -697G/C region in chronic (Belfast) cohort 
The methylation of the HTR2C -697G/C region compared between male and female 
(A), smoker and non-smoker (B), olanzapine or clozapine treatm ent and all o ther drugs 
(C), BMI obesity <30 and >30 kg/m 2 (D), presence of central obesity (E), and metabolic 
syndrome (F). Data are expressed as meaniSD. * * *  p<0.001. Gender was included as a 
covariate in the analyses B-F in the parametric test (GLM; UNIANOVA).
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Figure 3.17: Influence o f genetic polymorphism s on DNA m ethylation o f the  HTR2C - 
697G/C region in chronic (Belfast) cohort
The methylation o f the HTR2C -697G/C region compared between genotype subgroups 
of the FTO rs9939609 (A), HTR2C -759C/T (B), MTHFR 677C/T (C), MTHFR 1298A/C (D), 
and leptin -2548G/A (E) polymorphism. Data are expressed as mean±SD. * p<0.05,
***p<0.001.
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3.3.2.3 DNA methylation of the Hs_HTR2C_01_PM region
In the Hs_H77?2C_01_PM region, females had significantly higher methylation than 
males at all CpG sites (p<0.001) (Figure 3.18A). No significant association o f DNA 
methylation w ith smoking, olanzapine or clozapine treatm ent, BMI obesity, and 
metabolic syndrome was observed (Figure 3.18 B-D, and F), although the smoker 
group and olanzapine or clozapine groups were more likely to  have lower methylation, 
and the lower methylation levels were found in BMI obesity <30 kg/m 2, absence of 
metabolic syndrome and absence of central obesity. The absence of central obesity 
patient group had significantly lower methylation at CpGl (p=0.023) (Figure 3.18E).
There were no significant associations between the FTO rs9939609, HTR2C -759C/T, 
MTHFR 677C/T, and MTHFR 1298A/C polymorphisms and m ethylation o f the 
Hs_H77?2C_01_PM regions. However, there were similar patterns o f the results o f the 
FTO rs9939609 and the HTR2C -759C/T polymorphisms on methylation levels as 
observed in the HTR2C-697G/C region in which the AA genotype of the FTO rs9939609 
and the T allele of the HTR2C -759C/T exhibited slightly higher m ethylation levels 
(Figure 3.19); fo r example: the FTO rs9939609 AA genotype showed slightly higher 
levels o f methylation than the T allele group at CpG3 (6.92+3.32% vs 5.28±3.13%, 
p=0.092), and the C/CC genotype of the HTR2C -759C/T had slightly lower levels o f the 
methylation than T/CT/TT genotype at CpG3 (5.28±3.00% vs 6.57±3.67%, p=0.150). 
Interestingly, the GG genotype of the leptin -2548G/A polymorphism showed 
significantly higher methylation at CpGl (p=0.025) and CpG4 (p=0.009) (Figure 3.19E).
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Figure 3.18: DNA m ethylation o f the Hs_HTR2C_01_PM in chronic (Belfast) cohort 
The methylation of the Hs_H77?2C_01_PM region compared between male and female 
(A), smoker and non-smoker (B), olanzapine or clozapine treatm ent and all o ther drugs
(C), BMI obesity <30 and >30 kg/m 2 (D), presence of central obesity (E), and metabolic 
syndrome (F). Data are expressed as mean±SD. * p<0.05, * * *  p<0.001. Gender was 
included as a covariate in the analyses B-F in the parametric test (GLM; UNIANOVA).
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Figure 3.19: Influence of genetic polymorphisms on DNA methylation of the 
Hs_H77?2C_01_PM region in chronic (Belfast) cohort
The methylation o f the Hs_H77?2C_01_PM region compared between genotype 
subgroups of the FTO rs9939609 (A), HTR2C -759C/T (B), MTHFR 677C/T (C), MTHFR 
1298A/C (D), and leptin -2548G/A (E) polymorphism. Data are expressed as meaniSD. 
* p<0.05, * *  p<0.01.
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3.3.3 Association of DNA methylation of the HTR2C promoter
sequences with antipsychotic drug-induced weight gain in first 
episode Chinese Han and Spanish schizophrenia patients
DNA methylation levels o f two regions o f the HTR2C gene were investigated in both 
Chinese Han and Spanish cohorts. There were significant differences in DNA 
methylation levels of HTR2C between males and females in that females always had 
higher methylation levels than males at all CpG sites of both regions.
3.3.3.1 Chinese Han cohort
3.3.3.1.1 Methylation and weight gain
The percentages of methylation levels at each CpG site were tested fo r normal 
distribution against testing subgroups; fo r example: the analysis comparing two 
subgroups of patients having weight increase >7% and <7% found tha t methylation 
levels at all CpG sites o f Hs_HT/?2C_01_PM region and CpG-698, -691, and -644 o f the 
HTR2C -697G/C region were not normally distributed and therefore nonparametric 
statistical analyses were used; whereas the CpG-670 and -661 were normally 
distributed and parametric statistical analyses were performed. The outliers were also 
determined at each CpG site against d ifferential testing subgroups (for example, male 
vs female, weight increase >7% vs <7%, risperidone vs other drug treatm ent, HTR2C - 
759 T allele vs C/CC genotype, MTHFR 677 T allele vs CC genotype, etc.), then the 
outliers o f these tests were sumarized and removed before subsequent statistical 
analyses. The outlier removal citeria in SPSS is based on Tukey's hinges (Tukey, 1977) 
which calculate the upper and lower fences using equations as described below.
Interquartile range (IQR) = Q3-Q1 (equation 1)
Q1 is the first quartile (the 25th percentile) and Q3 is th ird quatile (the 75th percentile)
Then the IQR has been used to calculate fences 1.5 hinge-spreads below and above the 
hinges using equations below.
The lower fence (FenceLower) = Q1 - (1.5)(IQR) (equation 2)
The upper fence (Fenceupper) = Q3 + (1.5)(IQR) (equation 3)
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The extreme outliers located ouside the lower or upper fences were exclued. These 
outliers can be identified from stem-and-leaf plots and boxplots (box-and-whiskers 
plot) which show the frequncy and the raw data values at lower and upper fence.
Stepwise linear regression indicated a significant effect of gender, but not age on 
methylation at all CpG sites in both regions of the HTR2C; therefore, this was included 
in subsequent analysis as a covariate. M ethylation levels at all CpG sites, except at CpG 
-691, were normally distributed. No significant correlation of methylation levels w ith 
baseline weight, change in weight, baseline BMI, or change in BMI was observed in this 
cohort (p>0.05, data not shown).
Interestingly, the association between methylation levels at five CpG sites in the HTR2C 
-697G/C regions and weight change groups (>7% vs <7%) was observed in patients who 
had a weight increase of >7%, these patients had lower mean methylation at all CpG 
sites compared to  patients who had a weight increase of <7%, where only methylation 
at -644 site showed a significant difference (p=0.046) (Table 3.10, the raw data w ithout 
outlie r cut o ff is shown in Appendix 1, Table 1). Gender distribution between two 
weight change groups were not significantly d ifferent (%2=2.160, p=0.142). In this 
HTR2C -697G/C region, there was a genotype effect on methylation at the firs t CpG (- 
698) site, because the nucleotide sequences at positions -698,-697(SNP site G/C), and - 
696 was CGG; thus if the SNP was G, the methylation site was at position -698, but if 
the SNP was C, the methylation site was at position -697.
Table 3.10: M ethyla tion  levels at 5 CpGs in the HTR2C -697G/C prom oter sequences 
comparing between tw o  subgroups o f w eight increase in Chinese Han patients
HTR2C -697G/C CpGl CpG2 CpG3 CpG4 CpG5
promoter region -698 -691 -670 -661 -644
Weight increase>7% 19.5214.98 20.3915.74 19.1216.07 21.3016.36 17.8413.69
(n) (70) (82) (82) (81) (81)
Weight increase<7% 19.8214.87 21.1915.70 20.6216.13 23.2816.44 19.2013.81
(n) (76) (100) (100) (100) (93)
p value 0.654 0.424 0.355 0.165 0.046
Data is expressed as meaniSD.
The association between methylation levels at four CpG sites in the Hs_H77?2C_01_PM 
region and weight change groups (>7% vs <7%) were similar to the HTR2C -697G/C 
region; patients who had a weight increase of >7% had lower mean m ethylation at all
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CpG sites compared to patients who had a weight increase of <7%, when only 
methylation at the CpG3 site showed a significant difference (p=0.042) (Table 3.11, the 
raw data w ithou t outlier cut o ff is shown in Appendix 1, Table 2). Gender distribution 
between tw o weight change groups were not significantly d ifferent (%2=1.774, 
p=0.183).
Table 3.11: Methylation levels at 4 CpGs in the Hs_HT/?2C_01_PM sequences 
comparing between two subgroups of weight increase in Chinese Han patients
Hs HTR2C 01 PM CpGl CpG2 CpG3 CpG4
Weight increase>7% 
(n)
6.3912.81
(75)
6.8512.93
(78)
8.9413.58
(75)
5.2711.58
(67)
Weight increase<7% 
(n)
7.0812.75
(91)
7.5912.73
(92)
10.2913.56
(93)
5.6011.63
(86)
p value 0.296 0.240 0.042 0.458
Data is expressed as mean+SD.
These results suggest tha t the methylation levels in both regions of the HTR2C may be 
able to  be used in prediction o f weight increase in first episode schizophrenia patients 
follow ing antipsychotic drug treatm ent.
3.3.3.1.2 Polymorphisms and methylation
The influence of the polymorphisms and the extent o f DNA methylation o f the HTR2C 
were investigated and results show tha t patients who carried the C/CC genotype o f the 
HTR2C -759C/T polymorphism (which had missing genotype data n=3) had lower 
methylation levels compared to T allele carriers at all CpG sites except the -698 site. 
Methylation at -670 and -644 sites showed significant differences between the tw o 
genotype groups (p=0.010 and p=0.014) as shown in Table 3.12, the raw data w ithou t 
outlie r cut o ff is shown in Appendix 1, Table 3. Gender distribution between tw o 
genotype groups was not significantly d ifferent (%2=2.374, p=0.123 for CpG -670 and 
%2=2.761, p=0.097 fo r CpG -644). This result suggests tha t at some CpG sites DNA 
methylation o f the HTR2C is influenced by the HTR2C -759C/T polymorphism and the 
difference in DNA methylation may be a link between the HTR2C -759C/T 
polymorphism and antipsychotic drug-induced weight gain.
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Table 3.12: M ethyla tion  levels at 5 CpGs in the HTR2C -697G/C prom oter sequences 
comparing between tw o  subgroups o f the HTR2C -759C/T genotype in Chinese Han 
patients
HTR2C
-759C/T
CpGl
-698
CpG2
-691
CpG3
-670
CpG4
-661
CpG5
-644
C/CC 20.1515.06 20.4115.45 19.2815.57 21.9716.32 18.1613.78
(n) (114) (141) (141) (140) (136)
T/CT/TT 17.2612.49 21.9916.26 22.5517.34 23.9916.67 20.2013.56
(n) (29) (38) (38) (38) (35)
p value 0.004 0.214 0.010 0.265 0.014
Data is expressed as meaniSD.
The results in the Hs_H77?2C_01_PM region showed a similar direction in tha t the C/CC 
genotype group had lower methylation than tha t o f the T allele group; however, the 
difference in methylation between the genotype groups did not reach statistical 
significance (p>0.05) (Table 3.13, the raw data w ithout outlier cut o ff is shown in 
Appendix 1, Table 4).
Table 3.13: M ethyla tion  levels at 4 CpGs in the Hs_H77?2C_01_PM sequences 
comparing between tw o  subgroups o f the HTR2C -759C/T genotype in Chinese Han 
patients
HTR2C -759C/T CpGl CpG2 CpG3 CpG4
C/CC (n) 6.6512.70(131) 7.1912.89 (134) 9.4613.64(131) 5.3411.56 (118)
T/CT/TT (n) 7.4012.92 (34) 7.6612.48(35) 10.8413.16 (35) 5.8511.77 (34)
p value 0.352 0.846 0.148 0.236
Data is expressed as mean+SD.
The MTHFR 677C/T and MTHFR 1298A/C polymorphisms did not influence the 
methylation of the FITR2C at any CpG sites in either region (p>0.05, data not shown). 
The FTO rs9939609 A/T had an effect on methylation at CpG -698 in that there was a 
trend of the T allele to  be associated w ith lower methylation at CpG -698 than the AA 
genotype (19.9214.81 (n=140) vs 14.3915.61 (n=3), p=0.052). Gender d istribution 
between tw o subgroups of genotype was not significantly d ifferent (%2=0.355, 
p=0.551).
In addition, the BDNF rs6265G/A polymorphism also showed a significant difference in 
DNA methylation at CpG-698; the AA genotype carriers had higher m ethylation levels
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than the G allele carriers (21.22±5.23 (n=38) vs 19.32±4.70 (n=99), p=0.043. Gender 
distribution between two subgroups of genotype was not significantly d ifferent 
(X2=0.650, p=0.420).
The genotype of the HTR2A -1438G/A had a significant influence on DNA methylation 
o f the Hs_/-/77?2C_01_PM region at CpG3; the A allele carriers had lower methylation 
levels than the GG genotype group (9.44±3.70 (n=124) vs 10.74±3.57 (n=36), p=0.030. 
Gender distribution between tw o subgroups of genotype was not significantly 
d ifferent (%2=0.029, p=0.865).
3.3.3.2 Spanish c o h o rt
3.3.3.2.1 Methylation and weight gain
Methylation data at each CpG site were tested fo r normal d itribution and outliers. The 
methylation levels at CpG-698 were not normally distributed, thus non-parametric 
tests were used in analyses. Gender, but not age, showed a strong effect on 
methylation extent at all CpG sites in both regions of the HTR2C (p<0.05, data not 
shown).
The methylation levels were not significantly correlated w ith baseline weight, baseline 
BMI, BMI change, weight change, or percentage o f weight change at all CpG sites of 
both regions of the HTR2C sequences (p>0.05, data not shown).
The association of methylation levels w ith weight increase of >7% compared to  <7% 
after antipsychotic drug treatm ent fo r 3 months (missing data n=6) showed a similar 
direction to  the Chinese Han cohort in tha t patients who had a weight increase of >7% 
had lower mean methylation than patients who had a weight increase o f <7% at all 
CpG sites in both regions o f the HTR2C, the HTR2C -697G/C prom oter region (Table 
3.14, the raw data w ithou t outlier cut o ff is shown in Appendix 2, Table 5) and the 
Hs_H77?2C_01_PM region (Table 3.15, the raw data w ithou t outlier cut o ff is shown in 
Appendix 2, Table 6). However, the differences of methylation levels between the tw o 
subgroups of weight increase did not reach statistical significance.
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Table 3.14: M ethyla tion  levels at 5 CpGs in the HTR2C -697G/C prom oter sequences 
comparing between tw o  subgroups o f w eight increase in Spanish patients
HTR2C -697G /C C p G l CpG2 CpG3 CpG4 CpG5
p ro m o ter region -698 -691 -670 -661 -644
Weight increase>7% 18.79±16.90 15.00±9.31 16.62±10.55 16.44±11.37 15.67±9.15
(n) (43) (43) (42) (41) (43)
Weight increase<7% 20.17±17.54 17.61±11.38 16.41±10.28 20.19±12.77 18.09±10.04
(n) (23) (23) (22) (21) (23)
p value 0.666 0.620 0.496 0.842 0.538
Data is expressed as meaniSD.
Table 3.15: M ethyla tion  levels at 4 CpGs in the Hs_H77?2C_01_PM sequences 
comparing between tw o  subgroups o f w eight increase in Spanish patients
Hs HTR2C 01 PM CpGl CpG2 CpG3 CpG4
Weight increase>7% 
(n)
5.05±2.39
(42)
5.2811.24
(28)
7.2713.47
(42)
4.1911.97
(43)
Weight increase<7% 
(n)
5.9512.56
(20)
5.5211.60
(15)
9.1114.02
(23)
4.7712.24
(23)
p value 0.337 0.624 0.330 0.949
Data is expressed as meaniSD.
3.3.3.2.2 Polymorphisms and methylation
The influence of the polymorphisms on the extent o f DNA methylation o f the HTR2C 
were investigated and results show tha t the HTR2C -759C/T polymorphism did not 
influence the methylation levels at any CpG sites in e ither regions o f the HTR2C, except 
the methylation at CpG-698; the C/CC genotype carriers had higher m ethylation levels 
than that of the T allele carriers (C/CC 21.19±17.35 (n=54) vs T/TC/TT 10.94±12.83 
(n=18), p=0.037). There is a genotype effect on the methylation at this position as 
described before (section 3.3.3.1.1).
Patients who carried the T allele o f the FTO rs9939609 polymorphism (which had 
genotype missing data n=2) had lower methylation levels compared to  the AA 
genotype group at all CpG sites o f the HTR2C -697G/C region (Table 3.16, the raw data 
w ithou t outlier cut o ff is shown in Appendix 2, Table 7). Gender d istribution between 
tw o subgroups of the FTO genotype was tested and it was not significantly d iffe ren t at 
any CpGs (p>0.05, data not shown), except the CpG-670. However, there was only one 
female patient who carried the AA genotype o f the FTO rs9939609 at all CpG sites and 
no female patient who carried the AA genotype at CpG-670; therefore, analysis in male
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patients was carried out. The results were in a similar direction to  the analysis in the 
tota l patient group as shown in Figure 3.20. There was a trend of the AA genotype of 
FTO rs9939609 associated w ith higher DNA methylation levels o f the 
Hs_/-/T/?2C_01_PM region at CpG4 in male patients (p=0.060). No significant effect of 
the HTR2C -759C/T and the FTO rs9939609 A/T genotype interaction on DNA 
methylation of the HTR2C -697G/C region was found indicating an additive effect of 
these tw o polymorphisms.
Table 3.16: M ethyla tion  levels at 5 CpGs in the HTR2C -697G/C prom oter sequences 
comparing between tw o  subgroups of the FTO rs9939609 genotype in Spanish 
patients.
FTO
rs9939609
C p G l
-698
CpG2
-691
CpG3
-670
CpG4
-661
CpG5
-644
AA 3 0 .8 6 il6 .3 5 21.07i8.67 19.08i7.64 20 .2 3 il0 .7 6 19.00i9.43
(n) (14) (14) (13) (13) (14)
AT/TT 16 .1 6 il5 .7 8 14 .52 il0 .11 1 5 .6 9 ill.2 9 17 .00 il2 .08 15.73i9.67
(n) (56) (56) (55) (53) (56)
p value 0.004 0.001 0.009 0.020 0.072
Data is expressed as meaniSD.
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The MTHFR 677C/T and MTHFR 1298A/C polymorphisms did not show a significant 
influence on the methylation of the HTR2C at any CpG sites in both regions (p>0.05). 
However, the CC genotype of the MTHFR 677C/T had slightly higher methylation levels 
than the T allele at all CpG site of the HTR2C -697G/C region; whereas, the AA 
genotype of the MTHFR 1298A/C had slightly lower methylation levels than the T allele 
carriers (Figure 3.21).
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3.4 Discussion
The experiments in this chapter aimed to investigate the association of DNA 
methylation w ith antipsychotic drug-induced weight gain and BMI, and the influence 
of genetic polymorphisms in schizophrenia in both first episode and chronic patients. 
In chronic schizophrenia patients, DNA methylation of global LINE-1 repetitive 
elements and of the specific target gene, the HTR2C prom oter at and nearby the - 
697G/C polymorphism and the region nearby TSS, Hs_H77?2C_01_PM, were 
determined using bisulfite pyrosequencing. DNA methylations of the HTR2C o f both 
regions were also investigated in first episode schizophrenia patients.
3.4.1 DNA methylation of the HTR2C and global DNA methylation in 
chronic (Belfast) schizophrenia patients - key findings
•  LINE-1 methylation: Gender effect (F<M), no age effect, smoker effect (higher 
methylation), olanzapine/clozapine (trended lower methylation), no association 
w ith BMI, central obesity and metabolic syndrome, MTHFR 677C/T (T allele 
higher methylation) and FTO rs9939609 (AA genotype trends higher 
methylation).
•  HTR2C (-697G/C sequence) methylation: Gender effect (F>M), m ethylation 
increased w ith age, no association w ith smoking, drug treatm ent, BMI, central 
obesity and metabolic syndrome, HTR2C -759C/T SNP (T allele higher 
methylation), no association w ith FTO and MTHFR SNPs.
•  HTR2C (Hs_H77?2C_01_PM) methylation: Gender effect (F>M), m ethylation 
increased w ith age, central obesity (higher methylation), no association w ith  
smoking, drugs treatm ent, BMI, and metabolic syndrome, FTO AA trends higher 
methylation, no MTHFR, -759C/T HTR2CSNPs effect.
3.4.1.1 Global LINE-1 DNA methylation in chronic (Belfast) patients
The results showed females had lower levels o f the global LINE-1 m ethylation than 
males 0.55% on average. This finding is consistent w ith previous studies in children 
(Fluen et a t, 2014; Perng et al., 2013), adults (W ilhelm et at., 2010; El-Maarri et al., 
2011; Zhang et al., 2011) and also in cord blood (Burris et al., 2012; Fluen et al., 2014). 
This gender-specific effect on LINE-1 methylation is likely due to the association of
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LINE-1 w ith X-chromosome inactivation. One recent study measured DNA methylation 
o f 39 LINE-l\oc\ on the X-chromosome and 5 loci in autosomes and found the 
differential methylation in male and female was prim arily located in the X 
chromosome and also found the inactive X chromosome is hypomethylated (Singer et 
al., 2012).
The lack o f the significant correlation between age and LINE-1 DNA methylation 
observed in this study confirmed several previous findings tha t have reported a weak 
inverse relationship or no association o f age w ith LINE-1 methylation (Bollati et al., 
2009; Jintaridth and Mutirangura, 2010; El-Maarri et al., 2011). The weak or no 
association may be due to the small sample size and other factors such as life style, 
smoking, diet, exercise, disease conditions, and antipsychotic drug treatm ent tha t may 
contribute to  epigenetic changes.
Smoking was associated w ith higher levels o f LINE-1 methylation (0.76% on average) in 
the present study (see a diagram in Figure 3.22A) which was in line w ith  some other 
studies tha t found smoking is associated w ith global DNA hyperm ethylation 
(Piyathilake et al., 2001; Lin et al., 2007); in contrast to other studies tha t found 
hypomethylation (Smith et al., 2007; Hsiung et al., 2007). However, these studies 
investigated cancer cells or cancer patients tha t may lim it the relevance of these works 
to  the present study. Nicotine is one of the epigenetic modifiers tha t cause DNA 
hypermethylation and histone acetylation (Abdolmaleky, et al., 2013). Previous work 
found tha t nicotine induced DNA methylation o f the fragile histidine triad [FHIT) gene 
and was associated w ith increased DNMT3a expression in human esophageal 
squamous epithelial cells (Soma et al., 2006). However, nicotine adm inistration in mice 
caused a decrease in DNMT1 expression and GAD67 prom oter m ethylation in 
GABAergic interneurons which was also associated w ith an increase in GAD67 
expression in the fronta l cortex (Satta et al., 2008). A previous study using blood 
samples has reported a decrease in global DNA methylation in schizophrenia patients 
(n=28) while it was increased in healthy controls (n=26) (Bromberg et al., 2008). The 
differences between this study and the present study are d ifferent m ethod to 
characterize methylation which was based on the restriction by m ethylation-sensitive 
or insensitive enzymes; and also the patients were younger (39 years). The present 
study found a significant association of smoking w ith LINE-1 m ethylation at one of
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three CpG sites indicating a weak effect o f smoking on global DNA methylation. The 
influence of smoking on epigenetic modifications may be tissue specific or gene 
specific and it needs further studies in large sample sizes to  elucidate this effect.
The T allele o f the MTHFR 677C/T polymorphism was associated w ith higher levels of 
the methylation of LINE-1 (CpG3), specifically in female chronic schizophrenia patients 
(see a diagram in Figure 3.22A). The one previous study found the lowest level o f LINE- 
1 methylation in female patients w ith the TT genotype. That study differed from  the 
present investigation in the chronic patients in tha t the 133 patients had a d ifferent 
genotype frequency of the MTHFR 677C/T in tha t CC/CT/TT frequency was 61/30/9% 
(47/43/10% in the present study). However, fu rther studies in larger sample sizes are 
required to  elucidate the association of the MTHFR polymorphism and global DNA 
methylation.
In addition, this study found an interaction between smoking and the MTHFR 677C/T 
polymorphism on the methylation o f LINE-1 CpG3; smoking MTHFR 677T allele carriers 
had highest LINE-1 methylation levels. Previous studies in the general population have 
reported the association of the MTHFR 677C/T polymorphism and smoking behavior; 
the TT genotype had a higher frequency in smokers (Johnson et al., 2001; Linnebank et 
al., 2012). The interaction of this polymorphism and smoking on plasma homocysteine 
levels was also observed; plasma homocysteine levels were higher in smokers as well 
as in the T allele carriers, and the smoking MTHFR 677TT individual had the highest 
plasma homocysteine levels, non-smoking 677CC individuals the lowest (Linnebank et 
al., 2012). Although the MTHFR variant had an association w ith the decrease o f MTHFR 
enzyme activity and increased plasma homocysteine levels which disrupt DNA 
m ethylation (Friso and Choi, 2002), there is a recent study tha t reported the 
association o f an increment o f homocysteine and higher LINE-1 methylation (Perng et 
al., 2014). The increased global DNA methylation in smoking MTHFR 677T allele in this 
study may be due to this study investigating chronic schizophrenia patients who were 
receiving antipsychotic drugs. Responsiveness to  the drug treatm ent, physical activity, 
and genetic vulnerability may influence DNA methylation. However, this study 
provides evidence tha t the MTHFR 677C/T polymorphism-smoking interaction plays a 
role in epigenetic modification tha t might be implicated in human health and diseases. 
Further studies are needed to confirm this interaction.
158
This study did not observe a significant association o f the methylation of LINE-1 w ith 
BMI, body weight, waist circumference, waist-hip ratio, triglyceride, LDL, HDL, 
cholesterol, and plasma leptin. Lack of significant association o f LINE-1 methylation 
and BMI is in line w ith a recent study in postmenopausal overweight woman which 
found no significant difference in LINE-1 methylation levels in any intervention group 
(independent and combined effects of a reduced-calorie weight-loss diet, and exercise 
program for 1 year) versus control and also found no association o f LINE-1 methylation 
and weight loss at 12 months (Duggan et al., 2014). Other studies reported the 
association of weight gain and an increased LINE-1 methylation (Martin-Nunez et al., 
2014; Perng et al., 2014). A study in school-age children reported the association of 
adiposity development and lower LINE-1 methylation in boys (Perng et al., 2013). 
Another study in visceral adipose tissue of the severely obese found lower LINE-1 
methylation was negatively associated w ith fasting glucose, diastolic pressure, and 
metabolic status (Turcot et al., 2012). Therefore, the association of LINE-1 methylation 
and body weight is inconsistent which may be due to  the methylation o f LINE-1 may be 
influenced by gender, age, diet, tissue-specific, and other factors. Further studies are 
required to confirm this association.
3.4.1.2 DNA methylation of the HTR2C promoter regions in chronic (Belfast) 
patients
Similar to findings in first episode patients, gender had significant effect on the levels 
of DNA methylation of the HTR2C in both regions in chronic patients in which females 
had higher methylation levels at all CpG sites than males, this is probably due to  the X- 
chromosome inactivation.
Age was positively associated w ith  DNA methylation o f the HTR2C in both regions in 
the chronic (Belfast) study suggesting the influence o f age on gene-specific DNA 
methylation. Increased methylation of the HTR2C prom oter w ith age may result in 
decreased 5-HT2C receptor expression and modulate the control o f food intake. The 
influence o f aging on DNA methylation has been reported (Bell et al., 2012). A recent 
study has reported tha t CpG islands tended to  increase methylation while non-CpG 
islands lose methylation w ith increasing age suggesting tha t the age-related changes in 
DNA methylation are not homogeneous across a human genome (Christensen et al.,
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2009). An example of age-related hypermethylation is the increased DNA methylation 
of Arc (activity-regulated cytoskeletal-associated protein) prom oter region in the 
hippocampus which was accompanied by decreased Arc transcripts in aged rats 
compared w ith adult rats (Penner et al., 2011). There has been a study in postmortem 
human brain samples that reported age effects on the HTR2C expression and/or 
histone H3 acetylation at lysine 9/14 in schizophrenia patients (Tang et al., 2011). 
There have been several studies reporting tha t treatm ent w ith histone deacetylase 
(HDAC) inh ib itor as well as DNMT inhibitors can improve the expression of several 
genes fo r schizophrenia in mouse brain.
Although the FTO rs9939609 polymorphism showed significantly associated w ith BMI 
in this chronic Belfast cohort, this polymorphism did not show a significant effect on 
DNA methylation o f the HTR2C prom oter region. However, the AA genotype which was 
significantly associated w ith higher BMI had slightly higher methylation levels o f the 
HTR2C in both regions. The AA genotype of the FTO polymorphism associated w ith 
higher HTR2C methylation may decrease 5-HT2C receptor expression to  reduce 5-HT 
neurotransm itter function resulting in increased food intake and obesity. Lack o f 
statistical significance may be due to  small sample size, thus fu rther studies in larger 
sample size are needed to confirm this finding.
The T allele of the FITR2C -759C/T polymorphism was significantly associated w ith  
higher DNA methylation of the HTR2C prom oter region (-697G/C region) in which the 
CpG sites are located near the polymorphism (Figure 3.22). This finding indicates the 
polymorphism may have a strong influence on nearby cytosine m ethylation rather 
than the long distance region (Hs_H77?2C_01_PM region) or other polymorphisms from  
other genes such as the MTFIFR and FTO polymorphisms.
However, interestingly, the leptin -2548G/A polymorphism showed significant 
associations w ith the methylation o f the F1TR2C in both regions (CpGl and CpG4 o f the 
Hs_H77?2C_01_PM, and CpG-698 of the HTR2C -697G/C prom oter regions). Finding 
tha t carriers w ith the GG genotype had significantly higher levels o f m ethylation than 
the A allele carriers (Figure 3.22) indicating the influence of the leptin polymorphism 
on DNA methylation of the FITR2C tha t might fu rther affect 5-HT2C receptor 
expression. In this cohort of chronic patients, the GG genotype o f leptin -2548G/A
160
polymorphism had slightly higher plasma leptin compared to AG/AA genotype (not 
significant). However, the role of 5HT-leptin interaction in controlling food intake is still 
unclear. The 5-HT2C receptors have been reported to  be involved in leptin-induced 
anorexia (von Meyenburg et al., 2003b; Yamada et al., 2003). Other studies reported 
that leptin did not have a direct influence on 5-HT neurons and did not modulate 
appetite via 5-HT neuron function (Lam et al., 2011). It also has been suggested that 
leptin and 5-HT have separate pathways in the control of food intake and suggested 
tha t the effects o f leptin are long lasting (tonic) whereas 5-HT is involved in short 
acting (episodic) satiety signals (Weigle et al., 1995).
The present study did not find a significant association of the leptin -2458G/A 
polymorphism and plasma leptin as well as BMI in chronic schizophrenia patients. 
However, the GG genotype had slightly higher plasma leptin and this may affect 5- 
HT2C receptor expression by increased methylation o f the HTR2C prom oter region. No 
link between leptin polymorphism and methylation o f the HTR2C was investigated. A 
study in 39 non-obese female subjects has reported tha t the AA genotype o f the leptin 
-2548G/A polymorphism was associated w ith increased plasma leptin and increased 
adipose tissue leptin mRNA and leptin secretion than G allele subjects (Hoffstedt et al., 
2002). However, meta-analysis did not find any difference of the leptin mRNA 
expression between the leptin -2548G/A genotypes among d ifferent ethnicities (He et 
al., 2013). Templeman et al. (2005) has reported a trend of A allele o f the -2548G/A 
polymorphism and higher plasma leptin in first episode schizophrenia patients. The 
variability o f leptin among leptin genotypes in these studies and the present study may 
be due to  differences in subjects that gender, age, obese or non-obese, ethnicity, first- 
episode or chronic schizophrenia patients, and the antipsychotic drug trea tm ent may 
affect plasma leptin. In addition, the small sample size may confound the findings. 
Therefore, fu rthe r studies are needed to elucidate the association o f the leptin 
polymorphism or plasma leptin and DNA methylation of the HTR2C or 5-HT2C receptor 
expression.
The same direction w ith global LINE-1 methylation, antipsychotic drugs (olanzapine or 
clozapine) treatm ent decreased methylation of the HTR2C prom oter sequences was 
also observed (Figure 3.22B, and C) indicating tha t not only the global DNA 
methylation but also the specific HTR2C prom oter was modified by antipsychotic
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drugs. Whereas smoking was more likely to increase global DNA methylation, it 
decreased methylation levels of the HTR2C prom oter sequences suggesting the gene- 
specific influence of smoking on DNA methylation.
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Figure 3.22: Diagrams summarize the associations o f DNA m ethylation o f the  LINE-1 
m ethylation (A), the HTR2C -697G/C (B), and the Hs_H77?2C_01_PM regions (C), w ith  
polymorphisms, smoking, antipsychotic drugs, and obesity variables in chronic 
cohort.
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3.4.2 DNA methylation of the HTR2C in first episode drug naive 
schizophrenia patients - key findings
Chinese Han cohort:
•  HTR2C (-697G/C sequence) methylation: Gender effect (F>M), no age effect, no 
association w ith baseline BMI and change in BMI, HTR2C -759C/T SNP (T allele 
higher methylation), HTR2C SNP effect on CpG-698 site, FTO rs9939609 T allele 
(trends lower methylation at -698 site), no MTHFR SNPs effect
• HTR2C (Hs_H77?2C_01_PM) methylation: Gender effect (F>M), no age effect, no 
association w ith  baseline BMI and change in BMI, no effects o f HTR2C -759C/T, 
FTO and MTHFR SNPs
Spanish cohort:
•  HTR2C (-697G/C sequence) methylation: Gender effect (F>M), no age effect, no 
association w ith baseline BMI and change in BMI, HTR2CSNP effect on CpG-698 
site, FTO rs9939609 (T allele lower methylation, in male), no MTHFR SNPs 
effect
•  HTR2C (Hs_H77?2C_01_PM) methylation: Gender effect (F>M), no age effect, no 
association w ith baseline BMI and change in BMI, FTO rs9939609 (T allele 
trends lower methylation, in male), no effects o f HTR2C -759C/T and MTHFR 
SNPs
The results o f this section revealed that the methylation levels of the HTR2C -697G/C 
region and the Hs_/-/77?2C_01_PM region in peripheral blood at baseline were 
negatively associated w ith body weight change groups (>7% vs <7%) fo llow ing 
antipsychotic drug treatm ent in first episode schizophrenia patients. In addition, the 
lower methylation levels o f both regions were found in the CC/C genotype o f the 
HTR2C -759C/T polymorphism compared to T allele carriers. The results were 
predominantly seen in the Chinese Han cohort; however, a similar directionwas found 
in the Spanish cohort indicating replication of the findings (Figure 3.23). The statistical 
significant differences tha t were found at some CpG sites in Chinese cohort and the 
lack o f significant difference in Spanish cohort may be due to  the small sample size or 
the weak association of methylation levels on weight gain as well as genotype effect
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on methylation levels. Further studies in larger sample size are required to confirm 
these findings.
This is the first study investigating the association of the DNA methylation of the 
HTR2C prom oter sequences and antipsychotic drug-induced weight gain. The 
association between the extent of DNA methylation o f the HTR2C prom oter regions 
and the weight increase after receiving antipsychotics in both Chinese Han and Spanish 
cohorts as summarized diagram in Figure 3.23, suggests that the epigenetic changes in 
the HTR2C may be used to  predict the extent o f weight gain follow ing antipsychotic 
drug treatm ent in firs t episode, drug na we schizophrenia patients.
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Figure 3.23: Diagrams summarize the association of the DNA m ethyla tion  o f the 
HTR2C -697G/C and Hs_H7Y?2C_01_PM regions and polymorphism s in Chinese (A, B) 
and Spanish (C, D) cohorts.
The effect of gender on the methylation o f the HTR2C in this study may be due to  the
contribution from  the X-chromosome inactivation because it is located on the X
chromosome and one of the X chromosomes in females is subject to  inactivation
resulting in CpG sites exhibiting highly significant difference between gender w ith
hemi-methylated patterns in female (Bell et al., 2011). The selection o f the X
chromosome to be inactivated is random in somatic cells (Goto and Monk, 1998). The
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X-chromosome inactivation is accompanied by changing in DNA methylation 
particularly in CpG islands which the m ajority of CpG islands show increased 
methylation on the inactive X chromosome which silences gene expression; however, 
about 7% of CpG islands show decreased methylation levels (Sharp et al., 2011) and 
about 5% of X-linked genes have been reported to have increased expression in 
females compared to male (Johnston et al., 2008). There are some X-linked genes 
escaping X-chromosome inactivation to some degree and they are expressed from  
both X chromosomes (Carrel and Willard, 2005). A report shows many CpG sites 
located at upstream of the HTR2C transcription start site (TSS) had similar patterns of 
DNA methylation in both male and female thus it was suggested tha t the HTR2C gene 
escapes from  X-chromosome inactivation in human (Hernando-Herraez et al., 2013); 
however, the authors did not provide specific CpG sites or regions. In addition, a 
female-specific increased expression o f the HTR2C gene was not observed in the 
published RNAseq data (Brawand et al., 2011). It has been also suggested tha t many 
genes escaping X-chromosome inactivation show no clear gender differences in 
expression levels (Johnston et al., 2008). Therefore, it is clear that the tested CpG sites 
of the HTR2C in this study are subject to X-chromosome inactivation. The contribution 
of X-chromosome inactivation of the HTR2C in various degrees in individuals may be 
the causes of the high variability o f measured DNA methylation in this study.
Comparing between two regions, the DNA methylation levels of the HTR2C -697G/C 
region were always higher than those o f the Hs_H77?2C_01_PM region which are 
located around the TSS of the gene. This result supported previous findings tha t there 
are differences in DNA methylation distribution across the genome in which CpG sites 
located around TSS are not methylated while CpG sites tha t are located in the gene 
body, intergenic, and distant to TSS, around lkb-1.5kb, are highly methylated (Bell et 
al., 2011; Hernando-Herraez et al., 2013). M ethylation of CpG sites o f the TSS is 
associated w ith long-term silencing such as X-chromosome inactivation, im printing, 
and w ith some tissue specific genes (Jones, 2012). Thus, lower methylation o f CpGs at 
TSS of the gene allows transcription in itiation.
The influence of the HTR2C -759C/T polymorphism on DNA methylation o f the HTR2C 
prom oter region provides an additional fu rthe r mechanism underlying the previous 
finding by Hill and Reynolds which reported the reduction o f prom oter activity in the
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presence of the HTR2C -759T or -697C allele (Hill and Reynolds, 2007)(Figure 3.24). The 
T allele o f the HTR2C -759C/T polymorphism that was the less active allele was more 
likely to be methylated than the active C allele. This finding indicates the influence of 
the HTR2C -759C/T polymorphism on the nearby DNA methylation of the prom oter 
region of the HTR2C gene tha t may be a link between the polymorphism and prom oter 
activity, and also antipsychotic drug-induced weight gain. Further study requires 
investigating the influence of the HTR2C -759C/T polymorphism and/or the 
methylation of this prom oter region on 5-HT2C receptor expression.
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Figure 3.24: Diagram summarizes the association o f the DNA m ethylation  o f the 
HTR2C -697G/C region and HTR2C -759C/T polym orphism .
The BDNF rs6265 G/A polymorphism showed significant association w ith DNA 
methylation levels at only the CpG-698 SNP site, but a similar pattern at o ther CpG 
sites o f the HTR2C -697G/C prom oter region was also observed in the Chinese Han 
cohort; patients w ith the AA genotype had higher methylation levels than the G allele 
carriers. The link between the polymorphism of the BDNF and this specific CpG 
methylation o f the HTR2C prom oter is unknown. The variant methionine (A allele) was 
associated w ith decreased BDNF synthesis and secretion (Chen et al., 2004). BDNF 
influences the serotonergic system and is associated w ith schizophrenia and eating 
disorders (Gratacos et al., 2007; Lyons et al., 1999). Brain infusion of BDNF in rats 
resulted in appetite suppression, weight loss and increased 5-HT (Pelleymounter et al., 
1995). The AA genotype which had slightly higher change in BMI (see chapter 2) 
showed higher DNA methylation of the FITR2C prom oter compared to  G allele. This
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result may provide a link between the reduction o f BDNF of the AA genotype and the 
seroternergic dysfunction; high methylation may decrease 5-HT2C receptor expression 
and result in weight gain (Figure 3.25). However, fu rther studies are required to 
address the role of BDNF on the expression and DNA methylation o f the HTR2C gene.
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Figure 3.25: Diagram summarizes the association o f the DNA m ethyla tion  o f the 
HTR2C -697G/C region and BDNF rs6265 G/A polym orphism .
The HTR2A polymorphism at CpG3 of the Hs_H77?2C_01_PM region was significantly 
associated w ith weight gain in the Chinese Han cohort and similar patterns were also 
found at other CpGs in this region. The link between the HTR2A and the m ethylation of 
the HTR2C is unknown.
In the Spanish cohort, the influence o f the HTR2C -759C/T polymorphism and DNA 
methylation of the HTR2C show the same direction but did not reach statistical 
significant levels. However, patients w ith the AA genotype of the FTO rs9939609 A/T 
showed significantly higher levels o f HTR2C DNA methylation than the T allele carriers, 
particularly in males. The A allele o f this polymorphism has been reported to  be 
associated w ith increased BMI (Frayling et al., 2007) and also increased FTO transcripts 
(Berulava and Horsthemke, 2010), although no significant association between the SNP 
and change in BMI was observed in firs t episode Chinese and Spanish cohorts. 
However, in the Spanish cohort, the BMI at baseline o f patients who carried the AA 
genotype of the FTO rs9939609 had higher than those of T allele carriers but did not
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reach statistically significant differences (23.50±3.41 kg/m 2, n=14 vs 21.58±3.71 kg/m 2, 
n=56, p= 0.172 correction fo r gender). The influence of the FTO polymorphism on the 
HTR2C prom oter methylation may explain the obesity associated w ith  FTO rs9939609 
(Figure 3.26) tha t the AA genotype of the FTO polymorphism caused increase 
methylation of the HTR2C prom oter region and may result in decreased 5-HT receptor 
expression and serotonergic neurotransm itter system and that affects food intake and 
satiety. However, the exact mechanism is still unknown, as the FTO play a role in 
DNA/RNA demethylation. FTO may act on other components such as RNA or other 
genes.
Figure 3.26: Diagram summarizes the association o f the DNA m ethyla tion  o f the 
HTR2C -697G/C region and FTO rs9939609 A /T  polymorphism .
3.4.3 Comparison between chronic and first episode schizophrenia
Some findings were observed in both chronic and firs t episode patients including; 1) 
there was strong gender effect on DNA methylation o f the FITR2C sequences between 
males and females; 2) DNA methylation o f the FITR2C sequences was not associated 
w ith BMI or BMI changes; 3) FITR2C -759C/T polymorphism was associated w ith 
methylation of HTR2C prom oter sequence; 4) MTFIFR SNPs did not have an effect on 
methylation of FITR2C in both chronic and first episode patients.
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The d ifferent findings between chronic and first episode patients and d iffe rent findings 
between global UNE-1 methylation and specific FITR2C methylation including; 1) there
168
was an age effect on DNA methylation of the HTR2C sequences in chronic but not first 
episode patients; 2) smoking and antipsychotic drugs influence global LINE-1 
methylation but not HTR2C methylation in chronic patients; 3) FTO and MTHFR SNPs 
did not influence methylation of HTR2C gene but there were effects on global 
m ethylation in chronic patients; 4) FTO SNP did not influence methylation of HTR2C in 
chronic patients but it has strong effect in firs t episode Spanish male patients.
3.4.4 Limitations in this study
In firs t episode schizophrenia patients, DNA methylation was determined at baseline 
but not after antipsychotic drug treatm ent. Therefore, comparison of the methylation 
changes between before and after antipsychotic drug treatm ent as well as the 
association of DNA methylation and weight gain cannot be investigated.
The small sample size leads to lack of statistical power in determ ining small effect of 
polymorphisms on DNA methylation, or DNA methylation on BMI gain or BMI.
DNA samples from  peripheral blood of schizophrenia patients were used to  determ ine 
DNA methylation o f the HTR2C and global LINE-1 methylation may be lim itation in the 
present study to reflect the alteration of DNA methylation in brain. Because o f the 
extent o f global DNA methylation differs between tissues (Lokk et al., 2014) and the 
antipsychotic drugs or the environmental factors may affect DNA m ethylation in a 
tissue-specific manner (Shimabukuro et al., 2006). Although, there have recently been 
several studies reported tha t the DNA methylation changes in peripheral blood or 
saliva were well correlated w ith tha t o f d ifferent brain regions and could serve as 
markers fo r disease diagnostic and/or therapeutic biomarkers fo r schizophrenia 
(Horvath et al., 2012; Abdolmaleky et al., 2014; Ota et al., 2014; M ill and Petronis, 
2007), fu rthe r studies are required to  compare DNA methylation o f the HTR2C gene in 
peripheral blood and brain in animal models.
3.4.5 Conclusions
In this study, the association of the DNA methylation of the HTR2C prom oter regions at
baseline w ith increased weight groups (<7% vs >7%) was observed suggesting the DNA
methylation status of the HTR2C prom oter may account fo r the weight gain in firs t
episode schizophrenia patients a fter receiving antipsychotic drugs. The HTR2C -759C/T
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and the FTO rs9939609 associated w ith the extent o f DNA methylation of the HTR2C 
prom oter sequences indicating tha t the genetic-epigenetic interaction may influence 
the HTR2C -759C/T or the FTO rs9939609 polymorphism-associated weight changes 
in schizophrenia patients. In o ther words, the polymorphisms of the FITR2C and FTO 
may affect the body weight regulation through epigenetic modification. The findings 
give a novel insight into the mechanistic link between the genetic polymorphism 
effects and weight gain.
In chronic schizophrenia patients, the significant association of the FITR2C -759C/T 
polymorphism w ith the extent o f methylation of the FITR2C prom oter at CpG sites 
located near the SNP suggests that the effect o f the polymorphism on epigenetic 
changes may strongly influence at nearby CpG sites rather than at distant CpG sites. 
The leptin -2458G/A polymorphism was associated w ith the methylation levels o f the 
HTR2C at CpG sites near the transcription start site, although lack o f the link between 
leptin and FITR2C methylation, these results indicate the interaction between leptin 
genotype and the FITR2C methylation tha t might be involved in the control o f satiety.
Data in this chronic patient group also showed tha t smoking was significantly 
associated w ith higher global LINE-1 methylation while olanzapine/clozapine 
treatm ent tended to have lower methylation. These results indicate tha t 
environmental factors impact on global DNA methylation. Furthermore, the 
association between the MTFIFR 677C/T polymorphism and global LINE-1 m ethylation 
suggests a genetic-epigenetic interaction and tha t the influence o f the MTFIFR 
polymorphism on global DNA methylation may be related to  obesity in schizophrenia. 
The significant interaction between smoking and the MTFIFR 677C/T polymorphism on 
global DNA methylation also indicates a genetic-environment interaction tha t may play 
an im portant role in body weight regulation in schizophrenia patients.
Therefore, the DNA methylation of the FITR2C prom oter region may be used as an 
epigenetic marker fo r antipsychotic drug-induced weight gain. The genetic-epigenetic 
interactions provide more understanding of the molecular mechanism underlying 
antipsychotic drug-induced weight gain. However, fu rthe r studies in a larger sample 
size are required to  obtain confirmation o f these findings.
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Chapter 4: Effect of antipsychotic drugs on DNA 
methylation and expression of the HTR2C gene in 
SH-SY5Y cells
4.1 Introduction
This chapter describes experiments that aim to  determ ine the effect o f antipsychotic 
drugs on DNA methylation of the HTR2C prom oter and 5-HT2C receptor mRNA 
expression. Two antipsychotics, clozapine and haloperidol, were chosen according to 
the ir a ffin ity fo r the 5-HT2C receptor fo r these cell culture experiments. Clozapine has 
a high a ffin ity to  the 5-HT2C receptor w ith  an equilibrium dissociation constant (Kd) = 
4.8 nM whereas haloperidol has a markedly low affin ity  to the 5-HT2C receptor w ith 
Kd = 4,700 nM in human brain (Richelson and Souder, 2000). A few  studies have 
reported a reduction of 5-HT2C receptor binding in rat brain (Kuoppamaki et al., 1993, 
1995), but no alteration in HTR2C mRNA expression after chronic clozapine and 
haloperidol treatm ent (Burnet et al., 1996). However, some studies found clozapine 
and haloperidol treatm ent causes changes in HTR2C mRNA expression in specific 
regions o f rat brain (Buckland et al., 1997; Huang et al., 2007). There have been no 
previous studies on the effect o f antipsychotic drugs on HTR2C mRNA expression as 
well as on HTR2C DNA methylation in cell culture. As mentioned in the previous 
chapter, the -759C/T polymorphism of the HTR2C gene is the most consistently 
identified SNP associated w ith antipsychotic drug-induced weight gain (see section 
2.1), however the nearby -697G/C SNP has also been implicated. Due to the repetitive 
nucleotides and high GC density o f the sequence at and nearby the -759C/T it proved 
impossible to  design suitable primers to  amplify this sequence. Therefore, the effects 
o f antipsychotic drug treatm ent on DNA methylation levels around the nearest SNP 
(-697G/C) were investigated.
In the present study 5-Aza-2-deoxycytidine, a demethylating agent inh ib iting DNA 
methyltransferase, was also used in cell culture treatm ent to serve as a positive 
control fo r DNA methylation inhibition. These experiments use the SH-SY5Y neuronal
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cell line and PCR techniques to  investigate the effects of these drugs on receptor gene 
expression and specific prom oter sequence DNA methylation around the -697G/C 
polymorphism of the HTR2C gene.
4.1.1 SH-SY5Y human neuroblastoma cell
SH-SY5Y human neuroblastoma cells (ATCC® CRL-2266™) are a neuronal-like cell line 
originally established from a bone marrow biopsy o f a woman patient w ith 
sympathetic adrenergic ganglial neuroblastoma and deposited w ith the American Type 
Culture Collection (ATCC) by June L. Biedler in the early 1970's (Biedler et al., 1973). 
SH-SY5Y cells are a sub-line of the parental line SK-N-SH which were subcloned three 
times (SK-N-SH to SH-SY, SH-SY to SH-SY5, and SH-SY5 to SH-SY5Y). SH-SY5Y cell culture 
properties are mixed type of adherent and floating cells and both of them are viable. 
The cells grow as clusters or clumps and pile on top of each other. For this reason, they 
slough o ff into the media. The cells attach better when they are more dilute; 
therefore, to facilitate cell attachment, subculturing at a high subculture ratio (1:20 to 
1:50) fo r 100% confluence should be done. The SH-SY5Y cell line has been extensively 
used in various experimental neurological studies; fo r example: neurodegenerative 
and neuroadaptive processes, neurotoxicity, and neuroprotection (Xie et al., 2010).
The SH-SY5Y cell line exhibits neuronal marker enzyme activity such as tyrosine 
hydroxylase and dopamine-|3-hydroxylase, specific uptake fo r norepinephrine, as well 
as expressing neurofilam ent proteins, and opioid, muscarinic and nerve growth factor 
receptors (Ciccarone et al., 1989). The SH-SY5Y cell line constitutively expresses HTR2C 
mRNA (Biedler et al., 1978; Cavarec et al., 2013). It also expresses HTR1A, HTR1B and 
HTR2A in addition to dopamine D1 and D2 receptors (Rohm et al., 2013). Furthermore, 
SH-SY5Y cells release dopamine, norepinephrine and serotonin (Shaul et al., 2003; 
Rohm et al., 2013).
Due to  its capability o f proliferating in culture fo r long periods w ithout contam ination
this SH-SY5Y cell line is suitable fo r in vitro  study. In addition, SH-SY5Y cells exhibit
stem cell properties because they are derived from  imm ature neoplastic neural crest
cells, and can be induced to differentiate to  more mature neuron-like cells upon
treatm ent w ith a variety of agents such as retinoic acid (Singh and Kaur, 2007). Other
agents used to induce d ifferentiation are phorbol ester 12-0-tetradecanoylphorbol-13-
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acetate (TPA)(Pahlman et al., 1981), brain-derived neurotrophic factor (BDNF) 
(Cernaianu et al., 2008), dibutyryl cyclic AMP (dBcAMP)(Kume et a i,  2008), purine 
(Guarnieri et al., 2009), or staurosporine (Mollereau et a i,  2007). However, both 
differentiated and undifferentiated SH-SY5Y cells have been w idely used in 
neuroscience research.
4.1.2 Differentiation of SH-SY5Y human neuroblastoma cell by 
retinoic acid
Upon differentiation, cells become a functionally mature neuronal phenotype showing 
extensive outgrowth o f neurites (Cheung et a i, 2009). Cells stop pro liferating and 
become a stable population and have biochemical, ultrastructural, morphological, and 
electrophysiological sim ilarity to neurons when differentiated. They express various 
neuronal-specific markers; fo r example: growth-associated protein (GAP-43), 
noradrenaline (NA), neuropeptides, neuronal nuclei (NeuN), receptors for 
neurotrophic factors, neuron-specific enolase (NSE), neurosecretory granula, vesicle 
proteins such as synaptophysin, and neuronal-specific cytoskeletal proteins such as 
m icrotubule associated protein (MAP), Tau, and neurofilam ent proteins (Cheung et al., 
2009; Fagerstrom et al., 1996). GAP-43, MAO, NeuN, and synaptophysin are the 
classical markers o f mature neurons.
Different agents used in differentiation induction can bring about various phenotypes 
of SH-SY5Y cells, including cholinergic, adrenergic, or dopaminergic phenotypes. For 
example, treatm ent w ith phorbol esters induces d ifferentiation to  an adrenergic 
neuronal phenotype, whereas retinoic acid treatm ent results in cholinergic (Pahlman 
et al., 1984) and dopaminergic phenotypes (Korecka et al., 2013).
Retinoic acid (RA) is the most common method used fo r inducing d ifferentia tion of SH- 
SY5Y cells (Kovalevich and Langford, 2013). The effects o f RA on SH-SY5Y cells are well 
described; RA exerts its effect by acting at two classes o f non-steroid nuclear hormone 
receptors, including the retinoic acid receptors (RARs) and the retinoic X receptors 
(RXRs). Although RA can bind only to the RAR receptors, activated RAR is able to 
heterodimerize w ith RXR and then RAR/RXR heterodimers can bind to  the RA response 
element (RARE) giving rise to transcriptional activation (Joshi et al., 2006).
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4.1.3 Polymerase Chain Reaction (PCR)
The polymerase chain reaction (PCR) is the most powerful laboratory technique used 
in molecular biology to  amplify a huge number of copies of a specific segment o f DNA. 
The key components to  enable selective and repeated amplification are the primers 
and DNA polymerase. Primers are oligonucleotides or short DNA fragments containing 
sequences complementary to  the target region. DNA primers are required fo r in itiation 
o f DNA synthesis at a specific region. DNA polymerase used in PCR is a heat-stable DNA 
polymerase, such as Taq polymerase which is an enzyme originally isolated from  the 
bacterium Thermus aquaticus. This DNA polymerase enzymatically assembles a new 
DNA strand from the nucleotides by using single stranded DNA as a tem plate.
The PCR is performed in a therm al cycler and relies on thermal cycling which consists 
o f cycles o f repeated heating and cooling of the reaction for DNA melting and 
enzymatic replication of DNA. There are three major steps in a PCR cycle (Figure 4.1), 
which are repeated fo r 25-50 cycles.
•  Denaturation or DNA melting at 94°C
During this denaturation step, the double stranded DNA tem plate is heated to 
94-95°C fo r separating to single-stranded DNA, the hydrogen bonds which hold 
the two strands together are broken. In the first step, this may also serve to 
activate the DNA polymerase.
•  Annealing or connecting at annealing temperature
After separating the double stranded DNA, each single-stranded is then used as 
the tem plate in DNA synthesis. The tem perature is decreased to the annealing 
tem perature, around 54-60°C so primers can bind to  a specific point on the 
single-stranded DNA tem plate. The DNA polymerase can then attach and start 
copying the DNA template. The annealing tem perature (Ta) depends on the 
primers used in the PCR reaction, usually 5°C lower than the melting point o f 
the primers.
•  Extension at 72°C
This tem perature is the ideal working tem perature fo r the DNA polymerase. In 
this final step, the DNA polymerase enzyme synthesizes the com plem entary
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strand of DNA. In other words, the bases that are complementary to the DNA 
tem plate are coupled to the primer on the 3' side.
PCR : Polymerase Chain Reaction
30 - 40 cycles o f 3 steps :
Step 1 : denaturation
mi nut 94 °C
5'rriTiTnTiTim
5 f  .ijM
Step 2 : annealing
45 seconds 54 °C
forward and reverse 
primers !!!
Step 3 : extension
2 minutes 72 CC 
only dNTP's
Figure 4.1: Cycling reaction o f PCR
(http ://users.ugent.be/~avierstr/princip les/pcr.htm l)
As PCR progresses, the amplified DNA products act as a tem plate fo r am plification in 
the next cycle. Because both strands are copied during PCR, there is an exponential 
increase of the number o f copies o f the gene.
At the end of PCR, the PCR products are checked by gel electrophoresis to  see whether 
there is product amplified and whether it is the expected size.
4.1.4 Real-time PCR
Real-Time PCR is a valuable technique used extensively in biological research 
nowadays in order to quantify nucleic acid amplification and detection. In real-time 
PCR, the accumulation of amplified PCR product is detected and measured as the
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reaction progresses. The detection of PCR product is made by including fluorescent 
molecules in the PCR reaction. The fluorescence used includes DNA-binding dyes and 
fluorescently labelled sequence specific primers or probes. In addition, the fluorescent 
dye, the components of real-time PCR are similar to  traditional PCR. The measured 
fluorescence reflects the amount o f amplified product in each cycle.
During the progression of the real-time PCR assay, the fluorescence which is 
proportional to the amount o f amplified product is detected and can be used to 
generate an amplification plot (Figure 4.2). In this plot, the PCR cycle number is shown 
on the x-axis and the fluorescence is shown on the y-axis. The plot shows two phases, 
an exponential phase followed by a plateau phase. In the first phase, the amount of 
PCR product approximately doubles in each cycle. However, the reaction components 
are consumed as the reaction proceeds, and ultim ately one or more of the 
components becomes lim iting. So the reaction slows and enters the plateau phase.
Exponential phase
O .G
m 0 2  CD
V>
CDb3
CT valuem
Threshold line
0 10 20 30 40
Cycle
Figure 4.2: Am plifica tion p lo t from  RT-qPCR
(http://www.gene-quantification.de/real-tim e-pcr-guide-b io-rad)
Initially, an increase in fluorescence cannot be detected, so it remains at the 
background levels (cycle 1-18) even though the PCR products are accumulated 
exponentially. Eventually, the amplified PCR products are accumulated enough to  
yield a detectable fluorescent signal. The cycle number at which the amplified products 
are detectable is called the threshold cycle, or Ct (Figure 4.2). This Ct value is measured
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in the exponential phase in which the reagents are not lim ited. The Ct value is 
determined mainly by the amount of tem plate present at the start o f the amplification 
reaction. If a large amount of DNA tem plate is present at the start o f the reaction, the 
reaction will have an early or low Ct value, meaning tha t relatively few  PCR cycles are 
required to  accumulate enough PCR products to  give a fluorescent signal above 
background. In contrast, if a small amount o f DNA tem plate is present at the start of 
the PCR reaction this will result in late or high Ct value, meaning tha t more PCR cycles 
are required fo r the fluorescent signal to  rise above background. This relationship is 
the basis fo r the quantitative aspect o f real-time PCR.
Real-time PCR results can either be qualitative (the presence or absence of a 
sequence) or quantitative (number o f copies o f DNA) which is also known as qPCR. In 
addition, real-time PCR data can be evaluated w ithou t gel electrophoresis, therefore, 
the experimental tim e is reduced.
4.1.5 Quantitative Reverse Transcription PCR (RT-qPCR)
Quantitative reverse transcription PCR (RT-qPCR) is the combination of techniques to 
determ ine mRNA expression level. It is a combination of reverse transcription PCR and 
real-time PCR. The principle o f RT-PCR is tha t the starting material is mRNA tha t is 
reverse transcribed into complementary DNA (cDNA) by reverse transcriptase which is 
then used as a tem plate fo r amplification using PCR.
The mRNA expression level o f the gene of interest can be determined by tw o  methods; 
standard curve and relative methods. The standard curve (or absolute quantification) 
method is used to determine the absolute target quantity of transcripts in samples. 
The amplification of samples and a standard dilution series containing a range of 
known quantities of transcripts are measured. Data from  the standard d ilu tion series 
are used to  generate a standard curve, then the absolute quantity o f target in the 
samples are obtained.
The relative quantification method uses the house-keeping gene transcripts which act 
as reference transcripts used to  normalize the target transcripts o f samples. The best 
reference genes should be expressed at a constant level between the cells o f d ifferent 
tissues and under d ifferent experimental conditions (Thellin et al., 1999). Selection of
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the housekeeping genes is a crucial requirem ent for real-time RT-PCR experiments 
because they are highly specific fo r a particular experimental model. Experimental 
conditions can induce an alteration in gene expression of some housekeeping genes 
causing the high variability and affecting the reliable normalization (Dheda et al., 
2004). The house keeping genes w ith high variability can lead to  increased noise or 
erroneous results (Bustin, 2000). Therefore, the appropriate validation of internal 
reference genes is necessary to  avoid m isinterpretation o f gene expression results.
Once normalized, the relative transcripts o f mRNA among m ultip le samples or 
treatm ents or d ifferent gene transcripts can be compared. By this relative method, the 
quantification of the results is analyzed by comparing the linear range o f both target 
and internal control amplification; therefore, it is essential to  determ ine the 
amplification efficiency prior to starting the analysis. The details o f calculations of the 
relative expression and amplification efficiency are described in the methods (see 
section 4.2.6).
4.1.6 Aims
1. To determine the effect o f antipsychotic drugs on 5-HT2C receptor mRNA 
expression using reverse-transcription real-time PCR to  quantify 5-HT2C 
receptor mRNA levels.
2. To determ ine the effect o f antipsychotic drugs on DNA methylation of the 
HTR2C prom oter sequences around the -697G/C polymorphism using bisulfite 
pyrosequencing to quantify DNA methylation levels.
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4.2 Materials and methods
4.2.1 Materials
All solutions for cell culture were purchased from Life Technologies including fetal 
bovine serum (FBS), trypsin/EDTA, Dulbecco's modified Eagle's medium (DMEM), 
Penicillin-Streptomycin, Phosphate-Buffered Saline (PBS). 3-(3, 4-dimethylthiazol-2-yl)- 
2, 5-diphenyltetrazolium bromide (MTT), retinoic acid (RA), clozapine, haloperidol, 5- 
Aza-2-deoxycytidine, 2-mercaptoethanol (2-ME), ethidium bromide, ethanol, and 
dimethyl sulphoxide (DMSO) were purchased from Sigma-Aldrich, UK. Agarose was 
purchased from Invitrogen, UK. Bisulfite conversion kit, DNA extraction kit, all solutions 
fo r pyrosequencing, RNA extraction kit and RT kit were purchased from  QIAGEN, UK.
4.2.2 Cell culture
The human neuroblastoma SH-SY5Y cell line was maintained in Dulbecco's modified 
Eagle's medium (DMEM) supplemented w ith 10% fetal bovine serum, 100 U/mL 
penicillin and 100 U/mL streptomycin in a humidified, 5% C02, 37°C incubator. Cells 
were subcultured before confluence was reached. Cell passage numbers o f less than 
15 were used in the experiments.
4.2.3 Cell line stocks
SH-SY5Y cells were suspended in 1 ml of fetal bovine serum containing 10% (v/v) of 
DMSO. Cells were stored in cryovial tubes immersed in liquid nitrogen until required 
fo r use.
4.2.4 Drug Treatment
The drug treatm ents were designed using three models; 1) trea tm ent in 
undifferentiated SH-SY5Y cells, 2) treatm ent in differentiated SH-SY5Y cells, and 3) 
treatm ent in undifferentiated cells and then induced differentiation after treatm ent.
4.2.4.1 Treatment in undifferentiated SH-SY5Y cells
The SH-SY5Y cells were plated into 6-well plates at a density o f 5x10s cells per well and 
cultured fo r 24 hours before drug treatm ent. Cells were treated w ith clozapine at
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doses of 2 pM and 10 pM and haloperidol at doses of 10 nM and 10 pM for 48 hours. 
Cells were also treated w ith 5-Aza-2-deoxycytidine at the doses of 0.5, 1, and 2 pM for 
72 hours. The freshly prepared medium containing drugs was replaced every 24 hours. 
The control (no drug) was also performed by treatm ent w ith DMSO at the same 
concentration as in the drug treatm ent (control 0.01% DMSO fo r clozapine and 
haloperidol treatm ent, and control 0.002% DMSO for 5-Aza-2-deoxycytidine 
treatm ent). The treated cells were harvested by trypsinization and washed w ith PBS 
before being stored at -80°C until used. DNA was extracted to  determ ine DNA 
methylation o f HTR2C gene, while RNA was extracted to  determine mRNA expression 
o f 5-HT2C receptor. The experiments were performed in trip licate and 3 independent 
experiments were carried out.
4 .2A .2  T re a tm e n t in  d if fe re n tia te d  SH-SY5Y ce lls
To induce differentiation of human neuroblastoma SH-SY5Y cells to become more 
mature neuronal cells, the SH-SY5Y cells were seeded into 75 cm2 culture flask at the 
density o f 2 x l0 4 cells/cm2 in the culture medium containing 10 pM retinoic acid 
(Cheung et al.,, 2009). The differentiation induction was carried out fo r 7-8 days prior 
to  treatm ent.
In order to  study the effect o f antipsychotic drugs on gene expression and DNA 
m ethylation of the HTR2C gene in mature neuronal cells, d ifferentiated cells at the 
density o f 5 x l0 5cells/well were seeded overnight into 6-well plates. Cells were treated 
w ith clozapine at the doses of 2 pM and 10 pM and haloperidol at the doses o f 10 nM 
and 10 pM for 48 hours. Differentiated cells were also treated w ith 5-Aza-2- 
deoxycytidine at the doses of 0.5, 1, and 2 pM fo r 72 hours. The freshly prepared 
medium containing drugs was replaced every 24 hours. The control (no drug) was also 
performed by treatm ent w ith DMSO at the same concentration as drug treatm ent 
(control 0.01% DMSO for clozapine and haloperidol treatm ent, and control 0.002% 
DMSO for 5-Aza-2-deoxycytidine treatm ent). The treated cells were fu rthe r processed 
to  determine DNA methylation o f HTR2C gene and mRNA expression of 5-HT2C 
receptor as described in section 4.2.4.1.
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4.2A.3 Treatment in undifferentiated SH-SY5Y cells followed by 
differentiation induction
The SH-SY5Y cells were plated into 6-well plate at a density o f 5x10s cells per well and 
cultured for 24 hours before drug treatm ent. Cells were treated w ith 5-Aza-2- 
deoxycytidine at a dose of 0.5 pM for 72 hours. The freshly prepared medium 
containing drugs was replaced every 24 hours. The control (no drug) was also 
performed by treatm ent w ith DMSO at the same concentration as drug treatm ent 
(control 0.002% DMSO). A fter 72 hours of treatm ent, the culture medium w ith drug 
was removed and replaced by culture medium containing retinoic acid (10 pM) to  
induce differentiation or replaced by 0.001% DMSO which served as a parallel control 
undifferentiation induction. At the end of d ifferentiation period (7 days), the treated 
cells were fu rther processed to determine DNA methylation o f HTR2C gene and mRNA 
expression o f 5-HT2C receptor as described in section 4.2.4.1.
4.2.5 Determination of cell viability by MTT assay
Cell v iability was determined by a mitochondria enzyme dependent reaction of MTT 
(Datki et al., 2003; Cheung et al., 2009). Briefly, the SH-SY5Y cells at a density o f 1 x 104 
cells per well were cultured onto 96-well plates fo r 24 hours before treatm ent. A fter 
treatm ent, 10 pi o f MTT stock solution (5 mg/m l) was added to  each well (100 pi) and 
left to incubate at 37°C for 3 hours. Metabolically active cells cleaved the yellow 
tetrazolium salt MTT to purple formazan crystal. At the end of incubation tim e, the 
medium was removed and the formazan crystals were solubilised w ith 150 pi of 
DMSO. The absorbance was measured by a m icroplate reader at 570 nm. Results were 
expressed as percentage of the vehicle control. All MTT assays were perform ed in 
trip licate model.
4.2.6 Determination of HTR2C mRNA expression by real time RT-PCR
4.2.6.1 RNA extraction
The extraction of RNA from cultured cells was carried out w ith the RNeasy Mini Kit 
(QIAGEN) follow ing the protocol provided by the manufacturer. This kit used spin 
columns to extract RNA.
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Initially, cell lysis solution was prepared by addition o f 10 pi of 2-mercaptoethanol (2- 
ME) per 1 ml o f provided lysis buffer (Buffer RLT). 350 pi of 2-ME/lysis solution was 
added to each cell pellet and mixed thoroughly by vortexing to lyse the cells and 
inactivate RNases. The lysate was also homogenized and DNA sheared by passing at 
least 5 times through a 20-gauge needle (0.9 mm diameter) fitted  to an RNase-free 
syringe. An equal volume (350 pi) of 70% ethanol was added to  the homogenized 
lysate to prepare fo r RNA binding. The lysate/ethanol solution was transferred to an 
RNeasy spin column which was placed in a 2 ml collection tube. Then centrifugation 
was done at 8000xg fo r 15 seconds. RNA was bound to the spin column membrane. 
The flow-through was discarded and the collection tube was reused.
The spin column w ith bound RNA was washed by addition of 700 pi o f wash buffer 1 
(buffer RW1) followed by centrifugation at 8000xg for 15 seconds. The flow-through 
was discarded and the collection tube was reused. Then 500 pi of wash buffer 2 (buffer 
RPE) was run through the spin column by fu rther centrifugation at 8000xg fo r 15 
seconds. This step was repeated w ith a th ird column wash w ith buffer RPE and was 
again centrifuged at 8000xg for 2 minutes to  dry the column. The spin column must be 
free of ethanol before the elution step; therefore, a further drying spin column was 
performed by centrifugation at maximum speed fo r 1 minute.
The RNA was eluted from the spin column by adding 40 pi of elution buffer d irectly to 
the centre o f membrane. A fter incubation at room tem perature fo r 1 minute, the spin 
column was centrifuged at 8000xg fo r 1 minute. The purified RNA was stored at -80 °C.
4.2.6.2 Determination of RNA quantity and quality
The yield o f each tota l RNA sample was obtained from  A26o measurements w ith 
Nanodrop-1000 UV-VIS spectrophotom eter in RNA-40 nucleic acid mode. Absorbance 
at 260 nm, 1 absorbance unit (A26o) equals 40 pg o f single-stranded RNA/ml. Initially, 
the spectrophotom eter was initialised using nuclease-free water, and then blanked 
using the elution buffer from  the kit or nuclease-free water. 1 pi o f each RNA sample 
was used to  obtain the accurate RNA concentration. RNA was stored at -80°C for use in 
cDNA synthesis.
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Extracted RNA must be clear from  any contaminants such as salt, protein, solvents and 
genomic DNA (gDNA). Poor quality RNA can interfere w ith downstream processing. 
The purity o f RNA was estimated by spectrophotom etry from  the relative absorbance 
at 230, 260, and 280 nm i.e. A260/A 280 and A260M 230 ratios. Pure RNA exhibits A260/A 280 
ratios range of 1.7 to 2.1. A low RNA ratio refers to  contamination by salt, solvent, 
protein, etc. A low A260M 280 ratio is typically due to  protein contamination while a low 
A260M 230 ratio is typically due to  salt or solvent contamination such as guanidine 
thiocyanate.
RNA integrity was determined using agarose gel electrophoresis. The ratio o f 28S to 
18S eukaryotic ribosomal RNAs should be approximately 2:1 by ethidium  bromide 
staining, indicating that no gross degradation of RNA has occurred. In RNA samples 
tha t have been degraded, 28S:18S ratio will be reversed because the 28S rRNA 
characteristically is degraded to an 18S-like species.
4.2.6.3 Complementary DNA (cDNA) synthesis
The first strand complementary DNA (cDNA) synthesis was carried out using the 
QuantiTect Reverse Transcription Kit (QIAGEN). Complementary DNA was synthesized 
according to the manufacturer's protocol. In brief, the gDNA elim ination reaction was 
initia lly set up which consisted of 1 pg o f the tota l RNA adjusted to a volume of 12 pi 
using a variable amount o f nuclease-free water and 2 pi o f gDNA W ipeout Buffer (7x). 
The reaction was set up on ice in a 0.2 ml m icrocentrifuge tube. Then the reaction was 
incubated at 42°C fo r 2 minutes and placed immediately on ice. The reverse- 
transcription master mix was prepared on ice and consisted o f 1 pi of Quantiscript 
Reverse Transcriptase, 1 pi o f RT Primer Mix, and 4 pi o f Quantiscript RT Buffer(5x). 
The master mix (6pl) was added to the tem plate RNA from the previous gDNA 
elim ination step and then the reaction m ixture was mixed and stored on ice. A fte r this 
the reaction mixture was incubated for 15 minutes at 42°C. The reverse-transcription 
reaction was inactivated by incubating the reaction m ixture at 95°C fo r 3 minutes. The 
cDNA was stored on ice and preceded directly to  real-time PCR or stored at or below - 
20°C for later use.
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4.2.6.4 Reference gene selection
Twelve housekeeping (HK) genes including ACTB, ATP5B, B2M,CYC1, EIF4A2, GAPDH, 
RPL13A, SDHA, TOPI, UBC, YWHAZ, and 18S from Primerdesign (Primerdesign, UK) 
were tested on SH-SY5Y cells across differentiated and undifferentiated cells under 
d ifferent treatm ent conditions such as clozapine and haloperidol treatm ent by using 
RT-qPCR to assess the stability of expression (Table 4.1). Each sample was carried out 
in duplicate. A negative control PCR reaction o f each gene was performed in which no 
cDNA tem plate was added. The expression stability o f these HK genes were analysed 
using GeNorm qbasePLUS Software (Precision, Primer Design, UK), w ith  stability 
defined by M  value, where higher M  value indicates less stability (Vandesompele et al., 
2002). The Ct values of HK genes obtained from  real-time PCR were input into software 
which were log2 transformed and obtained the expression ratios calculated by the 
equation:
^(C t o f contro l- Ct o f sample)
The control in this case was the lowest expressing sample (the highest Ct value) to 
have positive values for all expression ratios. The software calculated the most stable 
expressing HK genes by step-wise removal o f genes after analysis by pair-wise variation 
o f all possible combinations of all HK genes then the most stable expressing HK gene 
was left w ith  a lowest stability value M. Two or three HK genes tha t were the most 
stable expressing genes selected from  the GeNorm were used as reference control 
genes in determ ining relative expression of gene of interest.
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Table 4.1: Housekeeping genes analysed for expression stability in SH-SY5Y cells 
using RT-qPCR
Gene symbol Name and function
ACTB beta-actin, cytoskeletal structural protein
ATP5B ATP synthase subunit beta, H+ transporting, m itochondrial FI 
complex, beta polypeptide, ATP production
B2M Beta-2-microglobulin, beta-chain of major h istocom patibility 
complex class 1 molecules
CYC1 Cytochrome c-1, electron transport chain
EIF4A2 Eukaryotic translation in itiation factor 4A2, ATP-dependent 
RNA helicase, mRNA binding to  ribosome
GAPDH Glyceraldehyde-3-phosphate dehydrogenase, oxidoreductase 
in glycosis and gluconeogenesis
RPL13A Ribosomal protein L13a, structural component o f the large 
60S ribosomal subunit
SDHA Succinate dehydrogenase complex, subunit A, flavoprotein 
(Fp), electron transporter in the TCA cycle and respiratory 
chain
TOPI Topoisomerase 1, DNA repair
UBC Ubiquitin C, protein degradation
YWHAZ Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, zeta polypeptide, signal transduction by 
binding to  phosphorylated serine residues on a variety o f 
signalling molecules
18S 18S ribosomal RNA, ribosome subunit
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4.2.6.5 D e te rm in a tio n  o f  p r im e r  e ffic iency
The amplification efficiency o f primers used in this expression study including 5-HT2C 
receptor, GAPDH and CYC1, was determined using RT-qPCR. To determ ine primer 
efficiency o f 5-HT2C receptor, the cDNA tem plate was diluted in d ilution series (1:5, 
1:10, 1:50 and 1:100) w ith nuclease-free distilled water and 4 pi o f each dilution 
sample was a subject to  real-time PCR reaction (section 4.2.6.6). The serial d ilutions of 
1:1, 1:10, 1:100, and 1:1000 were also performed to determine prim er efficiency of 
GAPDH and CYC1. Each sample was carried out in duplicate. The prim er efficiency of 
each prim er set was calculated by the method described by Pfaffl (2001) as follows:
Efficiency (E) = 10('1/slope)
Percentage of Efficiency = (10(1/slope)-l)*1 0 0
The slope was calculated by plotting semi-log between cDNA concentration or d ilution 
factor on the x axis of a scatter plot and Ct values on y axis using M icrosoft Excel 
software. An ideal efficiency value 2.00 representing 100 percent efficiency was 
corresponded to a slope of -3.32 which indicated precisely double am plify the amount 
o f PCR product during each cycle o f PCR. Primer efficiencies between 90-110% were 
considered acceptable fo r use in subsequent analyses (Pfaffl, 2001).
4.2.6.6 Q u a n tita tiv e  RT-PCR (RT-qPCR)
The expression of reference genes and the 5-HT2C receptor were assessed using the 
cDNA as the template. The reaction mixture volume o f 20 pi was prepared containing 
cDNA, 20 ng, (4pl), 1 pi o f 10 pM oligonucleotide forward and reverse primers, and 10 
pi o f (2x) qPCR mastermix (Precision, Primer Design) and nuclease-free distilled water. 
This mastermix contains 2x reaction buffer, 0.025 U/pl Taq Polymerase, 5 mM MgCI2, 
dNTP mix (200 pM each dNTP), and SYBR®Green and ROX passive reference dye.
The prim er sequences of 5-HT2C receptor were shown in Table 4.2 which were 
purchased from  Primerdesign.
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Table 4.2: O ligonucleotide prim er sequences fo r 5-HT2C receptor mRNA
Primer Sequence (5'-3') Tm (°C) Product length
HTR2CJ G CAAGTTG AG AATTT AG AGTT ACCA 56.7 97 bp
HTR2C_R CGTAGGAAAAGACTGTGCTGTT 57.4
The PCR reactions were set up in a 96-well PCR plate, the reactions were then run in a 
real-time PCR system, StepOne Plus (Applied Biosystems, USA). The PCR cycles fo r 
determ ining 5-HT2C receptor mRNA expression were set as follows;
95°C for 10 minutes to  activate hotstart enzyme 
94°C for 15 seconds
64°C for 30 seconds w ith data collection ^  40 cycles
72°C for 30 seconds 
M elt curve 
95°C for 15 seconds
50°C for 60 seconds increasing in 1°C increment
The PCR cycles fo r determ ining mRNA expression of HK gene were set as follows;
95°C for 10 minutes to  activate hotstart enzyme
94°C for 15 seconds V 40 cycles
60°C for 1 m inute w ith data collection
M elt curve
95°C for 15 seconds
50°C for 60 seconds increasing in 1°C increment
The final melt curve step was used to estimate the specificity o f the primers in 
SYBR®Green real-time RT-PCR. One single peak o f melt curve should be obtained to  
ensure only one PCR product was amplified. If the primers have low specificity binding 
to  tem plate sequences, more than one PCR products were amplified and resulted in 
m ultiple peaks showing on melt curve.
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The expression o f 5-HT2C receptor mRNA transcript was normalized to those of 
reference genes and relative to control treatm ent using the comparative Ct method 
(2’AACt method) according to formula below (Livak and Schmittgen, 2001).
Expression ratio = 2-[ACtsample-ACtcontrol]
Expression ratio = 2~AACt
Where AC{ sample -  sample "  Q : reference 
and ACt control = contro l '  Q: reference
4.2.7 Determination of DNA methylation of HTR2C gene
The prom oter sequence of the HTR2C gene at and nearby the -697G/C SNP site was 
used to investigate the effect o f antipsychotic drug treatm ent on the extent of DNA 
methylation o f CpGs in this region. Initially, the CpGs at and nearby the -759C/T SNP 
site were targetted but there was a problem w ith pyrosequencing as mentioned in 
section 4.1. Instead, the nearby region (at -697G/C and nearby CpG sites) was 
investigated.
The extraction of DNA from cultured cells was carried out using QIAamp® DNA Mini
and Blood Mini kit (Qiagen) follow ing the protocol provided by the manufacturer.
Initially, cell lysis solution was prepared by resuspending the cell pellet w ith 200 pi o f
PBS, and then 20 pi o f proteinase was added into the mixture followed by the addition
of 200 pi o f lysis buffer (Buffer AL) and mixing by pulse-votexing fo r 15 seconds. The
lysate was incubated at 56°C for 10 minutes. 200 pi o f 70% ethanol was added to  the
lysate and mixed by pulse-vortexing fo r 15 seconds to prepare for DNA binding. Then
the mixture was transferred to  a QIAamp Mini spin column which was placed in a 2 ml
collection tube. Then centrifugation was done at 6,000xg (8,000 rpm) fo r 1 m inute.
DNA was bound to the spin column membrane. The flow-through was discarded and
then the QIAamp M ini spin column was placed in a new 2.0 ml collection tube. The
spin column w ith bound DNA was washed by addition o f 500 pi of wash buffer 1
(buffer AW1) followed by centrifugation at 6,000xg for 1 minute. The flow -through was
discarded and the spin column was placed in a new 2.0 ml collection tube. Then 500 pi
o f wash buffer 2 (buffer AW2) was run through the spin column by fu rthe r
centrifugation at full speed 20,000xg (14,000 rpm) fo r 3 minutes. The column was
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again centrifuged at full speed fo r 1 minute to dry the column. The DNA was eluted 
from  the spin column by adding 50 pi o f elution buffer (buffer AE) or distilled water 
directly to  the centre o f membrane. After incubation at room tem perature fo r 1 
minute, the spin column was centrifuged at 6,000xg fo r 1 minute. The purified DNA 
was stored at -20°C.
Genomic DNA was extracted and used in bisulfite pyrosequencing. The methods for 
bisulfite treatm ent, PCR, gel electrophoresis, and pyrosequencing were mentioned 
earlier in a previous chapter (see chapter 3, section 3.2). All methods fo r determ ining 
DNA methylation, analysing CpG sites, PCR primers and conditions, sequencing primer, 
and the pyrosequencing protocol were the same as described in the previous chapter 
(see section 3.2).
4.2.8 Statistical analysis
The effects o f antipsychotic drugs on HTR2C mRNA expression and DNA m ethylation of 
HTR2C prom oter sequence were tested using SPSS for Windows. The expression of 
HTR2C mRNA was expressed as fold change comparing to  control untreated group. 
DNA methylation o f HTR2C prom oter sequence was expressed as mean percentage 
m ethylation of all CpGs. The normal d istribution was tested by using the Kolm ogorov- 
Smirnov test. One-way ANOVA was used to compare means between m ultip le groups 
when the values had a normal distribution w ith Bonferroni post hoc test. The Kruskal- 
Wallis test was used for non-parametric tested when the values did not have normal 
d istribution. Statistical significance was considered when P value was less than 0.05.
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4.3 Results
4.3.1 Effect of antipsychotic drug treatments on cell viability
The cell viability o f various drug treatments in SH-SY5Y cells at 24, 48, 72, and 96 hours 
determined by the MTT assay is shown as percentage of control at each tim e period. 
The highest concentration of DMSO that can be used as a drug solvent and the highest 
concentration o f drugs tha t can be used in the experiment were determ ined as when 
the cell viabilities were more than 80% of the ir untreated controls. The results showed 
tha t the highest concentration of chemicals tha t can be used in the experiments were 
up to 1% for DMSO, 20 pM for 5-Aza-2-deoxycytidine (w ithin 72h incubation period), 
50 pM for haloperidol, and 25 pM for clozapine (Figure 4.3 and Figure 4.4). The cell 
viability o f some cell treated w ith DMSO (1%) at 96h was increased above 100% of the 
control. In addition, treatm ent w ith 5-Aza-2-deoxycytidine (<5pM) fo r 24-72h resulted 
in increased cell viability.
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Figure 4.3: The percentage o f cell v iab ility  when treated w ith  (A) DMSO (n=4); and (B) 
5-Aza-2-deoxycytidine (n=3) fo r 24, 48, 72, and 96 hours compared to  contro l 
untreated cells (0% DMSO).
Data presented as mean±SEM.
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Data presented as meaniSEM, n=4.
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4.3.2 Effect of antipsychotic drug treatments on HTR2C mRNA 
expression
4.3.2.1 RNA extraction
The total RNA was extracted from  cultured cells and its concentration was determined 
using the Nanodrop-1000 spectrophotometer. The absorbance ratio o f A260M 280 and 
A260/A 230 were between 1.8 to  2.2 (data not shown) tha t reflected the purity of 
extracted RNA. In addition, the integrity o f RNA was also determined by running on 
agarose gel electrophoresis. The ratio o f 28S to 18S ribosomal RNAs showed 
approximately 2:1 by ethidium bromide staining, indicating that no gross degradation 
of RNA occurred (Figure 4.5).
18S
Figure 4.5: RNA on gel electrophoresis determining integrity of RNA
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4.3.3 Selection of housekeeping genes as internal control genes
The internal reference control genes fo r normalizing the expression of the gene of 
interest were selected from 12 HK genes. Initially, the expression of 12 HK genes was 
analysed in undifferentiated SH-SY5Y cells treated w ith clozapine compared to 
untreated control. The melt curve of each reference gene showed a single peak 
indicating that single specific PCR product was amplified; the amplification plots and 
melt curves of reference genes were illustrated in Figure 4.6.
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Figure 4.6: Amplification plots and melt curves of the house keeping genes tested for 
transcript expression stability
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The results from qPCR were evaluated by GeNorm software to select HK genes with 
the most stable expression fo r using as internal reference control genes. The results 
from the GeNorm software indicated several HK genes that had high average 
expression stability values (M  value or geNorm M  <0.2) (Figure 4.7). The program 
elim inated the worst-scoring HK gene tha t is the one w ith the highest M  value and 
recalculated of new M  values fo r the remaining genes. Therefore, genes w ith the 
lowest M  values have the most stable expression. The software suggested GAPDH and 
CYC1 as the most stable reference genes. In addition, the minimum required number 
o f HK gene was suggested by a geNorm V value which should be lower than 0.15 
(Figure 4.8) indicating that at least tw o reference genes should be used in subsequent 
analyses. This V value indicates the systemic variation fo r repeated RT-qPCR 
experiments on the same gene reflecting the variation o f the machine, enzymatic 
reaction and pipetting error. In summary, the most stable expressing HK genes 
observed across undifferentiated and differentiated cells and all treatm ents were 
found to  be GAPDH and CYC1. Two HK genes were used as reference internal control 
genes fo r subsequent quantitative reverse transcription PCR analyses.
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Figure 4.7: The geNorm M  of 12 housekeeping genes of undifferentiated and 
differentiated cells treated with clozapine, haloperidol, and untreated control 
samples.
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4.3.4 The primer efficiency of HTR2C, GAPDH and CYC1
The amplification efficiency of primers including HTR2C, GAPDH, and CYC1 were 
determined. The slopes tha t were obtained from  semi-log plots between cDNA 
concentration and Ct values of each primer set were used to calculate primer efficiency 
(Figure 4.9). The slope values fo r HTR2C, GAPDH, and CYC1 were -3.1418, -3.375,
and -3.4457, respectively. It should be noted that the narrow range of HTR2C dilution 
series compared to HK genes indicated the low quantity o f transcripts. The percentage 
of primer efficiency were calculated as described in section 4.2.6.5; E(%) = ( io (1/slope)- 
1)*100, and shown in Table 4.3.
In addition, the specificity o f each prim er set was also assessed by m elt curves as 
shown in Figure 4.10. Every primer set amplified only one single product indicating 
tha t no non-specific PCR product was amplified.
Table 4.3: The amplification efficiencies of primers used in expression study in SH- 
SY5Y cells
Primers Efficiency (%) (mean ± SD) (n=3)
HTR2C 108.12 ± 1.40
GAPDH 97.86 ± 1.90
CYC1 95.11 ±2.15
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Figure 4.9: Semi-log plots between cDNA concentrations and Ct values o f each prim er 
set using fo r primers efficiency calculation
Efficiencies o f all primer sets were determined including HTR2C, GAPDH, and CYC1. The 
Ct values of each dilution series o f each transcript were used to calculated slope o f the 
trend line. Data presented as mean±SD (n=3). The percentage of efficiency was 
calculated using E= [ I0 (1/slope)- l ]  *100. The slope values fo r HTR2C, GAPDH, and CYC1 
were -3.1418, -3.375, and -3.4457, respectively. The means calculated prim er 
efficiency (n=3) of HTR2C, GAPDH, and CYC1 were 108.12%, 97.86%, and 95.11%, 
respectively.
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Figure 4.10: M e lt curve o f HTR2C, GAPDH, and CYC1 transcripts when am plified by 
primers which used in determ ining o f prim er efficiency in SYBR Green rea l-tim e RT- 
PCR in SH-SY5Y cells
4.3.5 Effect of drug treatment on HTR2C mRNA expression in 
undifferentiated SH-SY5Y cells
The effect of antipsychotic drug treatm ent on the expression o f the HTR2C transcript in 
undifferentiated SH-SY5Y cells was determined by quantitative RT-PCR. Treatm ent w ith 
clozapine fo r 48 hours in undifferentiated SH-SY5Y cells at doses of 2 pM and 10 pM as 
well as treatm ent w ith haloperidol at doses of 0.01 and 10 pM had no effect on the
2 0 0
expression o f the HTR2C transcript relative to control untreated cells (DMSO 0.01%) at 
day 0 as shown in Figure 4.12. However, treatm ent w ith 5-Aza-2-deoxycytidine, a 
demethylating reagent, at doses of 0.5, 1, and 2 pM resulted in an increase in the 
expression of the 5-HT2C receptor transcript, but this did not reach significant levels 
(p>0.05) a fter 72 hours o f treatm ent (Figure 4.13). In addition to  observing the melt 
curve, the PCR products from  RT-qPCR were run using gel electrophoresis which 
confirmed that only one PCR product was amplified w ithout any non-specific PCR 
product, indicating the specificity o f primer sets used in SYBR®Green RT-qPCR (Figure 
4.11).
4.3.6 Effect of drug treatment on HTR2C mRNA expression in 
differentiated SH-SY5Y cells
The expression of the HTR2C transcript in d ifferentiated cells was also determ ined by 
quantitative RT-PCR and results were similar to previous experiments in 
undifferentiated SH-SY5Y cells. Treatment w ith clozapine fo r 48 hours in d ifferentiated 
SH-SY5Y cells at doses of 2 pM and 10 pM as well as treatm ent w ith haloperidol at 
doses of 0.01 and 10 pM had no effect on the expression o f HTR2C transcript relative 
to control untreated cells at day 0 (Kruskal-Wallis test) as shown in Figure 4.14. 
However, treatm ent w ith 5-Aza-2-deoxycytidine, a demethylating reagent, at doses of 
0.5, 1, and 2 pM resulted in an increase in the expression o f the HTR2C transcript but 
this did not reach significant levels (p>0.05) after 72 hours o f treatm ent (Figure 4.15).
Figure 4.11: PCR products resulted from RT-qPCR were run on agarose gel 
electrophoresis to assess the specificity of primer sets used in SYBR®Green RT-qPCR
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Figure 4.12: HTR2C mRNA expressions o f various concentrations o f clozapine and 
haloperidol trea tm en t in undifferentia ted  SH-SY5Y cells. Expression was normalized 
to  GAPDH and CYC1.
Data presented as meaniSEM.
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Figure 4.14: HTR2C mRNA expressions o f various concentrations o f clozapine and 
haloperidol trea tm en t in d iffe rentia ted  SH-SY5Y cells. Expression was normalized to  
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Data presented as meaniSEM.
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4.3.7 Effect of 5-Aza-2-deoxycytidine treatment on HTR2C mRNA 
expression in undifferentiated SH-SY5Y cells followed by 
differentiation induction
The results from  previous sections showed tha t the antipsychotic drugs, clozapine and 
haloperidol, did not have an effect on HTR2C mRNA expression whereas 5-Aza-2- 
deoxycytidine treatm ent led to increased HTR2C mRNA expression in both 
undifferentiated and differentiated SH-SY5Y cells. Therefore, in this experim ent only 5- 
Aza-2-deoxycytidine treatm ent was carried out to  assess the effect o f 5-Aza-2- 
deoxycytidine on HTR2C mRNA expression in undifferentiated cells followed by 
d ifferentiation induction using retinoic acid fo r 7 days. The results show that 5-Aza-2- 
deoxycytidine had a long lasting effect on HTR2C mRNA expression even if it was 
removed before induction of d ifferentiation (Figure 4.16B). This effect was observed in 
undifferentiated cells when cells were grown for the same period o f tim e w ith no 
retinoic acid treatm ent, as well as differentiated cells; 5-Aza-2-deoxycytidine resulted 
in an increase in 5-HT2C receptor transcript under both conditions (Figure 4.16A).
50
P 45
40
c  35 o
30
03
* p< 0.001 
#p  <0.001
* p < 0.001 
#p  <0.001I/)co
CD
x  20 o»
CU 15 
>
ControlControl ControlAza Aza
dayO treatment 0.5 pM treatment 0.5 pM
(-RA) (-RA) (+RA) (+RA)
Figure 4.16: HTR2C mRNA expression w ith  0.5 pM  5-Aza-2-deoxycytidine trea tm en t 
fo r 72 hours in und ifferentia ted SH-SY5Y cells fo llow ed by w ith  (B) o r w ith o u t (A) 
d iffe ren tia tion  induction fo r 7 days.
Expression was normalized to  GAPDH and CYC1. Data presented as meaniSEM. * 
indicates statistical significant difference compared to control (DMSO 0.002%) at day 0, 
# indicates statistical significant difference compared to  the ir control treatm ents 
(DMSO 0.002% (-RA) or retinoic acid (+RA) fo r same experimental periods).
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4.3.8 Effect of drug treatment on DNA methylation extent of HTR2C 
gene in undifferentiated SH-SY5Y cells
The effect o f antipsychotic drug treatm ent on DNA methylation of the 5-HT2C receptor 
gene (HTR2C) in undifferentiated SH-SY5Y cells was determined by bisulfite 
pyrosequencing. Treatment w ith clozapine fo r 48 hours in undifferentiated SH-SY5Y 
cells at doses o f 2 pM and 10 pM as well as treatm ent w ith haloperidol at doses of 
0.01 and 10 pM had no effect on DNA methylation of HTR2C prom oter sequences 
compared to  tha t of control untreated cells at day 0 (treated w ith DMSO 0.01% as 
same as treatm ent solution) as shown in Figure 4.17. However, trea tm ent w ith 5-Aza- 
2-deoxycytidine, a demethylating reagent, at doses of 0.5, 1, and 2 pM significantly 
decreased DNA methylation of HTR2C (p<0.001) when compared to  control (DMSO 
0.002%) at 72 hours of treatm ent period (Figure 4.18).
4.3.9 Effect of drug treatment on DNA methylation extent of HTR2C in 
differentiated SH-SY5Y cells
The effect o f antipsychotic drug treatm ent on DNA methylation o f HTR2C gene in 
d ifferentiated SH-SY5Y cells was also determined by bisulfite pyrosequencing and the 
results were similar to undifferentiated cells. Treatment w ith clozapine fo r 48 hours in 
differentiated SH-SY5Y cells at doses of 2 pM and 10 pM as well as trea tm ent w ith 
haloperidol at doses of 0.01 and 10 pM had no effect on DNA m ethylation of HTR2C 
prom oter sequences compared to that o f control untreated cells at day 0 (treated w ith 
DMSO 0.01% as same as treatm ent solution) as shown in Figure 4.19. However, 
treatm ent w ith 5-Aza-2-deoxycytidine at doses of 0.5, 1, and 2 pM significantly 
decreased DNA methylation o f HTR2C (p<0.001) when compared to  control (DMSO 
0.002%) at 72 hours of treatm ent period (Figure 4.20).
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Figure 4.17: Mean DNA m ethylation levels o f 5 CpGs o f HTR2C p rom oter sequences 
trea tm en t w ith  clozapine 2 pM  and 10 pM  and haloperidol 0.01 pM  and 10 pM 
compared to  contro l (DMSO 0.01%) at Oh and 48h in und ifferentia ted  SH-SY5Y cells.
Data presented as meaniSEM.
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Figure 4.18: Mean DNA m ethylation levels o f 5 CpGs o f HTR2C p rom oter sequences 
trea tm en t w ith  5-Aza-2-deoxycytidine 0.5, 1 and 2 pM  compared to  contro l (DMSO 
0.002%) at Oh and 72h in und ifferentia ted  SH-SY5Y cells.
Data presented as meaniSEM. * indicates statistical significant difference compared to 
control (DMSO 0.002%) at Oh, # indicates statistical significant difference compared to 
control (DMSO 0.002% at 72h.
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Figure 4.19: Mean DNA m ethylation levels o f 5 CpGs o f HTR2C p rom oter sequences 
trea tm en t w ith  clozapine 2 pM and 10 pM and haloperidol 0.01 pM  and 10 pM 
compared to  contro l (DMSO 0.01%) at Oh and 48h in d iffe rentia ted SH-SY5Y cells. 
Data presented as meaniSEM.
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Figure 4.20: Mean DNA m ethylation levels o f 5 CpGs o f HTR2C p rom oter sequences 
trea tm en t w ith  5-Aza-2-deoxycytidine 0.5, 1 and 2 pM  compared to  contro l (DMSO 
0.002%) at Oh and 72h in d iffe rentia ted  SH-SY5Y cells.
Data presented as meaniSEM. * indicates statistical significant difference compared to 
control (DMSO 0.002%) at Oh, # indicates statistical significant difference compared to 
control (DMSO 0.002% at 72h.
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4.3.10 Effect of 5-Aza-2-deoxycytidine treatment on DNA methylation 
extent of HTR2C in undifferentiated SH-SY5Y cells followed by 
differentiation induction
The results from previous sections showed tha t the antipsychotic drugs, clozapine and 
haloperidol, did not have an effect on DNA methylation of HTR2C prom oter sequences 
around the -697G/C polymorphism whereas 5-Aza-2-deoxycytidine treatm ent led to  a 
decrease in DNA methylation in both undifferentiated and differentiated SH-SY5Y cells. 
Therefore, this experiment aimed to  assess the effect of 5-Aza-2-deoxycytidine 
treatm ent on undifferentiated cells followed by d ifferentiation induction using retinoic 
acid fo r 7 days. The results showed that 5-Aza-2-deoxycytidine had a long lasting effect 
on DNA methylation even if it was removed before induction o f d ifferentiation (Figure 
4.21B). This effect was observed in undifferentiated cells when cells were grown for 
the same period o f tim e w ith no retinoic acid treatm ent, as well as d ifferentiated cells; 
5-Aza-2-deoxycytidine resulted in a decrease in DNA methylation o f the HTR2C 
prom oter sequences (Figure 4.21A).
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Figure 4.21: Mean DNA m ethylation levels o f 5 CpGs o f HTR2C p rom oter sequences 
trea tm en t w ith  0.5 pM  5-Aza-2-deoxycytidine fo r 72 hours in und iffe ren tia ted  SH- 
SY5Y cells fo llow ed by w ith  (b) or w ith o u t (a) d iffe ren tia tion  induction fo r 7 days.
Data presented as meaniSEM. * indicates statistical significant difference compared to 
control (DMSO 0.002%) at day 0, # indicates statistical significant difference compared 
to  the ir control treatments (DMSO 0.002% (-RA) or retinoic acid (+RA) fo r same 
experimental periods).
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4.4 Discussion
Previous findings reported the association o f HTR2C -759C/T and -697G/C 
polymorphisms and antipsychotic drug-induced weight gain (Reynolds et al., 2002; 
Shao et at., 2008; Godlewska et al., 2009); however, the mechanisms underlying this 
association were unknown. In addition, the -759T and -697C allele o f the HTR2C 
polymorphisms are associated w ith lower prom oter activity (Hill and Reynolds, 2007). 
Antipsychotic drugs might cause the alteration in HTR2C expression via, in part, 
epigenetic modification. Therefore, the experiments in this chapter were carried out 
w ith  the aim o f investigating the effect o f antipsychotic drugs on HTR2C gene 
expression and DNA methylation o f HTR2C prom oter sequences at and near -697G/C 
SNP site, (but not at and near -759C/T site due to  technical difficulties (see section 4.1) 
by using RT-qPCR and bisulfite pyrosequencing in SH-SY5Y human neuroblastoma cell 
line.
4.4.1 Validation of methodology
4.4.1.1 MTT assay
Clozapine, haloperidol, 5-aza-2-deoxycytidine, and DMSO which was used as the drug 
solvent were tested for cytotoxicity using the MTT assay. The drugs used in the 
experiments did not affect cell viability o f SH-SY5Y cells.
4.4.1.2 Reverse-transcription real-time PCR
4.4.1.2.1 RNA
RNA used in this study had a good quality observed from  the clear sharp bands o f 28S 
and 18S on the agarose gel whereby the 28S/18S rRNA ratio was approximately 2:1. 
The assessment o f RNA quality was determined by quantification of 28S and/or 18S 
ribosomal RNA on ethidium bromide gels (Sambrook and Russel, 2001). This method is 
a common and traditional method. RNA qua lity /in tegrity  affects downstream 
applications such as RT-qPCR and microarrays (Copois et al., 2007); therefore, it is 
essential to assess the integrity o f extracted RNA prior to  perform downstream 
applications to ensure the reliability o f the subsequent analysis.
209
4.4.1.2.2 Housekeeping gene validation
In the present study GAPDH and CYC1 were selected as the most stably expressed 
housekeeping genes using GeNorm software in order to  use them as internal reference 
control genes to normalise the expression of the gene of interest. These reference 
genes had the least M value determined by GeNorm software under various 
experimental conditions.
4.4.1.2.3 Amplification efficiency of primers
The amplification efficiency of the primer pairs used in this study was determ ined to 
quantify the relative gene expression. The primer efficiencies of all primer sets were 
w ith in the acceptable range, 90-110%. At 100% efficiency in PCR 1 cycle corresponds 
to  a 2-fold change. The analysis o f gene expression was calculated using the 
comparative Ct method according to the Livak and Schmittgen (Livak and Schmittgen, 
2001).
4.4.2 Validation of experimental procedure in determining HTR2C 
DNA methylation and mRNA expression using 5-aza-2- 
deoxycitidine
The present study demonstrates that treatm ent w ith 5-Aza-2-deoxycytidine, a 
demethylating agent inhibiting DNA methylation, increased mRNA expression of 
HT2CR whereas it decreased DNA methylation levels of the HTR2C prom oter 
sequences. These results not only verified the experimental model and procedure that 
indicated the change in mRNA expression level of the HTR2C in response to  treatm ent 
in SH-SY5Y cells, but also confirmed the role o f DNA methylation in the regulation of 
HTR2C gene expression. It should be noted that the effect of 5-Aza-2-deoxycytidine on 
the expression of HTR2C mRNA in undifferentiated cells was higher than in 
differentiated cells (approximately 5 fold higher). In addition, the effect o f 5-Aza-2- 
deoxycytidine on methylation showed levels approximately 10% lower in 
undifferentiated cells compared to  differentiated cells. This may be due to  the high 
potential for changes in DNA methylation in undifferentiated cells and/or tha t the 
d ifferentiated cells have a much less dynamic transition in gene expression pattern 
when comparing the differentiated state to  pluripotency (reviewed by Meissner, 
2010).
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5-aza-2-deoxycytidine and 5-azacytidine are epigenetic drugs tha t inh ib it DNA
methylation and have been widely studied especially in cancer research. 5-aza-2-
deoxycytidine and 5-azacytidine were first synthesized about 50 years ago and recently 
used in clinical as standards o f care fo r patient w ith myelodysplastic syndromes 
because of its antim etabolic activities which can lower malignant progression to acute 
myeloid leukemia and increase survival o f patients (Estey, 2013). There are many other 
diseases treated w ith 5-Azacytidine such as beta-thalassemia, sickle cell anemia,
leukemias, metastatic lung cancer, androgen insensitive prostate cancer, cervical
cancer, testicular cancer, colorectal, head and neck, renal malignant melanoma, 
ovarian cancer (Santini et al., 2001; Wongtrakoongate, 2015). Since these drugs are 
already in clinical use, and this study has shown tha t 5-aza-2-deoxycytidine can modify 
DNA methylation and change mRNA expression of HTR2C in this study, it m ight be 
useful in the future for alleviation of weight gain side effects follow ing antipsychotic 
drug treatm ent.
4.4.3 Effect of antipsychotic drugs on HTR2C mRNA expression
Clozapine, an atypical antipsychotic drug having a high a ffin ity for the 5-HT2C receptor 
was expected to  have an effect on 5-HT2C receptor comparing to  haloperidol which 
has a low a ffin ity to 5-HT2C receptor. The results in the present study show no 
alteration in the HTR2C mRNA expression after clozapine and haloperidol treatm ent 
fo r 48 hours in both undifferentiated and differentiated SH-SH5Y cells. The lack o f an 
effect o f clozapine at the mRNA level suggests tha t clozapine may affect the 5-HT2C 
receptor at the level o f translational or post-transcriptional regulation, whereas 
unaltered expression o f the HTR2C mRNA after haloperidol treatm ent m ight be due to 
its low affin ity fo r this receptor (Leysen et al., 1993).
The results in this study are consistent w ith previous studies in rats; an early study 
reported tha t chronic treatm ent w ith clozapine and haloperidol fo r 14 days did not 
change Htr2c mRNA levels in choroid plexus or other areas (Burnet et al., 1996). 
Another study did not find a change in the levels o f mRNA encoding the 5-Ht2c 
receptor in midbrain (containing choroid plexus cells) and also in whole brain o f rats 
a fter chronic clozapine treatm ent fo r 32 days (Buckland et al., 1997). However, chronic
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treatm ent w ith clozapine fo r 14 days caused down-regulation of the 5-HT2C receptor 
binding in the choroid plexus, while no change was found w ith haloperidol, 
chlorpromazine or risperidone treatm ent (Kuoppamaki et al., 1993, 1995). It is has 
been suggested tha t the decrease in 5-HT2C receptor binding can be explained by 
translational or post-transcriptional regulation (Burnet et al., 1996).
However, the results in the present study are not in line w ith several previous studies 
that reported an effect o f antipsychotic drug treatm ent on mRNA expression o f Htr2c 
in rat brain. One study found a reduction of mRNA levels of Htr2c in hippocampus, 
cerebellum and cortex after chronic treatm ent o f clozapine whereas chronic 
haloperidol treatm ent elicited a decrease in mRNA levels o f Htr2c in midbrain, 
cerebellum and cortex (Buckland et al., 1997). Another study found changes o f Htr2c 
mRNA levels in many brain areas after chronic clozapine treatm ent fo r 36 days, after 2 
hours of last drug adm inistration there was a decrease of Htr2c mRNA levels in 
posteromedial cortical amygdaloid nucleus (PMCo)(limbic system) and substantia nigra 
(SN)(brainstem), while at 48 hours after the drug w ithdrawal there was a decrease 
mRNA levels in PMCo, SN, superior colliculus and ventral tegmental area; haloperidol 
caused mRNA reduction only in SN at both 2 hours and 48 hours drug w ithdrawal 
(Huang et al., 2007). These findings indicate the region-specific and complex pattern of 
changes of Htr2c mRNA expression follow ing antipsychotic treatm ent.
The effect of acute treatm ent o f clozapine also has been reported by Buckland's group, 
acute treatm ent w ith clozapine (4 days) caused increased Htr2c mRNA levels in whole 
brain and also midbrain whereas Htr2c mRNA levels decreased in cerebellum and 
cortex. The transient rise in Htr2c mRNA levels may be explained by a classical 
compensation in response to  initial antagonism o f the receptor by clozapine leading to 
up-regulation o f 5-Ht2c receptor by increasing transcription (Buckland et al., 1997).
The different findings between the present study and these studies may be due to  the 
difference o f experimental model. Those studies were conducted in animal models 
tha t may have many other factors tha t affect the expression of the Htr2c gene for 
example female hormones can influence Htr2c mRNA (Zhou et al., 2002; Rivera et al., 
2012) and protein expression (Henderson and Bethea, 2008). The neuroblastoma SH- 
SY5Y cell line used in the current study may provide a good model to  study the direct
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effect of antipsychotic drugs on HTR2C expression because of its relevance to human 
neurons and the reproducible level o f HTR2C mRNA expression reported in these cells 
(Biedler et al., 1978; Cavarec et al., 2013); but, 5-HT2C receptor protein expression in 
this cell line has not been reported so far. However, because it is a neuroblastoma cell 
line, the properties o f the cells may d iffer from normal neurons and may cause 
d ifferent response to antipsychotic drugs. Further studies are required to  confirm  this 
finding.
4.4.4 Effect of antipsychotic drugs on DNA methylation of HTR2C 
promoter sequences
Clozapine and haloperidol treatm ents resulted in unaltered levels o f DNA methylation 
of the HTR2C prom oter sequences. These results were in accordance w ith the mRNA 
expression results showing tha t these tested antipsychotic drugs did not exert the ir 
effect on the expression o f HTR2C mRNA. Lack o f influence on DNA methylation and 
mRNA expression suggests that clozapine may have an effect on post-transcriptional 
regulation rather than transcriptional regulation, while haloperidol did not have any 
effect due to its low a ffin ity to 5-HT2C receptor. Post-transcriptional modification of 
HTR2C mRNA editing in SH-SY5Y by adenosine deaminases acting on RNA was reported 
by Cavarec et al., (2013); this regulation was altered in depressed suicide victims. This 
adenosine deamination editing mRNA of 5-HT2CR brings about a substantial increase 
in the functional plasticity o f the receptor and is thought to contribute to  homeostatic 
mechanisms in neurons (Di Narzo et al., 2014). No other studies have looked at the 
effect o f antipsychotic drugs on DNA methylation o f the HTR2C gene. Further studies 
are required to confirm the effect of antipsychotic drugs on HTR2C m ethylation.
4.4.5 Limitations
The lim itation in this study is the low expression levels o f the HTR2C mRNA. Although it 
has been shown tha t there is constitutive expression of the HTR2C in this cell line, SH- 
SY5Y human neuroblastoma cells (Biedler et al., 1978; Flomen et al., 2004; Cavarec et 
al., 2013), it may lim it the magnitude of alteration in both DNA methylation and mRNA 
expression. However, the SH-SY5Y cells response to  treatm ent at least w ith  the 5-aza- 
2-deoxycytidine and the changes in methylation and mRNA expression o f HTR2C gene 
can be detected.
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4.4.6 Conclusions /  further work
In summary, the results o f this chapter have shown no alteration o f HTR2C mRNA 
expression and DNA methylation of the HTR2C prom oter under treatm ent w ith 
clozapine and haloperidol. However, the results linked the increased mRNA expression 
of HTR2C and induced DNA hypomethylation after treatm ent w ith 5-aza-2- 
deoxycytidine. This observation might be relevant to  fu rther therapeutic development 
to  increase the receptor numbers in patients w ith  schizophrenia.
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Chapter 5: Effect of antipsychotics on leptin 
secretion and Htr2c mRNA expression in 3T3-L1 
adipocytes
5.1 Introduction
Weight gain is an im portant side effect o f antipsychotic medication, which increase a 
risk fo r developing chronic diseases or obesity-related complications such as type 2 
diabetes and cardiovascular diseases (Allison et al., 1999; Casey et al., 2004). Little is 
currently known about the mechanisms of antipsychotic drug-induced weight gain. 
One common hypothesis is an increase in appetite and food intake (Casey and Zorn, 
2001). In this context, many studies have investigated the role o f leptin in regulating 
appetite and adiposity during treatm ent w ith antipsychotic drugs.
Leptin is primarily secreted by adipocytes (Hamilton et al., 1995) which is a major 
source o f plasma leptin. The plasma leptin level is strongly and positively correlated 
w ith adiposity or BMI (Klein et al., 1996; Haupt et al., 2005; Venkatasubramanian et al.,
2010). The plasma leptin level is gender dependent w ith females normally having 
higher leptin levels than males (Wang et al., 2007b; Sentissi et al., 2009). This may 
explain the relationship o f adiposity and leptin levels because females have a higher 
percentage of adipose mass than men (Ranasinghe et al., 2013). Another explanation 
may be due to the effect o f sex hormones on leptin production. There is evidence that 
estrogen stimulates leptin expression in females, whereas testosterone levels in males 
are correlated w ith  decreased leptin levels (Wabitsch et al., 1997; Machinal et al., 
1999; Machinal-Quelin et al., 2002). However, this gender difference in leptin has been 
found in groups treated w ith conventional antipsychotics but not in the olanzapine or 
clozapine treatm ent groups (Melkersson and Hulting, 2001).
Increased plasma leptin levels during treatm ent w ith atypical antipsychotic drugs,
particularly olanzapine and clozapine have been reported in several studies. For
example, olanzapine treatm ent causes increased BMI, plasma leptin, adiponectin,
insulin, lipids, and neuropeptides (Melkersson et al., 2000; Amano et al., 2012; Ak et
al., 2013). Plasma leptin levels and body weight increase rapidly in the firs t 1-2 weeks
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after treatm ent w ith SGAs, but not FGAs haloperidol (Kraus et al., 1999; M onteleone et 
al., 2002; Sentissi et al., 2008), and was also observed after 6 weeks of treatm ent 
(Atmaca et al., 2003). Increased plasma leptin levels correlate w ith increased BMI after 
treatm ent w ith clozapine or olanzapine for 6 weeks (Kluge et al., 2009). Increased 
leptin levels, body weight, BMI, body fat mass, and lean body mass after 10 weeks of 
clozapine treatm ent has been reported (Bromel et al., 1998).
Risperidone is one of the second generation antipsychotic drug that cause weight gain 
follow ing treatm ent in schizophrenia patients (Goeb et al., 2010) and it also has been 
related to the increase in plasma leptin levels (Zhang et al., 2003, 2004). Risperidone 
treatm ent fo r 4 weeks increases BMI and plasma leptin in psychotic patients (Yanik et 
al., 2013). It has been hypothesized tha t antipsychotic drugs including risperidone 
induced weight gain may be in part, due to its action through 5-HT antagonism that 
a lter hypothalamic neuropeptides regulating appetite and food intake (Kursungoz et 
al., 2015).
Although an early increase in plasma leptin levels is observed after antipsychotic 
treatm ent, it has been suggested that the increased leptin levels are most likely due to 
weight gain during antipsychotic drug treatm ent rather than a direct effect of 
antipsychotic drugs on leptin production and release from  adipocytes (Bromel et al., 
1998; Kraus et al., 1999; Melkersson et al., 2000). The correlation o f plasma leptin and 
antipsychotic treatm ent does not appear after controlling fo r BMI or comparing to 
BMI-matched controls (Haupt et al., 2005; Jin et al., 2008). In this study, it has also 
been hypothesized tha t antipsychotic drugs including clozapine and risperidone 
treatm ent might a lter leptin secretion from adipocytes comparing to  haloperidol.
Genetic polymorphisms have also been reported to  be associated w ith  elevation of 
plasma leptin levels during antipsychotic medications. The SNP in the prom oter region 
o f the leptin gene, -2548A/G, is associated w ith obesity and plasma leptin levels 
(Mammes et al., 2000; Hinuy et al., 2008). The polymorphisms of leptin -2548A/G and 
the HTR2C -759C/T are associated w ith antipsychotic drug-induced weight gain 
(Templeman et al., 2005; Wu et al., 2011) and influence plasma leptin levels in 
schizophrenia patients (Templeman et al., 2005).
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The expression of 5-HT receptors including 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1F, 5-FIT2A, 
5-HT2C, 5-HT5A, 5-HT6, and 5-HT7 have been detected in mouse preadipocyte 3T3-L1 
cells and treatm ent w ith 5-HT enhances adipocyte differentiation while treatm ent w ith 
the 5-HT2A antagonist (ketanserin) and the 5-HT2C receptor antagonist (SB 242084) 
result in inhibited adipocyte differentiation (Kinoshita et al., 2010). This study 
identified 5-HT in adipose tissue as a novel autocrine factor tha t is required for 
adipocyte differentiation (Kinoshita et al., 2010). The role o f the 5-HT2C receptor in 
adipocyte differentiation and a decrease of this process when treated w ith a 5-HT2C 
receptor antagonist indicate the role o f the 5-HT2C receptor in adipogenesis. The 
functional system for serotonin synthesis, reuptake, and receptors including 5-HT2C 
and 5-HT2A receptors are also expressed in rat adipocytes and peripheral serotonin 
adm inistration fo r 5 days or longer treatm ent fo r 4 months results in decreased plasma 
leptin (Stunes et al., 2011); however, this reduction of leptin levels could be secondary 
effect o f serotonin decreasing insulin secretion from  pancreatic (3 cells (Zhang et al., 
2013c). The role of the 5-HT2C receptor on leptin secretion and the direct effect of 
antipsychotic drugs on the expression o f the 5-HT2C receptor in adipocytes as well as 
on leptin secretion in adipocytes have not been studied yet. The present study 
hypothesizes tha t treating adipocytes w ith antipsychotic drugs may change the mRNA 
expression o f the HTR2C and also alters leptin secretion. The results o f this study may 
provide data about the peripheral effect o f atypical antipsychotic drugs on weight gain.
5.1.1 Principle of ELISA in leptin secretion determination
An enzyme-linked immunosorbent assay (ELISA) is a technique used in this study fo r
determ ining leptin concentration in culture medium. It is a quantitative sandwich
enzyme immunoassay using tw o polyclonal antibodies specific to  m ouse/rat leptin.
The plate surface is pre-coated w ith the polyclonal antibody specific fo r m ouse/rat
leptin. The leptin in samples is bounded by the immobilized antibodies (Figure 5.1,
step 1). The unbound substances arewashed away before adding the enzyme-linked
polyclonal antibody specific fo r mouse/rat leptin (Figure 5.1, step 2). The enzyme used
in this assay kit is horseradish peroxidase (HRP). The unbound enzyme-linked
antibodies have been washed away before adding the substrate solution to  the wells.
The substrate solution contains tetramethylbenzidine and hydrogen peroxide. The
enzyme reaction yields a blue product o f tetramethylabenzidine diim ine which turns
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yellow when adding stop solution containing diluted hydrochloric acid (Figure 5.1, step 
3).
Quantikine® ELISA Assay Principle
Step 1 Step 2
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A microplate pre-coated 
with capture antibody is 
provided. Samples or 
standards are added and 
any analyte present is 
bound by the immobilized 
antibody. Unbound 
materials are washed 
away.
A second HRP-iabeled 
antibody (detection antibody) 
is added and binds to the 
captured analyte. Unbound 
detection antibody os washed 
away.
Yellow
Tetramethylbenzidine (TMB) substrate 
solution is added to the wells and a blue 
color develops in proportion to the 
amount of analyte present In the sample. 
Color development is stopped timing the 
color in the walls to yellow. The 
absorbance of toe color at 450 nm is 
measured.
Figure 5.1: ELISA assay principle 
(modified from  R&D Systems™ website;
www.rndsystems.com/product_detail_objectname_quantikineelisaassayprinciple.aspx) 
HRP, horseradish peroxidase; TMB, tetramethylbenzidine.
5.1.2 Aims
1. To investigate the influence of antipsychotic drugs on leptin secretion from  3T3-L1 
adipocytes.
2. To investigate the influence of antipsychotic drugs on Htr2c mRNA expression in 
3T3-L1 adipocytes.
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5.2 Materials and methods
The mouse 3T3-L1 preadipocyte cell line was cultured and induced by d ifferentiation 
to  be mature adipocyte cells fo r using in antipsychotic drug treatm ent experiments. 
Sterile cell culture techniques were performed to  avoid the contamination throughout 
the experimental period. The leptin concentration in the culture media was measured 
using ELISA and the mRNA expression of the Htr2c was determined using RT-qPCR. The 
experiments were carried out at least 3 times w ith tw o replicates fo r all experimental 
conditions.
5.2.1 3T3-L1 preadipocyte cell line
The mouse 3T3-L1 preadipocyte cell line obtained from  the American Type Culture 
Collection (ATCC, UK), was maintained in DMEM high glucose (Gibco®, UK) 
supplemented w ith 10% fetal bovine serum (FBS) and 1% Penicillin/Streptomycin 
(Complete Medium or CM) in a humidified, 5% C02, 37°C incubator. The medium was 
changed every 2-3 days. Cells were subcultured before 70-80% confluency was 
reached. Cell passage numbers of less than 6 were used in the experiments.
Cells were cultured in 75 cm2 culture flasks in 15 ml medium until 70-80% confluency 
was reached, cells then were trypsinized using 2-3 ml o f trypsin/EDTA solution (0.05% 
trypsin in 0.53mM EDTA, Gibco®, UK) after removing medium and briefly rinsing the 
cell layer w ith trypsin/EDTA solution. The flask was incubated at 37°C fo r 3-5 minutes 
or until cells have detached from  the surface. Once the cells' detachment was checked 
under a microscope, 6-8 ml o f complete medium was added to inh ib it the action of 
trypsin. The cell suspension was transferred to a sterile 50 ml Falcon tube and 
centrifuged at 1,000 rpm fo r 5 minutes. The supernatant was discarded and the cells 
were resuspended in 2-5 ml fresh complete medium. The cells were counted by mixing 
10 pi o f cell suspension w ith 10 pi o f 0.4% trypan blue solution (Gibco®, UK) and the 
cells were allowed to  stain at room tem perature fo r 1 minute. The m ixture (10 pi) was 
loaded into a Countess™ chamber slide (Countess™, Invitrogen, UK). Viable and dead 
cells were counted using an automated cell counter (Countess™, Invitrogen, UK). Live 
cells are not coloured whereas dead cells are stained blue. Total cell count, live cells, 
dead cells, cell viability, were obtained from  the instrument. An average o f live cell
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number was calculated from tw o slides and the viable cells were used in plating fo r the 
experiments, subculturing, or freezing.
5.2.2 Freezing and thawing
Mouse 3T3-L1 preadipocytes (T75 cm2 flask) were trpysinized, and resuspended in 3 ml 
of freezing medium containing 90% fetal bovine serum and 10% DMSO. Then 1 ml of 
cell suspension (1 -I.5 x l0 6 cells) was aliquoted into cryovial tubes. The tubes were 
wrapped w ith tissue and plastic bubble wrap then stored at -80°C fo r several days 
before transferring the tubes into a liquid nitrogen tank where the cells were 
immersed in liquid nitrogen vapour until required fo r use.
All pieces of equipment fo r cell culture, including a tube containing culture medium 
was prepared (9-10 ml in 50 ml-Falcon tube) in a laminar flow  tissue culture hood 
before taking the frozen cells from liquid nitrogen. The cryovial tube o f cells was 
agitated gently in a water bath at 37°C to thaw cells quickly, w ith in 2-3 minutes. Once 
the ice crystals were melted, the tube was decontaminated by spraying 70% ethanol. 
Cells were transferred into the prepared tube containing medium, gently mixed and 
centrifuged at 1,000 rpm for 5 minutes. The supernatant was discarded to  remove 
DMSO and the cells were resuspended in 1-2 ml of complete medium before 
transferring to a culture flask (T75 cm2) containing complete medium and mixing 
thoroughly by gentle rocking. The cultures were observed after 24 hours.
5.2.3 Differentiation induction of 3T3-L1 cells
To differentiate 3T3-L1 cells from  fibroblastic phenotype to adipocytes, the firs t stage 
is growth arrest which is achieved by contact inhibition at post confluence. The 
growth-arrested postconfluent 3T3-L1 preadipocytes re-enter the cell cycle (called 
m ito tic clonal expansion) immediately after induction by the d ifferentiating reagents, 
and start the adipocyte differentiation (Rosen and Spiegelman, 2000). The most 
commonly used reagents are insulin, dexamethasone, and 3-isobutyl-l-m ethylxanth ine 
(IBMX). Rosiglitazone was also added in the induction medium in the present study. 
These chemicals were purchased from Sigma-Aldrich, UK. The d ifferentia tion induction 
was performed according to  the methods described by Eseberri et al. (2013) w ith  slight 
modifications. Briefly, cells were seeded into 6-well plate at a density o f 5 x l0 4
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cells/well (in 2 ml). The complete medium was replaced every 48 hours until cells 
reached confluency which took about 5-7 days. On the day tha t cells reached 
confluency, the medium was replaced and the cells fu rther grown for 48 hours. A fter 
48 hours (day 0), differentiation was induced by changing the medium to  DMEM 
containing 10% FBS, 1% Penicillin/Streptomycin, 0.5 mM IBMX, 1 pM dexamethasone, 
10 pg/m l insulin, and 2 pM  rosiglitazone (differentiation medium, DMI). A fte r 48 h (day 
2), the medium was changed to  DMEM containing 10% fetal bovine serum, 1% 
Penicillin/Streptomycin, and 10 pg/m l insulin (DMII) and this medium was refreshed 
every 48 hours until drug treatm ent on day 14, which represents the usual tim e 
required to acquire a fully differentiated phenotype (Sertie et a!., 2011). The protocol 
fo r d ifferentiation induction was shown in Figure 5.2.
Day -2 to day 0 
(48 h confluence)
Complete medium 
(CM)
DMEM high glucose 
10% FBS
P/S
Day 0-2 (48 h) Differentiation medium I 
(DMI)
CM.
IBMX 0.5 mM
Insulin 10 pg/ml'
Dexameihason© 1 \M  
Rosiglitazone 2 pM
Day 2-14 
(every 48 h)
Day 14
Day 15
Differentiation medium II 
(DMII)
Antipsychotics treatment
Medium and cell collection
CM
Insulin 10 pg/ml
CM
insulin 10 pg/mfi
Antipsychotics
DMSO (final 0.1%)
Figure 5.2: Flowchart of 3T3-L1 differentiation protocol throughout the experimental 
period
5.2.4 Oil Red 0 staining
In this study, oil Red O staining was performed to  illustrate the presence o f lipids in the 
3T3-L1 differentiated adipocytes which is used as a marker o f d ifferentia tion, fo r 
fu rthe r details, see section 5.3.1. The oil red O is an oil-soluble dye which has high 
solubility in fa tty  substances. The staining results in bright red of lipid droplets in
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adipocytes when observed under microscope. Staining protocol was carried out 
according to the method described elsewhere (Oh et al., 2012; Mukherjee and Yun, 
2013) w ith slight modifications. In brief, 0.35% Oil Red 0  stock solution was prepared 
by stirring 0.7g Oil Red 0  in 200 ml isopropanol overnight. The overnight solution was 
filtered through a 0.2-pM filte r paper and stored at 4°C. Oil Red O working solution 
was freshly prepared by mixing stock solution w ith distilled water (6:4), followed by 
incubation at room tem perature fo r 10 min and fu rther filtra tion. The working solution 
was stable in 2 hours. Cells were washed tw ice w ith PBS and fixed w ith  4% 
formaldehyde in PBS at room tem perature fo r 1 hour. Cells were washed 3 times w ith 
distilled water, followed by 60% isopropanol, and then stained w ith Oil Red O working 
solution fo r 1 hour at room tem perature. Cells were then washed 4 times or more w ith 
distilled water and photographed.
5.2.5 Antipsychotic treatment
Differentiated cells were treated w ith antipsychotic drugs on day 14 after 
d ifferentiation induction when the full d ifferentiation was obtained. The antipsychotic 
drugs were dissolved in complete medium containing insulin 10 pg/m l. The treatm ent 
volume was 1 m l/well. The control treatm ent group was carried out in each 
experiment using the same amount o f DMSO (0.01%) tha t has been used as a solvent 
o f drug dissolves. The amount o f DMSO in all drug concentrations was equal 
concentration (at 0.1%) to elim inate the effect of unequal DMSO levels in d iffe rent 
drug concentrations.
Antipsychotics used in this study were composed of clozapine, SB 242084 (serotonin 
2C receptor antagonist), haloperidol, and risperidone which were purchased from  
Sigma-Aldrich, UK. The cells were treated fo r 24 hours before the medium was 
collected. Then the collected medium was centrifuged at 3,000 rpm for 30 minutes to 
remove remaining particles or cell debris. The supernatants were assayed to 
determ ine leptin level immediately or stored at -20° C fo r later use, in which case 
repeated freeze-thaw cycles were avoided.
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5.2.5.1 Dose response curve of antipsychotic treatment on leptin secretion
The adipocyte cells were treated w ith various concentrations o f antipsychotics 
including clozapine, SB 242084, haloperidol, and risperidone as shown in Table 5.1. 
The chosen concentrations covered the therapeutic plasma levels and the inhibition 
constant (Ki). All o f the cell culture experiments were performed in duplicate.
Table 5.1: Concentrations of antipsychotic drugs used in this study
Antipsychotics/chemicals Concentrations
Clozapine 0.3, 1, 10 pM
SB 242084 0.01, 0.1, 1 pM
Haloperidol 0.03, 0.1, 1 pM
Risperidone 0.01, 0.03, 0.3 pM
5.2.6 Determination of leptin secretion
The concentrations of leptin secreted from  adipocytes into the cell culture medium 
were measured by using the mouse leptin immunoassay (Mouse Leptin Quantikine® 
ELISA Kit, from  R&D SYSTEMS, UK). The assay procedures were perform ed follow ing 
the manufacturer's instructions. In brief, all reagents and samples were allowed to 
warm at room tem perature before perform ing the assay, and then the standard 
dilutions, wash buffer, and microplate strips were prepared. The serial d ilutions o f 
mouse leptin standard was performed at concentrations 62.5, 125, 250, 500, 1000, 
2000, and 4000 pg/ml w ith calibrator diluent RD5-3.
The assay was started by adding 50 pi of assay diluent RD1W to each well followed by 
adding of 50 pi of standards, control, or samples. The mixture was gently mixed by 
tapping the plate frame for 1 minute, and then the plate was covered by an adhesive 
strip before incubating fo r 2 hours at room tem perature. The m ixture was aspirated 
from  the wells and the wells were washed five times w ith wash buffer using a squirt 
bottle. A fter the last wash, the remaining liquid or wash buffer was completely 
removed using aspiration pump followed by inverting the plate and b lo tting it against 
clean paper towels. Then 100 pi o f mouse leptin conjugate was added into each well 
before covering w ith a new adhesive strip, and the plate was incubated fo r 2 hours at
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room tem perature. The mixture was aspirated from  the wells and the wells were 
washed five times w ith wash buffer using a squirt bottle. Then 100 pi o f substrate 
solution was added into each well followed by incubation at room tem perature fo r 30 
minutes protecting from  light. 100 pi o f stop solution was added into each well. The 
plate was mixed thoroughly by gently tapping before the optical density was read at 
450 nm w ith in 30 minutes using microplate reader. The readings at 450 nm were 
corrected using 570 nm readings which corrected fo r optical imperfections in the plate. 
All samples were assayed in duplicate.
5.2.7 Determination of Htr2c mRNA expression
5.2.7.1 RNA isolation and cDNA synthesis
After the culture medium was collected to  determine leptin level, cells were harvested 
by trypsinization and washed w ith PBS before extracting tota l RNA using RNeasy Mini 
kit (Qiagen). The extraction protocols were carried out follow ing the manufacturer's 
protocol as described in the previous chapter (see section 4.2.6.1).
RNA concentrations were quantified by Nanodrop-1000 UV-VIS spectrophotom eter 
and A260/A 280 as well as A260/A 230 ratios were recorded. RNA quality was checked on 
1.5% agarose gel as described before (see section 4.2.6.2).
Total RNA, 1000 ng, was reverse-transcribed using oligodT and random primers 
(QuantiTech Reverse Transcription kit, Qiagen) according the manufacturer's protocols 
as described in the previous chapter (see section 4.2.6.3). The minus RT (-RT) controls 
were performed by replacing reverse transcriptase w ith RNase-DNase free water 
during the RT step to  serve as negative control to assess to contam ination o f genomic 
DNA in RNA samples. In general, cDNA samples were diluted 1:10 in RNase-DNase free 
water before using in qPCR.
5.2.7.2 Reference controlgene(s) selection
Reference control gene selection was carried out using 8 housekeeping genes from  the 
mouse geNorm™ housekeeping gene selection kit (PrimerDesign Ltd, UK) and 11 
samples from d ifferent antipsychotic drug treatm ents and control untreated group. 
Candidate genes are listed in Table 5.2. The genes from  this geNorm kit were assessed
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because the primer sets were guaranteed by the company to have high efficiencies. 
The genes included members from distinct cellular pathways and they are groups of a 
number o f classical housekeeping genes which are in common use in expression 
studies.
Table 5.2: geNorm housekeeping gene candidates fo r selecting o f the most stable 
expressing gene(s) to  use as a reference contro l gene(s)
Gene symbol Gene name Function/Pathway/Process
Actb (3-actin Cytoskeletal protein
Gapdh Glyceraldehide-3-phosphate
dehydrogenase
Glycolysis
Canx Calnexin Protein folding
Atp5b ATP synthase subunit 5B Mitochondrial ATP synthesis
18s 18S ribosomal RNA Protein synthesis
Ywhoz Tyrosine 3-
monooxygenase/tryptophan 5- 
monooxygenase activation 
protein, zeta
Signal transduction
R pll3a Ribosomal protein L13A Protein synthesis
Ubc Ubiquitin C Protein turnover
The PCR reactions were set up in a 96-well PCR plate. The reactions were then run in a 
real-time PCR system, StepOne Plus (Applied Biosystems, USA). The PCR reaction 
m ixture consisted o f 10 ng o f cDNA tem plate (2 pJ o f 1:10 dilution), 1 pJ o f 10 p,M 
forward and reverse primers, 10 pJ of 2x qPCR Mastermix (Precision, PromerDesign) 
and nuclease-free distilled water to  a final volume of 20 pJ. The precision Mastermix 
contains 2x reaction buffer, 0.025 U/pJ Taq Polymerase, 5 mM MgCI2/ dNTP mix (200 
pM each dNTP), and SYBR®Green and ROX passive reference dye. The PCR condition 
was set as shown in Table 5.3. The stability o f expression o f candidate reference genes 
were compared using geNorm software Demo version 2.6.1.
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Table 5.3: PCR condition fo r selecting the most stable expressing housekeeping 
gene(s)
Step Time Temperature
Enzyme activation 10 min 95°C
Denaturation 15 s 95°C Cycling
x40Data collection 60s 60°C
M elt curve 15 s 95°C
30 s 60°C increasing in 0.3°C 
increment till 95°C
5.2.7.3 Determination of primer efficiency
The amplification efficiencies o f primers used in this expression study including Htr2c 
and the most stable expressing housekeeping genes identified by geNorm including 
Actb, Ywhaz, and Canx were determined. Serial dilutions of cDNA samples were used 
to  determine primer efficiency as described in the previous chapter (section 4.2.6.5). 
The primer sequences for Htr2c, Actb, Ywhaz, and Canx are listed in Table 5.4.
Table 5.4: Nucleotide sequences of primers used in Htr2c expression in 3T3-L1 cells
Gene Primer sequences Product length
Htr2c Forward 5'-TCTCCCTTCCTTCCGTATTCC-3' (21bp) 
Reverse 5'-ACATCAACTTTTCCACATTCACAA-3' (24bp)
95 bp
Actb Forward 5'-CCTGTGCTGCTCACCGAGGC-3‘ (20bp) 
Reverse 5'-GACCCCGTCTCTCCGGAGTCCATC-3' (24bp)
174 bp
Ywhaz Forward 5'-AAAAACAGCTTTCGATGAAGCC-3' (22bp) 
Reverse 5'-GCCGGTTAAI 1 1 ICCCCTCC-3' (20bp)
168 bp
Canx No data
5.2.7.4 Determination ofHtr2cgene expression
The PCR reaction and PCR condition were set as described in the previous section in 
determ ining o f reference genes. The PCR conditions fo r determ ination o f Htr2c 
expression were slightly d ifferent (Table 5.5). Following qPCR, melt curve analysis and 
agarose gel electrophoresis were carried out to  identify the PCR product.
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Table 5.5: PCR condition fo r determ ining o f the Htr2c expression
Step Time Temperature
Enzyme activation 10 min 95°C
Denaturation 15 s 95°C
Cycling x40Annealing 30 s 62°C
Data collection 30 s 72°C
M elt curve 15 s 95°C
30 s 60°C increasing in 0.3°C 
increment till 95°C
5.2.8 Statistical Analyses
The effects of antipsychotic drugs on leptin secretion and Htr2c gene expression were 
tested using SPSS for Windows. Leptin secretion was expressed as a percentage of 
control (untreated) group. The expression o f Htr2c was expressed as fold change 
comparing to  control untreated group. The normal d istribution was tested by using the 
Kolmogorov-Smirnov test. One-way ANOVA was used to  compare means between 
multiple groups when the values were normally distributed w ith either Bonferroni post 
hoc test when variances were equal or Tamhane's T2 when variances were not equal. 
Kruskal-Wallis test was used fo r non-parametric data when the values were not 
normally distributed. Statistical significance was considered when P value was less 
than 0.05.
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5.3 Results
5.3.1 Differentiation induction of 3T3-L1 preadipocytes to mature 
adipocytes
The morphology o f a 3T3-L1 preadipocyte cell line was changed after inducing 
d ifferentiation from fibroblast-like cells to mature adipocytes. The process of 
d ifferentiation was easily observed under the microscope both w ith and w ithou t oil 
Red 0  staining. The d ifferentiated cells show characteristics o f lipid droplets. The 
intracellular lipid droplets started to be visible at around day 5 and increased in both 
number and size throughout the follow ing days of induction. A fter day 12 of 
d ifferentiation induction, the cells contained lipid droplets of d ifferent sizes and this 
d ifferentiation state was not changed until at least day 16 of observation (Figure 5.3). 
The differentiated 3T3-L1 adipocyte cells at day 14 were chosen in the subsequent 
experiments of antipsychotic drug treatm ents to  ensure the cells had been fu lly 
d ifferentiated.
Figure 5.3: M orphology o f 3T3-L1 cells
Figure shows the morphology of the 3T3-L1 preadipocyte cells before d ifferentia tion 
induction (A, xlOO), after d ifferentiation induction at day 5 (B, x200), day 12 (C, x200), 
day 14 (D, x200), day 16 (E, x200), and oil red O staining at day 16 (F, x200).
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5.3.2 Effect of antipsychotic treatment on leptin secretion from 3T3-L1 
adipocytes
The effects of clozapine, SB 284104, risperidone, and haloperidol at various 
concentrations on the amount o f leptin secreted from  mature adipocyte cells were 
determined by ELISA assay. The medium containing the same amount of DMSO 
(0.1%DMSO) was carried out as a control group.
The clozapine treatm ent at concentrations of 0.3, 1, and 10 pM did not show 
significant change in leptin levels compared to the control group (p>0.05) (Figure 
5.4A). Similar results were observed when treatm ent w ith SB 242084 at concentrations 
o f 0.01, 0.1, and 1 pM (Figure 5.4B), risperidone treatm ent at concentrations of 0.03, 
0.1, and 1 pM (Figure 5.4C), and haloperidol treatm ent at concentrations o f 0.01, 0.03, 
and 0.3 pM(Figure 5.4D).
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Figure 5.4: Effect of antipsychotic drug treatment on leptin secretion in 
differentiated 3T3-L1 cells
The figure shows the effect o f antipsychotic drugs; clozapine (A), SB 242084 (B), 
risperidone (C), and haloperidol (D) on leptin amount in mature adipocyte 3T3-L1 cells. 
Data are expressed as mean percentage o f control (±SEM), n=3-4.
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5.3.3 Effect of antipsychotics treatm ent on Htr2c mRNA expression in 
3T3-L1 adipocytes
5.3.3.1 RNA extraction
RNA was extracted from adipocyte 3T3-L1 cells at the end of antipsychotic drug 
treatm ent experiments. Extracted RNA concentration and purity were determined 
using Nanodrop spectrophotometry. The gel electrophoresis was performed to 
investigate the integrity of extracted RNA which presents both 28s and 18s rRNA bands 
indicating the good quality o f RNA (Figure 5.5).
28s
18s
Figure 5.5: Agarose gel electrophoresis o f RNA extracted from  3T3-L1 adipocytes 
Figure shows clearly visible bands of 28s and 18s ribosomal RNA w ith the 2:1 ratio o f 
28s:18s indicating the good integrity o f RNA extracted from 3T3-L1 adipocytes.
5,3.3.2 Reference gene(s) selection
The stability of expression o f eight housekeeping genes was determined using GeNorm 
software. Eleven cDNA samples from  d ifferent experimental conditions including 
control, clozapine, SB 242084, risperidone, and haloperidol treatm ents were used to 
determ ine reference genes. The GeNorm software calculates the expression ratio of 
each housekeeping gene from  input Ct values. The M value calculated by the software 
indicates the stability of each housekeeping gene. The lowest M value is the most 
stable expressing gene. As shown in Figure 5.6, the Actb, Canx, and Ywhaz were the
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most stably expressed housekeeping genes. The optimal number o f housekeeping 
genes was represented as V value. The result o f GeNorm V value indicates tha t 2 or 3 
most stable genes (GeNorm V <0.15) were optimal number of selected housekeeping 
genes fo r using as the reference genes in this experimental situation (Figure 5.7).
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Figure 5.6: GeNorm M value o f 8 housekeeping genes represented the s tab ility  o f 
expression o f each housekeeping gene
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Figure 5.7: GeNorm V value indicated optim al num ber o f reference genes
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5.3.3.3 Primer efficiency and specificity
Serial dilutions o f cDNA were amplified w ith the prim er sets of the Htr2c and selected 
reference genes, Actb, Canx, and Ywhaz to determine the ir primer efficiencies. The Ct 
values of dilutions of each prim er set were used to calculate the slope of the trend line 
when plotting Ct values against log cDNA concentrations (Figure 5.8). Then the prim er 
efficiency of each primer set was calculated using the equation %E = ( io ( 1/slope)- l )  x 
100. The percentage efficiencies o f the Htr2c, Actb, Canx, and Ywhaz were 107.48%, 
102.77%, 106.70%, and 102.49%, respectively.
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Figure 5.8: Efficiency o f prim er used in SYBR®Green RT-PCR in adipocyte 3T3-L1 cells 
The Ct values of each dilution series of each transcript were plotted against log cDNA 
concentrations to  obtain slope o f the trend line of the Htr2c (A), Actb (B), Canx (C), and 
Ywhaz (D). The slope has been used in prim er efficiency calculation. Data are 
expressed as mean ±SEM (n=3-4).
233
The specificity o f each primer set was observed by melt curve analyses follow ing RT- 
qPCR as shown in Figure 5.9 and it was also observed by agarose gel electrophoresis 
(Figure 5.10). Each primer sets amplified one single product indicates that no non­
specific PCR product was amplified.
(A) Htr2c (B) Actb (C) Canx (D) Ywhaz
I
I
1
I
i]
i
i;i
Figure 5.9: Melt curve of transcripts when amplified by different primer sets in 
adipocyte 3T3-L1 cells
Single peak of each transcript was obtained when amplified by prim er sets o f the Htr2c
(A), Actb (B), Canx {C), and Ywhaz (D) in SYBR®Green real-time RT-PCR in adipocyte 
3T3-L1 cells indicating the specificity of the primers used in this study.
bp
200
100 —
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100—
Htr2c
Actb
200  —
Canx
Ywhaz
Figure 5.10: PCR products of the Htr2c, Actb, Canx, and Ywhaz transcripts
Single PCR product o f each transcript was amplified indicating high specificity o f each
prim er set used in this RT-PCR experiment.
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5.3.3.4 Effect of antipsychotics treatment on Htr2c mRNA expression
The effect o f antipsychotic drug treatm ent on the expression o f the Htr2c mRNA in 
adipocyte 3T3-L1 cells was determined by RT-qPCR. Treatment w ith clozapine for 24h 
at concentrations o f 0.3, 1, and 10 pM produced no significant changes in expression 
of Htr2c mRNA relative to control group (p>0.05) as shown in Figure 5.11A. However, 
the expression levels o f the Htr2c mRNA treated w ith clozapine seems slightly 
decreased at or below the therapeutic concentration (0.3 and 1 pM).
Adipocyte 3T3-L1 cells treated w ith SB 242084 at the concentrations of 0.01, 0.1, and 1 
pM did not have a significant change in Htr2c mRNA expression (p>0.05), although it 
seems to  slightly increase the expression at all three concentration compared to 
control (Figure 5.11B).
Treatment w ith risperidone at concentrations of 0.03, 0.1, and 1 pM as well as 
haloperidol at concentrations o f 0.01, 0.03, and 0.3 pM produced no significant 
changes the Htr2c mRNA expression in adipocyte 3T3-L1 cells (p>0.05), although 
treatm ent w ith both drugs at all concentrations slightly decreased the expression 
(Figure 5.11C and D).
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Figure 5.11: Effect o f antipsychotic drug trea tm en t on Htr2c mRNA expression in 
d iffe ren tia ted  3T3-L1 cells
The figure shows the effect o f antipsychotic drugs; clozapine (A), SB 242084 (B), 
risperidone (C), and haloperidol (D) on Htr2c mRNA expression in mature adipocyte 
3T3-L1 cells. Data are expressed as mean percentage o f control (±SEM), n=3-4.
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5.4 Discussion
Plasma leptin level is strongly and positively correlated w ith adiposity or BMI (Klein et 
al., 1996; Haupt et al., 2005; Venkatasubramanian et al., 2010). Increased plasma 
leptin levels during atypical antipsychotic treatm ent, particularly olanzapine and 
clozapine (and risperidone), but not typical antipsychotic, haloperidol have been 
reported in several studies (Sentissi et al., 2008; Kluge et al., 2009; Kraus et al., 1999; 
Yanik et al., 2013; Zhang et al., 2004). It has been suggested tha t the increased leptin 
levels are most likely due to  weight increased during antipsychotic drug treatm ent 
rather than a direct effect o f antipsychotic drugs on leptin production and release from 
adipocytes. The 5-HT2C receptor is expressed in mature adipocytes and it plays role in 
adipocyte differentiation (Kinoshita et al., 2010). No previous study has investigated 
the role o f 5-HT2C receptor in regulating leptin secretion from mature adipocytes. In 
addition, the effects of antipsychotic drugs on expression of the 5-HT2C receptor in 
adipocytes and leptin secretion from adipocytes have not been studied yet. The 
present study hypothesizes that antipsychotic drugs treatm ent may change the mRNA 
expression of the HTR2C and also alter the leptin secretion from  adipocytes. The 
experiments in this chapter were carried out w ith the aim of investigating the effect o f 
antipsychotic drugs on leptin secretion and mRNA expression of the Htr2c  in 
adipocytes. The experiments were carried out in the 3T3-L1 adipocyte cell line tha t was 
induced by differentiation to become mature adipocytes fo r testing the effect o f 
antipsychotic drugs.
5.4.1 Validation of methodology
5.4.1.1 Differentiation of3T3-Ll cells
Full d ifferentiation of the preadipocyte 3T3-L1 was obtained from  day 12 after
induction of d ifferentiation. When observed under a microscope, the cell size and the
accumulation o f lipid droplets in the cells indicating the phenotype of an adipocyte cell
were not increased after day 12. D ifferentiated cells at day 14 were used in
antipsychotic drugs experiments in the present study to  ensure tha t the cells reached
full d ifferentiation. Other studies have reported tha t by about day 10 to day 14
follow ing differentiation induction by the standard method (w ithout rosiglitazone),
90%-95% of the 3T3-L1 cells d ifferentiated into adipocytes (Fu et al., 2005; Yang and
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Kim, 2015; Vestri et al., 2007). The detected leptin secretion from  3T3-L1 cells into 
culture medium after d ifferentiation induction also indicates the phenotype of 
adipocyte cells.
5.4.1.2 Housekeeping gene selection, primer efficiency and specificity
RNA extracted from cell cultures was intact and had a good quality observed from  the 
clear sharp bands of 28s and 18s on an agarose gel whereby the 28S/18S rRNA ratio 
was approximately 2:1.
The analysis o f a selection o f the most stably expressed reference genes to  be used in 
relative quantification of mRNA expression by using GeNorm software identified the 
Actb, Canx, and Ywhaz as the most stably expressed transcripts in 3T3-L1 adipocytes 
under the experimental conditions in this work.
The amplification efficiencies o f the Htr2c, Actb, Canx, and Ywhaz primers used in the 
present study were w ith in the acceptable range. The 2"AACt method was therefore used 
in the calculation o f the relative expression of the transcript.
The melt cure analysis in SYBR®Green real-time PCR and also the gel electrophoresis of 
the PCR product showed one single product was amplified indicating the specificity of 
the primers.
5.4.2 Effect of antipsychotic drugs on leptin secretion from 3T3-L1 
adipocytes
The effect o f antipsychotic drugs on leptin secretion from adipocytes was investigated 
using differentiated 3T3-L1 adipocytes. Cells were exposed to clozapine, SB 242084, 
risperidone, and haloperidol fo r 24h. Leptin levels in the culture medium were 
measured using ELISA kits.
5.4.2.1 Clozapine treatment and leptin secretion from 3T3-L1 adipocytes
There was no effect o f clozapine at the concentrations of 0.3, 1, and 10 pM on leptin 
secretion. The therapeutic plasma concentration of clozapine is 1.07-1.84 pM (Hiemke 
et al., 2011), thus clozapine even at a concentration about 10-fold higher than the 
typical plasma concentrations did not affect leptin secretion from  adipocytes. This
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result is consistent w ith previous findings in human differentiated adipocytes treated 
w ith clozapine at concentrations of 10"9-1CT5 M for 24h which showed no clozapine 
effect on leptin production and leptin mRNA expression (Hauner et al., 2003). The 
authors suggested tha t the clozapine may cause weight gain via central pathways 
rather than a peripheral action. However, there has been a study in 3T3-L1 cells that 
reported that clozapine at doses as low as 5 pM were able to directly impair insulin 
actions by reduced glucose transport, increased lipogenesis, and decreased lipolysis 
(Vestri et al., 2007). In addition, impaired insulin induced glucose uptake and insulin 
signaling has been reported both In vitro  and in vivo (Panariello et al., 2012). 
Furthermore, clozapine has been reported to enhance adipogenesis in white 
adipocytes, and 3T3-L1 cells (Yang et al., 2009; Hu et al., 2010), whereas it inhibited 
the differentiation accompanied by decreased mRNA expression o f leptin and other 
lipogenic genes in brown adipocytes (Oh et al., 2012). One study reported tha t 
clozapine treatm ent did not change intracellular triglyceride content during adipogenic 
d ifferentiation o f the human adipose-derived stem cells compared to  the control 
DMSO group (Sertie et al., 2011). However, a study in human adipocytes showed tha t 
clozapine treatm ent enhanced differentiation (Hemmrich et al., 2006). The d ifferent 
findings o f clozapine on adipogenesis may be due to  the d iffe rent cell types or 
d ifferent species, as well as the method for inducing differentiation. Taken together, 
clozapine may affect insulin-stimulated glucose uptake enhancing lipogenesis and 
adipogenesis during d ifferentiation rather than an acute effect on leptin secretion 
from  mature adipocytes. However, clozapine at the lowest concentration under this 
investigation (0.3pM) exceeds the binding affinities fo r many receptors in addition to 
5-HT2C including 5-HT2A, a l- ,  a2- adrenergic, H I, H2 receptors which are expressed in 
3T3-L1 adipocytes (Correll 2008; M orrow  et al., 2010), thus these receptors may 
mediate a clozapine effect on leptin secretion by way of antagonist action tha t may 
result in unchanged leptin levels. Further studies are required to elucidate the effect of 
antipsychotic drugs on leptin secretion.
5.4.2.2 SB 242084 treatment and leptin secretion from 3T3-L1 adipocytes
3T3-L1 adipocytes cells were treated w ith SB 242084, a selective 5-HT2C receptor 
antagonist to investigate whether the 5-HT2C receptor is involved in leptin secretion. 
SB 242084 treatm ent at concentrations of 0.01, 0.1, and 1 pM did not change leptin
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levels. The binding a ffin ity (Ki) of SB 242084 for 5-HT2C receptor is 9 nM (Kennett et 
al., 1997), thus the lowest concentration in this study was at the Ki, the second 
concentration is 10-fold, and the th ird concentration is 100-fold higher than the 
concentration at the Ki. The result did not observe any significant effect o f SB 242084 
on leptin secretion from  adipocyte 3T3-L1 cells. This is the first study tha t investigates 
the role o f 5-HT2C receptor in leptin secretion in adipocytes. The action o f SB 242084 
on adipogenesis has been reported in previous studies; SB 242084 treatm ent at high 
doses (40 pM and 80 pM) during induction of d ifferentiation significantly inhibited 
adipocyte differentiation in 3T3-L1 cells (Kinoshita et al., 2010). This study indicates the 
role o f the 5-HT2C receptor in adipogenesis, although the effect is only detectable at 
very high doses and they did not determine the cytotoxicity o f drug treatm ent. 
Therefore, SB 242084 may have a direct effect on adipogenesis or cytotoxicity and at 
very high doses of the substance may cause the reduction of d ifferentiation rate. In the 
present study, adipocytes were induced to  differentiate before treatm ent w ith 
antipsychotic drugs, however drug concentrations were not as high as in Kinoshita and 
colleague's work, thus any change in leptin secretion may not be detectable. Further 
treatm ent w ith higher concentration may cause detectable changes. Further studies 
are needed to  elucidate the role of 5-HT2C receptor in leptin secretion as well as in 
adipogenesis.
5.4.2.3 Risperidone treatment and leptin secretion from 3T3-L1 adipocytes
The effect o f risperidone treatm ent on leptin secretion from adipocytes 3T3-L1 cells
was investigated in this study. The result did not show any significant change o f leptin
levels when the adipocytes were treated w ith risperidone at concentration o f 0.03, 0.1,
and 1 pM compared to control group. The therapeutic plasma level o f risperidone is
50-150 nM (Hiemke et al., 2011) and the Ki of risperidone fo r 5-FIT2C receptor is 32 nM
(Correll, 2008) to 112 nM (Kuoppamaki et al., 1995). Thus the drug concentrations
used in this study cover the therapeutic plasma levels and Ki fo r 5-FIT2C receptor, as
well as 10-time higher than plasma level. The present study is the firs t study tha t
investigated the direct effect o f risperidone on leptin secretion from  adipocytes.
Risperidone has been reported to  impair insulin-stimulated glucose uptake and insulin-
mediated antilipolysis in primary cultured rat adipocytes (Vestri et al., 2007). Another
study reported that risperidone treatm ent at high doses (25pM and 50pM) showed
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significantly enhanced adipogenesis in 3T3-L1 cells w ithout drug-induced cytotoxicity 
(Hu et al., 2010). The current study, investigated the drug effect on leptin secretion 
from  mature adipocytes but not adipogenesis. The drug concentrations were not very 
high, although they covered therapeutic plasma levels. The lack of a significant effect 
of risperidone in this study may be due to the relatively low concentrations o f drug in 
treatm ent o f the cells. Further studies w ith supra-physiological concentration may 
result in detectable changes.
5.4.2.4 Haloperidol treatment and leptin secretion from 3T3-L1 adipocytes
The effect of haloperidol treatm ent on leptin secretion from  adipocytes 3T3-L1 cells 
were investigated in this study which aimed to  investigate the effect o f typical 
antipsychotic drugs compared to  atypical antipsychotic drugs. Adipocyte 3T3-L1 cells' 
treatm ent w ith haloperidol at concentrations of 0.01, 0.03, and 0.3 pM had no effect 
on leptin secretion into the culture medium. Haloperidol has very low 5-HT2C receptor 
binding affin ity compared to other tested drugs. The Ki o f haloperidol fo r 5-HT2C 
receptor is 4,700 nM and 2.6 nM for Dopamine D2 receptor (D2R) (Correll, 2008). The 
therapeutic plasma concentration of haloperidol is 2.66-26.6 nM (Hiemke et al., 2011) 
to  50 nM (Coryell et al., 1998). Thus drug concentrations used in this study are the 
therapeutic plasma concentration and about 10-fold higher than plasma level; 
however, all concentrations are lower than the Ki value o f haloperidol fo r the 5-HT2C 
receptor but cover the D2R. D2 receptors are expressed in 3T3-L1 adipocytes 
(Mukherjee and Yun, 2013). No significant change of leptin secretion a fter treatm ent 
w ith haloperidol was observed in this study indicating tha t D2R may not be associated 
w ith regulating leptin secretion.
The present study is the first study tha t investigated the direct effect o f haloperidol on 
leptin secretion from  adipocytes. A previous study in human in vitro  adipocyte-derived 
stem cells has reported tha t haloperidol had an effect on the control of the adipocyte 
differentiation program by increasing the gene expression levels o f peroxisome 
proliferator-activated receptor gamma 2 (PPARy2) and lipoprotein lipase (LPL) but only 
at high doses (20 pM and 40pM), the doses at therapeutic plasma concentrations and 
10-fold higher than this level had no effect; however, these high concentrations had no 
effect on triglyceride accumulation (Sertie et al., 2011). The authors also reported that
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haloperidol at 40 and 100 pM decreased insulin-stimulated lipogenesis (Sertie et al.,
2011). However, these studies may not reflect the results o f the present study because 
as mentioned above, the drugs were added to the differentiated cells instead of 
investigating adipogenesis, and also the relative low concentrations o f drugs may 
contribute to  the lack o f change in leptin secretion. Further studies are required to 
elucidate the role of haloperidol on leptin secretion from adipocytes.
5.4.3 Effect of antipsychotic drugs on Htr2c mRNA expression in 3T3- 
L1 adipocytes
The detection o f Htr2c mRNA expression in this study confirmed the expression o f the 
5-HT2C receptor in d ifferentiated 3T3-L1 adipocytes (Kinoshita et al., 2010). The 
expression o f Htr2c mRNA levels o f adipocyte 3T3-L1 cells treated w ith antipsychotic 
drugs were determined using real-time RT-qPCR. Treatm ent o f 3T3-L1 adipocytes w ith 
clozapine, SB 242084, risperidone, and haloperidol at the same concentrations as 
tested in the leptin secretion study did not alter the levels o f Htr2c mRNA expression 
compared to  the control (DMSO) group. A previous study investigated the expression 
of Htr2c mRNA in 3T3-L1 adipocytes and found an increase in the Htr2c mRNA levels 
during adipocyte differentiation. Treatment w ith the 5-HT2C receptor antagonist SB 
242084 inhibited adipocyte differentiation, although this inh ib itory effect is only 
detectable at high doses (Kinoshita et al., 2010). These authors also identified 5-HT in 
adipose tissue as a novel autocrine factor tha t is required fo r adipocyte d ifferentia tion 
(Kinoshita et al., 2010). The role o f 5-HT and the 5-HT2C receptor in adipocyte 
differentiation, suggest it is possible tha t the 5-HT2C receptor may also play a role in 
regulating leptin production and secretion. This is the firs t study tha t investigated the 
influence of antipsychotic drugs on mRNA expression o f HTR2C in adipocytes tha t 
might affect the secretion o f leptin. The lack o f significant changes o f the HTR2C mRNA 
expression as well as leptin secretion follow ing antipsychotic treatm ent in this study 
may be due to  the low concentrations of drugs tha t might not be high enough to 
induce intracellular changes at both mRNA or protein levels. Further studies are 
required to  elucidate the role o f antipsychotic drugs on the expression o f gene-related 
to leptin secretion that may provide more understanding about the effect of 
antipsychotic drugs on weight gain side effect through peripheral actions.
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To date, there have been several studies that reported the effect o f antipsychotic drug 
treatm ent at gene expression levels. Treatment w ith atypical antipsychotic drugs 
increased mRNA expression of proinflam m atory and adipogenic genes in human 
adipocytes in vitro  (Sarvari et al., 2014). Olanzapine treatm ent at high dose (50 pM) 
induced adipogenesis and triglyceride accumulation in 3T3-L1 cells, increased sterol 
regulatory element-binding protein 1 (SREBP-1) mRNA and protein levels upon 
treatm ent fo r 24h (50pM), and also increased mRNA expression of adiponectin and 
fa tty  acid synthase [FAS) upon treatm ent at lOpM  for 48h (Yang et al., 2007). 
Clozapine treatm ent in 3T3-L1 cells inhibited mRNA and protein expression o f LPL and 
increased mRNA expression of adipocyte determ ination and d ifferentiation 
factorl/SREBPic [ADD1/SREBP1C] (Yang et al., 2009). Risperidone (50pM) treatm ent in 
3T3-L1 cells fo r 8 days during differentiation resulted in increased mRNA expression o f 
gene involved in SREBP-1 pathway (SREBP-1, PPARy, C/EBPa, low density lipoprotein 
receptor (LDLR), adiponectin, and FAS), similar to  clozapine (15pM) treatm ent which 
also increased mRNA expression of these genes except FAS (Hu et al., 2010). A study in 
human adipocyte-derived stem cells showed tha t treatm ent w ith clozapine, 
olanzapine, or haloperidol increased mRNA expression of PPARy2 and LPL ((Sertie et 
al., 2011). A fu rthe r study in rat adipocytes treated w ith olanzapine fo r 5 weeks 
showed decreased lipolytic activity, decreased mRNA expression of hormone-sensitive 
lipase [FISL), and increased FAS mRNA expression (M inet-Ringuet et al., 2007). The 
effect of antipsychotic drugs on these adipogenesis-related genes indicates the 
influence of drugs in cellular processes of adipocytes tha t might include the production 
and secretion of adipokines.
In addition, the expression of other receptors that are the targets o f antipsychotic 
drugs has also been detected in adipocytes. The mRNA expression of histamine H I 
receptor has been reported in both preadipocytes and fu lly d ifferentiated adipocytes 
whereas the expression o f the H2 receptor was found only a fter d ifferentia tion 
(Kawazoe et al., 2004). This study also showed that knockdown of the H I receptor by 
small interfering RNA impaired insulin-induced adipogenesis (Kawazoe et al., 2004). 
Melanocortin MC2 and MC5 receptors are expressed in 3T3-L1 adipocytes and may 
mediate the ACTH and alpha-MSH actions in inhibiting leptin expression and secretion 
(Norman et al., 2003) as well as actions in stimulating lipolysis (M oller et al., 2011).
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Adrenergic receptors are also expressed in adipocytes (Fain et al., 1983); for examples, 
a2-adrenergic (Mukherjee and Yun, 2013), and (33-adrenergic receptors (M ottillo  et al., 
2010). Dopamine receptors are expressed in adipocytes (Borcherding et al., 2011; 
Pasqualini et al., 2009). Therefore, treatm ent w ith antipsychotic drugs may mediate 
the ir effect on leptin secretion through some of these receptors; there may be 
antagonistic actions that may result in a lack o f change in the net amount of leptin. 
Further studies are needed to elucidate the specific role o f the 5-HT2C receptor in 
leptin secretion and also the influence of antipsychotic drugs on 5-HT2C receptor- 
mediated leptin secretion.
5.4.4 Limitations of this study
The 3T3-L1 cell line is derived from  Swiss 3T3 mouse embryo fibroblasts. This, together 
w ith the differentiation induction protocol to  induce 3T3-L1 preadipocyte to  become 
mature adipocytes, may not represent human adipocyte cells. The drug concentrations 
used in the present experiments may not be specific to  only the 5-HT2C receptors; 
therefore, the effect o f antipsychotic drugs on leptin secretion may be the outcome of 
the drug effect on many receptors as well as affecting the expression of other 
receptors.
5.4.5 Conclusions
Antipsychotic drugs, both second generation including clozapine and risperidone, the 
selective 5-HT2C receptor antagonist SB 242084, and first generation haloperidol did 
not change the levels o f leptin secretion and the HTR2C mRNA expression in 3T3-L1 
adipocytes.
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Chapter 6: General discussion
6.1 Introduction
Weight gain follow ing antipsychotic treatm ent, particularly second generation 
antipsychotic drugs, is the most common and im portant adverse effect tha t increase a 
schizophrenic patient's risk o f many consequent diseases, such as cardiovascular 
disease and type 2 diabetes mellitus, as well as increasing the risk o f relapse because 
o f a lack o f compliance to  the medication. The mechanism underlying this adverse 
effect is not fu lly understood. There is high inter-individual variability o f weight gain 
and there are many factors tha t contribute to  this variation. The influence of types o f 
antipsychotic drugs, genetic factors, epigenetic factors, and other environmental 
factors may in part contribute to the aetiology of weight gain. Therefore an increased 
understanding of the mechanism involved in antipsychotic drug-induced weight gain is 
im portant and may be useful in recommending a therapeutic approach which brings 
about the least adverse effects. Study o f genetic factors as well as epigenetic factors in 
antipsychotic drug-induced weight gain may provide genetic or epigenetic markers fo r 
predicting the adverse effect o f an individual to design personal medication.
The common hypothesis used to  explain antipsychotic drug-induced weight gain is tha t 
they induce an abnormality in the regulation of appetite leading to an increase in 
energy intake and eventually weight gain. The target receptors fo r antipsychotic drugs 
have been of interest and have been investigated. One of the most consistent findings 
to  be associated w ith antipsychotic drug-induced weight gain is the genetic 
polymorphism of the HTR2C receptor -759C/T. However, other SNPs in many receptor 
genes of antipsychotic drugs such as HTR2A and ADRA2A, or the genes tha t encode 
neuropeptides involved in regulation of food intake such as MC4R, GNB3, BDNF, and 
FTO have been also reported, but there is still a lack o f replication of these studies. The 
aim of this study was, therefore, to  investigate the influence of genetic polymorphisms 
o f these genes on weight gain follow ing antipsychotic treatm ent in schizophrenia 
patients. In addition, the SNPs in the genes relating to  DNA methylation including 
MTFIFR (and FTO) have been hypothesized to be associated with weight gain and were 
investigated in this study.
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Although the HTR2C -759C/T polymorphism is the most consistently associated with 
antipsychotic drug-induced weight gain, the mechanistic link is still unclear. The 
influence of the polymorphism on the expression of the receptor may be the link. A 
previous study by Hill and Reynolds found an association o f the T allele of the HTR2C 
-759C/T polymorphism and lower prom oter activity in human neuroblastoma SH-SY5Y 
cells (Hill and Reynolds, 2007). It has been hypothesized tha t the difference in 
prom oter activity might be due to an epigenetic regulation. The aim of this study was 
therefore to investigate the association between levels o f DNA methylation o f the 
HTR2C prom oter sequences and antipsychotic drug-induced weight gain as well as the 
influence of genetic polymorphisms in patients w ith schizophrenia.
The effect of antipsychotic drugs on the expression o f the HTR2C has not been studied 
yet. In addition to weight gain, increased plasma leptin during antipsychotic drug 
treatm ent has been reported, but it has been suggested tha t the increased leptin 
levels might be due to the increased body weight or adiposity. The present study also 
hypothesized that the antipsychotic drugs may have an effect on DNA methylation and 
expression of the HTR2C and they may also have a direct effect on leptin secretion and 
expression o f the HTR2C in adipocyte cells. Therefore, the aims of this study were to 
investigate the role of antipsychotic drugs on DNA methylation and mRNA expression 
o f the HTR2C gene in human neuroblastoma cells, as well as the ir role on leptin 
secretion and Htr2c mRNA expression in 3T3-L1 adipocytes.
Data of the patient groups, the number o f patients, im portant characteristic of the 
patients, and the source of samples is summarized as shown in table 6.1.
Table 6.1: Summary of studied population groups
Groups Number Characteristic Sample
Chinese Han patients 182 First episode, drug na ve Blood DNA
schizophrenia
Spanish patients 72 First episode, drug na i/e Blood DNA
schizophrenia
Belfast patients 72 Chronic schizophrenia Blood DNA
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6.2 Genetic polymorphisms in antipsychotic drug-induced weight 
gain in patients with schizophrenia
6.2.1 First episode drug naive schizophrenia patients
6.2.1.1 MTHFR 677C/Tpolymorphism is associated with antipsychotic drug- 
induced weight gain in first episode schizophrenia patients
This study identified MTHFR 677C/T as a genetic risk factor fo r antipsychotic drug- 
induced weight gain in the first episode drug-na i/e  schizophrenia in both Chinese Han 
and Spanish patients, and showed that the T allele was a protective allele for 
antipsychotic drug-induced weight gain. This MTHFR 677C/T polymorphism showed an 
additive effect to the well-established HTR2C -759C/T polymorphism. The MTHFR 
enzyme plays an im portant role in DNA methylation, DNA synthesis and repair. The T 
allele causes decreased enzyme activity (Weisberg et al., 1998), via its role in DNA 
synthesis and methylation (Sugden, 2006) and may influence gene expression (Jirtle 
and Skinner, 2007). However, the MTHFR 677C/T polymorphism did not show an 
influence on DNA methylation o f the HTR2C prom oter sequences either in Chinese Han 
or Spanish patients. This may be due to  the small sample sizes relative to the modest 
effect o f this genetic factor on epigenetic change.
6.2.1.2 MC4R rs489693 polymorphism is associated with antipsychotic drug- 
induced weight gain in first episode Chinese Han schizophrenia 
patients
Another genetic risk factor, the MC4R rs489693 was also associated w ith antipsychotic 
drug-induced weight gain in first episode Chinese Han patients w ith schizophrenia; the 
C allele carriers had greater weight gain compared to the AA genotype. This finding is 
opposite to a previous finding tha t the AA genotype was associated w ith weight gain 
follow ing second generation antipsychotic treatm ent (Malhotra et al., 2012; 
Czerwensky et al., 2013b). This study differs from the present study in ethnicity; in 
addition, o ther factors such as prior drug exposure, the difference in drug treatm ents, 
clinical factors (19 years o f age or younger in Czerwensky's study patients), as well as 
environmental factors could influence antipsychotic drug-induced weight gain. Further 
studies are needed to elucidate the association between the MC4R rs489693 and
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antipsychotic drug-induced weight gain. The exact mechanism underlying the 
association of the MC4R rs489693 and antipsychotic drug-induced weight gain is 
unknown. No functional relevance of this polymorphism has been reported. The 
influence of the rs489693 may relate to other remote regulatory sites (Espinoza and 
Ren, 2011), or another polymorphism which is in LD tha t has actual biological function 
in the regulation of body weight.
6.2.1.3 HTR2A -1438G/A and ADRA2A -1291C/G polymorphisms are
associated with risperidone-induced weight gain in first episode 
Chinese Han schizophrenia patients
An interaction o f drug and genetic polymorphism was observed in Chinese Han 
schizophrenia patients. There was a significant drug x HTR2A -1438G/A genotype 
interaction and a non-significant indication of drug x ADRA2A -1291C/G genotype 
interaction when patients were analysed as groups receiving either risperidone or 
chlorpromazine. The drug-genetic polymorphism interaction may be due to  the high 
binding a ffin ity of the risperidone at the HTR2A and ADRA2A receptors. Therefore, 
post hoc analysis in a subgroup o f patients who had received risperidone was 
performed and found a significantly greater weight gain in the A allele carriers o f the 
HTR2A -1438G/A compared to GG genotype and also found a significantly greater 
weight gain in patients who carried the G allele of the ADRA2A -1291C/G compared to 
CC genotype carriers.
6.2.2 Chronic patients with schizophrenia
6.2.2.1 MTHFR 677C/Tand MTHFR 1298A/Cpolymorphisms are not 
associated with BMI in chronic schizophrenia patients
In chronic schizophrenia patients, the MTHFR 677C/T and 1298A/C were not 
associated w ith BMI. Previous findings did not observe associations between the 
polymorphisms of the HTR2C -759C/T and leptin -2548A/G w ith BMI in this chronic 
patient cohort (Yevtushenko et a t, 2008), whereas the FTO rs9939609 polymorphism 
was previously found to  be associated w ith  the measurements of obesity including 
BMI, waist circumference, waist-hip ratio, and central obesity (Reynolds et a i,  2013). It
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has been suggested that the FTO polymorphism may be enhanced in patients w ith 
chronic treatm ent and may also interact w ith other polymorphisms relating to 
antipsychotic drug-induced weight gain (Reynolds et a!., 2013), whereas the HTR2C - 
759C/T polymorphism may have strong effects on initial weight gain but lesser effects 
on long-term weight gain (Yevtushenko et a!., 2008). Taken together, the results 
suggest that the MTHFR and HTR2C polymorphisms may influence early weight gain 
while FTO polymorphism may affect long-term weight gain follow ing antipsychotic 
drug medication.
The findings o f the association of genetic polymorphism and weight gain or BMI in first 
episode and chronic patients w ith schizophrenia were summarized as shown in table 
6.2. Gender distribution between subgroups o f genotype of each polymorphism was 
tested using chi-square and there was no significant gender d istribution between each 
genotype group.
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Table 6.2: Summary of results of genetic polymorphism associated with weight gain 
or BMI in each studied population groups
Groups SNP rs number Result (finding) p value
Chinese Han HTR2C rs3813929* C allele -->greater WG 0.004
MTHFR rsl801133 C allele -->greater WG 0.003
MTHFR rsl801131 NA NS
ADRA2A rsl800544 G allele-->greater WG in 
risperidone subgroup
0.027
HTR2A rs6311 - A allele-->greater WG in 
risperidone subgroup
- genotype-drug interaction
0.047
0.017
MC4R rsl7782313 NA NS
MC4R rs489693 C allele ->grea te r WG 0.040
BDNF rs6265 NA NS
GNB3 rs5443 NA NS
FTO rs9939609 NA NS
Spanish MTHFR rsl801133 C allele -->greater WG 0.049
MTHFR rsl801131 NA NS
HTR2C rs3813929* C allele -->greater WG 0.012
FTO rs9939609* NA NS
Chronic (Belfast) MTHFR rsl801133 NA NS
MTHFR rsl801131 NA NS
HTR2C rs3813929* NA NS
FTO rs9939609* A alle le->greater BMI 0.029
LEP rs7799039* NA NS
In firs t episode drug na i/e  schizophrenia patients (Chinese Han and Spanish corhorts), 
the SNPs were analyzed w ith  weight gain (change in BMI), and w ith BMI in chronic 
patients.
* Previous genotyped SNPs (Reynolds et al., 2002; Templeman et al., 2005; 
Yevtushenko et al., 2008; Reynolds et al., 2013); WG, weight gain (change in BMI); NA, 
no association w ith weight gain or BMI; NS, non-significant statistical p value.
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6.3 DNA methylation of the HTR2C  promoter regions and 
antipsychotic drug-induced weight gain in patients with  
schizophrenia
6.3.1 First episode drug naive schizophrenia patients
The present study is the first study to investigate DNA methylation of the HTR2C in 
relation to  antipsychotic drug-induced weight gain as well as the influence of genetic 
polymorphisms of the HTR2C, MTHFR, and FTO on DNA methylation o f the HTR2C. The 
results indicated tha t there was a gender difference of DNA methylation o f HTR2C 
prom oter sequences in both Chinese Han and Spanish patients; females have higher 
methylation levels than males. This is because of X-chromosome inactivation in 
females leading to higher methylation levels.
6.3.1.1 DNA methylation of the HTR2C promoter sequences may be used as a 
predictor for antipsychotic drug induced weight gain in first episode 
schizophrenia patients
In first episode drug na ve schizophrenia patients, the methylation of the HTR2C 
prom oter sequences did not show any correlation w ith body weight and BMI. 
However, Chinese Han patients who have a weight increase by >7% had lower 
methylation levels of the HTR2C prom oter sequences than the <7% weight increase 
group. Because the levels o f DNA methylation were measured at baseline but not after 
treatm ent; therefore, DNA methylation should be in itia lly used to  predict the weight 
gain because other factors such as antipsychotic treatm ent, dietary, exercise, or 
smoking may contribute to  alterations in DNA methylation during trea tm ent of 
antipsychotic drugs. A similar effect was also observed in the Spanish cohort but it did 
not reach statistically significant levels which may be due to a small sample size or the 
difference in ethnicity that may contribute to the weak association. It should be noted 
tha t the methylation levels of the HTR2C at both regions in Chinese Han patients were 
slightly higher than those of Spanish patients (Table 3.10-Table 3.13).
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6.3.1.2 The T allele of the HTR2C-759C/T polymorphism is associated with 
higher DNA methylation of the HTR2C promoter sequences
The influences of genetic polymorphisms on DNA methylation o f the HTR2C prom oter 
polymorphisms in firs t episode drug na ive schizophrenia patients illustrated the effect 
of the HTR2C -759C/T polymorphism on the methylation of the cytosine bases in the 
prom oter region o f the HTR2C-, the T allele carriers had higher methylation levels of 
the HTR2C prom oter region near the SNP site compared to C/CC genotype. This finding 
may explain the previous finding tha t the T allele o f the HTR2C -759C/T had lower 
prom oter activity (Hill and Reynolds, 2007) in tha t the higher methylation levels of the 
T allele lead to lower prom oter activity, and this may result in decreased transcription 
and receptor expression, and finally influence antipsychotic drug-induced weight gain. 
The results from  this study may provide evidence of a link between epigenetic 
modification and prom oter activity and may also make the link between this genetic 
polymorphism and weight gain.
This effect of -759C/T polymorphism on DNA methylation o f the HTR2C was observed 
at the CpG sites tha t are located near the SNP site, whereas the CpG sites located far 
away near the transcription start site (TSS) did not show a significant difference 
indicating tha t the polymorphism may influence locally near the SNP sites. A similar 
direction was observed in first episode Spanish schizophrenia patients but did not 
reach statistical significance.
In addition, a lack o f a significant difference of DNA methylation at the CpG sites 
located near the TSS may be due to the CpG sites near the TSS maintaining low 
methylation levels in order to  facilitate transcription in itiation (Jones, 2012). As it has 
low levels and only slight changes of DNA methylation in this region, the influence of 
genetic polymorphisms was not observed. However, the influence of the HTR2C - 
759C/T polymorphism on DNA methylation o f the HTR2C near the TSS was observed to 
be in a similar direction (but not statistically significant) in first episode drug na'^e 
schizophrenia patients.
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6.3.1.3 The FTO rs9939609 polymorphism is associated with DNA methylation
of the HTR2C promoter sequences in Spanish male first episode
schizophrenia patients
The FTO rs9939609 polymorphism shows a significant effect on DNA m ethylation o f 
the HTR2C prom oter sequence in Spanish male patients in that the T allele carriers had 
lower methylation levels o f the HTR2C -697G/C region compared to the AA genotype. 
In this cohort, FTO rs9939609 did not show a significant association w ith weight gain 
(Reynolds et al., 2013). The result o f the influence of the FTO rs9939609 on 
methylation o f the FITR2C prom oter sequences suggests an indirect effect o f the FTO 
polymorphism on weight gain mediated through HTR2C DNA methylation, and this 
may also fu rther change the level o f receptor expression. Here is the firs t study 
demonstrating the effect o f the FTO polymorphism on DNA methylation o f the FITR2C 
prom oter sequence, although the finding was not replicated in the other firs t episode 
group of Chinese Han schizophrenia patients who have d ifferent ethnicity. However, 
fu rther studies in larger sample sizes are required to  confirm this finding.
6.3.2 Chronic schizophrenia patients
In chronic schizophrenia patients, global LINE-1 DNA methylation levels as well as DNA 
methylation o f FITR2C prom oter sequences were determined to  investigate the 
association o f the methylation levels w ith  BMI and antipsychotics, as well as the 
influence of genetic polymorphisms.
6.3.2.1 Global LINE-1 DNA methylation is not associated with BMI in chronic 
schizophrenia patients
The methylation levels o f LINE-1 did not correlate w ith BMI and also did not show a 
difference between BMI obesity groups (>30 vs <30 kg/m 2), central obesity, and 
metabolic syndrome in the chronic Belfast schizophrenia patients. This finding is 
similar to  a recent study in postmenopausal overweight woman tha t reported no 
association of LINE-1 methylation and weight loss at 12 months comparing a reduced- 
calorie weight-loss diet and/or exercise program intervention groups and control 
group (Duggan et al., 2014). However, studies in the adult general population reported 
the association of weight gain and an increased LINE-1 methylation (M artin-Nunez et
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al., 2014; Perng et al., 2014), whereas a study in school-age children reported the 
association of adiposity development and lower LINE-1 methylation in boys (Perng et 
al., 2013). A study in visceral adipose tissue of severely obese people found lower LINE- 
1 methylation was negatively associated w ith fasting glucose, diastolic pressure, and 
metabolic status (Turcot et al., 2012). In addition, global DNA methylation was 
inversely associated w ith plasma vitamin A, female gender, and C-reactive protein (a 
marker o f chronic inflammation), while positively associated w ith maternal BMI and 
socioeconomic status (Perng et al., 2012). An inconsistency of the association o f LINE-1 
methylation and body weight may be due to influences of gender, age, diet, tissue- 
specific variability, and other factors. The inform ation o f the association o f LINE-1 
methylation and body weight or BMI in schizophrenia patients is lim ited. The disease 
conditions, symptoms, medications, and patient's life style may also contribute to 
epigenetic modifications in both global and specific gene levels. Further studies are 
required to  confirm this association.
6.3.2.2 Gender difference and age associated of global LINE-1 DNA 
methylation in chronic schizophrenia patients
Gender had an influence on LINE-1 methylation in chronic schizophrenia patients. 
Females had lower levels o f the global LINE-1 methylation than males (0.55% on 
average). This finding is consistent w ith previous studies in normal populations (Huen 
et al., 2014; Perng et al., 2013; W ilhelm et al., 2010; El-Maarri et al., 2011; Zhang et al., 
2011; Burris et al., 2012). This gender-specific effect on LINE-1 methylation is likely due 
to  the association of LINE-1 w ith X-chromosome inactivation (Singer et al., 2012).
Age was not correlated w ith global LINE-1 DNA methylation in the chronic patients 
studied here which confirmed several previous studies that found a weak inverse 
relationship or no association o f age w ith LINE-1 methylation (Bollati et al., 2009; 
Jintaridth and Mutirangura, 2010; El-Maarri et al., 2011). The weak or no association 
may be due to the modest age effect on LINE-1 methylation and other factors such as 
life style, smoking, dietary, exercise, disease conditions, and antipsychotic drug 
treatm ent tha t may have a stronger effect on global DNA methylation.
254
6.3.2.3 Smoking is associated with higher global LINE-1 DNA methylation in 
chronic schizophrenia patients
Tobacco smoking was significantly associated w ith higher global LINE-1 DNA 
methylation at CpG3 and a similar trend at CpG2. The effect of smoking on global DNA 
methylation is still controversial in which studies in lung cancer found 
hyperm ethylation (Piyathilake et al., 2001; Lin et al., 2007); in contrast to  studies in 
head and neck cancer tha t found hypomethylation (Smith et al., 2007; Hsiung et al., 
2007). Smoking associated w ith higher global UNE-1 methylation may be due to the 
effect o f nicotine which has been reported to cause DNA hyperm ethylation and 
histone acetylation (Abdolmaleky et al., 2013).
6.3.2.4 Olanzapine or clozapine treatment trends to decrease global LINE-1 
DNA methylation in chronic schizophrenia patients
No significant differences o f global DNA methylation levels were observed between 
patients receiving olanzapine or clozapine and patients receiving all o ther 
antipsychotic drugs, although patients on olanzapine or clozapine trea tm ent had 
slightly lower levels o f global DNA methylation (0.46% on average, p=0.059 at CpG3) 
than all o ther drugs. This finding is in line w ith previous studies tha t reported the 
association of decreased methylation of reelin and GAD67 prom oters and 
antipsychotic drugs, particularly clozapine and the benzamide sulpiride, but not 
haloperidol and risperidone (Guidotti and Grayson, 2014; Melas et al., 2012; Guidotti 
et al., 2009; Melka et al., 2014; Dong et al., 2008). Melas et al. (2012) found global 
hypomethylation in schizophrenia patients and also reported tha t haloperidol 
treatm ent increased (normalized) this global hypomethylation. However, the role of 
antipsychotic drugs such as clozapine or olanzapine on global DNA m ethylation needs 
fu rthe r studies.
6.3.2.5 The MTHFR 677C/T and FTO rs9939609 polymorphisms and global 
LINE-1 DNA methylation in chronic schizophrenia patients
MTHFR 677C/T polymorphism was significantly associated w ith global LINE-1 DNA 
methylation in chronic patients w ith schizophrenia (Belfast cohort) in tha t the T allele 
carriers had higher methylation levels at CpG3 than the CC genotype carriers. At
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another SNP, the FTO rs9939609 T allele carriers had a trend of lower methylation 
levels o f LINE-1 than AA genotype at CpG2 and CpG3. The polymorphisms o f the 
MTHFR and FTO are involved in methylation processes tha t may influence the global 
DNA methylation. There was no MTHFR x FTO interaction on LINE-1 m ethylation, but 
interactions o f the MTHFR x smoking, and MTHFR x gender (correcting fo r smoking) 
were observed in that the T allele o f the MTHFR 677C/T polymorphism in smokers or in 
females had higher methylation than in other groups. The relationship o f the MTHFR 
677C/T polymorphism and smoking has been reported in previous studies in tha t the 
TT genotype of the MTHFR 677C/T polymorphism had higher frequency in smokers 
(Johnson et al., 2001; Linnebank et al., 2012). The alteration in plasma homocysteine 
may be a link between genetic factors and smoking. Linnebank et al. (2012) found 
increased levels o f plasma homocysteine in smokers as well as in the T allele carriers of 
the MTHFR 677C/T, and the smoking MTHFR 677TT carriers had the highest plasma 
homocysteine levels, the non-smoking 677CC carriers the lowest. A recent study 
reported the association of an increment o f homocysteine and higher LINE-1 
methylation (Perng et al., 2014). However, the present study did not obtain patient's 
plasma homocysteine levels.
6.3.2.6 The methylation of the HTR2C promoter sequences is gender difference 
in chronic schizophrenia patients
Females have higher levels o f DNA methylation in both regions o f the HTR2C (HTR2C - 
697G/C and Hs_/-/7Y?2C_01_PM). Taken w ith results in firs t episode schizophrenia 
patients, gender has a strong effect on the extent o f DNA methylation o f the HTR2C 
prom oter sequences, both before and after long-term antipsychotic treatm ent.
6.3.2.7 Smoking and antipsychotic treatment do not change the methylation 
levels of the HTR2C promoter sequences in chronic schizophrenia 
patients
Although tobacco smoking significantly increases global LINE-1 DNA m ethylation in this 
chronic schizophrenia cohort, it does not influence the methylation of the HTR2C 
prom oter sequences; in contrast, it is likely to decrease the methylation. These results 
suggest a gene specific influence o f smoking on DNA methylation.
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The same direction of decreased DNA methylation levels o f LINE-1 in patients receiving 
antipsychotic drugs (olanzapine or clozapine) was also observed in the HTR2C 
prom oter sequences indicating tha t not only the global DNA methylation but also the 
specific HTR2C gene was modified by antipsychotic drugs.
6.3.2.8 The methylation of the HTR2C promoter sequences is not associated 
with BMI in chronic schizophrenia patients
The methylation of the HTR2C prom oter sequences is not correlated w ith BMI in 
chronic (Belfast) schizophrenia patients. Levels o f DNA methylation of the HTR2C 
prom oter sequences of patients who have BMI obesity (>30 kg/m 2), central obesity, 
and metabolic syndrome were not d ifferent (slightly higher methylation levels) 
compared to patients who have BMI <30 kg/m 2, absence of central obesity and 
absence of metabolic syndrome. The lack o f association between HTR2C methylation 
and BMI or obesity may be due to  small sample size. Further studies in larger sample 
sizes are required to elucidate this association.
6.3.2.9 The genetic polymorphisms and the methylation of the HTR2C 
promoter sequences in chronic schizophrenia patients
The genetic polymorphisms of the HTR2C -759C/T and the leptin -2548G/A are 
associated w ith the methylation levels of the HTR2C prom oter sequences, whereas 
FTO rs9939609, MTHFR 677C/T and MTHFR 1298A/C polymorphisms are not 
associated w ith methylation levels o f the HTR2C prom oter sequences. A similar finding 
has been observed w ith firs t episode schizophrenia patients in tha t an association o f 
the T allele o f the HTR2C -759C/T polymorphism w ith higher levels o f the HTR2C 
methylation was also observed in chronic patients (at CpG-670, CpG-661, and trend at 
CpG-644). A similar direction was observed in the Hs-H77?2C_01_PM region but it did 
not reach significant levels. The result indicates the local effect o f the HTR2C -759C/T 
SNP on nearby DNA methylation rather than the distant CpG sites.
In contrast, the leptin -2548G/A polymorphism shows significant effects on the HTR2C 
prom oter methylation at CpG-698 (SNP site-697G/C) o f the HTR2C -697G/C region, and 
at the CpGl and CpG4 of the Hs_H77?2C_01_PM region. This finding is interesting 
because the leptin -2548G/A polymorphism affects the extent o f DNA m ethylation of
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the HTR2C at the SNP site and at the CpGs near the transcription start site which 
normally is associated w ith lower methylation to  in itiate transcription. An effect on 
this region indicates the role o f the leptin polymorphism on HTR2C methylation that 
might fu rther influence the transcription and expression of the 5-HT2C receptors.
Although the HTR2C -759C/T and the leptin -2548G/A polymorphisms are not 
associated w ith BMI in this chronic cohort, the effect o f these polymorphisms on DNA 
methylation of HTR2C suggests, at least, the interaction between leptin and HTR2C 
genes. However, the effect o f these tw o polymorphisms on HTR2C DNA methylation 
may not directly link to body weight or BMI.
The results o f the association of DNA methylation of the HTR2C and global LINE-1 
methylation w ith weight gain or BMI, and genetic polymorphism in firs t episode and 
chronic patients w ith schizophrenia are summarized in table 6.3.
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6.4 Effect of antipsychotic drugs on the HTR2C mRNA expression 
and DNA methylation of the HTR2C promoter sequences in 
SH-SY5Y cells
Methylation o f the HTR2C prom oter sequence near the -759C/T HTR2C SNP site as well 
as the mRNA expression of the 5-HT2C receptor were determined in a cell culture 
model to investigate the effect o f antipsychotic drug treatm ent on the expression of 
the HTR2C mRNA and DNA methylation o f the HTR2C prom oter sequence. Non­
differentiated and differentiated SH-SY5Y cells were used in this study to  compare the 
effect o f drugs on undifferentiated neuroblastoma cells and the more neuron like 
differentiated cells. Antipsychotic drugs used in this study consisted o f clozapine and 
haloperidol in order to make a comparison between second-generation and first 
generation antipsychotic drugs. In addition, 5-aza-2'-deoxycytidine was also used in 
this study to investigate the effect o f inhibiting DNA methylation on mRNA expression 
of the HTR2C gene.
Decreased DNA methylation of the HTR2C prom oter sequence near the HTR2C -759C/T 
polymorphism and including the -697G/C polymorphism was observed on treatm ent 
w ith 5-aza-2'-deoxycytidine in both undifferentiated and differentiated SH-SY5Y cells. 
Treatm ent w ith this substance also showed an increase in the levels o f the HTR2C 
mRNA expression. The changes in DNA methylation and mRNA expression o f HTR2C in 
response to 5-aza-2/-deoxycytidine treatm ent suggest the suitability o f the cells for 
studying the effect o f antipsychotic drugs on DNA methylation and mRNA expression 
o f HTR2C.
Clozapine and haloperidol did not change HTR2C prom oter DNA methylation and 
mRNA expression in both undifferentiated and differentiated SH-SY5Y cells. A lack o f 
significant changes of the HTR2C prom oter DNA methylation and mRNA expression 
after treatm ent w ith clozapine may be due to  the low concentration used (2 and 10 
pM) or the very small effect o f clozapine on the HTR2C prom oter DNA methylation and 
mRNA expression. However, SH-SY5Y cells may respond to  antipsychotic drugs in a 
d ifferent way from normal mature neurons because they are derived from  
neuroblastoma cells.
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The lack o f haloperidol influence on the HTR2C prom oter DNA methylation and mRNA 
expression may be due to the low binding affin ity o f the haloperidol for the 5-HT2C 
receptors resulting in a lack of alteration in any cellular signalling including the DNA 
methylation of the HTR2C prom oter and mRNA expression observed in the present 
study.
6.5 Effect of antipsychotic drugs on leptin secretion and the Htr2c 
mRNA expression in 3T3-L1 adipocytes
The present study is the firs t study to investigate the effect o f antipsychotic drugs 
including clozapine, risperidone, haloperidol, and SB 242084 which is a selective 5- 
HT2C receptor antagonist, on leptin secretion from adipocytes, although there is one 
previous study tha t reported tha t clozapine treatm ent did not influence leptin 
secretion in human adipocytes (Hauner et al., 2003). This study did not observe any 
change in leptin levels in the culture medium o f the 3T3-L1 adipocytes exposed to 
antipsychotic drugs compared to control cells. The concentrations of the drugs used in 
this study were the therapeutic plasma concentrations and about a 10-fold higher 
concentration. The lack o f an effect of antipsychotics on leptin secretion indicates tha t 
drugs may induce weight gain by acting at central pathways rather than peripheral 
action. Otherwise, the low concentrations of antipsychotic drugs used in this study 
may be the cause of no significant alteration, or the drugs may have effects on other 
receptors that might have antagonistic actions and result in unchanged leptin levels.
A previous study has reported an increased expression o f the Htr2c mRNA in 3T3-L1 
adipocytes during adipocyte differentiation and used these cells to investigate the role 
of this receptor in adipocyte differentiation (Kinoshita et al., 2010). The measurable 
mRNA expression of the Htr2c in the differentiated 3T3-L1 adipocytes in this study may 
provide a cellular model fo r investigating the effect o f antipsychotic drugs on its 
expression. This study did not find any change of the Htr2c mRNA expression in 3T3-L1 
adipocytes after treatm ent w ith antipsychotic drugs compared to  a control group. No 
influence of antipsychotic drugs on mRNA expression o f the Htr2c in adipocytes 
supports the theory o f central influence of antipsychotic drugs in inducing weight gain 
rather than the peripheral action. However, a change may be visible if cells are treated 
w ith very high concentrations of antipsychotic drugs.
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6.6 Future studies
Further studies need to be carried out to  confirm the findings o f the present study and 
to  establish the role o f genetic and epigenetic factors in antipsychotic drug-induced 
weight gain in patients w ith schizophrenia. The novel genetic risk factors for 
antipsychotic drug-induced weight gain and replicates o f the findings o f the previously 
identified genetic risk factors still need further investigation.
The work in the area of DNA methylation in this study may extend into o ther genes 
relating to antipsychotic drug-induced weight gain; fo r example: the MC4R, ADR A2A, 
HTR2A, MTHFR and FTO polymorphisms which are the SNPs associated w ith 
antipsychotic drug-induced weight gain in the present work.
Further studies in cell culture could be carried out using SH-SY5Y human 
neuroblastoma cells to confirm the findings in this study and to investigate the role of 
antipsychotic treatm ent on DNA methylation and also the expression o f the HTR2C 
gene or other genes.
The differentiated mouse 3T3-L1 adipocyte cells provide a good model fo r studying the 
leptin secretion and expression of the Htr2c transcripts. Further studies need to 
confirm  the effect o f antipsychotic drugs on leptin and the Htr2c mRNA expression by 
testing at the higher concentrations of antipsychotic drugs to point out the role o f the 
5-HT2C receptors in the regulation o f leptin secretion.
6.7 General conclusions
The key novel findings of this study include:
•  This study has identified a genetic risk factor fo r antipsychotic drug-induced 
weight gain in first episode schizophrenia. The T allele o f the MTHFR 677C/T 
polymorphism was a protective allele fo r antipsychotic drug-induced weight 
gain. The MC4R rs489693 was also associated w ith weight gain in firs t episode 
Chinese Han schizophrenia patients.
•  There are interactions o f drug x genetic polymorphism of HTR2A and ADRA2A
and these polymorphisms were associated w ith BMI gain in the risperidone
subgroup of first episode Chinese Han schizophrenia patients.
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•  The FTO rs9939609 was previously reported to be associated w ith BMI in 
chronic (Belfast) schizophrenia patients in which the A allele carries had higher 
BMI than the TT genotype in this cohort.
•  Global LINE-1 methylation was not associated w ith BMI in chronic (Belfast) 
patients. In addition, the FTO rs9939609 and FITR2C -759C/T polymorphisms 
are not associated w ith global LINE-1 DNA methylation. However, the MTHFR 
677C/T polymorphism was associated w ith the global LINE-1 DNA methylation 
(CpG3) in chronic Belfast schizophrenia patients.
•  The HTR2C prom oter DNA methylation showed a gender difference (females 
had higher methylation levels than males). The methylation of HTR2C also 
showed regional differences (the methylation levels of CpG sites located near 
the transcription start site have lower than those located far away from  the 
transcription start site). The HTR2C SNP was more likely to  have an effect on 
the extent o f DNA methylation o f the CpG sites tha t are located near to  the SNP 
site than the CpG sites that are located at distance from the SNP site.
• The association o f the T allele of the HTR2C -759C/T polymorphism and the 
higher levels o f the HTR2C prom oter DNA methylation in the firs t episode 
Chinese Han cohort and chronic (Belfast) patients may explain previous findings 
tha t the T allele has lower prom oter activity (Hill and Reynolds, 2007). 
Therefore, this finding may add more evidence to the mechanistic link between 
the polymorphism and antipsychotic drug-induced weight gain.
•  FTO rs9939609 was associated w ith HTR2C prom oter methylation (-697G/C 
region), especially in first episode Spanish male patients w ith  schizophrenia; 
however, no association between the FTO polymorphism and HTR2C prom oter 
methylation was observed in chronic (Belfast) schizophrenia patients.
•  The antipsychotic drugs, clozapine and haloperidol treatm ent did not have an 
effect on the HTR2C prom oter DNA methylation and mRNA expression in 
human neuroblastoma SH-SY5Y cells. Whereas treatm ent w ith 5-aza-2'- 
deoxycytidine inhibited DNA methylation of the HTR2C prom oter sequence and 
increased the HTR2C mRNA expression.
• The antipsychotic drugs including clozapine, risperidone, haloperidol treatm ent 
and the 5-HT2C receptor antagonist, SB 242084 treatm ent did not have any
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effect on Htr2c mRNA expression and leptin secretion from mouse 3T3-L1 
adipocyte cells.
The genetic factors and epigenetic factors implicated in antipsychotic drug-induced 
weight gain may provide genetic and epigenetic markers for weight gain following 
antipsychotic drug medication. This study provides more understanding of the 
mechanism underlying antipsychotic drug-induced weight gain. These genetic and 
epigenetic factors may be useful in the future for designing clinical medications such as 
antipsychotic drug treatment that is suitable for each individual (personalised 
medicine) in order to gain the most therapeutic efficacy and least adverse side effects.
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Appendix
1. Raw data analyses all cases of Chinese Han schizophrenia patients
Table 1: Methylation levels at 5 CpGs in the HTR2C -697G/C promoter sequences 
comparing between two subgroups of weight increase in Chinese Han patients
HTR2C -697G/C 
promoter region
CpGl
-698
CpG2
-691
CpG3
-670
CpG4
-661
CpG5
-644
Weight increase>7% 
(n=82)
20.5117.81 20.3915.74 19.1216.07 21.6016.88 17.6613.99
Weight increase<7% 
(n=100)
22.5919.82 21.1915.70 20.6216.13 23.2816.44 19.8015.18
p value 0.176 0.424 0.355 0.308 0.004
Data is expressed as mean+SD.
Table 2: Methylation levels at 4 CpGs in the Hs_H77?2C_01_PM sequences comparing 
between two subgroups of weight increase in Chinese Han patients
Hs_H77?2C_01_PM CpGl CpG2 CpG3 CpG4
Weight increase>7% 
(n=82)
7.4814.88 7.3813.71 9.5214.84 5.5012.87
Weight increase<7% 
(n=100)
7.8813.70 8.3613.74 10.8614.52 6.2613.13
p value 0.187 0.101 0.050 0.126
Data is expressed as mean±SD.
Table 3: Methylation levels at 5 CpGs in the HTR2C -697G/C promoter sequences 
comparing between two subgroups of the HTR2C -759C/T genotype in Chinese Han 
patients
HTR2C CpGl CpG2 CpG3 CpG4 CpG5
-759C/T -698 -691 -670 -661 -644
C/CC (n=141) 22.1518.78 20.4115.45 19.2815.57 22.1416.61 18.2314.63
T/CT/TT (n=38) 19.5319.72 21.9916.26 22.5517.34 23.9916.67 21.1714.81
p value 0.017 0.370 0.010 0.362 0.002
Data is expressed as mean+SD.
Table 4: Methylation levels at 4 CpGs in the Hs_H77?2C_01_PM sequences comparing 
between two subgroups of the HTR2C -759C/T genotype in Chinese Han patients
HTR2C -759C/T CpGl CpG2 CpG3 CpG4
C/CC (n=141) 7.3713.89 7.7013.62 9.8614.58 5.7012.85
T/CT/TT (n=38) 8.2413.72 8.4813.75 11.8214.62 6.6713.38
p value 0.116 0.345 0.017 0.063
Data is expressed as mean+SD.
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2. Raw data analyses all cases of Spanish schizophrenia patients
Table 5: M ethyla tion  levels at 5 CpGs in the HTR2C -697G/C prom oter sequences 
comparing between tw o  subgroups o f w eight increase in Spanish patients
HTR2C -697G/C 
promoter region
CpGl
-698
CpG2
-691
CpG3
-670
CpG4
-661
CpG5
-644
Weight increase>7% 
(n=43)
18.79±16.90 15.0019.31 17.37111.54 19.05116.33 15.6719.15
Weight increase<7% 
(n=23)
20.17117.54 17.61111.38 18.09112.87 24.87120.04 18.09110.04
p value 0.666 0.620 0.651 0.261 0.538
Data is expressed as mean+SD.
Table 6: M ethyla tion  levels at 4 CpGs in the Hs_H77?2C_01_PM sequences comparing 
between tw o  subgroups o f w eight increase in Spanish patients
Hs_H77?2C_01_PM CpGl CpG2 CpG3 CpG4
Weight increase>7% 
(n=43)
5.2812.80 5.7113.56 7.6514.26 4.1911.97
Weight increase<7% 
(n=23)
7.3614.46 6.8713.16 9.1114.02 4.7712.24
p value 0.064 0.172 0.043 0.949
Data is expressed as mean+SD.
Table 7: M ethyla tion  levels at 5 CpGs in the HTR2C -697G/C prom oter sequences 
comparing between tw o  subgroups of the FTO rs9939609 genotype in Spanish 
patients.
FTO CpGl CpG2 CpG3 CpG4 CpG5
rs9939609 -698 -691 -670 -661 -644
AA (n=14) 30.86116.35 21.0718.67 21.64112.09 23.21115.21 19.0019.43
AT/TT (n=56) 16.16115.78 14.52110.11 16.29112.04 20.21118.08 15.7319.67
p value 0.004 0.001 0.007 0.325 0.072
Data is expressed as mean±SD.
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677C/T polymorphism is associated w ith  
antipsychotic-induced weight gain in  
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Abstract
Genetic variants of the methylenetetrahydrofolate reductase (MTHFR) gene involved in homocysteine 
metabolism may be important predictors of antipsychotic drug-induced weight gain (AIWG). We tested whether 
two functional MTHFR polymorphisms are related to AIWG. Weight gain was studied in two cohorts of 
first-episode, initially drug-naive schizophrenia patients; Chinese Han (n = 182) and Spanish Caucasians (n =72) 
receiving antipsychotics for 10 wk and 3 months respectively. Blood DNA was genotyped for 677C/T and 
1298A/C MTHFR polymorphisms. Patients with the 677 CC genotype had a significantly greater increase in 
BMI compared to T-allele carriers in both Chinese (p = 0.012) and Spanish (p = 0.017) samples. The 677C/T 
MTHFR polymorphism showed an additive effect, but no significant interaction, with the -759C/T HTR2C 
polymorphism previously associated with AIWG.
These results suggest that the 677C/T MTHFR polymorphism might, along with the -759C/T HTR2C poly­
morphism and other genetic factors, provide a useful marker for the important and limiting side effect o f AIWG.
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In troduction
Schizophrenia is a severe, complex and chronic disorder, 
which for many patients is inadequately treated. A n ti­
psychotic drugs can, in many individuals, relieve the 
positive psychotic symptoms but have various adverse 
effects; notably several of the drugs can induce a substan­
tial weight gain in susceptible individuals. This weight 
gain may not only increase treatment noncompliance, 
but also affect m orbidity from metabolic consequences 
including lipid abnormalities, insulin resistance and dia­
betes mellitus (Henderson et al., 2000). Patients receiving 
antipsychotic treatment can develop metabolic abnor­
malities with increased risk of cardiovascular disease 
and m ortality (Casey et al., 2004; De Hert et al., 2009).
Susceptibility to antipsychotic-induced weight gain 
varies substantially between individuals in ways that can­
not be fully explained by differences between drug effects 
or other environm ental factors. Thus genetic influences
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Email: labboom@hotmail.coni
are strongly implicated, and associations between  
many genetic polymorphism s and antipsychotic-induced  
weight gain have been reported. The most consistently 
reported genetic factors involved in antipsychotic- 
induced weight gain include polym orphism s in genes 
for 5-hydroxytryptam ine 2C (5-HT2C), 5-H T2A , adrener­
gic alpha 2A and melanocortin 4 receptors, as well as 
leptin and fat mass and obesity associated (FTO ) genes 
(Reynolds, 2012).
Recently, genetic variants of the m ethylenetetra­
hydrofolate reductase (M T H FR ) gene have been pro­
posed as potential predictors for antipsychotic-induced  
metabolic side effects (Kuzm an and Muller, 2012). 
M TH FR  exerts an im portant role in folate and hom o­
cysteine metabolism by catalysing the reduction of
5,10-m ethylenetetrehydrofolate to 5-m ethylenetetrahy- 
drofolate (5-M TH F), which is used in m ethionine syn­
thesis from homocysteine. The m ethionine is further 
converted to S-adenosylmethionine (S A M ), which is a 
major methyl donor in a wide variety of enzym atic pro­
cesses including the methylation of D N A . M T H F R  de­
ficiency can increase serum homocysteine, whereas the 
decrease in 5 -M TH F  and SAM  causes deficits in D N A  
methylation, D N A  synthesis and repair, and may
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predispose to neurodevelopmental and oncogenic pro­
cesses, resulting in the development o f many disorders 
including cardiovascular disease, renal failure, cancer 
and congenital abnormalities (Ueland et al., 2001).
The association of M TH FR  polymorphism s with meta­
bolic syndrome has been reported in the general popu­
lation. Obesity has been associated with M T H F R  
1298A/C (Terruzzi et al., 2007) and 677C/T genotypes 
(Lewis et al., 2006). Carriage of the 677T allele is asso­
ciated with insulin resistance (Chen et al., 2010; 
Lunegova et al., 2011). Association of the 677T allele 
with central obesity, hypertrig lyceridem ia and low levels 
of high-density lipoprotein cholesterol (H D L-C ) was also 
reported in the latter study (Lunegova et al., 2011). A  
replicated study reported that the 677T allele but not 
the 1298A/C polym orphism  of M TH FR  was associated 
with a greater risk o f developing metabolic syndrome 
and the T T  genotype was associated with risk of insulin  
resistance with greater central adiposity induced by anti­
psychotic treatment (Ellingrod et al., 2008, 2012). Others 
have reported the association of metabolic syndrome in 
schizophrenia with the 1298A/C polym orphism  in 518 
Caucasian patients (van Winkel et al., 2010a). These 
authors also reported that the 1298C variant was asso­
ciated with an increased weight and impaired glucose 
tolerance in 104 Caucasian patients who received antipsy­
chotic treatment for 3 months (van Winkel et al., 2010b). 
In the present study, we examined the association of 
the M TH FR  677C/T and 1298A/C polym orphism s w ith  
antipsychotic-induced weight gain in first-episode 
drug-naive patients with schizophrenia.
M ethods  
Study p o p u la t io n
Two cohorts of first-episode, initially antipsychotic 
drug-naive patients with schizophrenia receiving 
treatment according to normal clinical practice were 
studied; one main sample of Chinese Han (n = 182) and 
a replication sample of Spanish Caucasians (n = 72). A ll 
patients gave written inform ed consent to the procedure 
of the study, which was approved by local ethical 
committees. Height and weight to determ ined body- 
mass index (B M I) were measured on initiation of anti­
psychotic drug treatment and after 8 or 10 wk (Chinese 
cohort) or 3 months (Spanish cohort) and weight gain 
was determ ined by change in B M I over the treatment 
period. Initial antipsychotic drug treatment for Chinese 
Han patients consisted prim arily of chlorpromazine  
(n = 60) risperidone (n = 114); eight patients received cloza­
pine, fluphenazine or sulpiride. Patients in the Spanish 
cohort received p rim arily  risperidone (n = 21) or olanza­
pine (n = 22)and two received both; others had quetiapine 
(n = 10), haloperidol (n = 8) or ziprasidone (n = 6) with three 
not receiving antipsychotics. In this group, as with a sub­
sample of the Chinese cohort (Reynolds et al., 2002),
association of the -759C/T polym orphism  of H TR 2C  
with weight gain had previously been identified  
(Templeman et al., 2005). These results were also included  
in a combined analysis with the M TH F R  findings.
G enotyp ing  o f M TH FR  p o lym o rp h ism s
Genomic deoxyribonucleic acid (D N A ) was isolated from  
blood using standard techniques and was genotyped for 
M TH FR  677C/T (rs l801133) and 1298A/C (rs l801131) 
using TaqM an00 SNP genotyping assays: assay ID
C_1202883_20 and C_850486_20, respectively (A pplied  
Biosystems, USA). The PCR conditions consisted of initial 
denaturation at 95 °C for lOmin, followed by 40 cycles o f 
95 °C for 15 s and 60 °C for 1 min. Assays were run on a 
Step One Plus Real-Time PCR System (A pp lied  
Biosystems, USA).
S ta t is t ic a l a n a ly s is
A ll statistical analysis o f results was perform ed using  
SPSS version 18.0. Data were expressed as mean±s.D. 
Stepwise linear regression was used to determ ine the po­
tential confounding effects of baseline B M I and age on 
antipsychotic-induced weight gain. Analysis of variance 
was used to determ ine the association between M T H F R  
genotypes and weight gain. Statistical significance was 
assumed for p values less than 0.05. The main Chinese co­
hort of 182 subjects had approxim ately 90% pow er to 
identify a significant genotype difference for a m edium  
effect size of 0.5.
Results
C lin ic a l ch a ra c te r is tic s  and genotype resu lts
The 182 (83 men, 99 w om en) Chinese Han patients had a 
mean age 26.24+7.35 years. The genotype distribution for 
677C/T M TH FR  was as follows: CC (n = 54), T T  (n = 28), 
and CT (n = 94), six samples failing genotyping, and for 
1298A/C was A A  (n=114), CC (n = 5), and AC (n = 56) 
with seven samples failing genotyping. On regression 
analyses, baseline B M I but not age had a significant con­
founding effect on weight gain after 8 -10  wk treatm ent 
(F = 2 4 .189, p< 0.001), whereas age had a significant con­
founding effect on baseline B M I (F=  11.036, p = 0.001). 
Therefore, the subsequent analyses were perform ed  
with adjustment for age or baseline B M I as covariates.
The second study sample of 72 (53 men, 19 w om en) 
Spanish patients had a mean age of 25.35 ±6.80 years. 
The 677C/T genotype distribution was CC (n = 20), TT  
(n = 13), and CT (n = 36) and the 1298A/C  genotypes 
were A A  (n=45), CC (n = 3 ), and AC (n = 21) with three 
samples failing genotyping. On regression analysis, age 
but not baseline B M I had a significant confounding effect 
on weight gain at 3 months (F = 7.026, p = 0.010). Therefore, 
the subsequent analysis was perform ed with adjustment 
for age as a covariate.
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Table 1. Sociodemographics, baseline body mass index (BMI) and change in BMI among methylenetetrahydrofolate reductase (M THFR) 
677C/T and 1298A/C genotypes in Spanish and Chinese Han samples. Data are expressed as Mean+s.D.
MTHFR 677C/T genotype MTHFR 1298A/C genotype
CC CT TT p* AA AC CC p*
Chinese Han sample
inIIc n=94 n=28 IIc n = 56 n=5
Age 25.04 ±6.84 26.21+7.18 28.45±8.60 0.136 26.54 ±7.77 25.61 ±6.61 27.20±5.54 0.710
Gender M/F (%male) 25/29 (46.3%) 57/65 (46.7%) 13/15 (46.4%) 0.998 53/61 (46.5%) 24/32 (42.9%) 4/1 (80%) 0.279
Baseline BMI (kg/m2) 20.99+2.69 21.43+2.77 21.92±3.53 0.607 21.47±3.06 21.20±2.59 21.78± 1.51 0.895
Change BM I (kg/m2) 1.58 + 1.25 0.92±1.15 1.43 + 1.10 0.003 1.27 ±1.24 1.04 ±1.18 1.63 ±0.94 0.228
Spanish sample n=20 n=36 n = 13 3 II -£■ n=21 n=3
Age 27.60+8.34 24.25+5.69 23.92+6.96 0.168 25.36±7.36 24.76±6.38 25.00 ±1.73 0.949
Gender M/F (%male) 14/6 (70.0%) 29/7 (80.6%) 9/4(69.2%) 0.578 32/13 (71.1%) 17/4 (81%) 3/0(100%) 0.412
Baseline BMI (kg/m2) 21.44+3.78 22.06+3.70 22.29+4.01 0.780 21.92±3.62 21.99±4.16 21.45±3.76 0.973
Change BMI (kg/m2) 2.86 + 1.53 2.09+1.44 1.85 + 1.81 0.049 2.18 ± 1.66 2.46 ±1.52 2.03±0.99 0.807
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Fig. 1. The association between methylenetetrahydrofolate reductase (MTHFR) 677C/T genotype and weight gain for Spanish 
(a) and Chinese Han (b) schizophrenia patients. Data are expressed as mean+s.E.M. BMI: body mass index.
The two polym orph ism s were found to be in strong  
linkage d isequilibrium  (D '= 0.866 and 1.00, 1^=0.127 and  
0.198 in Chinese and Spanish groups respectively) in  
which the 677T allele was almost exclusively carried 
with the 1298A allele.
A sso c ia tio n  o f  MTHFR 677C/T and 1298A/C  
p o ly m o rp h ism s  w ith  weight gain
As sh ow n  in Table 1, the baseline BMI, age, and gender  
distribution o f  both sam ples were not significantly differ­
ent betw een  genotypes o f  the 677C/T MTHFR p o ly ­
m orphism . The CC gen otyp e  had greater changes in 
BMI than T allele carriers: 1.58 + 1.25 vs. 1.04 +1.16 k g /m 2 
in Chinese (p= 0.012) and 2.86 + 1.53 vs. 2.02 +1.54 kg/m 2 
in the Spanish sample (p=0.017) (Fig. 1).
D iv id ing  the Spanish cohort into patients who received  
or did not receive o lanzapine, and the Chinese cohort into  
those receiving either risperidone or chlorprom azine, 
resulted in the absence o f a significant drug x MTHFR  
gen otyp e  interaction.
The baseline BMI, age, and gender distribution o f both  
study populations were not significantly associated w ith
the 1298A/C MTHFR po lym orph ism . Nor were the  
changes in BMI o f either study p op u lation  significantly  
different betw een  1298A/C AA g en o ty p e  and C carriers: 
1.27+1.24 vs. 1.08 + 1.17 k g /m 2 in Chinese Han sam ples  
(p = 0.242) and 2.18 + 1.66 vs. 2.40 +1.45 k g /m 2 in Spanish  
sam ples (p = 0.621) respectively.
Gene-gene in tera c tio n
Previous findings in these two cohorts (Reynolds et al., 
2002; T em plem an et al., 2005) sh o w ed  that the T allele o f  
the 5-HT2C receptor gene (HTR2C) -759C/T polym orp h ­
ism had a protective effect against an tipsych otic-ind uced  
weight gain. A ssociation  o f  this p o ly m o rp h ism  w ith  
changes in BMI were as follows: in the Chinese cohort T  
carriers 0.71 + 1.11 k g /m 2 (n = 38), C/CC gen o ty p e  1 .33 +  
1.21 kg/m 2 (n = 141) p=0.004; in the Spanish cohort T car­
riers 1.24 ± 1.46 kg/m 2 (n = 16), C/CC g en otyp e  2 .4 8  + 1.54 
kg/m 2 (n = 50) p = 0.012. The relationsh ip  b etw een  the  
effects o f the HTR2C -759C/T and the MTHFR 677C/T  
polym orphism s was investigated . A n alysin g  the associ­
ation o f weight gain with both polym orph ism s together  
in each cohort, no sign ifican t interaction b e tw een  the
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polymorphism s was detected but a significant overall 
effect was observed (p = 0.001 in the Chinese sample; 
p = 0.019 in the Spanish sample), indicating an additive  
effect of the two polymorphisms. Thus carriage of two  
risk factors (HTR2C C/CC genotype and M TH FR  677 
CC genotype) was associated with mean gains of 3.23 
and 1.81 kg /m 2 in Spanish (n = 14) and Chinese (n=41) 
cohorts respectively; equivalent values for subjects 
carrying neither risk factor were 1.35 (n=10) and 0.63 
(n = 25) kg /m 2.
Discussion
This study indicated that M TH FR  677C/T polymorphism  
is associated with antipsychotic-induced weight gain 
in first-episode patients with schizophrenia. Individuals  
carrying the T  allele showed less weight gain compared 
to the common CC genotype after 8-10 wk or 3 m onths’ 
treatment with antipsychotic drugs. This finding, 
observed in two patient cohorts of different ethnicity, 
indicates the effect to be a robust and reproducible one. 
The study had 90% pow er to identify a m edium  (0.50) 
effect size in the main cohort; previous studies of associ­
ation of the well-replicated -759C/T polymorphism of 
HTR2C with antipsychotic drug-induced weight gain in 
a subgroup of the Chinese sample and in the Spanish 
sample have demonstrated substantially larger effect 
sizes of 0.90 and 0.86 respectively (Reynolds et al., 2002; 
Tem plem an et al., 2005). In order for pharmacogenetic 
risk factors to explain a good proportion of the variance 
and thereby to have substantial predictive value, strong 
effects are needed. In this we are aided substantially by 
the cohorts studied here; each only included first-episode 
patients who had never previously received antipsychotic 
drug treatment. This eliminates much of the variance 
associated with prior drug treatment, which can induce 
significant weight gain w ith in  a few weeks of initial treat­
ment (Zhang et al., 2004).
The absence of an effect in the 1298A/C polym orphism , 
despite it being in strong linkage disequilibrium  (high D ' 
values) with the significantly associated 677 genotype, 
presumably relates to the large differences in allele fre­
quency between the two polymorphisms, as reflected by 
low r2 values.
In two previous cross-sectional studies the 677C/T  
polym orphism  is associated with metabolic syndrome 
following antipsychotic drug treatment (Ellingrod et al., 
2008, 2012), although these authors find the 677T allele 
to be a risk factor, whereas we find a consistent effect of 
the 677T allele in protecting against antipsychotic 
drug-induced weight gain. This may well indicate the d if­
ference between effects on initial weight gain and its long­
term consequences, in which differing pharmacogenetic 
influences are apparent (Reynolds et al., 2013). In another 
study the 1298A/C but not 677C/T polym orphism  was 
associated with metabolic syndrome in schizophrenia 
(van Winkel et al., 2010a). The one previous longitudinal
study of changes in weight and metabolic parameters fo l­
lowing 3 months’ treatment with second-generation anti­
psychotics also found an association with the 1298A/C  
but not 677C/T polym orphism  (van Winkel et al., 
2010b). This study differed from the present investigation 
of first-episode drug-naive patients in that weight but 
not B M I was measured, and the 104 patients were older 
(mean 31.3 yr) with first admission on average over 6yr 
previously; thus prior treatment may well have con­
founded subsequent weight gain. How ever, their 
finding that the 1298A allele is associated with less weight 
gain is not inconsistent with our finding given the close 
linkage disequilibrium between the two polymorphism s  
studied. As discussed by van Winkel et al. (2010b), 
there are no clinical or ethnic factors identified that may 
be responsible for the discrepancies between these 
findings, although it is notable that most studies were 
not powered to identify significant differences between 
the effects of the two closely linked polymorphism s. 
Nevertheless these various reports all indicate that func­
tional genetic variation in M TH FR  can influence antipsy­
chotic drug-induced weight gain.
It is conceivable that pharmacogenetic associations 
such as that identified here may vary depending on the 
treatment regime. Different drugs may have differing  
mechanisms underlying their effect on body weight -  cer­
tainly the greater effect of olanzapine over risperidone 
and several other antipsychotics supports this -  and
these pharmacological mechanisms may be differentially  
influenced by genetic polymorphism s. Our study was 
not powered to subdivide samples into treatment sub­
groups; however, further work needs to address the poss­
ible drug specificity of such pharmacogenetic findings.
There was no significant interaction between -75 9 C /T  
of HTR2C and 677C/T of M TH FR  on antipsychotic- 
induced weight gain, indicating that both polym orphism s  
exert independent influences on this side effect. H ow ever, 
the gene-gene analysis resulted in substantial increases in 
statistical significance, demonstrating an additive effect of 
the two polymorphisms. Clearly there are other genetic 
influences that are likely to contribute to determ ining
initial weight gain associated with antipsychotic  drug  
treatment, including polymorphism s for genes for 
leptin, melanocortin receptor 4, adrenoreceptor alpha2A  
and g-protein beta3 among probably many others 
(Reynolds, 2012).
The exact mechanism by which M TH FR  polym orph­
isms might contribute to determ ining antipsychotic 
drug-induced weight gain is unclear. Both variant alleles 
of 677C/T and 1298A/C M TH FR  polymorphisms cause 
decreased enzyme activity (Weisberg et al., 1998),
although it is not easy to distinguish effects of tw o
closely linked polymorphism s in vivo. M TH FR  is an im ­
portant enzym e in one-carbon metabolism and, via its 
role in D N A  synthesis and methylation (Sugden, 2006), 
may influence gene expression (Jirtle and Skinner, 2007); 
such epigenetic effects could be involved in antipsychotic
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drug-induced weight gain. D im inished levels o f genomic 
D N A  methylation (Stem et al., 2000) and gene-specific 
D N A  m ethylation (Burghardt et al., 2012) have been 
reported to be associated with the 677TT genotype. It is 
therefore possible that decreased M TH FR  enzym e activity 
in 677TT genotype results in decreased D N A  methylation  
of genes involved in body weight regulation.
D N A  methylation status is influenced by gene-nutri­
ent interaction. It has been suggested that the M TH F R  
677TT genotype affects D N A  m ethylation status through  
an interaction with folate status (Friso and Choi, 2002). 
These authors found that genomic D N A  methylation in 
peripheral blood mononuclear cells was directly corre­
lated with folate status, inversely correlated with homo­
cysteine levels, and only 677TT subjects with low folate 
accounted for decreased D N A  m ethylation (Friso et a l,  
2002). Thus folate status in addition to the 677C/T  
M TH FR  polym orphism  might modulate D N A  methyla­
tion of genes relating to the regulation of food intake, 
energy expenditure or body weight regulation, and thus 
could be an unexplored factor contributing to the vari­
ance in this and previous studies.
In conclusion, this present study indicates the associ­
ation of the M TH FR  677C/T single polym orphism  w ith  
weight gain following initial antipsychotic drug treat­
ment in first-episode psychotic patients. Furthermore, 
the effect o f the 677T allele appears to have a protective 
effect additional to that o f the well-established H TR 2C  
-759T allele against antipsychotic-induced weight gain. 
These two polymorphisms, in addition to several other 
possible genetic factors, might be valuable as pharmaco- 
genetic markers of this important and limiting side effect.
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M ethylation at a transcription factor-binding site 
on the 5-HT1A receptor gene correlates w ith ( W  
negative symptom treatment response in first 
episode schizophrenia
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Abstract
Individual variability and inadequate response of negative symptoms are major lim itations of antipsychotic treat­
ment in schizophrenia. A functional polymorphism, rs6295, in the 5-HT1 A-receptor gene (HTR1A) contributes to 
this variability in negative symptom response. The DNA sequence containing rs6295 is rich in cytosine methyla­
tion (CpG) sites; CpG methylation is an epigenetic factor that, like rs6295, can modify transcriptional control. To
investigate whether DNA methylation influences response to antipsychotic treatment, we determined methyla­
tion at CpG sites close to rs6295 in DNA from 82 Chinese subjects with a first psychotic episode. Methylation o f
one CpG site w ith in  a recognition sequence for HES transcriptional repressors was found to correlate w ith
changes in total PANSS score (p = 0.006)and negative factor sub-score (p<0.001) following 10 wk initial antipsy­
chotic treatment, as well as with baseline negative factor score (p = 0.019); the effect on symptom change remained 
after correction for this baseline score. An effect of rs6295 on negative symptom response was not seen in this 
sample, which may not have provided sufficient power for the pharmacogenetic association. These prelim inary 
results indicate that epigenetic modification of transcriptional regulation by specific cytosine methylation may 
modulate HTR1A expression, resulting in effects on emotional dysfunction and negative symptom response 
to antipsychotic treatment.
Received 16 August 2013; Reviewed 11 September 2013; Revised 8 October 2013; Accepted 30 October 2013;
First published online 16 December 2013
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Introduction
Response to antipsychotic drug treatment shows substan­
tial inter-individual variability, as well as a generally 
poorer im provem ent of negative than positive symptoms. 
In pharmacogenetic studies addressing this differential 
response, a replicated finding is the association of nega­
tive symptom response with the — 1019C/G polym orph­
ism (rs6295) in the 5-HT1 A-receptor gene (H TR 1A ) 
(Reynolds et al., 2006; Wang et al., 2008; Mossner et al.,
2009). This polym orphism , first found to be associated 
with depression and suicide (Lemonde et al., 2003), is 
also associated with response to antidepressant drugs 
(Lemonde et al., 2004; Yevtushenko et al., 2010). It is 
found to influence gene expression; the risk allele (G) dis­
rupts the repressor activity of the DEAF1, HES1 and 
HES5 transcription factors, resulting in overexpression 
of the presynaptic 5 -H T1 A-receptor (Lemonde et al., 
2003; Jacobsen et al., 2008).
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M ethylation of D N A  sequences is another established 
influence on transcription factor binding (Sharma et al.,
2010). Cytosine residues at CpG dinucleotide sequences 
are sites of D N A  methylation, one of several epigenetic 
mechanisms for the m odulation of D N A  function. It is 
notable that rs6295 is found w ith in  an island of 13 CpG  
sites in the HTR1A prom oter sequence; these adjacent 
m ethylation sites could conceivably contribute, along 
with rs6295, to m odifying the binding of transcription fac­
tors such as DEAF1. We hypothesised that the percentage 
m ethylation of one or more CpG sites close to the rs6295 
polym orphism  in the prom oter sequence of H TR 1A  may 
also influence symptom response to treatm ent with anti­
psychotic drugs.
M ethod
Chinese Han inpatients presenting with a first psychotic 
episode (45 male, 37 female; mean age 25.8 + 7.1 years) 
participated in our study. All patients met criteria for a 
diagnosis of schizophrenia according to the Diagnostic 
and Statistical M anual of the Am erican Psychiatric 
Association 4th Edition (D S M -IV ). Exclusion criteria
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included  prior history o f m edication with antipsychotics, 
antidepressants or mood stabilisers, co-morbid D SM -IV  
diagn osis o f substance abuse or dependence or other  
physical illness. Study subjects were treated according  
to standard clinical practice; initial treatm ent was w ith  
chlorprom azine (n= 57), risperidone (n = 18), clozapine  
(n = 4) or fluphenazine (n = 3) Drug treatm ent w as  
rev iew ed  after approxim ately 6 wk and m odified  as 
needed; this resulted in a further 26 subjects receiving  
clozapine: 21 from the chlorprom azine group and 5
from the risperidone group. A n ticholinergic and benzo­
diazep ine co-m edication were adm inistered as required  
for the alleviation o f  extrapyram idal sy m p to m s and  
need for sedation, respectively. The Positive and  
N egative  Syndrom e Scale (PANSS) was used for assess­
ment and evaluation  o f p sych opathology and therapeutic  
response to antipsychotic treatm ent. All patients were  
assessed  on the day o f  adm ission  by a psychiatrist trained  
in the use o f  PANSS and subsequently reassessed after 
10 wk o f antipsychotic treatment. PANSS items w ere  
d iv id ed  into five sym ptom  factors according to the con­
sensus scheme o f W allw ork et al. (2012). The five factors 
are defined by the following PANSS items: Positive  
Factor: P I, P3, P5, G9; N egative  Factor: N l,  N2, N3, N4, 
N6, G7; D isorganised/C oncrete Factor: P2, N5, G il ;  
Excited Factor: P4, P7, G8, G14; D epressed Factor: G2, 
G3, G6. The Nanjing Brain H ospital Ethical C om m ittee  
approved the study, and all patients gave written  
inform ed consent.
Genomic DNA, extracted from blood sam ples taken  
on the day o f  adm ission  prior to initiation o f  drug treat­
ment using a standard ch loroform -phenol m ethod, w as 
bisu lfite-m odified  to convert unm ethylated  cytosine resi­
dues to uracil using the EpiTect Fast Bisulfite Kit (UK) 
with a calculated mean conversion o f 99%. For analysis, 
a sequence containing 13 CpGs in the HTR1A prom oter  
(GRCh37.plO, C hrom osom e 5 bases 6 3 2 5 8 5 2 5 -6 3 2 5 8  
684) including the rs6295 C/G polym orphism , (w hich  
enables/rem oves CpG12) was identified  and am plified  
by PCR using prim ers, including a biotinylated reverse  
prim er, as follows: 5'-AGTAAGGTTGGATTGTTAGA- 
TGA-3' (forward) and 5'-[btn]CCTAAATCAATCTC- 
CCAATTATTACTAA-3' (reverse) (Eurofins M W G  
Operon). PCR reaction was carried out with 20 ng  
bisulfite-converted DN A using the PyroM ark PCR kit 
(UK) in a final volum e o f 25 pi containing 12.5 pi lx  Pyro­
Mark PCR Master Mix, 2.5 pi lx  CoralLoad Concentrate,
1 pi o f each prim er in a final concentration o f  0.05 p M , 
7 pi RNase-free water. A m plification conditions were as 
follows: 95°C for 15 min, 45 cycles o f  94°C for 30 s, 56°C  
for 30 s and 72°C for 30 s, finally, 72°C for 10 min. M ethy­
lation status o f  the sequence w ithin  the CpG island  
around rs6295, containing sites CpG9-13 (Fig. la), was de­
term ined with a PyroM ark Q24 pyrosequencer (Q iagen  
UK) using 15-20 pi PCR product and em p lo y in g  a 
sequ en cing  primer, 5'-TTTAGGTTGGAGTGTAATG-3' 
(Eurofins MWG Operon). Pyrosequence setup and data
(a)
-14(H) -12(H) -1 0 0 0  -8 0 0  -6 0 0  -4 0 0  -2 0 0  0
 I________ !________ I________ 1________ !________ I________ L
9 t f T '  11 *  12 (rx6295)  13
ATOeCCCCACAACCGAOGTACCTTTTT AAAAAHc /O I  GVCACAjOCT C c fc T C ^ _ _  
T*CCOCCCTCTTCCCTCCATCG«A>AAl I I I I K G /C K I i t l d fcTGACqC A S ^ ^ ^
DEAF1 H E S l,H E S 5 a n d  
Binding site  HES6 Binding site
(b)
25
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T-T0.41O 
p<().(H) 115
10
o cc
•  C (i and GCi
5
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Change in negative factor
Fig. 1. (a) CpG sites (numbered 9-13) are shown in bold in the 
DNA sequence of HTR1A that underwent pyrosequencing, 
with the rs6295 polymorphism in brackets and binding sites for 
DEAF1 and HES transcription factors shown in frames.
(b) Correlation between % methylation at CpG13 and 
improvement in the negative factor score.
reading were condu cted  by PyroM ark Q24 2.0.6.20 soft­
ware (UK). Samples underw ent PCR and pyrosequencing  
in duplicate; any inconsistencies betw een sam ples w ere  
resolved  fo llo w in g  further repetition. P yrosequencing  
also perm itted determ ination o f  gen o ty p e  for rs6295.
Data analysis was undertaken using SPSS version 16.0 
(SPSS Inc., USA). Pearson’s correlation was used to deter­
mine ind ividual relationships betw een  clinical m easure­
ments and percentage m ethylation. As we initially  
investigated  five CpG sites adjacent to, and including  
that of, the rs6295 p o lym orph ism  for their correlation  
with sym ptom  response, statistical significance was set 
at p<0.01 for a conservative Bonferroni correction; for  
subsequent, post-hoc analysis we app lied  p < 0 .0 5 . 
Stepwise regression analysis was used to determ ine the  
influence o f  clinical and dem ographic factors on sym p­
tom m easures. Power analysis dem onstrated that the  
sample size was adequate to identity a m edium  effect 
size (r=0.3) with 80% p o w er  at p< 0 .05 . Where sh ow n , 
variance in data is expressed as standard deviation .
R esu lts
Initial mean PANSS score on adm ission  was 99 .6+14.4; 
this reduced to 49.6 ±9 .6  after lO w k initial treatm ent 
with antipsychotic drugs. Mean m ethylation  was deter­
mined at m ethylation sites CpG9, CpG 10, CpG 11 and  
CpG13 as 13.8, 18.1, 20.5 and 13.9%, r esp e ctiv e ly ; at 
CpG12 (rs6295 C-allele carriers) it was 21.0%. R esults 
for CpG9 and CpG13 each contained one extreme outlier  
(z> 5 ) and were not norm ally distributed; rem oval o f  the 
two outlier data points norm alised  the distributions
exon 1
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Table 1. Methylation at CpG sites and their correlation with symptom changes after 10wk' treatment with antipsychotic drugs
Percentage methylation (mean+s.D.) 
Spearman's r and p values
CpG9 (n = 81) CpG 10 (n == 82) C pG ll (n = 82)
CpG 12 at C 
allele (n = 76) CpG 13 (n = 81)
13.60+2.73 18.10+4.35 20.49+3.87 21.01+4.74 13.73+2.91
r P r P r P r P r P
Change in total PANSS 0.15 0.17 0.11 0.31 0.04 0.74 0.13 0.27 0.30 0.006
Changes in symptom factors
Excited factor 0.25 0.024 0.15 0.18 0.08 0.49 0.07 0.53 0.16 0.17
Negative factor 0.09 0.41 0.11 0.35 0.08 0.49 0.13 0.26 0.41 0.000
Disorganised/concrete factor 0.01 0.92 -0 .06 0.61 -0.08 0.46 -0.04 0.75 0.10 0.36
Positive factor 0.11 0.34 0.05 0.67 -0.02 0.88 -0.00 0.99 0.09 0.45
Depressed factor 0.15 0.17 0.17 0.13 0.09 0.40 0.07 0.53 0.21 0.065
(Shapiro-W ilk test; p = 0.264, 0.234 respectively). O nly  
methylation at CpG13 showed a significant correlation 
with clinical measures (Table 1). CpG 13 m ethylation  
was significantly correlated with change in total PANSS 
(r = 0.300, n = 81, p = 0.006). This reflected a highly signifi­
cant positive correlation with change in the negative fac­
tor (r = 0.410, p <0.001) (Fig. lb). Stepwise linear regression 
indicated a significant effect of negative factor score be­
fore treatment on change in negative symptoms, but no 
significant effect o f age, sex or whether patients received 
clozapine. A significant correlation with CpG 13 methyla­
tion was also observed with this negative factor baseline 
score (r = 0.261, p = 0.019) but not with the baseline score 
of any other factor. After controlling for baseline negative 
symptom score the correlation between CpG 13 m ethyla­
tion and change in negative symptoms remained highly  
significant (r = 0.353, p = 0.001). CpG13 m ethylation  had 
a small effect on the change in the depressed factor 
(r = 0.206, p = 0.065); correlations with changes in other 
factors were also not significant (p > 0.1).
The subjects were found to have the following rs6295 
genotypes: 46 CC, 30 CG and 6 GG. Genotype had no 
significant influence on methylation of the invariant 
CpG sites, nor was genotype significantly related to 
PANSS measures of symptom response to treatment, in­
cluding negative symptom response. Thus CC genotype 
and G allele carriers had mean values for change in nega­
tive score of 7.93 ±3.93 and 7.31+4.22, respectively. W e  
investigated the relationship between CpG 13 methylation  
and change in negative symptoms separately w ith in  two  
rs6295 genotype subgroups of the sample. The correlation 
remained in both the CC genotype (r = 0.422, n=46, 
p = 0.004) and the G carrier (r = 0.421, n = 35, p = 0.012) sub­
jects (Fig. lb).
Discussion
In a hypothesis-driven search for effects o f D N A  methyla­
tion in the promoter region of a gene (H TR 1A ) known to
be associated with symptom response to antipsychotic 
medication, we have identified a correlation of the change 
in negative symptoms following initial antipsychotic 
drug treatment with m ethylation, determ ined prior to 
onset of treatment, at a specific CpG site adjacent to the 
functional polym orphism  rs6295. Thus epigenetic vari­
ation, as well as a genetic polym orphism , in a specific 
D N A  sequence in the HTR1A prom oter region can in flu ­
ence negative symptoms in schizophrenia and their sub­
sequent response to antipsychotic drug treatment.
CpG 13 is found w ith in  a recognition site for the re­
pressor activity of transcription factors HES1 and HES5 
(Fig. la); HES5 activity is also influenced by the nearby  
rs6295 allele (Jacobsen et al., 2008). The strong repressor 
activity of HES1 is thought to play an essential role in 
the developmental repression o f HTR 1A  expression, 
while the inhibitory effect o f HES6 on HES1, HES5 and 
DEAF1 repressor activity may regulate H TR 1A  ex­
pression (Jacobsen et al., 2008). Thus a m ethylation- 
induced variability  in the balance between effects of 
these transcriptional regulators may modulate the devel­
opmental control of HTR 1A  transcription and its effects 
on affective circuitry (Richardson-Jones et al., 2011); 
leucocyte D N A  m ethylation as determ ined here may  
well reflect epigenetic changes during, or even prior to, 
early developm ent (Rosa et al., 2008). However, effects 
on expression of H TR 1A  in the adult may also be im port­
ant; it is notable that a negative correlation between  
5-H T1  A-receptor binding potential in the am ygdala  
and PANSS-derived negative and depression/anxiety  
symptom scores has been reported in drug-free schizo­
phrenia (Yasuno et al., 2004). Certainly dysfunction of 
the am ygdala and its connectivity with the prefrontal cor­
tex are proposed to be involved in the emotional dysregu- 
lation underlying negative symptoms of schizophrenia  
(Aleman and Kahn, 2005).
By analogy with the association o f rs6295 with antipsy­
chotic drug response (Reynolds et al., 2006), we hypoth­
esise that poor symptom response to drug treatm ent
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is associated with loss of inhibitory control of H TR 1A  
expression, with a consequent increase in 5-H T1A  auto 
receptors and reduction in serotonin neurotransmission. 
That we find poorer response to be correlated w ith  
dim inished methylation at CpG 13, suggests that m ethyla­
tion might enhance transcriptional repressor activity, per­
haps by recruiting m ethyl-binding repressor proteins. 
However, the finding of a greater reduction in am ygdala  
5-H TlA -receptors in patients with more severe negative 
symptoms (Yasuno et al., 2004), along with our obser­
vation of a positive correlation between CpG13 m ethyla­
tion and baseline negative factor score, would be 
consistent with an alternative view where greater methy­
lation resulted in suppression of HTR1A expression. This 
could be brought about by disruption o f the enhancer ac­
tivity of DEAF1 on HTR 1A  expression that is found at 
post-synaptic sites (Czesak et al., 2006).
The 5-H T1 A-receptor is increasingly being recognised 
as a potential target for antipsychotic drug action, par­
ticularly with respect to negative and cognitive symptoms 
of schizophrenia (Newm an-Tancredi and Kleven, 2011). 
Certainly the 5-H T  system is implicated in negative 
symptoms and their response to drugs; selective sero­
tonin reuptake inhibitors as an adjunct to antipsychotic 
treatment can improve negative symptoms in some sub­
jects (Silver, 2004). Our findings add further evidence 
for 5-H T 1A receptor involvem ent in negative symptoms 
and response to antipsychotic drug treatment. These 
receptors mediate the action of atypical antipsychotic 
drugs on dopam ine release in the frontal cortex 
(D iaz-M ataix et al., 2005), one mechanism proposed to 
underlie drug effects on negative symptoms (e.g. 
Ichikawa et al., 2001). Thus genetically or epigenetically 
determined differences in 5 -H T  1 A -receptor density or 
its regulatory control may influence subsequent negative 
symptom response to antipsychotic drugs.
We recognise that the assessment of peripheral blood 
DN A , rather than D N A  from brain tissue, is an inevitable  
lim itation of our study, H ow ever, others have found psy­
chiatric correlates of H TR 1A  m ethylation in blood D N A : 
methylation of the HTR 1A  proxim al promoter region is 
reportedly increased in schizophrenia (Carrard et al.,
2011). Notably, a site-specific hypomethylation of the 
5-H T2A-receptor gene in schizophrenia and bipolar dis­
order is found in both brain- and saliva-derived D N A  
(Ghadirivasfi et al., 2011). We were unable to replicate 
in this sample the previously reported association o f 
rs6295 with negative symptom response to treatment. 
This is not easily explained given that the original result 
was seen with a smaller sample (Reynolds et al., 2006), 
although the combination of sample size, lower G allele 
frequency and perhaps other factors associated with this 
Asian population may have contributed.
Nevertheless, the sample demonstrates a strong effect 
of m ethylation at the recognition site for transcription fac­
tors implicated in the effect of the rs6295 polymorphism  
on HTR1A gene expression (Jacobsen et al., 2008). This
finding is replicated internally w ith in  the two genotype 
groups and represents a uniquely specific observation 
of an epigenetic factor relating to symptom response in 
the initial drug treatment of schizophrenia. As such the 
findings have an impact far beyond an understanding  
of the epigenetic influences on antipsychotic treatment 
response; as well as raising the question whether there 
might be an association of CpG 13 m ethylation w ith  
schizophrenia, they im m ediately generate hypotheses re­
lating to depression and antidepressant response, w ith  
which the adjacent HTR 1A  polym orphism  has estab­
lished associations (Lemonde et al., 2003; 2004).
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